

US011046978B2

# (12) United States Patent

# Gonzalez et al.

# (54) SYNTHESIS OF ISOPRENOIDS AND DERIVATIVES

- (71) Applicant: William Marsh Rice University, Houston, TX (US)
- Inventors: Ramon Gonzalez, Houston, TX (US);
   James M. Clomburg, Houston, TX (US);
   Seokjung Cheong, Houston, TX (US)
- (73) Assignee: WILLIAM MARSH RICE UNIVERSITY, Houston, TX (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 39 days.
- (21) Appl. No.: 16/081,756
- (22) PCT Filed: Mar. 15, 2017
- (86) PCT No.: PCT/US2017/022581
  § 371 (c)(1),
  (2) Date: Aug. 31, 2018
- (87) PCT Pub. No.: WO2017/161041PCT Pub. Date: Sep. 21, 2017

# (65) **Prior Publication Data**

US 2019/0352679 A1 Nov. 21, 2019

# **Related U.S. Application Data**

- (60) Provisional application No. 62/343,598, filed on May 31, 2016, provisional application No. 62/308,937, filed on Mar. 16, 2016.
- (51) Int. Cl. *C12P 7/42* (2006.01)
- (58) Field of Classification Search None

See application file for complete search history.

# (56) **References Cited**

# U.S. PATENT DOCUMENTS

2012/0144523 A1* 6/2012 P	Page C12P 7/22
	800/278
2013/0067619 A1* 3/2013 P	Page C12N 15/52
2012/0216412 41 11/2012 6	800/278
2013/0316413 A1 11/2013 C	Jonzalez et al. $C12N0/00$
2014/01414/0 Al - 5/2014 F	rage
2014/0273110 41 9/2014 6	Gonzalez et al
2015/0284743 A1* 10/2015 N	Marliere C12P 5/007
	435/167

# FOREIGN PATENT DOCUMENTS

WO	2012109176	8/2012
WO	2013036812	3/2013

# (10) Patent No.: US 11,046,978 B2

# (45) **Date of Patent:** Jun. 29, 2021

WO	2013053824 A1	4/2013
WO	2014076016 A1	5/2014
WO	2015191422	12/2015
WO	2015191972	12/2015
WO	2016007258	1/2016
WO	2016010827 A1	1/2016
WO	2017020043	2/2017

# OTHER PUBLICATIONS

Chica et al. Curr Opin Biotechnol. Aug. 2005;16(4):378-84. (Year: 2005).\*

Singh et al. Curr Protein Pept Sci. 2017, 18, 1-11 (Year: 2017).\* Kizer et al. Appl Environ Microbiol. May 2008;74(10):3229-41. (Year: 2008).\*

Prather et al. Curr Opin Biotechnol. Oct. 2008;19(5):468-74. (Year: 2008).\*

Zheng et al. Biotechnology for Biofuels 2013, 6:57 (Year: 2013).\* Kumano et al. Bioorganic & Medicinal Chemistry 16 (2008) 8117-8126 (Year: 2008).\*

Shindo et al. Biosci. Biotechnol. Biochem., 75 (3), 505-510, 2011 (Year: 2011).\*

Atsumi, S. et al. Metabolic engineering of *Escherichia coli* for 1-butanol production. Metab. Eng. 10, 305-311 (2008). Baba, T. et al. Construction of *Escherichia coli* K-12 in-frame,

Baba, T. et al. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2 (2006).

Blecher, M. (1981). Synthesis of long-chain fatty acyl-CoA thioesters using N-hydroxysuccinimide esters. Methods in Enzymology, 72: 404-408.

Chen, J. et al. Activating C4-dicarboxylate transporters DcuB and DcuC for improving succinate production. Appl. Microbiol. Biotechnol. 98, 2197-2205 (2014).

Cheong, S., et al. Energy- and carbon-efficient synthesis of functionalized small molecules in bacteria using non-decarboxylative Claisen condensation reactions. Nat Biotech 34, 556-561 (2016).

Choi, S.Y. et al. One-step fermentative production of poly(lactateco-glycolate) from carbohydrates in *Escherichia coli*. Nat Biotech 34, 435-440 (2016).

# (Continued)

Primary Examiner — Christian L Fronda (74) Attorney, Agent, or Firm — Boulware & Valoir

# (57) ABSTRACT

This disclosure generally relates to the use of enzyme combinations or recombinant microbes comprising same to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds. Novel metabolic pathways exploiting Claisen, aldol, and acyioin condensations are used instead of the natural mevalonate (MVA) pathway or 1-deoxy-d-xylulose 5-phosphate (DXP) pathways for generating isoprenoid precursors such as isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), and geranyl pyrophosphate (GPP). These pathways have the potential for better carbon and or energy efficiency than native pathways. Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups. Isoprenoid alcohols are key intermediary products for the production of isoprenoid precursors in these novel synthetic metabolic pathways.

### 12 Claims, 86 Drawing Sheets

Specification includes a Sequence Listing.

# (56) **References Cited**

## OTHER PUBLICATIONS

Clomburg, J.M., et al., A Synthetic Biology Approach to Engineer a Functional Reversal of the beta-Oxidation Cycle. ACS Synthetic Biology 1, 541-554 (2012).

Cracan, V., & Banerjee, R. Novel B12-dependent acyl-CoA mutases and their biotechnological potential. Biochemistry 51(31), 6039-6046 (2012).

Dellomonaco, C., et al., Engineered reversal of the beta-oxidation cycle for the synthesis of fuels and chemicals. Nature 476, 355-359 (2011).

Gao, Y., et al., Terpenoid synthase structures: a so far incomplete view of complex catalysis. Natural product reports 29, 1153-1175 (2012).

Haapalainen, A.M., et al., The thiolase superfamily: condensing enzymes with diverse reaction specificities. Trends in Biochemical Sciences 31, 64-71 (2006).

Heath, R.J. & Rock, C.O. The Claisen condensation in biology. Nat. Prod. Rep. 19, 581-596 (2002).

lijima, Y., et al., Characterization of Geraniol Synthase from the Peltate Glands of Sweet Basil. Plant Physiol. 134, 370-379 (2004). Jiang, C., et al., Divergent evolution of the thiolase superfamily and chalcone synthase family. Molecular Phylogenetics and Evolution 49, 691-701 (2008).

Jiang, Y. et al. Multigene Editing in the *Escherichia coli* Genome via the CRISPR-Cas9 System. Appl. Environ. Microbiol. 81, 2506-2514 (2015).

Kim, J., et al., W. 2-Hydroxyisocaproyl-CoA dehydratase and its activator from Clostridium difficile. Febs J. 272, 550-561 (2005).

Kitagawa, M. et al. Complete set of ORF clones of *Escherichia coil* ASKA library (A complete Set of *E. coli* K-12 ORF archive): Unique resources for biological research. DNA Res. 12, 291-299 (2005).

Kuzuyama, T., et al., Structural basis for the promiscuous biosynthetic prenylation of aromatic natural products. Nature 435, 983-987 (2005).

Liu, Y., Yan, Z., Lu, X., Xiao, D. & Jiang, H. Improving the catalytic activity of isopentenyl phosphate kinase through protein coevolution analysis. Scientific Reports 6, 24117 (2016).

Mabanglo, M.F., et al., Mutagenesis of Isopentenyl Phosphate Kinase to Enhance Geranyl Phosphate Kinase Activity. ACS Chem. Biol. 7, 1241-1246 (2012).

Magner, D.B. et al. RecQ Promotes Toxic Recombination in Cells Lacking Recombination Intermediate-Removal Proteins. Mol. Cell 26, 273-286 (2007).

Neidhardt, F.C., Bloch, P.L. & Smith, D.F. Culture medium for enterobacteria J. Bacteriol. 119, 736-747 (1974).

Parasaran, T., & Tarbell, D. S. (1964). Formic Ethylcarbonic Anhydride. The Journal of Organic Chemistry, 29(11): 3422-3423.

Reiling, K.K. et al. Mono and diterpene production in *Escherichia coli*. Biotechnol Bioeng 87 (2004).

Schrader, J. & Bohlmann, J., eds. Biotechnology of Isoprenoids. vol. 149. Springer, (2015).

Studier, F.W. & Moffatt, B.A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189, 113-130 (1986).

Thomason, L.C., Sawitzke, J.A., Li, X., Costantino, N. & Court, D.L. in Current Protocols in Molecular Biology (John Wiley & Sons, Inc., 2001).

Vick, J.E. et al. *Escherichia coli* enoyl-acyl carrier protein reductase (Fabl) supports efficient operation of a functional reversal of the beta-oxidation cycle. Appl. Environ. Microbiol. 81, 1406-1416 (2015).

Vick, J.E. et al. Optimized compatible set of BioBrickTM vectors for metabolic pathway engineering. Appl. Microbiol. Biotechnol. 92, 1275-1286 (2011).

Yazdani, S.S. & Gonzalez, R. Engineering *Escherichia coli* for the efficient conversion of glycerol to ethanol and co-products. Metab. Eng. 10, 340-351 (2008).

European Search Report dated Jul. 30, 2020 in European Application No. 17767472.8.

Fitzpatrick, A.H. et al.: "Farnesol kinase is involved in farnesol metabolism, ABA signaling and flower development in *Arabidopsis*", The Plant Journal, vol. 66, No. 6, Apr. 12, 2011. pp. 1078-1088, ISSN:0960-7412, DOI: 10.1111 /j.1365-313X.2011.04572.x, XP055716443.

Mabanglo M.F. et al.: "Mutagenesis of isopentenyl Phosphate Kinase to Enhance Geranyl Phosphate Kinase Activity", ACS Chemical Biology, vol. 7, No. 7, May 10, 2012, pp. 1241-1246, ISSN: 1554-8929, DOI: 10.1021/ cb300106e, XP055716533.

\* cited by examiner



Continue to FIG. 1B

# Jun. 29, 2021 Sheet 1 of 86

U.S.

Patent





















U.S.













S.D















8



U.S.
























Figure 20



U.S. Patent



Figure 22





Figure 24



Figure 25





Sheet 44 of 86



Figure 28



Figure 29

The invention includes any one or more of the following embodiment(s), in any A genetically engineered microorganism producing prenylated aromatic compounds, said microorganism comprising:

a) at least one overexpressed thiolase able to catalyze a non-decarboxylative Claisen condensation of an acyl-CoA thioester primer and acyl-CoA thioester extender unit,  $\beta$ -reduction enzymes, acyl-CoA mutases and termination pathways to form isoprenoid precursors selected from a group comprising isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate (GPP), or farnesyl pyrophosphate (FPP);

b) at least one overexpressed thiolase able to catalyze the non-decarboxylative Claisen condensation of an acyl-CoA thioester primer and acyl-CoA thioester extender unit,  $\beta$ -reduction enzymes, and termination pathways to form polyketide products;

c) at least one overexpressed aromatic prenyltransferase or 4-hydroxybenzoate grenyltransferase able to catalyze a prenyl transfer of said isoprenoid precursor to said polyketide product to form a prenylated aromatic compound; and,

d) a reduced expression of fermentation enzymes to reduced production of lactate, acetate, ethanol and succinate.

Any microorganism or method herein described, wherein the formation of said isoprenoid precursors comprises:

a) an overexpressed thiolase that catalyzes the non-decarboxylative Claisen condensation between an unsubstituted or functionalized acyl-CoA thioester primer and an unsubstituted or functionalized acyl-CoA thioester extender unit to form a  $\beta$ -keto-acyl-CoA thioester;

b) an overexpressed set of  $\beta$ -reduction enzymes that catalyzes the conversion of said  $\beta$ -keto-acyl-CoA thioester to a  $\beta$ -hydroxyacyl-CoA thioester, a trans-enoyl-CoA thioester, or an acyl-CoA thioester;

c) an overexpressed acyl-CoA mutase that catalyzes the carbon rearrangement of methyl branches on said  $\beta$ -keto-acyl-CoA thioester,  $\beta$ -hydroxy-acyl-CoA thioester, trans-enoyl-CoA thioester, or acyl-CoA thioester;

d) iterations of steps a, b, and c, wherein said iteration is achieved by utilizing the CoA thioesters generated in steps a, b, or c of the previous turn as a primer or an extender unit of step a in the next turn of iteration to elongate the CoA thioester chain by two carbons; and,

e) an overexpressed termination pathway that catalyzes the conversion of said  $\beta$ -keto-acyl-CoA thioester,  $\beta$ -hydroxy-acyl-CoA thioester, trans-enoyl-CoA thioester, or acyl-CoA thioester generated in steps a, b, c, or d into said isoprenoid precursors

Any microorganism or method herein described, wherein the formation of said polyketide products comprises:

a) an overexpressed thiolase that catalyzes the non-decarboxylative Claisen condensation between an acyl-CoA primer with an acyl-CoA thioester extender unit to form a polyketide CoA thioester;

b) iterations of step a, wherein said iteration is achieved by utilizing the polyketide CoA thioester generated in step a of the previous turn as a primer or an extender unit of step b in the next turn of iteration to elongate the polyketide chain by two carbons; and,

c) a termination pathway of the carbon chain elongation, wherein said termination pathway is consisting a CoA thioester removal hydrolysis reaction performed spontaneously or by an overexpressed thioesterase, and subsequent spontaneous reactions for the rearrangement or cycle generation of polyketide product.

Any microorganism or method herein described, wherein said acyl-CoA primer is an acyl-CoA thioester whose omega group is selected from the group consisting of hydrogen, alkyl group, hydroxyl group, carboxyl group, aryl group, halogen, amino group, hydroxyacyl group, carboxyacyl group, aminoacyl group, ketoacyl group, halogenated acyl group, and any other functionalized acyl groups.

Any microorganism or method herein described, wherein said acyl-CoA thioester extender unit is an acyl-CoA thioester whose omega group is selected from the group consisting of hydrogen, alkyl group, hydroxyl group, carboxyl group, aryl group, halogen, amino group, hydroxyacyl group, carboxyacyl group, aminoacyl group, ketoacyl group, halogenated acyl group, and any other functionalized acyl groups.

Any microorganism or method herein described, wherein said  $\beta$ -reduction enzymes are selected from the group consisting of:

a) an overexpressed 3-oxoacyl-[acyl-carrier-protein] reductase or overexpressed 3-hydroxyacyl-CoA dehydrogenase that catalyzes the reduction of a  $\beta$ -ketoacyl-CoA to a  $\beta$ -hydroxyacyl-CoA;

b) an overexpressed 3-hydroxyacyl-[acyl-carrier-protein] dehydratase or an overexpressed enoyl-CoA hydratase or 3-hydroxyacyl-CoA dehydratase that catalyzes the dehydration of a  $\beta$ -hydroxyacyl-CoA to a trans-enoyl-CoA; and,

c) an overexpressed enoyl-[acyl-carrier-protein] reductase or acyl-CoA dehydrogenase or trans-enoyl-CoA reductase that catalyzes the reduction of a transenoyl-CoA to an acyl-CoA.

Any microorganism or method herein described, wherein said termination pathway is selected from the group consisting of:

a) a thioesterase, or an acyl-CoA:acetyl-CoA transferase, or a phosphotransacylase and a carboxylate kinase;

b) an alcohol-forming coenzyme-A thioester reductase, or an aldehyde-forming CoA thioester reductase and an alcohol dehydrogenase;

c) an aldehyde-forming CoA thioester reductase;

d) an aldehyde-forming CoA thioester reductase and an aldehyde decarbonylase;

e) an alcohol dehydratase;

f) an alcohol kinase or an alcohol phosphotransferase; and,

g) an isopentenyl-diphosphate isomerase.

Any microorganism or method herein described, further comprising an overexpressed geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthase catalyzing the head-to-tail or head-to-head condensation of said isoprenoid precursors.

Any microorganism or method herein described, wherein said isoprenoid precursor is geranyl pyrophosphate, said polyketide product is olivetolic acid, and said prenylated aromatic compound is cannabigerolic acid.

The invention includes any one or more of the following embodiment(s), in any A genetically engineered microorganism comprising:

a) an overexpressed thiolase able to catalyze a non-decarboxylative Claisen condensation between an unsubstituted or functionalized acyl-CoA thioester primer and an unsubstituted or functionalized acyl-CoA thioester extender unit to form a  $\beta$ -keto-acyl-CoA thioester;

b) an overexpressed set of  $\beta$ -reduction enzymes able to catalyze the conversion of said  $\beta$ -keto-acyl-CoA thioester to a  $\beta$ -hydroxyacyl-CoA thioester, a trans-enoyl-CoA thioester, or an acyl-CoA thioester;

c) an overexpressed acyl-CoA mutase able to catalyze the carbon rearrangement of methyl branches within said  $\beta$ -keto-acyl-CoA thioester,  $\beta$ -hydroxy-acyl-CoA thioester, trans-enoyl-CoA thioester, or acyl-CoA thioester;

d) iterations of steps a, b, and c, wherein said iteration is achieved by utilizing the CoA thioesters generated in steps a, b, or c of the previous turn as a primer or an extender unit of step a in the next turn of iteration to elongate the CoA thioester chain by two carbons;

e) an overexpressed termination pathway that catalyzes the conversion of said  $\beta$ keto-acyl-CoA thioester,  $\beta$ -hydroxy-acyl-CoA thioester, trans-enoyl-CoA thioester, or acyl-CoA thioester generated in steps a, b, c, or d into a isoprenoid precursor selected from the group comprising isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate (GPP), or farnesyl pyrophosphate

(FPP);
f) an overexpressed prenyl transferase, terpene synthase, or terpene cyclase able to catalyze the conversion of said isoprenoid precursors to desired isoprenoid products; and,

g) reduced expressions of fermentation enzymes leading to reduced production of lactate, acetate, ethanol and succinate.

Any microorganism or method herein described, wherein said acyl-CoA primer is an acyl CoA thioester whose omega group is selected from the group consisting of hydrogen, alkyl group, hydroxyl group, or carboxyl group.

Any microorganism or method herein described, wherein said omega-functionalized CoA thioester extender unit is an acyl CoA thioester whose omega group is selected from the group consisting of hydrogen, alkyl group, or hydroxyl group.

Any microorganism or method herein described, wherein said  $\beta$ -reduction enzymes are selected from the group consisting of:

a) an overexpressed 3-oxoacyl-[acyl-carrier-protein] reductase or overexpressed 3-hydroxyacyl-CoA dehydrogenase that catalyzes the reduction of a  $\beta$ -ketoacyl-CoA to a  $\beta$ -hydroxyacyl-CoA;

b) an overexpressed 3-hydroxyacyl-[acyl-carrier-protein] dehydratase or an overexpressed enoyl-CoA hydratase or 3-hydroxyacyl-CoA dehydratase that catalyzes the dehydration of a  $\beta$ -hydroxyacyl-CoA to a trans-enoyl-CoA; and,

c) an overexpressed enoyl-[acyl-carrier-protein] reductase or acyl-CoA dehydrogenase or trans-enoyl-CoA reductase that catalyzes the reduction of a transenoyl-CoA to an acyl-CoA.

Any microorganism or method herein described, said termination pathway is selected from the group consisting of:

a) a thioesterase, or an acyl-CoA:acetyl-CoA transferase, or a phosphotransacylase and a carboxylate kinase;

b) an alcohol-forming coenzyme-A thioester reductase, or an aldehyde-forming CoA thioester reductase and an alcohol dehydrogenase;

- c) an aldehyde-forming CoA thioester reductase;
- d) an aldehyde-forming CoA thioester reductase and an aldehyde decarbonylase;
- e) an alcohol dehydratase;
- f) an alcohol kinase; and,
- g) an isopentenyl-diphosphate isomerase.

Any microorganism or method herein described, wherein said genetically engineered microorganism produces isoprenoids.

Any microorganism or method herein described, further comprising an overexpressed geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthase catalyzing the head-to-tail or head-to-head condensation of isoprenoid precursors isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate (GPP), or farnesyl pyrophosphate (FPP).

Any microorganism or method herein described, said aromatic prenyltransferase or 4hydroxybenzoate grenyltransferase is encoded by a gene selected from the group consisting of Arabidopsis thaliana ppt1, Lithospermum erythrorhizon pgt-1, Lithospermum erythrorhizon pgt-2, Schizosaccharomyces pombe coq2, Cannabis sativa CsPT1, and other homologs and mutants.

Any microorganism or method herein described, said overexpressed thiolase is encoded by a gene(s) selected from the group consisting of E. coli atoB, E. coli yqeF, E. coli fadA, E. coli fadI, Ralstonia eutropha bktB, Pseudomonas sp. B13 catF, E coli paaJ, Rhodococcus opacus pcaF, Pseudomonas putida pcaF, Streptomyces sp. pcaF, P. putida fadAx, P. putida fadA, Ralstonia eutropha phaA, Acinetobacter sp. ADP1 dcaF, Clostridium acetobutylicum thIA, Clostridium acetobutylicum thIB, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed 3hydroxyacyl-CoA dehydrogenase or 3-oxoacyl-[acyl-carrier-protein] reductase is encoded by a gene(s) selected from the group consisting of E. coli fabG, E. coli fadB, E. coli fadJ, E. coli paaH, P. putida fadB, P. putida fadB2x, Acinetobacter sp. ADP1 dcaH, Ralstonia eutrophus phaB, Clostridium acetobutylicum hbd and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydratase, or 3-hydroxyacyl-[acyl-carrierprotein] dehydratase is encoded by a gene(s) selected from the group consisting of E. coli fabA, E. coli fabZ, E. coli fadB, E. coli fadJ, E. coli paaF, P. putida fadB, P. putida fadB1x, Acinetobacter sp. ADP1 dcaE, Clostridium acetobutylicum crt, Aeromonas caviae phaJ, and other homologs and mutants.

Any microorganism or method herein described, wherein said acyl-CoA dehydrogenase, trans-enoyl-CoA reductase, or enoyl-[acyl-carrier-protein] reductase is encoded by a gene(s) selected from the group consisting of E. coli fadE, E. coli ydiO, Euglena gracilis TER, Treponema denticola TER, Clostridium acetobutylicum TER, E. coli fabI, Enterococcus faecalis fabK, Bacillus subtilis fabL, Vibrio cholerea fabV, and other homologs and mutants.

Any microorganism or method herein described, wherein said acyl-CoA mutase is encoded by a gene(s) selected from the group consisting Streptomyces cinnamonensis icmAB. Metallosphaera sedula Msed\_0638, Msed\_2055, Cupriavidus metallidurans icmF, Kyrpidia tusciae rcmAB, Rhodobacter sphaeroides meaA, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed thioesterase is encoded by a gene(s) selected from the group consisting of E. coli tesA, E. coli tesB, E. coli yciA, E. coli fadM, E. coli ydiI, E. coli ybgC, E. coli paaI, Mus musculus acot8, Alcanivorax borkumensis tesB2, Fibrobacter succinogenes Fs2108, Prevotella ruminicola Pr655, Prevotella ruminicola Pr1687, Lycopersicon hirsutum f glabratum mks2, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed acyl-CoA:acetyl-CoA transferase is encoded by a gene(s) selected from the group consisting of E. coli atoD, Clostridium kluyveri cat2, Clostridium acetobutylicum ctfAB, E. coli ydiF, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed phosphotransacylase is encoded by a gene(s) selected from the group consisting of Clostridium acetobutylicum ptb, Enterococcus faecalis ptb, Salmonella enterica pduL, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed carboxylate kinase is encoded by a gene(s) selected from the group consisting of Clostridium acetobutylicum buk, Enterococcus faecalis buk, Salmonella enterica pduW, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed alcoholforming coenzyme-A thioester reductase is encoded by a gene(s) selected from the group consisting of Clostridium acetobutylicum adhE2, Arabidopsis thaliana At3g11980, Arabidopsis thaliana At3g44560, Arabidopsis thaliana At3g56700, Arabidopsis thaliana At5g22500, Arabidopsis thaliana CER4, Marinobacter aquaeolei VT8 maqu\_2220, Marinobacter aquaeolei VT8 maqu\_2507, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed aldehyde-forming CoA thioester reductase is encoded by a gene(s) selected from the group consisting of Acinetobacter calcoaceticus acr1, Acinetobacter sp Strain M-1 acrM, Clostridium beijerinckii ald, E. coli eutE, Salmonella enterica eutE, E. coli mhpF, and other homologs and mutants.

Any microorganism or method herein described, wherein said overexpressed alcohol dehydrogenase is encoded by a gene(s) selected from the group consisting of E. coli betA, E. coli dkgA, E. coli eutG, E. coli fucO, E. coli ucpA, E. coli yahK, E. coli ybbO, E. coli ybdH, E. coli yiaY, E. coli yjgB, and other homologs and mutants.

Any microorganism or method herein described, wherein said aldehyde decarbonylase is encoded by a gene(s) selected from the group consisting of Synechococcus elongatus PCC7942 orf1593, Nostoc punctiforme PCC73102 npun\_R1711, Prochlorococcus marinus MIT9313 pmt1231, and other homologs and mutants.

Any microorganism or method herein described, wherein said alcohol dehydratase is encoded by a gene(s) selected from the group consisting of Elizabethkingia meningoseptica ohyA, and other homologs and mutants.

Any microorganism or method herein described, wherein said alcohol kinase or alcohol phosphotransferase is encoded by a gene(s) selected from the group consisting of Saccharomyces cerevisiae ERG12, Saccharomyces cerevisiae ERG8, Arabidopsis thaliana At5g58560, E. coli bacA, and other homologs and mutants.

Any microorganism or method herein described, wherein said isopentenyl diphosphate isomerase is encoded by a gene(s) selected from the group consisting of E. coli idi, and other homologs and mutants.

Any microorganism or method herein described, wherein said geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthase is encoded by a gene(s) selected from the group consisting of E. coli ispA, Ips pini GPPS, Abies grandis GPPS2, and other homologs and mutants.

Any microorganism or method herein described, wherein said prenyl transferase, terpene synthase, or terpene cyclase is encoded by a gene selected from carbon lyases (EC 4.2.3.-).

Any microorganism or method herein described, wherein said reduced expressions of fermentation enzymes are  $\triangle$ adhE, ( $\triangle$ pta or  $\triangle$ ackA or  $\triangle$ ackApta),  $\triangle$ poxB,  $\triangle$ ldhA, and  $\triangle$ frdA and less acetate, lactate, ethanol and succinate are thereby produced.

Any microorganism or method herein described, comprising one or more of the following mutations: fadR, atoC(c),  $\Delta$ arcA,  $\Delta$ crp, crp\*.

A genetically engineered microorganism producing prenylated aromatic compounds,			
said microorganism comprising:			
	a) an overexpressed acetolactate synthase catalyzing the conversion of 2 molecules		
	of pyruvate to acetolactate and enzymes converting said acetolactate to		
	isoprenoid precursors isopentenyl pyrophosphate (IPP), dimethylallyl		
	pyrophosphate (DMAPP), or geranyl pyrophosphate (GPP);		
	b) overexpressed thiolase(s) catalyzing the non-decarboxylative Claisen		
	condensation of an acyl-CoA thioester primer and acyl-CoA thioester extender		
	unit, $\beta$ -reduction enzymes, and termination pathways leading to the generation		
	of polyketide products:		
	c) an overexpressed aromatic prenvltransferase or 4-hydroxybenzoate		
	grenvltransferase catalyzing a prenvl transfer from said isoprenoid precursor(s)		
	to said polyketide product(s) forming a prenylated aromatic compound: and.		
	d) optionally comprising reduced expressions of fermentation enzymes leading to		
	reduced production of lactate, acetate, ethanol and succinate		
Ar	iv microorganism or method herein described, wherein the generation of said		
	isoprenoid precursors comprises		
a)	an overexpressed acetolactate synthase that catalyzes conversion of 2 molecules of		
/	pyruvate to acetolactate:		
6	an overexpressed acetohydroxyacid isomeroreductase catalyzing the conversion of		
	said acetolactate to 2 3-dibydroxy-3-methylbutanoate		
$(\mathbf{c})$	an overexpressed dibydroxyacid debydratase catalyzing the conversion of said 2.3-		
	dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutanoate		
1	an overexpressed 2-bydroxyacid debydrogenase catalyzing the conversion of said 3-		
<sup>u</sup> )	methyl_2-oxobutanoate to 3-methyl_2-hydroxybutanoate		
e)	one or more overexpressed enzymes converting said 3-methyl-2-hydroxybutanoate		
•,	to dimethylallyl phosphate, wherein said enzyme(s) is selected from:		
	i) a 2-hydroxyacid dehydratase and a carboxylate kinase.		
	i) an acyl-CoA synthese acyl-CoA transferase or carboxylate kinase and		
	nhosnhotransacylase a 2-hydroxyacyl-CoA debydratase a thioesterase acyl-		
	CoA transferase or phosphotransacylase and carboxylate kinase and a		
	carboxylate kinase.		
	iii) an acyl-CoA synthese acyl-CoA transferase or carboxylate kinase and		
	nhosnhotransacylase a 2-bydroxyacyl-CoA debydratase and a		
	nhosnhotransacylase.		
	iv) an acyl-CoA synthese acyl-CoA transferase or carboxylate kinase and		
	nhosphotransacylase a 2-bydroxyacyl.CoA debydratase an alcohol forming		
	$acvl_CoA$ reductase and an alcohol kinase.		
	y) an acyl-CoA synthese acyl-CoA transferase or carboxylate kinase and		
	nhosphotransacylase a 2-hydroxyacyl. CoA dehydratase an aldehyde forming		
	acyl.CoA reductase an alcohol dehydrogenase and an alcohol kinase		
Ð	an overexpressed phosphate kinese catalyzing the conversion of said dimethylally		
17	phosphate to dimethylallyl pyrophosphate (DMAPP).		
1	an overexpressed isopenterryl diphosphate isoperase catalyzing the conversion of		
<sup>B</sup>	an overexpressed isopenionyl upnosphate to isopentenyl pyrophosphate (IPD); and		
h)	an overexpressed geranyl nyrophosphate to isopentury pyrophosphate (if i), and,		
1 11)	an overexpressed geranyr pyrophosphate synnase cataryzing the conversion of sald		
	onnoniyi anyi pyrophosphate and isopenienyi pyrophosphate to geranyi		
	pyrophosphate (OII),		

	FIGURE 30B-6	
An	y microorganism or method herein described, wherein said generation of polyketide	
	products comprises:	
a)	an overexpressed thiolase that catalyzes the non-decarboxylative Claisen	
	condensation between an acyl-CoA primer with an acyl-CoA thioester extender unit	
	to form a polyketide CoA thioester;	
b)	an overexpressed 3-hydroxyacyl-CoA dehydrogenase or 3-oxoacyl-[acyl-carrier-	
	protein] reductase that catalyzes the reduction of β-keto group of said polyketide	
	CoA thioester to ß-hydroxy group;	
c)	an overexpressed enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydratase, or 3-	
	hydroxyacyl-[acyl-carrier-protein] dehydratase that catalyzes the dehydration of said	
	$\beta$ -keto group formed in step a to form a double bond between the alpha and beta	
	sites of said polyketide CoA thioester;	
d)	an overexpressed acyl-CoA dehydrogenase, trans-enoyl-CoA reductase, or enoyl-	
	[acyl-carrier-protein] reductase that catalyzes the reduction of said double bond	
	formed in step b to a single bond between the alpha and beta sites of said polyketide	
	CoA thioester;	
e)	iterations of reaction a, wherein said iteration is achieved by utilizing the polyketide	
	CoA thioester generated in steps a, b, c, or d of the previous turn as a primer or an	
	extender unit of step a in the next turn of iteration to elongate the polyketide chain	
	by two carbons; and,	
f)	a termination pathway of the carbon chain elongation, wherein said termination	
	pathway is consisting a CoA thioester removal hydrolysis reaction performed	
	spontaneously or by an overexpressed thioesterase, and subsequent spontaneous	
	reactions for the rearrangement or cycle generation of polyketide product.	
A	union on a mathed harrin described wherein said earl CoA minute is an	
AI	y microorganism or method herein described, wherein said acyr-CoA primer is an	
hud	r-CoA thoester whose onlega group is selected from the group consisting of	
aro	inogen, any group, nydroxy group, carboxy group, ary group, harogen, annio	
hal	ageneted acyl group, carboxyacyl group, annioacyl group, ketoacyl group,	
An	u microorganism or method herein described, said acul CoA thioester extender unit	
ie a	n acyl CoA thioaster whose omega group is selected from the group consisting of	
15 a	h acyr-CoA infoesier whose official group is selected from the group consisting of	
nyc	inogen, arkyr group, nydroxyr group, carboxyr group, aryr group, naiogen, annio	
hal	agenated acyl group, carboxyacyl group, annioacyl group, ketoacyl group,	
An	u microorganism or method herein described further comprising an overexpressed	
All	anyl farnesyl or geranylographyl diphosphate synthese catalyzing the head to tail	
ork	anyl-, famesyl- of, geranylgeranyl-uphosphate synthase catalyzing the head-to-tail	
dim	nethylallyl nyrophosphate (DMAPP) geranyl nyrophosphate (GPP) or farnesyl	
nyr	onhosnhate (EPP)	
$\frac{p_{y_1}}{\Delta m}$	v microarganism or method herein described, wherein said isoprenoid presursor is	
ner	anyl pyrophosphate, said polyketide product is olivetolic acid, and said prepulated	
gen	matic compound is cannabigeralic acid	
An	whice compound is cannadige one acid.	
tete	abydrocannabinolic acid synthese, cannabidiolic acid synthese, cannabichromenic	
acid synthese catalyzing the conversion of cannabigerolic acid to		
tetrahydrocannabinolic acid cannabidiolic acid or cannabicbromenic acid		
Any microorganism or method herein described wherein said genetically engineered		
mi	y meroorganism or method herein described, wherein said genericarly eligilitetted	
mic	noorganishi produces teranya veaniaunune avid, camapiduune acid, u	

cannabichromenic acid.

FIGURE 30B-7		
A genetically engineered microorganism comprising:		
a) an overexpressed acetolactate synthase that catalyzes conversion of 2 molecules of pyruvate to acetolactate:		
<ul> <li>b) an overexpressed acetohydroxyacid isomeroreductase catalyzing the conversion of said acetolactate to 2,3-dihydroxy-3-methylbutanoate;</li> </ul>		
c) an overexpressed dihydroxyacid dehydratase catalyzing the conversion of said 2,3- dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutanoate;		
<ul> <li>d) an overexpressed 2-hydroxyacid dehydrogenase catalyzing the conversion of said 3- methyl-2-oxobutanoate to 3-methyl-2-hydroxybutanoate;</li> </ul>		
e) one or more overexpressed enzymes converting said 3-methyl-2-hydroxybutanoate to dimethylallyl phosphate, wherein said enzyme(s) is selected from:		
1) a 2-hydroxyacid dehydratase and a carboxylate kinase;		
ii) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and		
phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, a thioesterase, acyl- CoA transferase, or phosphotransacylase and carboxylate kinase, and a		
carboxylate kinase;		
phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, and a		
phosphotransacylase;		
iv) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and		
acyl-CoA reductase, and an alcohol kinase;		
v) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and		
phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, an aldehyde forming acyl-CoA reductase, an alcohol dehydrogenase, and an alcohol kinase;		
f) an overexpressed phosphate kinase catalyzing the conversion of said dimethylallyl phosphate to dimethylallyl pyrophosphate (DMAPP);		
g) an overexpressed isopentenyl diphosphate isomerase catalyzing the conversion of said dimethylallyl pyrophosphate to isopentenyl pyrophosphate (IPP);		
h) an overexpressed geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthase		
catalyzing the head-to-tail or head-to-head condensation of isoprenoid precursors		
isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl		
pyrophosphate (GPP), or farnesyl pyrophosphate (FPP);		
i) an overexpressed prenyl transferase, terpene synthase, or terpene cyclase catalyzing		
the conversion of said isoprenoid precursors to desired isoprenoid products; and,		
j) reduced expressions of fermentation enzymes leading to reduced production of		
lactate, acetate, ethanol and succinate.		
Any microorganism or method herein described, wherein said genetically engineered microorganism produces isoprenoids.		
Any microorganism or method herein described, wherein said acetolactate synthase is		
encoded by a gene(s) selected from the group consisting of <i>E. coli ilvBN</i> , <i>E. coli ilvIH</i> ,		
and other homologs and mutants.		
Any microorganism or method herein described, wherein said acetohydroxyacid		
isomeroreductase is encoded by a gene(s) selected from the group consisting of E. coli		
<i>ilvC</i> and other homologs and mutants.		
Any microorganism or method herein described, wherein said 2-hydroxyacid		
dehydrogenase is encoded by a gene(s) selected from the group consisting of		
Acidaminococcus fermentans hgdH, Methanocaldococcus jannaschii mdh, M.		
jannaschii comC, E. coli mdh, E. coli serA, E. coli ldhA, Haloferax mediterranei ddh,		
and other homologs and mutants.		

Any microorganism or method herein described, wherein said 2-hydroxyacid dehydratase is encoded by a gene(s) selected from the group consisting of *E. coli fumA*,

FIGURE 30B-8
E. coli fumB, E. coli fumC, and other homologs and mutants.
Any microorganism or method herein described, wherein said carboxylate kinase is encoded by a gene(s) selected from the group consisting of <i>Clostridium acetobutylicum</i> buk Enterococcus facealis buk Salmonalla anterica nduW and other homologs and
mutante
Any microorganism or method herein described, wherein said overexpressed acyl CoA
synthase is encoded by a gene(s) selected from the group consisting of <i>E. coli sucC</i> , <i>E. coli sucD</i> , <i>E. coli paaK</i> , <i>E. coli prpE</i> , <i>E. coli menE</i> , <i>E. coli fadK</i> , <i>E. coli fadD</i> ,
Penicillium chrysogenum phl, Salmonella typhimurium LT2 prpE, Bacillus subtilis
bioW, Cupriavidus basilensis hmfD, Rhodopseudomonas palustris badA, R. palustris hbaA Pseudomonas aeruginosa PAO1 pasA Arabidopsis thaliang 4cl and other
homologs and mutants
Any microorganism or method herein described, wherein said overexpressed acyl-CoA transferase is encoded by a gene(s) selected from the group consisting of <i>E. coli atoD</i> , <i>E. coli scpC</i> , <i>E. coli ydiF</i> , <i>E. coli atoA</i> , <i>E. coli atoD</i> , <i>Clostridium acetobutylicum ctfA</i> , <i>C. acetobutylicum ctfB</i> , <i>Clostridium kluvyeri cat2</i> , <i>C. kluvyeri cat1</i> , <i>P. mutida pcal</i> , <i>P.</i>
putida pca.I. Megasphaera elsdenii pct. Acidaminococcus fermentans gctA.
Acidaminococcus fermentans gctB, Acetobacter aceti aarC, and other homologs and
Any microsuperium on method herein described wherein sold evenenmenesed
phosphotransacylase is encoded by a gene(s) selected from the group consisting of <i>Clostridium acetobutylicum ptb, Enterococcus faecalis ptb, Salmonella enterica pduL</i> , and other homologs and mutants.
Any microorganism or method herein described, wherein said 2-hydroxyacyl-CoA
dehydratase is encoded by a gene(s) selected from the group consisting of
Actuaminococcus jermentans ngaCAB, Closiriatum symotosum ngaCAB,
propionicum lcdCAB, and other homologs and mutants.
Any microorganism or method herein described, wherein said overexpressed
thioesterase is encoded by a gene(s) selected from the group consisting of <i>E. coli tesA</i> , <i>E. coli tesB</i> , <i>E. coli yciA</i> , <i>E. coli fadM</i> , <i>E. coli ydiI</i> , <i>E. coli ybgC</i> , <i>E. coli paaI</i> , <i>Mus</i> <i>musculus acot8</i> , <i>Alcanivorax borkumensis tesB2</i> , <i>Fibrobacter succinogenes Fs2108</i> , <i>Pravatalla ruminicola</i> Pr655, <i>Pravatalla ruminicola</i> Pr1687, <i>Lycoparsicon hirsutum</i> f
alabratum mks? and other homologe and mutante
Any microorganism or method herein described, wherein said overexpressed alcohol-
forming coenzyme-A thioester reductase is encoded by a gene(s) selected from the group consisting of <i>Clostridium acetobutylicum adhE2</i> , <i>Arabidopsis thaliana</i>
At3g11980, Arabidopsis thaliana At3g44560, Arabidopsis thaliana At3g56700,
Arabidopsis thaliana At5g22500, Arabidopsis thaliana CER4, Marinobacter aquaeolei VT8 maqu_2220, Marinobacter aquaeolei VT8 maqu_2507, and other homologs and
mutants.
Any microorganism or method herein described, wherein said overexpressed aldehyde- forming CoA thioester reductase is encoded by a gene(s) selected from the group consisting of <i>Acinetobacter calcoaceticus acrI</i> , <i>Acinetobacter sp Strain M-1 acrM</i> ,
Clostridium beijerinckii ald, E. coli eutE, Salmonella enterica eutE, E. coli mhpF, and
other homologs and mutants.
Any microorganism or method herein described, wherein said overexpressed alcohol
dehydrogenase is encoded by a gene(s) selected from the group consisting of <i>E. coli</i> betA, E. coli dkgA, E. coli eutG, E. coli fucO, E. coli ucpA, E. coli yahK, E. coli ybbO, E. coli vbdH, E. coli viaY, E. coli vigB, and other homologs and mutants.
Any microorganism or method herein described, wherein said alcohol kinase or alcohol phosphotransferase is encoded by a gene(s) selected from the group consisting of

Saccharomyces cerevisiae ERG12, Saccharomyces cerevisiae ERG8, Arabidopsis thaliana At5g58560, Mentha x piperita ipk, Methanocaldococcus jannaschi mvk, Arabidopsis thaliana mvk, E. coli ispE, E. coli glpK, and other homologs and mutants. Any microorganism or method herein described, wherein said phosphate kinase is encoded by a gene(s) selected from the group consisting of *Methanothermobacter* thermautotrophicus MTH 47, Thermoplasma acidophilum Ta0103, Enterococcus faecalis mvaK2, Streptococcus pneumoniae mvaK2, Staphylococcus aureus mvaK2, and other homologs and mutants. Any microorganism or method herein described, wherein said isopentenyl diphosphate isomerase is encoded by a gene(s) selected from the group consisting of E. coli idi, Arabidopsis thaliana IPP1, Arabidopsis thaliana IPP2, Bacillus subtilis idi, Saccharomyces cerevisiae IDI1, Staphylococcus aureus fni, and other homologs and mutants. Any microorganism or method herein described, wherein said geranyl pyrophosphate synthase is encoded by a gene(s) selected from the group consisting of E. coli ispA, Ips pini GPPS, Abies grandis GPPS2, and other homologs and mutants. Any microorganism or method herein described, wherein said overexpressed thiolase is encoded by a gene(s) selected from the group consisting of E. coli atoB, E. coli vqeF, E. coli fadA, E. coli fadI, Ralstonia eutropha bktB, Pseudomonas sp. B13 catF, E coli paaJ, Rhodococcus opacus pcaF, Pseudomonas putida pcaF, Streptomyces sp. pcaF, P. putida fadAx, P. putida fadA, Ralstonia eutropha phaA, Acinetobacter sp. ADP1 dcaF, *Clostridium acetobutylicum thlA, Clostridium acetobutylicum thlB*, and other homologs and mutants. Any microorganism or method herein described, wherein said overexpressed 3hydroxyacyl-CoA dehydrogenase or 3-oxoacyl-[acyl-carrier-protein] reductase is encoded by a gene(s) selected from the group consisting of E. coli fabG, E. coli fadB, E. coli fadJ, E. coli paaH, P. putida fadB, P. putida fadB2x, Acinetobacter sp. ADP1 dcaH, Ralstonia eutrophus phaB, Clostridium acetobutylicum hbd and other homologs and mutants. Any microorganism or method herein described, wherein said overexpressed enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydratase, or 3-hydroxyacyl-[acyl-carrier-protein] dehydratase is encoded by a gene(s) selected from the group consisting of E. coli fabA, E. coli fabZ, E. coli fadB, E. coli fadJ, E. coli paaF, P. putida fadB, P. putida fadB1x, Acinetobacter sp. ADP1 dcaE, Clostridium acetobutylicum crt, Aeromonas caviae phaJ, and other homologs and mutants. Any microorganism or method herein described, wherein said acyl-CoA dehydrogenase, trans-enoyl-CoA reductase, or enoyl-[acyl-carrier-protein] reductase is encoded by a gene(s) selected from the group consisting of E. coli fadE, E. coli vdiO, Euglena gracilis TER, Treponema denticola TER, Clostridium acetobutylicum TER, E. coli fabl, Enterococcus faecalis fabK, Bacillus subtilis fabL, Vibrio cholerea fabV, and other homologs and mutants. Any microorganism or method herein described, wherein said aromatic prenyltransferase or 4-hydroxybenzoate grenyltransferase is encoded by a gene(s) selected from the group consisting of Arabidopsis thaliana ppt1, Lithospermum erythrorhizon pgt-1, Lithospermum erythrorhizon pgt-2, Schizosaccharomyces pombe coq2, Cannabis sativa CsPT1, and other homologs and mutants. Any microorganism or method herein described, wherein said geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthase is encoded by a gene(s) selected from the group consisting of E. coli ispA, Ips pini GPPS, Abies grandis GPPS2, and other homologs and mutants.

Any microorganism or method herein described, wherein said prenyl transferase, terpene synthase, or terpene cyclase is encoded by a gene(s) selected from the group

HOOKE 50B-10			
consisting Arabidopsis thaliana AT3G25820, Picea abies TPS-Lim, Solanum			
lycopersicum MTS2, Lavandula angustifolia LaLINS, Streptomyces exfoliates penA,			
Nostoc punctiforme Npun_R3832, Mentha aquatic linS, Solanum lycopersicum MTS1,			
and other homologs and mutants.			
Any microorganism or method herein described, wherein said reduced expressions of			
fermentation enzymes are $\triangle adhE$ , ( $\triangle pta$ or $\triangle ackA$ or $\triangle ackApta$ ), $\triangle poxB$ , $\triangle ldhA$ , and			
$\Delta fr dA$ and less acetate, lactate, ethanol and succinate are thereby produced.			
Any microorganism or method herein described, comprising one or more of the			
following mutations: $fadR$ , $atoC(c)$ , $\Delta arcA$ , $\Delta crp$ , $crp^*$ .			
A method of producing isoprenoid precursors or products from isoprenoid precursors,			
comprising growing the microorganism of any one of claims 1-38 in a culture medium			
for a time and under conditions to produce isoprenoid precursors or products from			
isoprenoid precursors, and isolating said isoprenoid precursors or products from			
isoprenoid precursors.			
A method of producing dimethylallyl pyrophosphate (DMAPP) and isopentenyl			
pyrophosphate (IPP), or products from said DMAPP and IPP, comprising growing a			
microorganism in a culture medium for a time and under conditions sufficient to			
produce DMAPP and IPP or products from said DMAPP and IPP, and isolating said			
DMAPP and IPP, or products from said DMAPP and IPP, wherein said microorganism			
comprises:			
a) an overexpressed acetolactate synthase that catalyzes conversion of 2 molecules of			
pyruvate to acetolactate:			
b) an overexpressed acetohydroxyacid isomeroreductase catalyzing the conversion of			
said acetolactate to 2.3-dihydroxy-3-methylbutanoate;			
c) an overexpressed dihydroxyacid dehydratase catalyzing the conversion of said 2.3-			
dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutanoate:			
d) an overexpressed 2-hydroxyacid dehydrogenase catalyzing the conversion of said 3-			
methyl-2-oxobutanoate to 3-methyl-2-hydroxybutanoate;			
e) one or more overexpressed enzymes for converting said 3-methyl-2-			
hydroxybutanoate to dimethylallyl phosphate:			
f) an overexpressed phosphate kinase catalyzing the conversion of said dimethylallyl			
phosphate to DMAPP; and			
g) an overexpressed isopentenvl diphosphate isomerase catalyzing the conversion of			
said DMAPP to IPP.			
A method of producing dimethylallyl pyrophosphate (DMAPP) and isopentenyl			
pyrophosphate (IPP), or products from said DMAPP and IPP, comprising growing a			
microorganism in a culture medium for a time and under conditions sufficient to			
produce DMAPP AND IPP or products from said DMAPP and IPP and isolating said			
DMAPP and IPP or products from said DMAPP and IPP wherein said microorganism			
comprises.			
a) an overexpressed acetolactate synthase that catalyzes conversion of 2 molecules of			
nyministe to acetolactate.			
b) an overexpressed acetahydroxyacid isomeroreductase catalyzing the conversion of			
said seatelectate to 2.3 dihydroxy 3 methylbutaneate:			
a) an overexpressed dihydroxy acid dehydratese actalyzing the conversion of said 2.3			
dihudrovu 2. methulhuteneete to 2. methul 2. evoluteneete			
dinydroxy-5-methyloutanoate to 5-methyl-2-oxobutanoate,			
uj an overexpressed 2-nydroxyacid denydrogenase catalyzing the conversion of said 3-			
mcunyi-2-oxooutanoate to 5-methyi-2-nydroxyoutanoate;			
e) one or more overexpressed enzyme(s) for converting said 5-methyl-2-			
nyaroxybutanoate to dimethylallyl phosphate, , wherein said enzyme(s) is selected			
mom:			
1) a 2-hydroxyacid denydratase and a carboxylate kinase;			

ii) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, a thioesterase, acyl-CoA transferase, or phosphotransacylase and carboxylate kinase, and a carboxylate kinase; iii) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, and a phosphotransacylase; iv) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, an alcohol forming acyl-CoA reductase, and an alcohol kinase; v) an acyl-CoA synthase, acyl-CoA transferase, or carboxylate kinase and phosphotransacylase, a 2-hydroxyacyl-CoA dehydratase, an aldehyde forming acyl-CoA reductase, an alcohol dehydrogenase, and an alcohol kinase; f) an overexpressed phosphate kinase catalyzing the conversion of said dimethylallyl phosphate to DMAPP; and, g) an overexpressed isopentenyl diphosphate isomerase catalyzing the conversion of said DMAPP to IPP.

The invention includes any one or more of the following embodiment(s), in any combination(s) thereof:				
A reco	mbinant microorganism producing an isoprenoid precursor(s) or optionally an			
isonrer	anid(s) or a derivative(s) thereof said recombinant microorganism comprising.			
aj	one or more condensation product(s) selected from:			
а)	a a beta-ketoacul-CoA produced by an enzyme-catalyzed non-decarboxylative			
	a. a beta-ketoacyr-cork produced by an enzyme-cataryzed non-accarooxyrative			
	h a hata hataanii Ca A maduaad hu an amuma aataliyad dagarbamilatiya			
	o. a bela-ketbacyi-CoA produced by an enzyme-cataryzed decarboxyranve			
	Claisen concensation of an acyl-CoA plus a beta-carboxylic acyl-CoA;			
	c. an aldol produced by an enzyme-catalyzed aldol condensation of an			
	aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an			
	aldehyde plus a carboxylic acid;			
	d. an acyloin produced by an enzyme-catalyzed non-decarboxylative acyloin			
	condensation of a ketone and an aldehyde, or an aldehyde and a second			
	aldehyde; or			
	e. an acyloin produced by an enzyme-catalyzed decarboxylative acyloin			
	condensation of a ketone and an alpha-keto acid, or an aldehyde and an			
	alpha-keto acid, or an alpha-keto acid and a second alpha-keto acid;			
b)	three (or two, or one) or more enzymes to convert said condensation product(s)			
,	to an isoprenoid alcohol(s), with at least three (or two, or one) of said enzymes			
	selected from an acetohydroxy acid isomeroreductase, an acetoacetate			
	decarboxylate an acyl-CoA dehydrogenase an acyl-CoA reductase an acyl-			
	CoA synthase an acyl-CoA transferase an alcohol dehydratase an alcohol			
	dabudrogangea an aldabuda dagarboyulaga an alpha kato agid dagarboyulaga			
	on alpha kata agid dahudraganaga a garbaudata kiranga a garbaudata raduataga			
	an alpha-keto acid denydrogenase, a carooxylate kinase, a carooxylate reductase,			
	a denydratase, a unydroxyacid denydratase, a dioi denydratase, an enoate			
	nydratase, an enoyl-CoA hydratase, an enoyl-CoA reductase, a glutaconyl-CoA			
	decarboxylase, an hydroxyacid dehydratase, an hydroxyacid dehydrogenase, an			
	hydroxyacyl-CoA dehydratase, an hydroxyacyl-CoA dehydrogenase, an			
	hydroxymethylacyl-CoA synthase, an isomeroreductase, an isopropylmalate			
	dehydrogenase, an isopropylmalate isomerase, an isopropylmalate synthase, a			
	mutase, an omega-oxidation enzyme, a phosphotransacylase, a thioesterase, or a			
	thiolase, where said conversion optionally proceeds through an isoprenoid acyl-			
	CoA;			
c)	one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to			
	an isoprenoid precursor(s); and			
d)	optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to			
	another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof:			

wherein one or more of said enzyme(s) is heterologous.

A recombinant microorganism producing an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said recombinant microorganism comprising; a) one or more condensation product(s) selected from: a. a beta-ketoacyl-CoA produced by an enzyme-catalyzed non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA; b. a beta-ketoacyl-CoA produced by an enzyme-catalyzed decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA; c. an aldol produced by an enzyme-catalyzed aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid; d. an acyloin produced by an enzyme-catalyzed non-decarboxylative acyloin condensation of a ketone and an aldehyde, or an aldehyde and a second aldehyde; or e. an acyloin produced by an enzyme-catalyzed decarboxylative acyloin condensation of a ketone and an alpha-keto acid, or an aldehyde and an alphaketo acid, or an alpha-keto acid and a second alpha-keto acid; b) three (or two, or one) or more enzymes to convert said condensation product(s) to an isoprenoid alcohol(s), with at least one of said enzymes comprising an alcohol forming termination enzyme(s); c) one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to an isoprenoid precursor(s); and d) optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof; wherein one or more of said enzyme(s) is heterologous. A recombinant microorganism comprising one or more enzyme-produced intermediate products selected from 2-acetolactate, 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate. A recombinant microorganism comprising: a) one or more enzyme-produced intermediate products selected from 2-acetolactate, 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate. b) one or more enzyme(s) to convert said intermediate product(s) to an isoprenoid alcohol(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step c), or dimethylallyl phosphate which proceeds directly to step d); c) one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to an isoprenoid precursor(s); and d) optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof: wherein one or more of said enzyme(s) is heterologous.

A recombinant microorganism comprising: a) one or more condensation product(s) selected from: a. a beta-ketoacyl-CoA produced by an enzyme-catalyzed non-decarboxylative Claisen condensation of an acvl-CoA plus a second acvl-CoA; b. a beta-ketoacyl-CoA produced by an enzyme-catalyzed decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA; c. an aldol produced by an enzyme-catalyzed aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid; d. an acyloin produced by an enzyme-catalyzed non-decarboxylative acyloin condensation of a ketone and an aldehyde, or an aldehyde and a second aldehyde; or e. an acyloin produced by an enzyme-catalyzed decarboxylative acyloin condensation of a ketone and an alpha-keto acid, or an aldehvde and an alphaketo acid, or an alpha-keto acid and a second alpha-keto acid; b) one or more enzymes to convert said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate; c) one or more enzyme(s) to convert said intermediate product(s) to an isoprenoid alcohol(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e); d) one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to an isoprenoid precursor(s); and e) optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof: wherein one or more of said enzyme(s) is heterologous. A recombinant microorganism comprising: a) an enzyme-produced isoprenoid alcohol(s); b) one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to an isoprenoid precursor(s); and

c) optionally one or more enzymes to convert said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof.

۸.,			
AI	A recombinant microorganism comprising:		
a)	a thiolase or a ketoacetyl-CoA synthase enzyme catalyzing a condensation of an		
	acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl CoA, each said acyl-CoA		
	selected from acetyl-CoA, glycolyl-CoA, propionyl-CoA, malonyl-CoA, an		
	unsubstituted acyl-CoA, or a functionalized acyl-CoA;		
b)	optionally one or more iteration(s) wherein said beta-ketoacyl CoA is modified		
	using one or more enzymes and then used as an acyl-CoA primer unit for a new		
	condensation iteration of step a);		
c)	three (or two, or one) or more enzyme(s) to convert said beta-ketoacyl CoA to an		
	isoprenoid alcohol, said enzyme(s) comprising a beta-reduction enzyme(s), and an		
	alcohol forming termination enzyme(s);		
d)	one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol(s) to an		
	isoprenoid precursor(s); and		
e)	optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another		
	isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof;		
wh	erein one or more said enzyme(s) is heterologous.		
A	recombinant microorganism comprising:		
a)	an acetolactate synthase enzyme catalyzing a decarboxylative condensation between		
	two pyruvates to form 2-acetolactate;		
b)	an acetohydroxy acid isomeroreductase plus a dihydroxy acid dehydratase to		
-)	convert said 2-acetolactate to 2-oxoisovalerate:		
c)	four (or three, or two, or one) or more enzymes to convert said 2-oxoisovalerate to		
-)	an isoprenoid alcohol(s) with at least four (or three or two or one) of said enzymes		
	selected from an acetohydroxy acid isomeroreductase an acetoacetate		
	decarboxylate an acyl.CoA debydrogenase an acyl.CoA reductase an acyl.CoA		
	supphase an acul CoA transferase an alcohol debudratase an alcohol		
	debudrogenese en eldebude decerboxulace en alpha keto acid decerboxulace en		
	alpha lasta anid dabudtaganaga a anthamilata linaga a anthamilata naduataga a		
	alpha-keto actu denydrogenase, a carboxylate kinase, a carboxylate reductase, a		
	denydratase, a umydroxyacid denydratase, a dior denydratase, an enoaie nydratase,		
	an enoyi-CoA nyaratase, an enoyi-CoA reductase, a giutaconyi-CoA decarboxyiase,		
	an nydroxyacid denydratase, an nydroxyacid denydrogenase, an nydroxyacyi-CoA		
	dehydratase, an hydroxyacyl-CoA dehydrogenase, an hydroxymethylacyl-CoA		
	synthase, an isomeroreductase, an isopropylmalate dehydrogenase, an		
	isopropylmalate isomerase, an isopropylmalate synthase, a mutase, an omega-		
	oxidation enzyme, a phosphotransacylase, a thioesterase, or a thiolase, where said		
	conversion optionally proceeds through an isoprenoid acyl-CoA;		
d)	one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol to an		
	isoprenoid precursor(s); and		
e)	optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another		
	isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof;		
wh	erein one or more said enzyme(s) is heterologous.		

A recombinant microorganism comprising:

- a) an acetolactate synthase enzyme catalyzing a decarboxylative condensation between two pyruvates to form 2-acetolactate;
- b) an acetohydroxy acid isomeroreductase plus a dihydroxy acid dehydratase to convert said 2-acetolactate to 2-oxoisovalerate;
- c) four (or three, or two, or one) or more enzymes to convert said 2-oxoisovalerate to an isoprenoid alcohol(s), with at least one of said enzymes comprising an alcohol forming termination enzyme(s);
- d) one or more phosphorylation enzyme(s) to convert said isoprenoid alcohol to an isoprenoid precursor(s); and
- e) optionally one or more enzyme(s) to convert said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof;
   wherein one or more said enzyme(s) is heterologous.

wherein one or more said enzyme(s) is heterologous.

Any recombinant microorganism or process (or method) herein described, that comprises

- a) a thiolase catalyzing conversion of an acetyl-CoA and a propionyl-CoA to 2methylacetoacetyl-CoA;
- b) a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said 2methylacetoacetyl-CoA to 3-hydroxy-2-methylbutanoyl-CoA;
- c) an enoyl-CoA hydratase catalyzing conversion of said 3-hydroxy-2-methylbutanoyl-CoA to 2-methyl-2-butenoyl-CoA;
- d) a mutase catalyzing conversion of said 2-methyl-2-butenoyl-CoA to 3-methyl-2butenoyl-CoA;
- e) a thiolase catalyzing conversion of said 3-methyl-2-butenoyl-CoA and an acetyl-CoA to 3-oxo-5-methyl-4-hexenoyl-CoA;
- f) a 3-hydroxyacyl-CoA dehydrogenase plus a 3-hydroxyacyl-CoA dehydratase plus an enoyl-CoA reductase catalyzing conversion of said 3-oxo-5-methyl-4-hexenoyl-CoA to 5-methyl-4-hexenoyl-CoA;
- g) a thiolase catalyzing conversion of said 5-methyl-4-hexenoyl-CoA plus a propionyl-CoA to 3-oxo-2,7-dimethyl-6-octenoyl-CoA;
- h) a 3-hydroxyacyl-CoA dehydrogenase plus a 3-hydroxyacyl-CoA dehydratase plus an enoyl-CoA reductase catalyzing conversion of said 3-oxo-2,7-dimethyl-6octenoyl-CoA to 2,7-dimethyl-2,6-octadienoyl-CoA;
- i) a mutase catalyzing conversion of said 2,7-dimethyl-2,6-octadienoyl-CoA to 3,7dimethyl-2,6-octadienoyl-CoA;
- j) one or more enzyme(s) catalyzing conversion of said 3,7-dimethyl-2,6-octadienoyl-CoA to geraniol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase; and
- k) one or more enzyme(s) catalyzing conversion of said geraniol to GPP, said enzyme(s) selected from an alcohol kinase plus a phosphate kinase, or an alcohol diphosphokinase.

Any recombinant microorganism or method herein described, that comprises:

- a) a thiolase catalyzing conversion of a glycolyl-CoA plus a propionyl-CoA to 4hydroxy-3-oxo-2-methylbutanoyl-CoA;
- b) a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said hydroxy-3-oxo-2-methylbutanoyl-CoA to 3,4-dihydroxy-2-methylbutanoyl-CoA;
- c) an enoyl-CoA hydratase 3 catalyzing conversion of said 3,4-dihydroxy-2methylbutanoyl-CoA to 4-hydroxy-2-methyl-2-butenoyl-CoA;
- d) an enoyl-CoA reductase catalyzing conversion of said 4-hydroxy-2-methyl-2butenoyl-CoA to 4-hydroxy-2-methylbutanoyl-CoA;
- e) one or more enzyme(s) catalyzing conversion of said 4-hydroxy-2-methylbutanoyl-CoA to 2-methyl-1,4-butanediol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- f) a dehydratase catalyzing conversion of said 2-methyl-1,4-butanediol to 3-methyl-3buten-1-ol;
- g) one or more enzyme(s) catalyzing conversion of said 3-methyl-3-buten-1-ol to IP or IPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase;
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- h) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said IPP to DMAPP; and
- i) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described, that comprises:

- a) a thiolase catalyzing conversion of a glycolyl-CoA and a propionyl-CoA to 2hydroxy-3-oxopentanoyl-CoA;
- b) a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said 2-hydroxy-3oxopentanoyl-CoA to 2,3-dihydroxypentanoyl-CoA;
- c) an enoyl-CoA hydratase catalyzing conversion of said 2,3-dihydroxypentanoyl-CoA to 2-hydroxy-2-pentenoyl-CoA;
- d) an enoyl-CoA reductase catalyzing conversion of said 2-hydroxy-2-pentenoyl-CoA to 2-hydroxypentanoyl-CoA;
- e) a mutase catalyzing conversion of said 2-hydroxypentanoyl-CoA to 2-hydroxy-3methylbutanoyl-CoA;
- f) a dehydratase catalyzing conversion of said 2-hydroxy-3-methylbutanoyl-CoA to 3methyl-2-butenoyl-CoA;
- g) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to 3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- h) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to DMAP or DMAPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase;
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- i) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- j) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

	FIGURE 30C-8
An	v recombinant microorganism or process herein described that comprises
2 LD	a thislass estaluzing conversion of an acatal CoA and a pronional CoA to 3
aj	oxopentanoyl-CoA;
b)	a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said 3-oxopentanoyl-
	CoA to 3-hydroxypentanoyl-CoA;
c)	a mutase catalyzing conversion of said 3-hydroxypentanoyl-CoA to 3-hydroxy-3-
	methylbutanoyl-CoA;
d)	an enoyl-CoA hydratase catalyzing conversion of said 3-hydroxy-3-methylbutanoyl-
(م	one or more engrand(c) cetaluring conversion of said 3 methyl 2 botanoul CoA to
6)	3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
	a. an alcohol-forming acyl-CoA reductase;
	b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase;
	e – a carboxylate reductase plus an alcohol dehydrogenase plus an
	enzyme(s) selected from an acyl. CoA synthase an acyl. CoA transferace
	a thioesterase or a carboxylate kinase plus a phosphotrapsocylase
Ð	a model and a carboxy and a material a phosphotian sacy as to
ij	DMAP or DMAPP, whorein spid enzyme(s) is selected from:
	a an alashal kinasa:
	a. an alashal kinasa nina a ninasahata kinasay ar
	c an alcohol kindse plus a phosphate kindse, of
e)	optionally an inconstant diphosphota isomerose pathwing conversion of said
g)	DMAPP to IPP; and
h)	optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP
	and IPP to GPP.
An	y recombinant microorganism or process herein described,, that comprises:
a)	a thiolase catalyzing conversion of an acetyl-CoA and a propionyl-CoA to 2-
	methylacetoacetyl-CoA;
b)	a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said 2-
	methylacetoacetyl-CoA to 3-hydroxy-2-methylbutanoyl-CoA;
c)	an enoyl-CoA hydratase catalyzing conversion of said 3-hydroxy-2-methylbutanoyl-
	CoA to 2-methyl-2-butenoyl-CoA;
d)	a mutase catalyzing conversion of said 2-methyl-2-butenoyl-CoA to 3-methyl-2-
$\sim$	one or more approximately actalyzing conversion of said 2 methyl 2 bytanovil CoA to
e)	3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
	a. an alcohol-forming acyl-CoA reductase;
	b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase;
	e – a cathoxylate reductase plus ap alcohol debydrogenase plus ap
	enzyme(c) selected from an acyl. CoA synthese an acyl. CoA transferase
	a thiossteress, or a aerhouselate kinger plus a phosphotropsoulase.
ຄ	a infoesterase, or a carboxylate kinase plus a phosphotransacylase;
1)	Diff D = DMADD = therein and a manual (a) is related from the
	Diviar of Diviarr, wherein said enzyme(s) is selected from:
	a. an alconol kinase;
	o. an alcohol kinase plus a phosphate kinase; or
a)	e. an accurat upprosprokiliase,
g)	optionarry, an isoperateny i uphosphate isomerase catalyzing conversion of said
	DWAFF WIFF, abu

h) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described, that comprises:

- a) a thiolase catalyzing conversion of 2 molecules of acetyl-CoA to acetoacetyl-CoA or a ketoacyl-CoA synthase catalyzing conversion of malonyl-CoA plus acetyl-Co to acetoacetyl-CoA;
- b) a hydroxymethylglutaryl-CoA synthase catalyzing conversion of said acetoacetyl-CoA plus acetyl-CoA to 3-hydroxy-3-methylglutaryl-CoA;
- c) an enoyl-CoA hydratase catalyzing conversion of said 3-hydroxy-3-methylglutaryl-CoA to 3-methylglutaconyl-CoA;
- d) a glutaconyl-CoA decarboxylase catalyzing conversion of said 3-methylglutaconyl-CoA to 3-methyl-2-butenoyl-CoA;
- e) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to 3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- f) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to
  - DMAP or DMAPP, wherein said enzyme(s) is selected from:
    - a. an alcohol kinase;
    - b. an alcohol kinase plus a phosphate kinase; or
    - c. an alcohol diphosphokinase;
- g) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- h) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described, with metabolic pathways that comprise:
a) a thiolase catalyzing conversion of 2 molecules of acetyl-CoA to acetoacetyl-CoA or a ketoacyl-CoA synthase catalyzing conversion of malonyl-CoA plus acetyl-Co to acetoacetyl-CoA;

- b) an acyl-CoA synthase, or an acyl-CoA transferase, or a thioesterase, or a carboxylate kinase plus phosphotransacylase catalyzing conversion of said acetoacetyl-CoA to acetoacetate;
- c) an acetoacetate decarboxylase or a spontaneous reaction catalyzing conversion of said acetoacetate to acetone;
- d) a thiolase or hydroxymethylglutaryl-CoA synthase catalyzing a non-decarboxylative condensation of said acetone and acetyl-CoA to 3-methyl-3-hydroxybutyryl-CoA;
- e) an enoyl-CoA hydratase catalyzing conversion of said 3-methyl-3-hydroxybutyryl-CoA to 3-methyl-2-butenoyl-CoA;

f) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to 3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:

- a. an alcohol-forming acyl-CoA reductase;
- b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
- c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- g) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to
  - DMAP or DMAPP, wherein said enzyme(s) is selected from:
    - a. an alcohol kinase;
    - b. an alcohol kinase plus a phosphate kinase; or
    - c. an alcohol diphosphokinase;
- h) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- i) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.
Any recombinant microorganism or process herein described, that comprises:

- a) an acetolactate synthase catalyzing conversion of 2 molecules of pyruvate to acetolactate;
- b) an acetohydroxyacid isomeroreductase catalyzing conversion of said acetolactate to 2,3-dihydroxy-3-methylbutanoate;
- c) a dihydroxyacid dehydratase catalyzing conversion of said 2,3-dihydroxy-3methylbutanoate to 3-methyl-2-oxobutanoate;
- d) a 2-hydroxyacid dehydrogenase catalyzing conversion of said 3-methyl-2oxobutanoate to 3-methyl-2-hydroxybutanoate;
- e) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-hydroxybutanoate to 3-methyl-2-buten-1-ol, wherein said enzymes(s) is selected from:
  - a. a 2-hydroxyacid dehydratase plus a carboxylate reductase plus an alcohol dehydrogenase;
  - a 2-hydroxyacid dehydratase plus an alcohol forming acyl-CoA reductase plus one or more enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase;
  - c. a 2-hydroxyacid dehydratase plus an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase plus one or more enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase; or
  - d. a 2-hydroxyacyl-CoA dehydratase plus an alcohol forming acyl-CoA reductase plus a diol dehydratase plus an aldehyde forming acyl-CoA reductase plus an acyl-CoA dehydrogenase plus one or more additional enzyme(s) selected from:
    - a. an acyl-CoA synthase;
    - b. an acyl-CoA transferase; or
    - c. a carboxylate kinase plus a phosphotransacylase,

plus one or more additional enzyme(s) selected from:

- a. an alcohol forming acyl-CoA reductase;
- b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
- c. a carboxylate reductase plus an alcohol dehydrogenase plus one or more enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase;
- f) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to DMAP or DMAPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase;
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- g) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- h) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

An	y recombinant microorganism or process herein described, that comprises (FIG 9-7):
a)	an acetolactate synthase catalyzing conversion of 2 molecules of pyruvate to
	acetolactate;
b)	an acetohydroxyacid isomeroreductase catalyzing conversion of said acetolactate to
	2,3-dihydroxy-3-methylbutanoate;
(c)	a dihydroxyacid dehydratase catalyzing conversion of said 2,3-dihydroxy-3-
	methylbutanoate to 3-methyl-2-oxobutanoate;
(d)	an isopropylmalate synthase catalyzing conversion of said 3-methyl-2-oxobutanoate
	to 2-isopropylmalate;
e)	an isopropylmalate isomerase catalyzing conversion of said 2-isopropylmalate to 3-
	isopropylmalate;
f)	an isopropylmalate dehydrogenase catalyzing conversion of said 3-isopropylmalate
	to 4-methyl-2-oxopentanoate;
<b>g</b> )	one or more enzyme(s) catalyzing conversion of said 4-methyl-2-oxopentanoate to
	isovaleryl-CoA, wherein said enzyme(s) is selected from:
	a. an alpha-keto acid dehydrogenase; or
	b. an alpha-keto acid decarboxylase plus an aldehyde forming acyl-CoA
	reductase;
h)	an acyl-CoA dehydrogenase catalyzing conversion of said isovaleryl-CoA to 3-
	methyl-2-butenoyl-CoA;
i)	one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to
	3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
	a. an alcohol-forming acyl-CoA reductase;
	b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase;
	or
	c. a carboxylate reductase plus an alcohol dehydrogenase plus an
	enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase,
	a thioesterase, and a carboxylate kinase plus a phosphotransacylase;
[j)	one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to
	DMAP or DMAPP, wherein said enzyme(s) is selected from:
	a. an alcohol kinase;
	b. an alcohol kinase plus a phosphate kinase; or
	c. an alcohol diphosphokinase;
k)	optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said
	DMAPP to IPP; and
] ])	optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP
	and IPP to GPP.

Any recombinant microorganism or process herein described, that comprises:

- a) a thiolase catalyzing conversion of 2 molecules of acetyl-CoA to acetoacetyl-CoA or a ketoacyl-CoA synthase catalyzing conversion of malonyl-CoA plus acetyl-Co to acetoacetyl-CoA;
- b) a 3-hydroxyacyl-CoA dehydrogenase catalyzing conversion of said acetoacetyl-CoA to 3-hydroxybutyryl-CoA;
- c) an enoyl-CoA hydratase catalyzing conversion of said 3-hydroxybutyryl-CoA to crotonyl-CoA;
- d) an enoyl-CoA reductase catalyzing conversion of said crotonyl-CoA to crotonyl-CoA to butyryl-CoA;
- e) a mutase catalyzing conversion of said butyryl-CoA to isobutyryl-CoA;
- f) an aldehyde forming acyl-CoA reductase catalyzing conversion of said isobutyryl-CoA to isobutanal;
- g) a 2-hydroxyacyl-CoA lyase catalyzing conversion of said isobutanal and formyl-CoA to 3-methyl-2-hydroxybutanoyl-CoA;
- h) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-hydroxybutanoyl-CoA to 3-methyl-2-butenoyl-CoA, wherein said enzyme(s) is selected from:
  - a. a 2-hydroxyacyl-CoA dehydratase; or
  - an aldehyde forming acyl-CoA reductase plus an acyl-CoA dehydrogenase plus a diol dehydratase plus one or more additional enzyme(s) selected from:
    - a. an alcohol forming acyl-CoA reductase;
    - b. an alcohol dehydrogenase; or
    - a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- i) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to 3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- j) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to DMAP or DMAPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase;
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- k) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- 1) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

## Any recombinant microorganism or process herein described, that comprises: a) an aldolase catalyzing conversion of pyruvate and acetaldehyde to 4-hydroxy-2oxopentanoate; b) a mutase catalyzing conversion of said 4-hydroxy-2-oxopentanoate to 3-hydroxy-2oxo-3-methylbutanoate; c) a 2-hydroxyacid dehydrogenase catalyzing conversion of said 3-hydroxy-2-oxo-3methylbutanoate to 2,3-dihydroxy-3-methylbutanoate; d) a dihydroxyacid dehydratase catalyzing conversion of said 2,3-dihydroxy-3methylbutanoate to 3-methyl-2-oxobutanoate; e) a 2-hydroxyacid dehydrogenase catalyzing conversion of said 3-methyl-2oxobutanoate to 3-methyl-2-hydroxybutanoate; f) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-hydroxybutanoate to 3-methyl-2-buten-1-ol, wherein said enzymes(s) is selected from: a. a 2-hydroxyacid dehydratase plus a carboxylate reductase plus an alcohol dehydrogenase; b. a 2-hydroxyacid dehydratase plus an alcohol forming acyl-CoA reductase plus one or more enzyme(s) selected from thioesterase, acyl-CoA synthase, acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase; c. a 2-hydroxyacid dehydratase plus an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase plus one or more enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase; or d. a 2-hydroxyacyl-CoA dehydratase plus an alcohol forming acyl-CoA reductase plus a diol dehydratase plus an aldehyde forming acyl-CoA reductase plus an acyl-CoA dehydrogenase plus one or more additional enzyme(s) selected from: a. an acyl-CoA synthase; b. an acyl-CoA transferase; or c. a carboxylate kinase plus a phosphotransacylase, plus one or more additional enzyme(s) selected from: a. an alcohol forming acyl-CoA reductase; b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or c. a carboxylate reductase plus an alcohol dehydrogenase plus one or more enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase; g) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to DMAP or DMAPP, wherein said enzyme(s) is selected from:

- a. an alcohol kinase;
- b. an alcohol kinase plus a phosphate kinase; or
- c. an alcohol diphosphokinase;
- h) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- i) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described, that comprises:

- a) an aldolase catalyzing conversion of pyruvate and acetaldehyde to 4-hydroxy-2oxopentanoate;
- b) a mutase catalyzing conversion of said 4-hydroxy-2-oxopentanoate to 3-hydroxy-2oxo-3-methylbutanoate;
- c) a 2-hydroxyacid dehydrogenase catalyzing conversion of said 3-hydroxy-2-oxo-3methylbutanoate to 2,3-dihydroxy-3-methylbutanoate;
- d) a dihydroxyacid dehydratase catalyzing conversion of said 2,3-dihydroxy-3methylbutanoate to 3-methyl-2-oxobutanoate;
- e) an isopropylmalate synthase catalyzing conversion of said 3-methyl-2-oxobutanoate to 2-isopropylmalate;
- f) an isopropylmalate isomerase catalyzing conversion of said 2-isopropylmalate to 3isopropylmalate;
- g) an isopropylmalate dehydrogenase catalyzing conversion of said 3-isopropylmalate to 4-methyl-2-oxopentanoate;
- h) one or more enzyme(s) catalyzing conversion of said 4-methyl-2-oxopentanoate to isovaleryl-CoA, wherein said enzyme(s) is selected from:
  - a. an alpha-keto acid dehydrogenase; or
  - b. an alpha-keto acid decarboxylase plus an aldehyde forming acyl-CoA reductase;
- i) an acyl-CoA dehydrogenase catalyzing conversion of said isovaleryl-CoA to 3methyl-2-butenoyl-CoA;
- j) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-butenoyl-CoA to 3-methyl-2-buten-1-ol, wherein said enzyme(s) is selected from:
  - a. an alcohol-forming acyl-CoA reductase;
  - b. an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - c. a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from an acyl-CoA synthase, an acyl-CoA transferase, a thioesterase, or a carboxylate kinase plus a phosphotransacylase;
- k) one or more enzyme(s) catalyzing conversion of said 3-methyl-2-buten-1-ol to DMAP or DMAPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase:
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- 1) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said DMAPP to IPP; and
- m) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described,, that comprises:

- a) an aldolase catalyzing conversion of 2-oxobutanoate and acetaldehyde to 4hydroxy-2-oxo-3-methylpentanoate;
- b) a mutase catalyzing conversion of said 4-hydroxy-2-oxo-3-methylpentanoate to 4hydroxy-2-oxo-4-methylpentanoate;
- c) a 2-oxopent-4-enoate hydratase catalyzing conversion of said 4-hydroxy-2-oxo-4methylpentanoate to 4-methyl-2-oxopent-4-enoate;
- d) one or more enzyme(s) catalyzing conversion of said 4-methyl-2-oxopent-4-enoate to 3-methyl-3-buten-1-ol, wherein said enzymes(s) is selected from:
  - a. an alpha-ketoacid decarboxylase plus an alcohol dehydrogenase;
  - b. an alpha-ketoacid dehydrogenase plus an alcohol forming acyl-CoA reductase;
  - c. an alpha-ketoacid dehydrogenase plus an aldehyde forming acyl-CoA reductase plus an alcohol dehydrogenase; or
  - an alpha-ketoacid dehydrogenase plus a carboxylate reductase plus an alcohol dehydrogenase plus an enzyme(s) selected from a thioesterase, an acyl-CoA synthase, an acyl-CoA transferase, or a carboxylate kinase plus a phosphotransacylase;
- e) one or more enzyme(s) catalyzing conversion of said 3-methyl-3-buten-1-ol to IP or IPP, wherein said enzyme(s) is selected from:
  - a. an alcohol kinase;
  - b. an alcohol kinase plus a phosphate kinase; or
  - c. an alcohol diphosphokinase;
- f) optionally, an isopentenyl diphosphate isomerase catalyzing conversion of said IPP to DMAPP; and
- g) optionally a geranyl pyrophosphate synthase catalyzing conversion of said DMAPP and IPP to GPP.

Any recombinant microorganism or process herein described,, wherein said isoprenoid precursor(s) is selected from dimethylallyl phosphate (DMAP), isopentenyl phosphate (IP), isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), or geranylgeranyl diphosphate (GGPP).

Any recombinant microorganism or process herein described,, comprising one or more enzyme(s) selected from a prenyl transferase, a terpene synthase, or a terpene cyclase catalyzing conversion of said isoprenoid precursor(s) to an isoprenoid(s) or a derivative(s) thereof.

Any recombinant microorganism or process herein described,, wherein said isoprenoid(s) is selected from hemiterpenoid(s), monoterpenoid(s), sesquiterpenoid(s), diterpenoid(s), sesterterpenoid(s), triterpenoid(s), tetraterpenoid(s), polyterpenoid(s), or a derivative(s) thereof.

Any recombinant microorganism or process herein described,, wherein said isoprenoid derivative(s) is a prenylated aromatic compound(s).

Any recombinant microorganism or process herein described,, wherein said isoprenoid derivative(s) is a prenylated aromatic compound(s), said recombinant microorganism comprising:

- a) an aromatic prenyltransferase or a 4-hydroxybenzoate geranyltransferase enzyme catalyzing a prenyl transfer from an isoprenoid precursor(s) to an aromatic polyketide(s) forming a prenylated aromatic compound(s);
- b) a metabolic pathway for the production of an aromatic polyketide(s) or an extracellular source of an aromatic polyketide(s), where optionally said metabolic pathway is a thiolase enzyme(s) catalyzing one or multiple iterative nondecarboxylative condensation(s) of an acyl-CoA and acyl-CoA plus beta-reduction enzyme(s) plus termination pathway enzyme(s); and
- c) optionally one or more enzymes catalyzing conversion of said prenylated aromatic compound(s) to another prenylated aromatic compound(s) or a derivative(s) thereof.
- A recombinant microorganism producing a prenylated aromatic compound(s), said recombinant microorganism comprising:
- a) an aromatic prenyltransferase enzyme catalyzing a prenyl transfer from an isoprenoid precursor(s) to an aromatic polyketide(s) forming a prenylated aromatic compound(s), said enzyme encoded by a gene(s) selected from *Arabidopsis thaliana ppt1*, *Lithospermum erythrorhizon pgt-1*, *Lithospermum erythrorhizon pgt-2*, *Schizosaccharomyces pombe coq2*, *E. coli ubiA*, *Streptomyces sp. strain CL190 nphB*, *Streptomyces sp. CNQ-509 cnqp3*, *Phleum pretense phl p4*, *Streptomyces coelicolor SCO7190*, *Streptomyces Coelicolor SCO7190 or Phleum pretense phl p4*;
- b) a metabolic pathway for the production of an aromatic polyketide(s) or an extracellular source of an aromatic polyketide(s), where optionally said metabolic pathway is a thiolase enzyme(s) catalyzing one or multiple iterative nondecarboxylative condensation(s) of an acyl-CoA and acyl-CoA plus beta-reduction enzyme(s) plus termination pathway enzyme(s); and
- c) optionally one or more enzymes catalyzing conversion of said prenylated aromatic compound(s) to another prenylated aromatic compound(s) or a derivative(s) thereof.
   wherein said enzyme(s) or gene(s) includes its homolog(s).

Any recombinant microorganism or process herein described,, wherein said isoprenoid precursor is GPP, said one or more aromatic polyketide product(s) is selected from olivetolic acid, olivetol, divarinolic acid or divarinol.

Any recombinant microorganism or process herein described,, wherein said isoprenoid derivative(s) is a cannabinoid(s).

Any recombinant microorganism or process herein described,, further comprising one or more enzyme(s) selected from tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, cannabichromenic acid synthase, tetrahydrocannabivarinic acid synthase, cannabidivarinic acid synthase, or cannabichrovarinic acid synthase.

Any recombinant microorganism or process herein described,, wherein said cannabinoid(s) is selected from cannabigerolic acid (CBGA), cannabigerol (CBG), cannabigerovarinic acid (CBGVA), and cannabigerovarin (CBGV),

tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabichromenic acid (CBCA), cannabichromene (CBC), tetrahydrocannabivarinic acid (THCVA), tetrahydrocannabivarin (THCV), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabichrovarinic acid

(CBCVA), cannabichrovarin (CBCV), cannabinolic acid (CBNA), cannabinol (CBN); cannabivarinic acid (CBVA), or cannabivarin (CBV).

Any recombinant microorganism or process herein described,, that comprises one or more enzymes selected from:

- a) a thiolase encoded by a gene(s) selected from *E. coli atoB, E. coli yqeF, E. coli fadA, E. coli fadI, Ralstonia eutropha bktB, Pseudomonas sp. B13 catF, E coli paaJ, Rhodococcus opacus pcaF, Pseudomonas putida pcaF, Streptomyces sp. pcaF, P. putida fadAx, P. putida fadA, Ralstonia eutropha phaA, Acinetobacter sp. ADP1 dcaF, Clostridium acetobutylicum thlA, or Clostridium acetobutylicum thlB;*
- b) an acetolactate synthase or an acyloin condensation enzyme encoded by a gene(s) selected from *E. coli ilvBN, B. subtilis alsS*, or *E. coli ilvIH*;
- c) a 2-hydroxyacyl-CoA lyase encoded by a gene(s) selected from *Homo sapiens* hacl1, Rattus norvegicus hacl1, Dictyostelium discoideum hacl1, or Mus musculus hacl1;
- d) an aldolase encoded by a gene(s) selected from *E. coli mhpE*, *Pseudomonas putida xylK*, or *Pseudomonas* sp. CF600 *dmpG*;
- e) a ketoacyl-CoA synthase encoded by a gene(s) selected from *Gluconobacter* oxydans GOX0115, Pseudomonas aeruginosa fabH2, Streptomyces sp. MMG1121 PRK09352, Streptomyces tendae acs2, Streptomyces sp. strain CL190 nphT7, Physaria fendleri KCS3, Saccharomyces cerevisiae ELO2, Arabidopsis thaliana col KCS1, Arabidopsis thaliana col FAE1, or Arabidopsis thaliana col CER6;
- f) a prenyltransferase or 4-hydroxybenzoate geranyltransferase encoded by a gene(s) selected from Arabidopsis thaliana ppt1, Lithospermum erythrorhizon pgt-1, Lithospermum erythrorhizon pgt-2, Schizosaccharomyces pombe coq2, Cannabis sativa CsPT1, E. coli ubiA, Streptomyces sp. strain CL190 nphB, Streptomyces sp. CNQ-509 cnqp3, Phleum pretense phl p4, Streptomyces Coelicolor SCO7190, Streptomyces Coelicolor SCO7190 or Phleum pretense phl p4;

wherein said enzyme(s) or gene(s) includes its homolog(s).

Any recombinant microorganism or process herein described, that further comprises reduced expression of gene(s) encoding one or more fermentation enzymes leading to reduced production of one or more of lactate, acetate, ethanol or succinate.

Any recombinant microorganism or process herein described, that comprises a homologous chromosomal expression of one or more enzyme(s) selected from an acetolactate synthase, a ketoacyl-CoA synthase, a 2-hydroxyacyl-CoA lyase, an aldolase, an acyloin synthase, an acetohydroxy acid isomeroreductase, an acetoacetate decarboxylate, an acyl-CoA dehydrogenase, an acyl-CoA reductase, an acyl-CoA synthase, an acyl-CoA transferase, an alcohol dehydratase, an alcohol dehydrogenase, an alpha-keto acid decarboxylase, an alpha-keto acid dehydrogenase, a carboxylate kinase, a carboxylate reductase, a dehydratase, a dihydroxyacid dehydratase, a diol dehydratase, an enoyl-CoA hydratase, an enoyl-CoA reductase, a glutaconyl-CoA decarboxylase, an hydroxyacid dehydratase, an hydroxyacid dehydrogenase, an hydroxyacyl-CoA dehydratase, an hydroxyacyl-CoA dehydrogenase, an hydroxymethylacyl-CoA synthase, an isomeroreductase, an isopropylmalate dehydrogenase, an isopropylmalate isomerase, an isopropylmalate synthase, a mutase, a phosphotransacylase, a thioesterase, or a thiolase, an aromatic prenyltransferase, a 4hydroxybenzoate geranyltransferase, an alcohol kinase, a phosphate kinase, or an alcohol diphosphokinase.

Any recombinant microorganism or process herein described, that comprises a recombinant vector expressing one or more enzyme(s) selected from an acetolactate synthase, a ketoacyl-CoA synthase, a 2-hydroxyacyl-CoA lyase, an aldolase, an acyloin synthase, an acetohydroxy acid isomeroreductase, an acetoacetate decarboxylate, an acyl-CoA dehydrogenase, an acyl-CoA reductase, an acyl-CoA synthase, an acyl-CoA transferase, an alcohol dehydratase, an alcohol dehydrogenase, an alpha-keto acid decarboxylase, an alpha-keto acid dehydrogenase, a carboxylate kinase, a carboxylate reductase, a dehydratase, a dihydroxyacid dehydratase, a diol dehydratase, an enoyl-CoA hydratase, an enoyl-CoA reductase, a glutaconyl-CoA decarboxvlase, an hydroxyacid dehydratase, an hydroxyacid dehydrogenase, an hydroxyacyl-CoA dehydratase, an hydroxyacyl-CoA dehydrogenase, an hydroxymethylacyl-CoA synthase, an isomeroreductase, an isopropylmalate dehydrogenase, an isopropylmalate isomerase, an isopropylmalate synthase, a mutase, a phosphotransacylase, a thioesterase, or a thiolase, an aromatic prenyltransferase, a 4-hydroxybenzoate geranyltransferase, an alcohol kinase, a phosphate kinase, or an alcohol diphosphokinase. Any recombinant microorganism or process herein described, wherein said vector is a prokaryotic vector, a viral vector, or a eukaryotic vector. Any recombinant microorganism or process herein described, wherein said vector is an Escherichia coli expression vector. Any recombinant microorganism or process herein described, wherein said recombinant microorganism is a bacteria or yeast cell. Insect, plant, algal and mammalian cells could also be used. Escherichia and Escherichia coli cells are preferred. A method of producing an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said method comprising growing any recombinant microorganism herein described in a culture medium for a time and under conditions to produce an isoprenoid(s), an isoprenoid precursor(s), or a derivative(s) thereof. Any recombinant microorganism or process herein described, wherein said isoprenoid precursor(s), isoprenoid(s), or derivative(s) thereof is isolated from the culture medium or said recombinant microorganism or both. Any recombinant microorganism or process herein described, wherein said isoprenoid derivative(s) is a prenylated aromatic compound(s). Any recombinant microorganism or process herein described, wherein said isoprenoid derivative(s) is a cannabinoid(s).

more enzyme(s).

## FIGURE 30C-20

	indone poor po		
A	A process for the production of an isoprenoid precursor(s), or optionally an		
	isoprenoid(s) or a derivative(s) thereof, said process comprising:		
a)	catalyzing condensation of two compounds to form a condensation product(s)		
	selected from:		
	a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-		
	CoA to form a beta-ketoacyl-CoA;		
	b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic		
	acyl-CoA to form a beta-ketoacyl-CoA;		
	c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second		
	aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;		
	d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an		
	aldehyde plus a second aldehyde to form an acyloin; or		
	e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an		
	aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto		
	acid to form an acyloin;		
b)	catalyzing conversion of said condensation product(s) to an isoprenoid alcohol(s)		
	using three (or two, or one) or more enzymes, with at least three (or two, or one) of		
	said enzymes selected from an acetohydroxy acid isomeroreductase, an acetoacetate		
	decarboxylate, an acyl-CoA dehydrogenase, an acyl-CoA reductase, an acyl-CoA		
	synthase, an acyl-CoA transferase, an alcohol dehydratase, an alcohol		
	dehydrogenase, an aldehyde decarboxylase, an alpha-keto acid decarboxylase, an		
	alpha-keto acid dehydrogenase, a carboxylate kinase, a carboxylate reductase, a		
	dehydratase, a dihydroxyacid dehydratase, a diol dehydratase, an enoate hydratase,		
	an enoyl-CoA hydratase, an enoyl-CoA reductase, a glutaconyl-CoA decarboxylase,		
	an hydroxyacid dehydratase, an hydroxyacid dehydrogenase, an hydroxyacyl-CoA		
	dehydratase, an hydroxyacyl-CoA dehydrogenase, an hydroxymethylacyl-CoA		
	synthase, an isomeroreductase, an isopropyimalate dehydrogenase, an		
	isopropylmalate isomerase, an isopropylmalate synthase, a mutase, an omega-		
	oxidation enzyme, a phosphotransacylase, a thioesterase, or a thiolase, where said		
	conversion optionally proceeds through an isoprenoid acyl-CoA;		
c)	catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s)		
•.	using one or more phosphorylation enzyme(s); and		
d)	optionally catalyzing conversion of said isoprenoid precursor(s) to another		
	isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or		

## FIGURE 30C-21 A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: a) catalyzing condensation of two compounds to form a condensation product(s) selected from: a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl-CoA; b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA; c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol; d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin; b) catalyzing conversion of said condensation product(s) to an isoprenoid alcohol(s) using three (or two, or one) or more enzymes with at least one of said enzyme(s) comprising an alcohol forming termination enzyme(s). c) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and d) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s). A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising one or more enzymeproduced intermediate products selected from 2-acetolactate, 2-hydroxy-isovalerate, 2oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al. geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4methylpentanoate, geraniol, or dimethylallyl phosphate. A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: a) one or more enzyme-produced intermediate products selected from 2-acetolactate, 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutvryl-CoA, 4hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate; b) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step c), or dimethylallyl phosphate which proceeds directly to step d); c) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and d) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).

<ul> <li>isoprenoid(s) or a derivative(s) thereof, said process comprising: <ul> <li>a) catalyzing condensation of two compounds to form a condensation product(s) selected from:</li> <li>a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutryrl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-2-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate product s -methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme(s) threeof, said process comprising:</li> <li>a) one or more enzyme(s) thereof,</li></ul></li></ul>	A process for the production of an isoprenoid precursor(s), or optionally an			
<ul> <li>a) catalyzing condensation of two compounds to form a condensation product(s) selected from:</li> <li>a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldehyde, or an aldehyde plus a carboxylic acid to form an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid precursor(s) to an other isoprenoid precursor(s) or an isoprenoid (s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid geonversion of said isoprenoid alcoh</li></ul>	iso	isoprenoid(s) or a derivative(s) thereof, said process comprising:		
<ul> <li>selected from:</li> <li>a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a acylon condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-coA, 3-methyl-3-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s), or optionally an isoprenoid precursor(s) or an isoprenoid grecursor(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s);</li></ul>	a)	catalyzing condensation of two compounds to form a condensation product(s)		
<ul> <li>a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-hydroxybutyryl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or a misoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme(s) erroriod precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enphosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); an</li></ul>		selected from:		
<ul> <li>CoA to form a beta-ketoacyl-CoA;</li> <li>a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-hydroxybutyryl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-cox-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>datalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s), or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s</li></ul>		a. a non-decarboxylative Claisen condensation of an acyl-CoA plus a second acyl-		
<ul> <li>b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or a misoprenoid (s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid precursor(s), or optionally an isoprenoid (s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isopre</li></ul>		CoA to form a beta-ketoacyl-CoA;		
<ul> <li>acyl-CoA to form a beta-ketoacyl-CoA;</li> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid grecursor(s), or optionally an isoprenoid soft process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid precursor(s) to an</li></ul>		b. a decarboxylative Claisen condensation of an acyl-CoA plus a beta-carboxylic		
<ul> <li>c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohol(s);</li> <li>b) catalyzing conversion of said isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process compr</li></ul>		acyl-CoA to form a beta-ketoacyl-CoA;		
<ul> <li>aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;</li> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s);</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to an other isoprenoid (s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to an other</li> </ul>		c. an aldol condensation of an aldehyde plus a ketone, or an aldehyde plus a second		
<ul> <li>d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid (s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme(s); thereof, said process comprising:</li> <li>a) one or more phosphorylation enzyme(s); to an isoprenoid precursor(s) using one or more enzyme(s).</li> </ul>		aldehyde, or an aldehyde plus a carboxylic acid to form an aldol;		
<ul> <li>aldehyde plus a second aldehyde to form an acyloin; or</li> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s);</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s); and</li> <li>c) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s); and erivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s</li></ul>		d. a non-decarboxylative acyloin condensation of a ketone plus an aldehyde, or an		
<ul> <li>e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-hydroxybutyryl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or a derivative(s) thereof using one or more enzyme(s);</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising;</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s); and</li> <li>c) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohol(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally ca</li></ul>		aldehyde plus a second aldehyde to form an acyloin; or		
<ul> <li>aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s).</li> </ul>		e. a decarboxylative acyloin condensation of a ketone plus an alpha-keto acid, an		
<ul> <li>acid to form an acyloin;</li> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s), sing one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s), and erivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li></ul>		aldehyde plus an alpha-keto acid, or an alpha-keto acid plus a second alpha-keto		
<ul> <li>b) catalyzing conversion of said condensation product(s) to an intermediate product(s) selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s);</li> <li>c) catalyzing conversion of said isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohols(s);</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohols(s) to an other</li> </ul>		acid to form an acyloin;		
<ul> <li>selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an other</li> </ul>	b)	catalyzing conversion of said condensation product(s) to an intermediate product(s)		
<ul> <li>hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methylcotonyl-CoA, 3-methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		selected from 2 hydroxy-isovalerate, 2-oxo-isocaproate, 3-methyl-3-		
<ul> <li>methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl-2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e;</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to an isoprenoid (s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		hydroxybutyryl-CoA, 4-hydroxy-2-methylbutanoyl-CoA, 3-methylcrotonyl-CoA, 3-		
<ul> <li>ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl- 2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid grecursor(s) to another isoprenoid grecursor(s) or an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more enzyme-produced isoprenoid precursor(s), or optionally an isoprenoid grecursor(s) of said isoprenoid alcohol(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s)</li> </ul>		methyl-3-butenoyl-CoA, 3-methyl-2-buten-1-al, geranyl-CoA, 3-methyl-2-buten-1-		
<ul> <li>dimethylallyl phosphate, using one or more enzyme(s);</li> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl- 2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to an other</li> </ul>		ol, 3-methyl-3-buten-1-ol, 4-hydroxy-2-oxo-4-methylpentanoate, geraniol, or		
<ul> <li>c) catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s) using one or more enzyme(s), except in the case of intermediate products 3-methyl- 2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to an other</li> </ul>		dimethylallyl phosphate, using one or more enzyme(s);		
<ul> <li>using one or more enzyme(s), except in the case of intermediate products 3-methyl- 2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>	c)	catalyzing conversion of said intermediate product(s) to an isoprenoid alcohol(s)		
<ul> <li>2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		using one or more enzyme(s), except in the case of intermediate products 3-methyl-		
<ul> <li>directly to step d), or dimethylallyl phosphate which proceeds directly to step e);</li> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		2-buten-1-ol or 3-methyl-3-buten-1-ol which are isoprenoid alcohols and proceed		
<ul> <li>d) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohols(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		directly to step d), or dimethylallyl phosphate which proceeds directly to step e);		
<ul> <li>using one or more phosphorylation enzyme(s); and</li> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: <ul> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul> </li> </ul>	d)	catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s)		
<ul> <li>e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: <ul> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul> </li> </ul>		using one or more phosphorylation enzyme(s); and		
<ul> <li>isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: <ul> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul> </li> </ul>	e)	optionally catalyzing conversion of said isoprenoid precursor(s) to another		
<ul> <li>more enzyme(s).</li> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising: <ul> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul> </li> </ul>		isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or		
<ul> <li>A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>		more enzyme(s).		
<ul> <li>isoprenoid(s) or a derivative(s) thereof, said process comprising:</li> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>	A	process for the production of an isoprenoid precursor(s), or optionally an		
<ul> <li>a) one or more enzyme-produced isoprenoid alcohols(s);</li> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>	iso	prenoid(s) or a derivative(s) thereof, said process comprising:		
<ul> <li>b) catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and</li> <li>c) optionally catalyzing conversion of said isoprenoid precursor(s) to another</li> </ul>	a)	one or more enzyme-produced isoprenoid alcohols(s);		
using one or more phosphorylation enzyme(s); and c) optionally catalyzing conversion of said isoprenoid precursor(s) to another	b)	catalyzing conversion of said isoprenoid alcohol(s) to an isoprenoid precursor(s)		
c) optionally catalyzing conversion of said isoprenoid precursor(s) to another		using one or more phosphorylation enzyme(s); and		
	c)	optionally catalyzing conversion of said isoprenoid precursor(s) to another		
isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or		isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or		
more enzyme(s).		more enzyme(s).		

A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:

- a) catalyzing condensation between an acyl-CoA plus a second acyl-CoA, each said acyl-CoA selected from acetyl-CoA, glycolyl-CoA, propionyl-CoA, malonyl-CoA, an unsubstituted acyl-CoA, or a functionalized acyl-CoA to form a beta-ketoacyl CoA using an enzyme selected from a thiolase or a ketoacetyl-CoA synthase;
- b) optionally one or more iteration(s) wherein said beta-ketoacyl CoA is modified using one or more enzymes and then used as an acyl-CoA primer unit for a new condensation iteration of step a);
- c) catalyzing conversion of said beta-ketoacyl CoA to an isoprenoid alcohol using three (or two, or one) or more enzyme(s) comprising a beta-reduction enzyme(s), and an alcohol forming termination enzyme(s);
- d) catalyzing conversion of said isoprenoid alcohol to an isoprenoid precursor(s) using or more phosphorylation enzyme(s); and
- e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).

A process for the production of an isoprenoid precursor(s), or optionally an isoprenoid(s) or a derivative(s) thereof, said process comprising:

- a) catalyzing condensation of two pyruvates to form 2-acetolactate using acetolactate synthase;
- b) catalyzing conversion of said 2-acetolactate to 2-oxoisovalerate using acetohydroxy acid isomeroreductase plus dihydroxyacid dehydratase;
- c) catalyzing conversion of 2-oxoisovalerate to an isoprenoid alcohol(s) using four (or three, or two, or one) or more enzymes, with at least four (or three, or two, or one) of said enzymes selected from an acetohydroxy acid isomeroreductase, an acetoacetate decarboxylate, an acyl-CoA dehydrogenase, an acyl-CoA reductase, an acyl-CoA synthase, an acyl-CoA transferase, an alcohol dehydratase, an alcohol dehydrogenase, an aldehyde decarboxylase, an alpha-keto acid decarboxylase, an alpha-keto acid dehydrogenase, a carboxylate kinase, a carboxylate reductase, a dehydratase, a dihydroxyacid dehydratase, a diol dehydratase, an enoyl-CoA hydratase, an enoyl-CoA reductase, a glutaconyl-CoA decarboxylase, an hydroxyacid dehydratase, an hydroxyacyl-CoA dehydrogenase, an hydroxyacyl-CoA synthase, an isomeroreductase, an isopropylmalate dehydrogenase, an isopropylmalate isomerase, an isopropylmalate synthase, a mutase, an omegaoxidation enzyme, a phosphotransacylase, a thioesterase, or a thiolase, where said conversion optionally proceeds through an isoprenoid acyl-CoA;
- d) catalyzing conversion of said isoprenoid alcohol to an isoprenoid precursor(s) using one or more phosphorylation enzyme(s); and
- e) optionally catalyzing conversion of said isoprenoid precursor(s) to another isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).

A process for the production of an isoprenoid precursor(s), or optionally an		
isoprenoid(s) or a derivative(s) thereof, said process comprising:		
a) catalyzing condensation of two pyruvates to form 2-acetolactate using acetolactate synthase:		
b) catalyzing conversion of said 2-acetolactate to 2-oxoisovalerate using acetohydroxy		
acid isomeroreductase plus dihydroxyacid dehydratase;		
c) catalyzing conversion of 2-oxoisovalerate to an isoprenoid alcohol(s) using four (or three, or two, or one) or more enzymes with at least one of said enzyme(s)		
comprising an alcohol forming termination enzyme(s);		
d) catalyzing conversion of said isoprenoid alcohol to an isoprenoid precursor(s) using		
one or more phosphorylation enzyme(s); and		
e) optionally catalyzing conversion of said isoprenoid precursor(s) to another		
isoprenoid precursor(s) or an isoprenoid(s) or a derivative(s) thereof using one or more enzyme(s).		
Any method or process herein described, wherein said isoprenoid precursor is selected		
from dimethylallyl phosphate (DMAP), isopentenyl phosphate (IP), isopentenyl		
pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), geranyl pyrophosphate		
(GPP), farnesyl pyrophosphate (FPP), or geranylgeranyl diphosphate (GGPP).		
Any method or process herein described, comprising one or more enzyme(s) selected		
from a prenyl transferase, a terpene synthase, or a terpene cyclase catalyzing conversion		
of said isoprenoid precursor(s) to an isoprenoid(s) and a derivative(s) thereof.		
Any method or process herein described, wherein said isoprenoid(s) is selected from		
hemiterpenoid(s), monoterpenoid(s), sesquiterpenoid(s), diterpenoid(s),		
sesterterpenoid(s), triterpenoid(s), tetraterpenoid(s), polyterpenoid(s), or a derivative(s)		
thereof.		
Any method or process herein described, wherein said isoprenoid derivative(s) is a prenylated aromatic compound.		
Any method or process herein described, wherein:		
a) said isoprenoid derivative(s) is a prenylated aromatic compound(s); and		
b) said process further comprising:		
a. catalyzing a prenyl transfer from an isoprenoid precursor(s) to an aromatic		
polyketide(s) forming a prenylated aromatic compound(s) using an aromatic		
prenyltransferase or a 4-hydroxybenzoate geranyltransferase;		
b. optionally said aromatic polyketide(s) is formed by catalyzing one or multiple		
iterative non-decarboxylative condensation(s) of an acyl-CoA and a second acyl-		
CoA plus beta-reduction enzyme(s) plus termination pathway enzyme(s); and		
c. optionally catalyzing conversion of said prenylated aromatic compound(s) to		
another prenylated aromatic compound(s) or a derivative(s) thereof using one or		
more enzymes.		

A process for the production of a prenylated aromatic compound(s), said process		
comprising:		
a) catalyzing a prenyl transfer from an isoprenoid precursor(s) to an aromatic		
polyketide(s) forming a prenylated aromatic compound(s) using an aromatic		
prenyltransferase enzyme, said enzyme encoded by a gene(s) selected from		
Arabidopsis thaliana ppt1, Lithospermum erythrorhizon pgt-1, Lithospermum		
erythrorhizon pgt-2, Schizosaccharomyces pombe coq2, Cannabis sativa CsPT1, E.		
coli ubiA, Streptomyces sp. strain CL190 nphB, Streptomyces sp. CNQ-509 cnqp3,		
Phleum pretense phl p4, Streptomyces Coelicolor SCO7190, Streptomyces		
Coelicolor SCO7190 or Phleum pretense phl p4;		
b) optionally said aromatic polyketide(s) is formed by catalyzing one or multiple		
iterative non-decarboxylative condensation(s) of an acyl-CoA and a second acyl-		
CoA plus beta-reduction enzyme(s) plus termination pathway enzyme(s); and		
c) optionally catalyzing conversion of said prenylated aromatic compound(s) to		
another prenylated aromatic compound(s) or a derivative(s) thereof using one or		
more enzymes;		
wherein said enzyme(s) or gene(s) includes its homolog(s).		
Any method or process herein described, wherein said isoprenoid derivative(s) is a		
cannabinoid(s).		
Any method or process herein described, wherein said cannabinoid(s) is selected from		
cannabigerolic acid (CBGA), cannabigerol (CBG), cannabigerovarinic acid (CBGVA),		
and cannabigerovarin (CBGV), tetrahydrocannabinolic acid (THCA),		
tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD),		
cannabichromenic acid (CBCA), cannabichromene (CBC), tetrahydrocannabivarinic		
acid (THCVA), tetrahydrocannabivarin (THCV), cannabidivarinic acid (CBDVA),		
cannabidivarin (CBDV), cannabichrovarinic acid (CBCVA), cannabichrovarin (CBCV),		
cannabinolic acid (CBNA), cannabinol (CBN); cannabivarinic acid (CBVA), or		
cannabivarin (CBV).		
Any method or process herein described, wherein each of said enzyme(s) is purified, or		
partially purified, or is contained in a recombinant microorganism producing said		
enzyme(s) or a lysate thereof, or combinations thereof, and wherein said isoprenoid		

precursor(s), isoprenoid(s) or derivative(s) thereof is optionally isolated.

A bacteria comprising  $\Delta fadE \ bktB^{CT5} \ \Delta atoB \ fadB^{CT5} \ \Delta fadA \ egter^{CT5}$  or  $\Delta fadE \ bktB^{CT5}$  $\Delta atoB fadB^{CT5} \Delta fadA egter^{CT5} AccABCD+ or bkdF+ bkdG+ bkdH+ lplA+ lpdA1+$ leuA+ leuB+ or HMGS+ aibA+ aibB+ liuC or HMGS+ aibA+ aibB+ liuC maqu 2507 or atoB<sup>CT5</sup>  $\Delta$ fadB HMGS+ aibAB+ cbjALD+ liuC + or HMGS+ aibAB+ cbjALD+ liuC+ yigB+ or HMGS+ aibAB+ cbjALD+ liuC+ yahK+ or idi+ trGPPS2+ ges+ ychB+ mtipk+ or MK+ HMGS+ HMGR+ or MK+ PMK+ PMD+ HMGS+ HMGR+ or idi+ trGPPS2+ CymR+ CT5+ NphB+ or idi+ trGPPS2+ CymR+ NphB+ or  $\Delta$ glcD bktB+ phaB1+ phaJ+ pct+ tdter+ or fadB2x+ fadB1x+ ydiI+ or idi+ trGPPS2+ ges+ or idi+ trGPPS2+ ges+ ychB+ mtipk or idi+ trGPPS2+ ges+ thaipk+ mtipk+ or bktB+ phaB1+ phaJ+ or pct+ tdter+ or bktB+ or phaB1+ phaJ+ or ilvC+ ilvD+ alsS+ panE+ or bkdF+ bkdG+ bkdH+ lplA+ lpdA1+ or leuABCD+ or HMGS+ or aibAB+ P2-liuC+ or JC01(DE3): MG1655 (DE3)  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA or JST06 (DE3): MG1655 (DE3)  $\Delta ldhA \Delta poxB \Delta pta \Delta adhE \Delta frdA \Delta yciA \Delta ybgC \Delta ydiI \Delta tesA \Delta fadM$  $\Delta$ tesB or JST06 (DE3) atoBCT5: MG1655 (DE3) atoBCT5  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB or JST06 (DE3) atoBCT5  $\Delta$ fadB: MG1655 (DE3) atoBCT5  $\Delta$ fadB  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI ΔtesA ΔfadM ΔtesB or JST10 (DE3): MG1655 (DE3) bktBCT5 ΔatoB fadBCT5 ΔfadA egTERCT5  $\Delta ldhA \Delta poxB \Delta pta \Delta adhE \Delta frdA \Delta yciA \Delta ybgC \Delta ydiI \Delta tesA \Delta fadM \Delta tesB$  $\Delta$ fadE or  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB or atoB<sup>C15</sup>  $\Delta$ IdhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB or atoBCT5  $\Delta$ fadB  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB or bktBCT5  $\Delta$ atoB fadBCT5  $\Delta$ fadA egTERCT5  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$  frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB  $\Delta$ fadE or any of the bacteria descried herein, or any combination(s) thereof or any bacteria with any of the plasmids described herein added thereto.

### SYNTHESIS OF ISOPRENOIDS AND DERIVATIVES

#### PRIOR RELATED APPLICATIONS

This application is a National Phase filing under 35 U.S.C. § 371 of International Application PCT/US2017/022581, filed on Mar. 15, 2017, which claims priority to U.S. Ser. Nos. 62/308,937, titled SYNTHESIS OF ISOPRENOIDS AND DERIVATIVES THROUGH THIOLASE-CATA-<sup>10</sup> LYZED NON-DECARBOXYLATIVE CONDENSATION REACTIONS, and 62/343,598, filed May 31, 2016, titled BIOLOGICAL SYNTHESIS OF ISOPRENOIDS AND PRENYLATED AROMATICS. Each application is incorporated by reference herein in its entirety for all purposes.<sup>15</sup>

#### FIELD OF THE DISCLOSURE

This disclosure generally relates to the use of enzyme combinations or recombinant microorganisms comprising <sup>20</sup> same to make various isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds. Novel enzymes and cells for making cannabinoids and olivoteic acid are also provided.

#### BACKGROUND OF THE DISCLOSURE

The biosynthesis of fatty acids, polyketides, isoprenoids, and many other molecules with applications ranging from biofuels and green chemicals to therapeutic agents, rely on 30 reactions catalyzing the formation of carbon-carbon bonds. Small precursor metabolites serve as building blocks for these pathways, which are subsequently condensed and modified until the desired chain length and functionality are achieved. 35

Isoprenoids represent one of the largest and most diverse classes of these natural products, with more than 40,000 different structures found in all kingdoms of life. These natural products have a wide range of ecological, physiological and structural functions and have been utilized for 40 their very different properties in applications such as medicines, flavors, and fragrances. Furthermore, modern industry has harnessed these compounds as pharmaceuticals, components of personal hygiene and cosmetic products, antimicrobial agents, solvents, and commodity materials such 45 natural rubbers and biofuels.

Despite this high diversity and product functionality, all isoprenoids are formed from the 5-carbon (C<sub>5</sub>) building blocks isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). These two building blocks are 50 formed from one of two native pathways: the mevalonate (MVA) pathway (native to most archaea and eukaryotes) or the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate (DXP/MEP) pathway (native to most bacteria). The MVA pathway utilizes 3 acetyl-CoA molecules 55 for the formation of the  $C_5$  intermediates, while the 3-carbon intermediates pyruvate and glyceraldehyde-3-phosphate serve as the starting point in the DXP pathway. Following the synthesis of IPP and DMAPP through either pathway, these intermediates are condensed and modified by various 60 combinations of for example geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, prenyl transferase, terpene synthases, or terpene cyclases to form thousands of products.

While these native pathways have been exploited for the 65 synthesis of various isoprenoid products, there are limitations in using the native pathways. For example, the syn-

thesis of the required  $C_5$  building blocks from either the MVA or DXP pathway results in the inevitable loss of carbon from the starting intermediates (3 acetyl-CoA molecules or pyruvate and glyceraldehyde-3-phosphate). Furthermore, both the MVA and DXP pathways are energy (ATP) intensive, with the net consumption of 3 ATP equivalents from starting intermediates. Thus, there exists a need for methods to overcome the inherently low carbon and energy efficiency of natural isoprenoid precursor synthesis pathways. Preferably, such pathways would further diversify the range of products, and provide a more carbon and energy efficient route.

#### SUMMARY OF THE DISCLOSURE

This disclosure generally relates to the use of either enzyme combinations or recombinant microbes expressing those enzyme combinations to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds through novel synthetic metabolic pathways instead of the natural mevalonate (MVA) pathway or 1-deoxy-d-xylulose 5-phosphate (DXP) pathways, that can be exploited to achieve better carbon and or energy efficiency than the natural pathways.

Several approaches are described herein. In one approach, the enzymes are made and combined in one or more in vitro reactions to make the desired products. In another approach, recombinant cells are harvested and used as temporary bioreactors containing the enzymes to do all or part of the reactions for as long as the enzymes remain active. In another approach, the cells are lysed and the lysate is used to catalyze the needed reactions. In yet another approach, recombinant cells are used in a growing, living system to continually make products. Combinations of the various approaches can also be used.

Further, there are three basic products types made herein, a) isoprenoid precursors, b) isoprenoids and derivatives thereof including prenylated aromatic compounds, and c) polyketides. Prenylated aromatic compounds are made by condensing isoprenoid precursors and aromatic polyketides, which can be made either by the methods of the invention or can be purchased or made by prior art recombinant synthesis methods.

As described herein, the novel pathways for the synthesis of these products exploit enzymes catalyzing Claisen, aldol, or acyloin condensation reactions for the generation of longer chain length intermediates from central carbon metabolites (FIG. 1). Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors, isoprenoids and derivatives thereof, polyketides, and prenylated aromatic compounds when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups (FIG. 1).

One aspect of the invention is a CoA-dependent elongation platform based on the use of Claisen condensations, which accept functionalized acyl-CoAs as primers and extender units in a reverse beta-oxidation like pathway. Products can be pulled out at any point, and further modified if desired. In other aspects of the invention, aldol or acyloin condensations serve as the starting condensation reaction to enable product synthesis from central carbon metabolites such as pyruvate through various enzyme combinations (FIG. 1) Isoprenoid acyl-CoAs, such as 3-methyl-but-2enoyl-CoA and 3-methyl-but-3-enoyl-CoA, and isoprenoid alcohols, such as prenol and isoprenol, are key pathway intermediates that can be converted to isoprenoid precursors, such as isopentenyl phosphate (IP), dimethylallyl phosphate (DMAP), IPP and DMAPP, through phosphorylation enzymes (FIG. 1). As above, any of the products can be <sup>5</sup> further modified if desired.

In one embodiment, native or engineered thiolases catalyze the condensation between an acyl-CoA primer and another acyl-CoA serving as the extender unit, forming a beta-keto acyl-CoA. FIG. 1 demonstrates the general CoA- 10 dependent elongation platform, which can also utilize decarboxylative Claisen condensation reactions catalyzed by ketoacyl-CoA synthases. Primers and extender units can be omega-functionalized to add required functionalities to the carbon chain. The beta-keto group of the beta-keto acyl-CoA formed via condensation can be reduced and modified step-wise by the beta-reduction reactions catalyzed by dehydrogenase(s), dehydratase(s) and/or reductase(s). Dehydrogenases reduce the beta-keto group of a CoA intermediate synthesized by the condensation(s) to a beta-hydroxy group. 20 Dehydratases catalyze the dehydration of beta-keto group to an alpha, beta double bond. Reductases reduce the alpha, beta double bond to the single bond. Furthermore, various carbon re-arrangement enzymes, such as acyl-CoA mutases, can be employed to modify the carbon structure and branching of the acyl-CoAs. These CoA intermediates can then 25 serve as the primer for the next round of condensation with the extender unit or as direct intermediates to IP, DMAP, IPP, DMAPP, or other isoprenoid precursors. After termination by spontaneous or enzyme-catalyzed CoA removal, reduction, and/or phosphorylation, and subsequent structure re- 30 arrangement, isoprenoids precursors (e.g., IPP, DMAPP, GPP, GGPP, FPP) are produced, and isoprenoids and derivatives thereof can be produced from those. Examples of pathways based on these Claisen condensation reactions are shown in FIGS. 2-6.

In another embodiment, either non-decarboxylative or decarboxylative Claisen condensation is used to form acetoacetyl-CoA as an intermediate. In one such pathway, acetoacetyl-CoA is subsequently converted to 3-hydroxy-3methylglutaryl-CoA, which is then dehydrated and decarboxylated to form the isorenoid acyl-CoA 3-methyl-2butenoyl-CoA (FIG. 7). In another pathway from acetoacetyl-CoA, acetone generated from the decarboxylation of acetoacetic acid is converted to 3-methyl-3-hydroxy-butyryl-CoA through a non-decarboxylative Claisen condensation, which is then dehydrated to form 3-methyl- 45 2-butenoyl-CoA (FIG. 8). 3-methyl-2-butenoyl-CoA can then be converted to prenol through various alcohol forming termination pathways (FIG. 7 and FIG. 8). This 5-carbon isoprenoid alcohol is then converted to DMAPP through a two-step phosphorylation with DMAP as an intermediate, or 50 a one step diphosphorylation catalyzed by an alcohol diphosphokinase. DMAPP can be isomerized into IPP, generating the two required C5 isoprenoid precursors.

Isoprenoid precursors, such as DMAPP, IPP, and GPP, can be condensed and modified by various combinations of geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, prenyl transferase, terpene synthases, or terpene cyclases to form numerous isoprenoid products and derivatives thereof (FIG. **15**). Combining this route for isoprenoid precursor formation for example with a route to aromatic polyketides enables the production of prenylated aromatic compounds through prenyl transfer of hydrocarbon units of isoprenoid intermediates to aromatic polyketides.

Examples of routes to polyketides include those based on thiolase-catalyzed condensation reactions or polyketide synthases. The route to polyketides via condensation and betareduction reactions involves the use of native or engineered thiolases that catalyze the non-decarboxylative condensation

in an iterative manner (i.e. a single or multiple turns of the cycle) between two either unsubstituted or functionalized acyl-CoAs each serving as the primer and the extender unit to generate and elongate polyketide CoA intermediates. Before the next round of thiolase reaction, the beta-keto group of the polyketide chain can be reduced and modified step-wise by dehydrogenase or dehydratase or reductase reactions. Dehydrogenase reaction converts the beta-keto group to beta-hydroxy group. Dehydratase reaction converts beta-hydroxy group to alpha-beta-double-bond. the Reductase reaction converts the alpha-beta-double-bond to a single bond. Spontaneous or enzymatically catalyzed termination reaction(s) terminate the elongation of polyketide chain at any point through CoA removal and spontaneous rearrangement of the structure, generating the final functional polyketide products. This approach is the subject of patent application WO2017020043, BIOSYNTHESIS OF POLYKETIDES, filed Aug. 1, 2016, and 62/198,764, filed Jul. 30, 2015.

Alternatively, polyketide molecules can be formed through polyketide synthases (PKS). This large class of secondary metabolites formed by bacteria, fungi and plant are synthesized through these multi-domain enzymes or enzyme complexes. From a relatively small set of starting and extending molecules, these enzymes are capable of producing a vast array of complex metabolites through combinatorial and iterative carbon-carbon bond formation. Here, PKSs can be exploited for the synthesis of targeted polyketide molecules that can be further combined with isoprenoids and isoprenoid precursors synthesized through various pathways to form different molecules. This includes prenyl transfer of the hydrocarbon moiety of isoprenoid precursors to aromatic polyketides, forming prenylated aromatic compounds.

This disclosure also relates to the use of enzyme combinations or recombinant microbes to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds through acyloin condensation reactions (FIG. 1). Certain examples involve using value biosynthetic enzymes through acetolactate as an intermediate (FIG. 9 and FIG. 10). The pathway begins from a central carbon intermediate, in which two molecules of pyruvate are combined to form acetolactate through decarboxylative acyloin condensation, followed by subsequent isomeroreduction and dehydration to form 3-methyl-2-oxobutanoate. These reactions, catalyzed by acetolactate synthase, aceto-45 hydroxyacid isomeroreductase, and dihydroxyacid dehydratase, respectively, are part of the ubiquitous valine biosynthesis pathway.

Following initial use of this amino acid synthesis pathway for the generation of 3-methyl-2-oxobutanoate, several metabolic routes to isoprenoid precursors can be exploited. One such pathway involves a keto-reduction and combinations of dehydration and phosphorylation, either converting the free acid intermediate or its CoA derivative to prenol (FIG. 9). Alternatively, the addition of 2-carbons to 3-methyl-2-oxobutanoate, followed by subsequent isomerization, and decarboxylation results in the generation of isovaleryl-CoA, which can then be converted to prenol through a series of reactions (FIG. 10). For either pathway, prenol is then converted to DMAPP, which can be isomerized into IPP generating the two required C5 isoprenoid precursors. As with the above pathways, DMAPP and IPP can be condensed and modified by various combinations of geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, prenyl transferase, terpene synthases, or terpene cyclases to form numerous isoprenoid products and derivatives thereof, including prenylated aromatic compounds.

In another embodiment, the non-decarboxylative acyloin condensation of isobutanal and formyl-CoA to 3-methyl-2-

hydroxybutanoyl-CoA catalyzed by 2-hydroxyacyl-CoA lyase is utilized (FIG. 11). Isobutanal is generated through the use of Claisen condensation and beta-reduction reactions, with carbon rearrangement and an aldehyde forming termination pathway. Formyl-CoA can be generated directly 5 from formate or formaldehyde. Following acyloin condensation, 3-methyl-2-hydroxybutanoyl-CoA is converted to prenol through various pathways (FIG. 11). As with the above pathways, prenol is subsequently converted into DMAPP and IPP, which can be condensed and modified by 10 various combinations of geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, prenyl transferase, terpene synthases, or terpene cyclases to form numerous isoprenoid products and derivatives thereof, including prenylated aromatic compounds.

This disclosure also relates to the use of enzyme combinations or recombinant microbes to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds through aldol condensation reactions (FIG. 1). Pathways exploiting this reaction utilize an aldolase catalyzing the aldol condensation of a ketone, aldehyde, or carboxylic acid with an aldehyde to produce an aldol product. Depending on the compounds undergoing aldol condensation, a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups can be utilized for the synthesis of key 25 isoprenoid intermediates including isoprenoid acyl-CoAs, such as 3-methyl-but-2-enoyl-CoA and 3-methyl-but-3enoyl-CoA, and isoprenoid alcohols, such as prenol and isoprenol (FIG. 1). These intermediates are subsequently converted to isoprenoid precursors.

In one embodiment, an aldolase catalyzes the aldol condensation of pyruvate and acetaldehyde forming 4-hydroxy-2-oxopentanoate (FIG. 12 and FIG. 13). Carbon rearrangement catalyzed by a mutase and reduction through the action of a 2-hydroxyacid dehydrogenase converts 4-hydroxy-2-35 oxopentanoate to 2,3-dihydroxy-3-methylbutanoate, an intermediate of the aforementioned value biosythensis pathway. Following dehydration to 3-methyl-2-oxobutanoate, several metabolic routes to isoprenoid precursors can be exploited, including keto-reduction and combinations of dehydration and phosphorylation, either converting the free acid intermediate or its CoA derivative to prenol (FIG. 12). Alternatively, the addition of 2-carbons to 3-methyl-2oxobutanoate, followed by subsequent isomerization, and decarboxylation results in the generation of isovaleryl-CoA, which can then be converted to prenol through a series of 45 reactions (FIG. 13). For either pathway, prenol is then converted to DMAPP, which can be isomerized into IPP generating the two required  $C_5$  isoprenoid precursors.

In another embodiment, an aldolase catalyzes the aldol condensation of 2-oxobutanoate and acetaldehyde forming 50 4-hydroxy-2-oxo-3-methylpentanoate (FIG. 14). Conversion of this intermediate to 4-methyl-2-oxopent-4-enoate, through the action of a mutase and a dehydratase, enables the use of a number of pathways to generate isoprenol from 4-methyl-2-oxopent-4-enoate. This 5-carbon isoprenoid alcohol is then converted to IPP through a two-step phosphorylation with IP as an intermediate, or a one step diphosphorylation catalyzed by an alcohol diphosphokinase. IPP can be isomerized into DMAPP generating the two  $C_5$ isoprenoid precursors. As with the above pathways, IPP and DMAPP can be condensed and modified by various combinations of geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, prenyl transferase, terpene synthases, or terpene cyclases to form numerous isoprenoid products and derivatives thereof, including prenylated aromatic compounds.

The in vivo process involves for example performing traditional fermentations using industrial organisms (for 6

example bacteria or yeast, such as E. coli, B. subtilus, S. cerevisiae, P. pastoris and the like) that convert different feedstocks into isoprenoid precursors, isoprenoids, and derivatives thereof including prenylated aromatic compounds. These organisms are considered workhorses of modern biotechnology. Media preparation, sterilization, inoculum preparation, fermentation and product recovery are some of the main steps of the process.

As an alternative to the in vivo expression of the pathway(s), a cell free, in vitro, version of the pathway(s) can be constructed. By purifying, or partially purifying, the relevant enzyme for each reaction step, the overall pathway can be assembled by combining the necessary enzymes. Alternatively, crude protein extract of cells expressing the pathway(s) can be utilized. With the addition of the relevant cofactors and substrates, the pathway can be assessed for its performance independently of a host. As yet another alternative, whole wet or dried cells can be used as bioreactors.

As used herein, a "primer" is a starting molecule for a Claisen condensation reaction to add one or multiple carbon extender units to a growing acyl-CoA. The reactions can be performed once or can be repeated in a cycle for increased carbon chain length. The typical "initial" or "initiating" primer is either acetyl-CoA or propionyl-CoA, but as the chain grows by adding extender units in each cycle, the primer will accordingly increase in size. In some cases, recombinant microbes or enzyme systems can also be provided with larger primers, e.g, C4 primers, etc. added to the media or obtained from other cell pathways. In this invention, non-traditional primers can also be used in which the primer is functionalized, e.g., the terminal omega carbon has been functionalized (i.e., omega-hydroxylated, omega-carboxylated, etc).

It should be noted that there is a second type of primer used herein, which are the short oligonucleotides used in amplification reactions. These should not be confused with the "primer" used in the carbon chain elongation cycles described herein.

As used herein, the "extender unit" is an acyl-CoA that reacts with the primer in one or more condensations to add carbons on the acyl-CoA primer. In biological systems, the extender unit is typically acetyl-CoA. In this invention, traditional extenders or non-traditional extender units can be used, for example, when the terminal omega carbon has been functionalized (e.g., omega-hydroxylated extender unit, omega-carboxylated extender unit, etc).

Thiolases are ubiquitous enzymes that have key roles in many vital biochemical pathways, including the beta-oxidation pathway of fatty acid degradation and various biosynthetic pathways. Members of the thiolase family can be divided into two broad categories: degradative thiolases (EC 2.3.1.16), and biosynthetic thiolases (EC 2.3.1.9). The forward and reverse reactions are shown below:



These two different types of thiolases are found both in eukaryotes and prokaryotes: for example acetoacetyl-CoA thiolase (EC: 2.3.1.9) and 3-ketoacyl-CoA thiolase (EC: 2.3.1.16). 3-ketoacyl-CoA thiolase (also called thiolase I) has a broad chain-length specificity for its substrates and is involved in degradative pathways such as fatty acid beta-oxidation. Acetoacetyl-CoA thiolase (also called thiolase II) is specific for the thiolysis of acetoacetyl-CoA and is involved in biosynthetic pathways such as poly beta-hydroxybutyric acid synthesis.

The degradative thiolases can be made to run in the forward direction by building up the level of left hand side reactants (primer and extender unit), thus driving the equilibrium in the forward direction and/or by overexpressing same or by expressing a mutant of same.

As used herein, a "thiolase" is an enzyme that catalyzes the condensation of an either unsubstituted or functionalized acyl-CoA as the primer and another either unsubstituted or <sup>15</sup> functionalized acyl-CoA for chain elongation to produce a beta-keto acyl-CoA in a non-decarboxylative condensation reaction:



wherein R1 or R2 throughout are independently an hydro-35 gen, alkyl group, hydroxyl group, carboxyl group, aryl group, halogen, amino group, hydroxyacyl group, carboxyacyl group, aminoacyl group, ketoacyl group, halogenated acyl group, or any other functionalized acyl groups.

As used herein, a "ketoacyl-CoA synthase" is an enzyme 40 that catalyzes the condensation of an either unsubstituted or functionalized acyl-CoA as the primer and either unsubstituted or functionalized beta-carboxylic acyl-CoA for chain elongation to produce a beta-keto acyl-CoA in a decarboxylative condensation reaction:



As used herein, a "hydroxyacyl-CoA dehydrogenase 65 (HACD)" is an enzyme that catalyzes the reduction of a beta-keto acyl-CoA to a beta-hydroxy acyl-CoA:





As used herein, "enoyl-CoA hydratase (ECH)" is an enzyme that catalyzes the dehydration of a beta-hydroxy acyl-CoA to an enoyl-CoA:



As used herein, an "enoyl-CoA reductase (ECR)" is an <sub>30</sub> enzyme that catalyzes the reduction of an enoyl-CoA to an acyl-CoA:



An acyl-CoA

As used herein, the "beta-reduction enzymes" include HACD, ECH and ECR.

As used herein, an "acyloin condensation enzyme" is an enzyme that catalyzes the acyloin condensation of a ketone or aldehyde with either an alpha-ketoacid or an aldehyde to produce an acyloin product:



10





a) Alcohol forming acyl-CoA reductase;

b) Aldehyde forming acyl-CoA reductase plus alcohol dehydrogenase;

c) The transformation of acyl-CoA to a carboxylic acid (for example through a thioesterase, acyl-CoA transferase or phosphotransacylase plus carboxylate kinase), a carboxylic acid reductase plus an alcohol dehydrogenase;

d) Aldehyde forming acyl-CoA reductase, an aldehyde decarboxylase, plus an omega-oxidation enzyme.

As used herein, a "phosphorylation enzyme" refers to one or more enzymes (or genes encoding same) that convert an alcohol to a phosphate or diphosphate. For example, an 15 alcohol kinase, an alcohol kinase plus a phosphate kinase, or an alcohol diphosphokinase.



As used herein, "acetolactate synthase" or "ALS" enzyme (also known as acetohydroxy acid synthase, or AHAS) (EC 2.2.1.6) is a protein found in plants and microorganisms. ALS catalyzes the first step in the synthesis of the branchedchain amino acids (valine, leucine, and isoleucine) through 35 a decarboxylative acyloin condensation between two pyruvate molecules. "Acetohydroxyacid isomeroreductase" or "AHAIR" (EC1.1.1.86) (also known as (ketol-acid reductoisomerase or "KARI") is the second enzyme in the pathway for valine production. "Dihydroxyacid dehydratase" 40 (EC 4.2.1.9) is the third enzyme in the valine pathway. Table E provides a variety of examples of these enzymes.

As used herein, an "aldolase" is an enzyme that catalyzes the aldol condensation of a ketone, aldehyde, or carboxylic acid with an aldehyde to produce an aldol product:



As used herein, a "termination pathway" or "termination enzymes" refers to one or more enzymes (or genes encoding same) that convert a CoA intermediate to a direct product (e.g. acid, alcohol, etc.)

As used herein, an "alcohol forming termination enzyme" 65 refers to one or more enzymes (or genes encoding same) that converts an acyl-CoA to an alcohol, for example:

As used herein, "isoprenoid acyl-CoAs" are a class of intermediate products including 3-methyl-but-2-enoyl-CoA (3-methylcrotonyl-CoA), 3-methyl-but-3-enoyl-CoA, and intermediates with one or more prenyl (3-methyl-but-2-en-1-yl) or isoprenyl (3-methyl-but-3-en-1-yl) units attached to 3-methyl-but-2-enoyl-CoA or 3-methyl-but-3-enoyl-CoA:



As used herein, "isoprenoid alcohols" are a class of intermediate products including 3-methyl-but-2-en-1-ol 55 (prenol), 3-methyl-but-3-en-1-ol (isoprenol), and products with one or more prenyl (3-methyl-but-2-en-1-yl) or isoprenyl (3-methyl-but-3-en-1-yl) units attached to 3-methyl-but-2-en-1-ol or 3-methyl-but-3-en-1-ol:



30

60

15



As used herein, "dimethylallyl pyrophosphate" or "DMAPP" is an intermediate product of both mevalonic acid (MVA) pathway and the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate pathway 10 (DXP/MEP) pathway. It is an isomer of isopentenyl pyrophosphate (IPP) and exists in virtually all life forms.



12

As used herein, "isopentenyl pyrophosphate" or "IPP" is an intermediate product of both mevalonic acid (MVA) pathway and the 2-C-methyl-D-erythritol 4-phosphate/1deoxy-D-xylulose 5-phosphate pathway (DXP/MEP) pathway.



Isopentenyl pyrophosphate isomerase (IPP isomerase) catalyzes the interconversion of the relatively un-reactive IPP and the more-reactive electrophile DMAPP:



As used herein, "geranyl pyrophosphate" or "GPP", also known as geranyl diphosphate (GDP), is an intermediate used by organisms in the biosynthesis of farnesyl pyrophosphate, geranylgeranyl pyrophosphate, cholesterol, terpenes, prenylated aromatic compounds, terpenoids and the like:



IPP and DMAPP are condensed to make GPP:



DMAPP and IPP-also known as "isoprenoid precursors" herein-can be further condensed and modified to make a wide range of products, including prenylated aromatic compounds and terpenoids. "Isoprenoid precursors" also includes isoprenoid monophosphates, such as dimethylallyl 5 phosphate (DMAP) and isopentenyl phosphate (IP), as well as longer chain length intermediates with a hydrocarbon chain bound to a mono- or pyro-phosphate, such as geranyl pyrophophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP) which can be 10 formed through iterative condensation(s) of DMAPP and IPP. The terpenoids-also called "isoprenoids"-are a large and diverse class of naturally occurring organic chemicals derived from five-carbon isoprene units assembled and modified in thousands of ways.

As used herein, a "prenylated aromatic compound" is a derivative of an isoprenoid containing one or more prenyl units (3-methyl-but-2-en-1-yl) attached to a compound containing one or more aromatic group.

As used herein, a "cannabinoid" is a prenylated aromatic 20 compound naturally found in the Cannabis sativa L plant, or a derivative thereof. Over 60 cannabinoids have been identified to date. Many of the more common cannabinoids have either 21 or 22 carbon atoms. Examples of cannabinoids include (CBGA), cannabigerol (CBG), cannabigerovarinic 25 acid (CBGVA), cannabigerovarin (CBGV), tetrahydrocannabinolic acid (THCA), etrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannbichromenic acid (CBCA), cannbichromene (CBC), tetrahydrocannabivarinic acid (THCVA), tetrahydrocan- 30 nabivarin (THCV), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabichrovarinic acid (CBCVA), and cannabichrovarin (CBCV).

As used herein, references to cells or bacteria or strains and all such similar designations include progeny thereof. 35 The use of the singular "cell" does not imply that a single cell is to be used in any method, but includes all progeny produced by growing such cell. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations that have been added 40 originated from the species in question, without regard to to the parent. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

The terms "operably associated" or "operably linked," as 45 used herein, refer to functionally coupled nucleic acid sequences

As used herein "recombinant" or "engineered" is relating to, derived from, or containing genetic material that has been intentionally altered by the action on man.

"Reduced activity" or "inactivation" is defined herein to be at least a 75% reduction in protein activity, as compared with an appropriate control species, usually wild type of that gene. Preferably, at least 80, 85, 90, 95% reduction in activity is attained, and in the most preferred embodiment, 55 the activity is eliminated (100%, aka a "knock-out" or "null" mutants). Proteins can be inactivated with inhibitors, by mutation, or by suppression of expression or translation, and the like. Use of a frame shift mutation, early stop codon, deletions or insertions, gene editing, e.g., with CRISPR/cas9 60 and the like, or point mutations of critical residues, and the like, can completely inactivate (100%) of a gene product by completely preventing transcription and/or translation of the active protein.

"Overexpression" or "overexpressed" is defined herein to 65 be at least 150% of protein activity as compared with an appropriate control species (e.g., wild type of the gene in

14

question), and preferably 200, 500, 1000% or more. Any expression in a host species that otherwise lacks the gene would be overexpression. Overexpression can be achieved by mutating the protein to produce a more active form or a form that is resistant to inhibition, by removing inhibitors, by gene editing, e.g, with CRISPR/cas9 and the like, or adding activators, and the like. Overexpression can also be achieved by removing repressors, adding multiple copies of the gene to the cell, or upregulating the endogenous gene, and the like.

The term "heterologous" as used herein means containing or derived from a polymer of nucleic acids wherein at least one of the following is true: (a) the sequence of nucleic acids is foreign to (i.e., not naturally found in) a given cell; (b) the sequence may be naturally found in a given cell, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not naturally found in the same relationship to each other in a given host. For example, regarding instance (c), a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid. The unrelated genes of part (c) may be either foreign to or naturally found in the recombinant microorganism. A heterologous enzyme is one that is produced by the transcription and translation of heterologous DNA. Overexpression and reduced expression is typically achieved through heterologous DNA

The microbes of the invention are generally made by transforming the host cell with an expression vector encoding one or more of the proteins, but the genes can also be added to the chromosome by recombineering, homologous recombination, and similar techniques. Where the needed protein is endogenous, as is the case in some instances, it may suffice as is, but it is usually overexpressed for better functionality and control over the level of active enzyme. The symbol "@" is used to indicate where a gene is inserted into the genome, otherwise it is placed into the native locus.

The term "endogenous" or "native" means that a gene subspecies or strain, although that gene may be naturally or intentionally mutated, or placed under the control of a promoter that results in overexpression or controlled expression of said gene. Thus, genes from Clostridia would not be endogenous to Escherichia, but a plasmid expressing a gene from E. coli would be considered to be endogenous to any genus of Escherichia, even though it may now be overexpressed. By contrast, a "heterogenous" gene would come from a different species.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims or the specification means one or more than one, unless the context dictates otherwise.

The term "about" means the stated value plus or minus the margin of error of measurement or plus or minus 10% if no method of measurement is indicated.

The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or if the alternatives are mutually exclusive.

The terms "comprise", "have", "include" and "contain" (and their variants) are open-ended linking verbs and allow the addition of other elements when used in a claim.

The phrase "consisting of" is closed, and excludes all additional elements.

The phrase "consisting essentially of" excludes additional material elements, but allows the inclusions of non-material elements that do not substantially change the nature of the

invention, such as instructions for use, buffers, background mutations that do not effect the invention, and the like.

As used herein, reference to the accession number of an enzyme or its gene is intended to include the sequence data incorporated therein, as well as all known homologs linked 5 thereto. Furthermore, reference to any protein by accession number includes all those homologs that catalyze the same reaction, although Km and Kcat can vary. Bacterial homologs preferably have >50% amino acid identity, but mammalian homologs are typically >80%.

In calculating "% identity," the unaligned terminal portions of the query sequence are not included in the calculation. The identity is calculated over the entire length of the reference sequence, thus short local alignments with a query sequence are not relevant (e.g., % identity=number of 15 aligned residues in the query sequence/length of reference sequence). Alignments are performed using BLAST homology alignment as described by Tatusova T A & Madden T L (1999) FEMS Microbiol. Lett. 174:247-250. The default parameters were used, except the filters were turned OFF. As 20 of Jan. 1, 2001 the default parameters were as follows: BLASTN or BLASTP as appropriate; Matrix=none for BLASTN, BLOSUM62 for BLASTP; G Cost to open gap default=5 for nucleotides, 1 1 for proteins; E Cost to extend gap [Integer] default=2 for nucleotides, 1 for proteins; q 25 Penalty for nucleotide mismatch [Integer] default=-3; r reward for nucleotide match [Integer] default=1; e expect value [Real] default=10; W word size [Integer] default=1 1 for nucleotides, 3 for proteins; y Dropoff (X) for blast extensions in bits (default if zero) default=20 for blastn, 7 for other programs; X dropoff value for gapped alignment (in bits) 30 for blastn, 15 for other programs; Z final X dropoff value for gapped alignment (in bits) 50 for blastn, 25 for other programs. This program is available online at NCBI™ (ncbi.nlm.nih.gov/BLAST/).

This summary is provided to introduce a selection of concepts that are further described below in the detailed description. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used as an aid in limiting the scope of the 40 claimed subject matter.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-B: Synthesis of isoprenoid precursors, isopre- 45 noids and derivatives thereof, and prenylated aromatic compounds using Claisen, aldol, or acyloin condensation reactions. Thiolases catalyze the non-decarboxylative condensation between an acyl-CoA, serving as the primer, and another acyl-CoA, serving as the extender unit, forming 50 beta-keto acyl-CoA. Ketoacyl-CoA synthases catalyze the decarboxylative condensation between acyl-CoA and a betacarboxylic acyl-CoA to form a beta-ketoacyl-CoA forming a beta-keto acyl-CoA. Aldolases or 2-hydroxyacyl-CoA lyases catalyze the aldol condensation of an aldehyde and a 55 ketone, or an aldehyde and a second aldehyde, or an aldehyde and a carboxylic acid to form an aldol. Acyloin synthases or acetolactate synthase catalyze the non-decarboxylative acyloin condensation of a ketone and an aldehyde, or an aldehyde and a second aldehyde, or the decar- 60 boxylative acyloin condensation of a ketone and an alphaketo acid, an aldehyde and an alpha keto acid, or an alpha-keto acid and a second alpha-keto acid to form an acyloin. Following condensation of starting compounds to initiate a given pathway, a variety of metabolic pathways 65 and enzymes (dotted lines or multiple arrows) for carbon rearrangement and the addition/removal of functional

groups can be utilized for the synthesis of key isoprenoid intermediates including isoprenoid acyl-CoAs, such as 3-methyl-but-2-enoyl-CoA and 3-methyl-but-3-enoyl-CoA, and isoprenoid alcohols, such as prenol and isoprenol. Isoprenoid alcohols are then converted to isoprenoid precursors such as DMAPP, IPP, and GPP. Prenylated aromatic compounds are formed from the prenyl transfer of the hydrocarbon units of isoprenoid precursors to aromatic polyketides. Isoprenoids and derivatives thereof can be formed from the isoprenoid precursors via prenyl transferase, terpene synthase, or terpene cyclases.

FIG. 2A-B: Generation of isoprenoid precursor GPP through non-decarboxylative condensations, beta-reductions, acyl-CoA mutases, and termination pathways starting with acetyl-CoA as the primer and propionyl-CoA as the extender unit.

FIG. 3A-B: Generation of isoprenoid precursors IPP, DMAPP, and GPP through non-decarboxylative condensation, beta-reductions, and termination pathways starting with glycolyl-CoA as the primer and propionyl-CoA as the extender unit.

FIG. 4A-B: Generation of isoprenoid precursors IPP, DMAPP and GPP through non-decarboxylative condensation, beta-reductions, acyl-CoA mutase, and termination pathways starting with propionyl-CoA as the primer and glycolyl-CoA as the extender unit.

FIG. 5A-B: Generation of isoprenoid precursors IPP, DMAPP and GPP through non-decarboxylative condensations, beta-reductions, acyl-CoA mutase, and termination pathways starting with propionyl-CoA as the primer and acetyl-CoA as the extender unit.

FIG. 6A-B: Generation of isoprenoid precursors IPP, DMAPP and GPP through non-decarboxylative condensation, beta-reductions, acyl-CoA mutase, and termination 35 pathways starting with acetyl-CoA as the primer and propionyl-CoA as the extender unit.

FIG. 7A-B: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the central carbon intermediate acetyl-CoA through decarboxylative or nondecarboxylative Claisen condensation. Conversion of 2 acetyl-CoA or an acetyl-CoA and a malonyl-CoA to acetoacetyl-CoA initiates the pathway, which then proceeds through 3-hydroxy-3-methylglutaryl-CoA as an intermediate. Exemplary enzymes for each step shown in Table C.

FIG. 8A-B: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the central carbon intermediate acetyl-CoA CoA through decarboxylative or non-decarboxylative Claisen condensation. Conversion of 2 acetyl-CoA or an acetyl-CoA and a malonyl-CoA to acetoacetyl-CoA initiates the pathway, which proceeds through 3-hydroxy-3-methylbutyryl-CoA as an intermediate. Exemplary enzymes for each step shown in Table D.

FIG. 9A-B: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the acyloin condensation of the central carbon intermediate pyruvate. Conversion of 2 pyruvate to acetolactate initiates the pathway, which proceeds through 2-hydroxyisovalerate as an intermediate. Exemplary enzymes for each step shown in Table E.

FIG. 10A-B: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the acyloin condensation of the central carbon intermediate pyruvate. Conversion of 2 pyruvate to acetolactate initiates the pathway, which proceeds through 2-isopropylmalate as an intermediate. Exemplary enzymes for each step shown in Table F.

FIG. 11A-C: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the non-decarboxylative acyloin condensation of isobutanol and formyl-CoA. Exemplary enzymes for each step shown in Table G.

FIG. 12A-B: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the aldol condensation of acetaldehyde and pyruvate. Condensation to 4-hy- 5 droxy-2-oxopentanote initiates the pathway, which proceeds through 2-hydroxyisovalerate as an intermediate. Exemplary enzymes for each step shown in Table H.

FIG. 13A-C: Pathways for the synthesis of isoprenoid precursors IPP, DMAPP and GPP from the aldol condensa- 10 tion of acetaldehyde and pyruvate. Condensation to 4-hydroxy-2-oxopentanote initiates the pathway, which proceeds through 2-isopropylmalate as an intermediate. Exemplary enzymes for each step shown in Table I.

FIG. 14A-B: Pathways for the synthesis of isoprenoid 15 precursors IPP, DMAPP and GPP from the aldol condensation of acetaldehyde and 2-oxobutanoate. Exemplary enzymes for each step shown in Table J.

FIG. 15: Pathways for the synthesis of isoprenoids from isoprenoid precursors such as DMAPP, IPP, GPP, and FPP. 20 comparison to olivetolic acid standard. Generation of isoprenoid precursors through described routes can be combined with various isoprenoid forming enzymes such as prenyl transferases, terpene synthases, or terpene cyclases to synthesize isoprenoids and derivatives thereof. Exemplary enzymes for each step shown in Table K. 25

FIG. 16: Pathways for the synthesis of polyketides, olivetolic acid and olivetol, through thiolases-catalyzed nondecarboxylative condensations, beta-reductions, and termination pathways.

FIG. 17: Synthesis of prenylated aromatic compound 30 cannabigerolic acid through olivetolic acid prenylation with the hydrocarbon unit of geranyl pyrophosphate. Geranyl pyrophosphate generated through various example routes as shown in FIG. 2-14, or through native pathways such as MVA or DXP pathway or commercial sources. Olivetolic 35 acid generated through thiolases-catalyzed non-decarboxylative condensations, beta-reductions, and termination pathways, with examples shown in FIG. 16 or through alternative pathways or from commercial sources. Exemplary enzymes prenyl transfer step shown in Table L. 40

FIG. 18: Titers of tiglic acid of JST06(DE3) strain overexpressing thiolase FadAx, hydroxyacyl-CoA dehydrogenase FadB2x and enoyl-CoA hydratase FadB1x along with acyl-CoA transferase Pct with or without thioesterase YdiI in shake flasks or bioreactor.

FIG. 19: Total ion GC-MS chromatogram showing peak of synthesized 2,3-dihydroxybutyric acid synthesized by MG1655(DE3) ΔglcD pET-P1-bktB-phaB1-P2-phaJ pCDF-P1-pct-P2-tdter.

FIG. 20: Results of in vitro enzymatic assays of acyl-CoA 50 transferases Pct and Pct540 on different substrates.

FIG. 21: 2-hydroxyisovaleric acid titer of JST06(DE3) expressing alsS, ilvC, ilvD and panE when grown on various carbon sources.

FIG. 22: Absorbance at 340 nm of in vitro assay samples 55 and controls on dehydration of ethylene glycol to acetaldehyde by PddABC, coupled with actaldehyde oxidization to acetyl-CoA by Lmo1179. Red: control without B12 coenzyme; B;ue: control without cell lysates; Green: reaction sample with lyate and B12 coenzyme.

FIG. 23: Butyric acid production of JC01 strain overexpressing AtoB, FadB and EgTer in combination with overexpression of different thioesterase through pZS vector.

FIG. 24: in vitro characterization of HACL1. Top left, the result of assay on degradation of 2-hydroxyhexadecaonyl- 65 CoA to formyl-CoA and pentadecanal; Top right, the result of assay on acyloin condensation of pentadecanal and

formyl-CoA to 2-hydroxyhexadecanoyl-CoA, which is hydrolyzed to 2-hydroxyhexadecanoic acid; Down left: the result of assay on acyloin condensation between formyl-CoA and acetaldehyde to lactyl-CoA, which is hydrolyzed to lactate; Down right, the result of assay on acyloin condensation between formaldehyde and formyl-CoA to glycolyl-CoA, which is hydrolyzed to glycolate.

FIG. 25: NADH oxidization of samples and controls of in vitro formate activation assay by E. coli acyl-CoA synthase ACS (EcAcs) coupled by Listeria monocytogenes acyl-CoA reductase Lmo1179 (LmACR).

FIG. 26: Prenol production in E. coli through the pathway via HMG-CoA with usage of different acyl-CoA reductases and alcohol dehydrogenase and different number of vectors.

FIG. 27: Geraniol production of E. coli strains harboring novel GPP synthesis pathway via HMG-CoA and prenol with usage of acyl-CoA reductases AdhE2 or CbjALD and alcohol dehydrogenase YahK.

FIG. 28: GC-MS spectra of olivetolic produced in vivo in

FIG. 29: GC-MS spectra of cannabigerolic acid (CBGA) produced in vivo in comparison to CBGA standard.

FIG. 30: Embodiments of the invention.

### DETAILED DESCRIPTION

This disclosure generally relates to the use of enzyme combinations or recombinant microbes comprising the same to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds through novel synthetic metabolic pathways. As described herein, the novel pathways for the synthesis of these products exploit enzymes catalyzing Claisen, aldol, or acyloin condensation reactions for the generation of longer chain length intermediates from central carbon metabolites (FIG. 1). Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors, isoprenoids and derivatives thereof, polyketides, and prenylated aromatic compounds when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups (FIG. 1). Isoprenoid alcohols are key intermediary products for the production of isoprenoid precursors in these novel synthetic metabolic pathways.

One such pathway employs native or engineered thiolases that catalyze the condensation between an acyl-CoA, serving as the primer, and another acyl-CoA, serving as the extender unit, enabling the formation of beta-keto acyl-CoA intermediate (FIG. 1). Primers and extender units can be omega-functionalized to add required functionalities to the carbon chain, which can be further modified to form isoprenoid intermediates. The beta-keto group of the beta-keto acyl-CoA formed via condensation can be reduced and modified step-wise by one or more of the beta-reduction enzymes-dehydrogenase, dehydratase, and/or reductase reactions. Furthermore, various carbon re-arrangement enzymes, such as acyl-CoA mutases, can be employed to 60 modify the carbon structure and branching of the acyl-CoAs. These CoA intermediates can then serve as the primer for the

next round of condensation with the extender unit or as direct precursors to IPP, DMAPP, or other isoprenoid intermediates. After the termination by spontaneous or enzymecatalyzed CoA removal, reduction, and/or phosphorylation, and subsequent structure re-arrangement, isoprenoids precursors (e.g. IPP and DMAPP), isoprenoids and derivatives thereof are produced. Many examples of thiolase enzymes which can potentially catalyze the condensation of an acyl-CoA primer and acyl-CoA extender unit are provided herein and the following Table A provides several additional examples which can also serve as templates for engineered 5 variants. In another embodiment, ketoacyl-CoA syntheses can be employed in place of thiolases, catalyzing decarboxylative Claisen condensations.

By employing these thiolase- or ketoacyl-CoA synthase catalyzed condensations with unsubstituted or functional-10 ized acyl-CoAs serving as the primer and the extender unit, various beta-keto acyl-CoAs can be generated that through additional beta-reduction and carbon rearrangement modifications serve as direct precursors to the C5 isoprenoid intermediates IPP or DMAPP. For example, FIGS. 2-6 15 depict various primer/extender unit combinations that through condensation and beta-reduction/carbon rearrangement reaction form CoAs that can be converted to IPP and DMAPP through various termination pathways. These building blocks can then be converted to longer chain length 20 isoprenoid intermediates and products through, for example, known geranyl-, farnesyl- or, geranylgeranyl-diphosphate synthases, such as the formation of the C<sub>10</sub> intermediate geranyl pyrophosphate (GPP) from IPP and DMAPP by GPP synthase.

In addition to serving as precursors to IPP and DMAPP, the above described acyl-CoA intermediates can also serve as a primer for the next round of condensation with an extender unit enabling the synthesis of longer chain betaketo acyl-CoAs. Additional rounds of elongation/beta-re- 30 duction/carbon rearrangement result in CoA intermediates that can be converted to longer chain length (e.g. C<sub>10</sub>, C<sub>15</sub>, etc.) isoprenoid intermediates. For example, FIG. 2 depicts the direct synthesis of GPP through condensation and betareduction/carbon rearrangement formation of an isoprenoid 35 acyl-CoA that can be converted to GPP. This type of strategy can be utilized to target not only C10 isoprenoid intermediates, but also longer chain length compounds as well. Following either route to isoprenoid precursors various prenyl transferases, terpene synthases, or terpene cyclases 40 can be used to convert the isoprenoid precursors into desired isoprenoid products and derivatives thereof. Exemplary materials that can be used with the invention include those in Tables A and B.

In another embodiment, the formation of isoprenoid pre- 45 cursors, isoprenoids and derivatives thereof including prenylated aromatic compounds proceeds from acetoacetyl-CoA formed as an intermediate through the nondecarboxylative condensation of 2 acetyl-CoA molecules catalyzed by thiolase(s) or decarboxylative condensation of 50 acetyl-CoA and malonyl-CoA catalyzed by keto-acyl-CoA synthase(s). In one such pathway, acetoacetyl-CoA is first 3-hydroxy-3-methylglutaryl-CoA converted to by hydroxymethylglutaryl-CoA synthase (FIG. 7). 3-hydroxy-3-methylglutaryl-CoA is then dehydrated and decarboxy- 55 lated through the action of an enoyl-CoA hydratase and glutaconyl-CoA decarboxylase, respectively, to form 3-methyl-2-butenoyl-CoA (FIG. 7). From 3-methyl-2butenoyl-CoA, a number of routes are available leading to the formation of dimethylallyl phosphate. The formation of 60 the isoprenoid precursors IPP and DMAPP then proceeds as described. These pathways are depicted in FIG. 7 and Table C provides examples of enzymes that can be used.

In another pathway from acetoacetyl-CoA, acetone generated from the decarboxylation of acetoacetic acid is con-5 verted to 3-methyl-3-hydroxy-butyryl-CoA through a condensation (FIG. 8). Dehydration of 3-methyl-3-hydroxy-

butyryl-CoA through the action of an enoyl-CoA hydratase then forms 3-methyl-2-butenoyl-CoA. From 3-methyl-2butenoyl-CoA, a number of routes are available leading to the formation of dimethylallyl phosphate, and then to IPP and DMAPP as described. These pathways are depicted in FIG. 8 and Table D provides examples of enzymes that can be used.

This disclosure also relates to the use of enzyme combinations or recombinant microbes to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds through acyloin condensation reactions (FIG. 1). In one embodiment, the pathway begins from the central carbon intermediate pyruvate, with a decarboxylative acyloin condensation of 2 molecules of pyruvate forming acetolactate. Subsequent isomeroreduction and dehydration convert acetolactate to 3-methyl-2-oxobutanoate (FIG. 9 and FIG. 10). These first 3 reactions are catalyzed by acetalactate synthase, acetohydroxyacid isomeroreductase, and dihydroxyacid dehydratase, respectively.

Following the formation of 3-methyl-2-oxobutanoate, several potential pathways can be exploited for the conversion of 3-methyl-2-oxobutanoate to isoprenoid precursors. One such pathway to isoprenoid precursors involves a keto-reduction to 3-methyl-2-hydroxybutanoate, catalyzed 25 by 2-hydroxyacid dehydrogenase. A series of different reactions can then be employed to convert 3-methyl-2-hydroxybutanoate into prenol (FIG. 9). In general, these steps involve the dehydration and phosphorylation of either the acid intermediate (3-methyl-2-hydroxybutanoate) or its CoA derivative to into prenol. Conversion of the acid intermediate requires a 2-hydroxyacid dehydratase for the formation of an alpha-beta-double bond, and the subsequent conversion to 3-methyl-2-butenoyl-CoA through the action of any of an acyl-CoA synthetase, an acyl-CoA transferase, or the combination of a carboxylate kinase and phosphotransacylase (FIG. 9). From 3-methyl-2-butenoyl-CoA, a number of routes are available leading to the formation of prenol. The formation of the isoprenoid precursors IPP and DMAPP then proceeds from prenol through an alcohol kinase and phosphate kinase or an alcohol diphosphokinase to form DMAPP, with isopentenyl diphosphate isomerase able to interconvert DMAPP and IPP. These pathways are also depicted in FIG. 9 and Table E.

Alternatively, 3-methyl-2-hydroxybutanoate can be converted into its CoA derivative (3-methyl-2-hydroxybutanoyl-CoA) before the dehydration reaction. This can be accomplished through any of an acyl-CoA synthetase, an acyl-CoA transferase, or the combination of a carboxylate kinase and phosphotransacylase. Following activation to 3-methyl-2-hydroxybutanoyl-CoA, the dehydration reaction forms 3-methyl-2-butenoyl-CoA, which is catalyzed by a 2-hydroxyacyl-CoA dehydratase, for which a number of candidate enzymes are available (Table E). From 3-methyl-2-butenoyl-CoA, a number of routes are available leading to the formation of prenol. The formation of the isoprenoid precursors IPP and DMAPP proceeds as described. These pathways are also depicted in FIG. **9** and Table E.

An alternative route from 3-methyl-2-oxobutanoate involves the addition of 2 carbons (with acetyl-CoA as the donor) through the action of isopropylmalate synthases to form (2S)-isopropylmalate (FIG. **10**). Isopropylmalate isomerase and isopropylmalate dehydrogenase then convert (2S)-isopropylmalate to 4-methyl-2-oxopentanoate, which is subsequently converted to 3-methyl-2-butenoyl-CoA through a branched chain alpha-keto acid dehydrogenase and an acyl-CoA dehydrogenase (FIG. **10**). From 3-methyl-2-butenoyl-CoA, a number of routes are available leading to the formation of prenol. The formation of the isoprenoid precursors IPP and DMAPP is as described above. These pathways are depicted in FIG. **10** and Table F provides examples of enzymes that can be used.

In another embodiment, the non-decarboxylative acyloin 5 condensation of isobutanal and formyl-CoA to 3-methyl-2hydroxybutanoyl-CoA catalyzed by 2-hydroxyacyl-CoA lyase is utilized (FIG. 11). Isobutanal is generated through the use of Claisen condensation and beta-reduction reactions, with carbon rearrangement and an aldehyde forming 10 termination pathway. Formyl-CoA can be generated directly from formate or formaldehyde. Following acyloin condensation, 3-methyl-2-hydroxybutanoyl-CoA is converted to prenol through various pathways (FIG. 11). Prenol is subsequently converted into DMAPP and IPP. These pathways 15 are depicted in FIG. 11 and Table G provides examples of enzymes that can be used.

This disclosure also relates to the use of enzyme combinations or recombinant microbes to make isoprenoid precursors, isoprenoids and derivatives thereof including pre- 20 nylated aromatic compounds through acyloin condensation reactions (FIG. 1). In one embodiment, the pathway begins from the central carbon intermediate pyruvate, which is condensed with acetealdeyhde in an aldol condensation to form 4-hydroxy-2-oxopentanoate (FIG. 12). Carbon rear- 25 rangement catalyzed by a mutase and reduction through the action of a 2-hydroxyacid dehydrogenase converts 4-hydroxy-2-oxopentanoate to 2,3-dihydroxy-3-methylbutanoate, an intermediate of the aforementioned valine biosythensis pathway. Following dehydration to 3-methyl-2- 30 oxobutanoate, several metabolic routes to isoprenoid precursors can be exploited, including keto-reduction and combinations of dehydration and phosphorylation, either converting the free acid intermediate or its CoA derivative to prenol (FIG. 12). Prenol is subsequently converted into 35 DMAPP and IPP. These pathways are depicted in FIG. 12 and Table H below provides examples of enzymes that can be used.

Alternatively, the addition of 2-carbons to 3-methyl-2oxobutanoate, followed by subsequent isomerization, and 40 decarboxylation results in the generation of isovaleryl-CoA, which can then be converted to prenol through a series of reactions (FIG. **13**). Prenol is then converted to DMAPP, which can be isomerized into IPP generating the two  $C_5$ isoprenoid precursors. These pathways are depicted in FIG. 45 **13** and Table I below provides examples of enzymes that can be used.

In another embodiment, an aldolase catalyzes the aldol condensation of 2-oxobutanoate and acetaldehyde forming 4-hydroxy-2-oxo-3-methylpentanoate (FIG. 14). Conver- 50 sion of this intermediate to 4-methyl-2-oxopent-4-enoate, through the action of a mutase and a dehydratase, enables the use of a number of pathways to generate isoprenol from 4-methyl-2-oxopent-4-enoate. This 5-carbon isoprenoid alcohol is then converted to IPP through a two-step phos-55 phorylation with IP as an intermediate, or a one step diphosphorylation catalyzed by an alcohol diphosphokinase. IPP can be isomerized into DMAPP generating the two  $C_5$ isoprenoid precursors. These pathways are depicted in FIG. 14 and Table J below provides examples of enzymes that can 60 be used.

The synthesis of IPP, DMAPP, GPP, FPP or other isoprenoid precursors can then be combined with the rearrangement of these intermediates into the desired isoprenoid product. The 5-carbon isomers IPP and DMAPP are the 65 fundamental building blocks of isoprenoid products. From these  $C_5$  units, an immense number of products can be

synthesized through the action of for example prenyl transferases, terpene synthases, or terpene cyclases, which involves the prenyl transfer, head-to-tail condensation, head-to-head condensation, tail-to-tail condensation, or cyclization, among other biochemical reactions, of IPP, DMAPP, and other longer chain isoprenoid precursors synthesized from the  $C_5$  building blocks. As such, the generation of these intermediates can enable the synthesis of for example a variety of monoterpenes ( $C_{10}$ ), sesquiterpenes ( $C_{15}$ ), diterpenes ( $C_{20}$ ), sesterterpenes ( $C_{25}$ ), triterpenes ( $C_{30}$ ), sesquarterpenes ( $C_{40}$ ), among other isoprenoid compounds and derivatives thereof (FIG. **15**). Table K below provides examples of enzymes that can be used.

The isoprenoid precursors synthesized through these routes can also be exploited for the synthesis of hybrid products, which contain as an example, the C<sub>5</sub> (dimethylallyl),  $C_{10}$  (geranyl), or  $C_{15}$  (farnesyl) isoprenoid attached to an aromatic core structure. The prenylation of these aromatic compounds with the isoprenoid units offers another route to diverse products. One route to polyketides involves native or engineered thiolases catalyzing the condensation in an iterative manner (i.e. one or multiple rounds) between two either unsubstituted or functionalized acyl-CoAs each serving as the primer and the extender unit to generate and elongate polyketide CoAs. Before an optional next round of thiolase reaction, the beta-keto group of the polyketide chain can be reduced and modified step-wise by the beta-reduction reactions. Spontaneous or enzymatically catalyzed termination reaction terminates the elongation of the polyketide chain at any point through CoA removal and reactions rearranging the structure, generating the final functional polyketide products. Examples of enzymes that can be used for these key reactions are shown in Tables A and B. This approach is the subject of patent application WO2017020043, BIOSYN-THESIS OF POLYKETIDES, filed Aug. 1, 2016, and 62/198,764, filed Jul. 30, 2015.

The polyketides synthesized through this route or other routes such as to polyketide synthases can be combined with isoprenoid precursors for the formation of prenylated aromatic compounds. For example, FIG. **16** demonstrates olivetolic acid generation through condensation and beta-reduction reactions and generation of isoprenoid precursor geranyl pyrophosphate, which when combined through the action of an aromatic prenyltransferase or 4-hydroxybenzoate grenyltransferase, enables the synthesis of the cannabinoid cannabigerolic acid (FIG. **17**). Cannabigerolic acid can then be converted into a number of other cannabinoids, including  $\Delta^9$ -tetrahydrocannabinolic acid, cannabidiolic acid, and cannabichromenic acid. Examples of enzymes that can be used for these key reactions are shown in Table L.

As such, through the use of these novel pathways based on Claisen, aldol, or acyloin condensation, this platform can be exploited to make not only isoprenoids precursors, isoprenoids and derivatives thereof, but also diverse hybrid products with wide ranging applications.

#### (Prophetic) GPP Biosynthesis Through Utilization of Beta-Oxidation Reversal and Methyl Group Transferring Mutase

The purpose of this example is to demonstrate the biosynthesis of GPP through a novel pathway that recruits condensation and beta-reduction reactions as well as a mutase that moves the methyl group by one carbon. *E. coli* serves as the host organism. This pathway starts from non-decarboxylative Claisen condensation between acetyl-CoA, which serves as the primer, and propionyl-CoA, which serves as the extender unit, by thiolase FadAx (AAK18171.1) from P. putida. In the pathway, propionyl-CoA is activated from propionic acid, which is either supplemented or synthesized through overexpressed native pathway of conversion of succinate to propionic acid, catalyzed 5 by M. elsdenii acyl-CoA transferase Pct (BAU59368.1). After two beta-reduction steps catalyzed by hydroxyacyl-CoA dehydrogenase FadB2x (AAK18170.1) and enoyl-CoA hydratase FadB1x (AAK18173.1), both from P. putida, 2-methylcrotonyl-CoA (tiglyl-CoA) is generated. Then, 10 mutase moves the methyl group from alpha-site to beta-site on tiglyl-CoA, generating 3-methyl-2-butenoyl-CoA (3-methylcrotonyl-CoA). 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydro-15 genase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from the group consisting C. acetobutylicum 20 AdhE2 (YP 009076789.1) and M. aquaeolei VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consist- 25 ing E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. SE19 ChnD (BAC80217.1).

Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first 30 step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phos- 35 phate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. Then, DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA 40 (NP\_414955.1, with S80F mutation to make the enzyme exclusive active on GPP synthesis, Reiling et al. 2004) or Abies grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation to improve the activity). 3-methylcrotonyl-CoA can also serve as the primer for the next 45 iteration composed of reactions by thiolase, hydroxyacyl-CoA dehydrogenase, enoyl-CoA hydratase and enoyl-CoA reductase, with acetyl-CoA as the extender unit, generating 5-methyl-4-hexenoyl-CoA. 5-methyl-4-hexenoyl-CoA, serving as the primer, is condensed with extender unit 50 propionyl-CoA through condensation by P. putida thiolase FadAx. After two beta-reduction steps catalyzed by P. putida hydroxyacyl-CoA dehydrogenase FadB2x and enoyl-CoA hydratase FadB1x, 2,7-dimethyl-2,6-octadienoyl-CoA is formed. Then, mutase moves the methyl group from alpha-55 site to beta-site, converting 2,7-dimethyl-2,6-octadienoyl-CoA to 3,7-dimethyl-2,6-octadienoyl-CoA, namely geranyl-CoA. Geranyl-CoA is converted to geraniol by alcoholforming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase. Geraniol is then con- 60 verted to GPP by one or two steps of phosphorylation. If phosphorylated through two steps, the first step is catalyzed by Arabidopsis thaliana alcohol kinase AT5G58560 (NP\_200664.1) and the second step is catalyzed by Thermoplasma acidophilum phosphate kinase ThaIPK 65 (WP 010900530.1, Y70A, V130A and I130A mutations to increase specificity on geranyl phosphate over isopentenyl

24

phosphate, Mabanglo et al. 2012). The one-step phosphorylation is catalyzed by alcohol diphosphokinase. *Ocimum basilicum* geraniol synthase GES (AR11765.1, with N-terminal 65 aa truncated to improve the activity, Iijima et al. 2004) converts GPP to geraniol, which serves as the proxy product of GPP to demonstrate the synthesis pathway.

JST06(DE3) serves as the *E. coli* host strain for demonstration of this novel pathway. JST06(DE3) (MG1655(DE3)  $\Delta$ ldhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA  $\Delta$ yciA  $\Delta$ ybgC  $\Delta$ ydiI  $\Delta$ tesA  $\Delta$ fadM  $\Delta$ tesB) (Cheong et al. 2016) is an *E. coli* strain deficient in mixed-acid fermentation pathways due to deletions of genes ldhA, poxB, pta, adhE and frdA, which maximize the supply of acetyl-CoA, and deletions of genes encoding major thioesterases (yciA, ybgC, ydiI, tesA, fadM and tesB), which minimize the hydrolysis of CoA intermediates.

The genes for overexpression are either cloned into appropriate vectors or inserted into chromosome with strong synthetic constitutive promoter, such as M1-93. When cloned into vectors, these genes are amplified through PCR using appropriate primers to append homology on each end for recombination into the vector backbone with e.g., Phusion polymerase (Thermo Scientific, Waltham, Mass.) to serve as the gene insert. Plasmids are linearized by the appropriate restriction enzymes (New England Biolabs, Ipswich, Mass., USA) and recombined with the gene inserts using the In-Fusion HD Eco-Dry Cloning system. The mixture is subsequently transformed into Stellar competent cells. Transformants that grow on solid media (LB+Agar) supplemented with the appropriate antibiotic are isolated and screened for the gene insert by PCR. Plasmids from verified transformants are isolated and the sequence of the gene insert is further confirmed by DNA sequencing. The sequence confirmed plasmids are then introduced to host strain through electroporation.

When inserted into chromosome, CRISPR is used and genetic sites of tesB, adhE and ldhA are suitable loci, although others could be used. CRISPR method is based on the method developed by Jiang et al. (Jiang et al. 2015). First, the host strain is transformed with plasmid pCas, the vector for expression of Cas9 and  $\lambda$ -red recombinase. The resulting strain is grown under 30° C. with L-arabinose for induction of  $\lambda$ -red recombinase expression, and when OD reaches ~0.6, competent cells are prepared and transformed with pTargetF (AddGene 62226) expressing sgRNA and N20 spacer targeting the locus and template of insertion of target gene. The template is the inserted gene plus M1-93 promoter with ~500 bp sequences homologous with upstream and downstream of the insertion locus, constructed through overlap PCR with usage of Phusion polymerase or synthesized by GenScript (Piscataway, N.J.) or GeneArt® (Life Technologies, Carlsbad, Calif.). The way to switch N20 spacer of pTargetF plasmid is inverse PCR with the modified N20 sequence hanging at the 5' end of primers with usage of Phusion polymerase and followed by self-ligation with usage of T4 DNA ligase and T4 polynucleotide kinase (New England Biolabs, Ipswich, Mass., USA). Transformants that grow under 30° C. on solid media (LB+Agar) supplemented with spectinomycin and kanamycin (or other suitable antibiotic) are isolated and screened for the chromosomal gene insert by PCR. The sequence of the gene insert, which is amplified from genomic DNA through PCR using Phusion polymerase, is further confirmed by DNA sequencing. The pTargetF can then be cured through IPTG induction, and pCas can be cured through growth under higher temperature like 37-42° C.

All molecular biology techniques are performed with standard methods (Miller, 1972; Sambrook et al., 2001) or by manufacturer protocol. Strains are stored in glycerol stocks at  $-80^{\circ}$  C. Plates are prepared using LB medium containing 1.5% agar, and appropriate antibiotics are 5 included at the following concentrations: ampicillin (100 µg/mL), kanamycin (50 µg/mL), spectinomycin (50 µg/mL) and chloramphenicol (12.5 µg/mL).

MOPS minimal medium (Neidhardt et al., 1974) with 125 mM MOPS and Na<sub>2</sub>HPO<sub>4</sub> in place of K<sub>2</sub>HPO<sub>4</sub> (2.8 mM), 10 supplemented with 20 g/L glycerol or 40 g/L glucose, 10 g/L tryptone, 5 g/L yeast extract, 100  $\mu$ M FeSO<sub>4</sub>, 5 mM calcium pantothenate, 5 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and 30 mM NH<sub>4</sub>Cl is used for fermentations. If required, 55 g/L of CaCO<sub>3</sub> is also supplemented as pH buffer. 20 mM propionic acid is supple-15 mented, if it is not synthesized intracellularly and needed for the experiment. Antibiotics (50  $\mu$ g/mL carbenicillin, 50  $\mu$ g/mL spectinomycin and 50  $\mu$ g/mL kanamycin) are included when appropriate. All chemicals are obtained from Fisher Scientific Co. (Pittsburg, Pa.) and Sigma-Aldrich Co. 20 (St. Louis, Mo.).

Fermentations are performed in 25 mL Pyrex Erlenmeyer flasks (narrow mouth/heavy duty rim, Corning Inc., Corning, N.Y.) filled with appropriate volume of fermentation medium and sealed with foam plugs filling the necks. A 25 single colony of the desired strain is cultivated overnight (14-16 hrs) in LB medium with appropriate antibiotics and used as the inoculum with initial  $OD_{550}$  as ~0.05. After inoculation, flasks are incubated in a NBS I24 Benchtop Incubator Shaker (New Brunswick Scientific Co., Inc., Edi- 30 son, N.J.) at 200 rpm and 37° C. or 30° C. When optical density (550 nm, OD<sub>550</sub>) reached ~0.3-0.5, appropriate concentration of isopropyl beta-D-1-thiogalactopyranoside (IPTG) (or other suitable inducer) is added for plasmid gene induction. Additional fermentations are conducted in a Six- 35 Fors multi-fermentation system (Infors HT, Bottmingen, Switzerland) with an air flowrate of 2 N L/hr, independent control of temperature (37° C.), pH (controlled at 7.0 with NaOH and H<sub>2</sub>SO<sub>4</sub>), and appropriate stirrer speed. Precultures are grown in 25 mL Pyrex Erlenmeyer flasks as 40 described above and incubated for 4 hours post-induction. An appropriate amount of this pre-culture is centrifuged, washed twice with fresh media, and used for inoculation (400 mL initial volume). The fermentations in bioreactor use described fermentation media with 30 g/L glycerol or 40 g/L  $_{45}$ glucose, with the optional inclusion of 5 µM sodium selenite to promote FHL activity, and appropriate IPTG and antibiotics. If required, propionic acid (20 mM) is added at 0, 24, and 48 hours.

After the fermentation, the supernatant obtained through 50 5000 g, 5 min centrifuge in an Optima L-80XP Ultracentrifuge (Beckman-Coulter, Schaumburg, Ill.) of 2 mL culture is prepared for GC-FID/GC-MS analysis of geraniol. The supernatant aliquots of 2 mL are transferred to 5 mL glass vials (Fisher Scientific Co., Pittsburgh, Pa.). Then, organic 55 solvent (typically hexane) is added at a 1:1 ratio to a fermentation broth sample (e.g. 2 mL for a 2 mL aqueous solution) for extraction. Following an appropriate extraction (vortex samples for 15 seconds, spin on a rotator at 60 rpm for 2 hours, and vortex again for 15 seconds), 1 mL of the 60 organic phase is removed. 50  $\mu L$  pyridine and 50 uL BSTFA are then added to the 1 mL organic phase for derivatization, with the reaction allowed to proceed at 70° C. for 30 minutes. After cooling to room temperature, this mixture is used for GC analysis. 65

GC analysis is conducted on an Agilent 7890B Series Custom Gas Chromatography system equipped with a 5977B Inert Plus Mass Selective Detector Turbo EI Bundle (for identification) or a Flame Ionization Detector (for quantification) and an Agilent HP-5 capillary column (0.25 mm internal diameter, 0.25  $\mu$ m film thickness, 30 m length). The following temperature profile is used with helium as the carrier gas at a flowrate of 1.5 mL/min: Initial 50° C. (hold 3 min); ramp at 20° C./min to 270° C. (hold 6 min). The injector and detector temperature are 250° C. and 350° C, respectively. 1 uL of sample is injected with a 4:1 split ratio.

Among above enzymes, the activities of thiolase FadAx, hydroxyacyl-CoA dehydrogenase FadB2x and enoyl-CoA hydratase FadB1x, required for the above described GPP synthesizing reverse beta-oxidation pathways, have already been demonstrated in vivo. JST06(DE3) overexpressing these enzymes along with E. coli thioesterase YdiI (NP\_416201.1) and Pct have been grown in shake flasks with 20 g/L glycerol and 20 mM propionic acid for 48 hours at 20 mL volume and in a controlled bioreactor for 72 hours with 30 g/L glycerol and supplementation of 20 mM propionic acid every 24 hours, both induced by induced by 5 µM IPTG at 37° C., leading to production of 1.39 g/L of 2-methyl-2-butenoic acid or tiglic acid in shake flasks, and 3.79 g/L of tiglic acid in bioreactors (FIG. 18). If YdiI is not overexpressed, no tiglic acid production was detected, indicating that YdiI is able to hydrolyze 2-methyl-2-butenoyl-CoA (tiglyl-CoA), generated through FadAx condensation between primer acetyl-CoA and extender unit propionyl-CoA and subsequent beta-reduction steps by FadB2x and FadB1x, to tiglic acid.

In the above demonstration, the genes encoding FadAx and Pct were expressed from pCDF-P1-pct-fadAx and the genes encoding FadB1x, FadB2x and YdiI were expressed from pET-P1-fadB2x-fadB1x-P2-ydiI. The primers used in constructions of these plasmids are listed in Table M. For the construction of pCDF-P1-pct-fadAx, the pct gene insert was first PCR amplified with pct-f1/pct-r1 primers and inserted into vector pCDFDuet-1 (Novagen, Darmstadt, Germany) cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system (Clontech Lab., CA) to construct pCDF-P1pct. Then, the fadAx gene insert was PCR amplified with fadAx-f1/fadAx-r1 and inserted into vector pCDF-P1-pct cleaved by EcoRI through In-Fusion cloning, generating pCDF-P1-pct-fadAx. For the construction of pET-P1fadB2x-fadB1x-P2-ydiI, the fadB2x gene insert was first PCR amplified with fadB2x-f1/fadB2x-r1 primers and inserted into vector pETDuet-1 (Novagen, Darmstadt, Germany) cleaved by NcoI and EcoRI through In-Fusion cloning, generating pET-P1-fadB2x. Then, the fadB1x gene insert was PCR amplified with fadB1x-f1/fadB1x-r1 primers and inserted into pET-P1-fadB2x cleaved by EcoRI through In-Fusion cloning, generating pET-P1-fadB2x-fadB1x. Finally, the ydiI gene insert was PCR amplified with ydiIf1/ydiI-r1 primers and inserted into pET-P1-fadB2x-fadB1x cleaved by NdeI (New England Biolabs, Ipswich, Mass., USA) through In-Fusion cloning, generating pET-P2fadB2x-fadB1x-P2-ydil. Before the introduction to host strain, the sequences of constructed plasmids were confirmed by DNA sequencing.

Two plasmids for expressing the pathway that converts prenol to GPP and geraniol (or "Lower alcohol pathway" as shown in FIG. 1) and can be used in above pathway have been constructed and are listed in Table N. To construct pET-P1-idi-trGPPS2-P2-ges-ychB-mtipk and pET-P1-idi-trGPPS2-P2-ges-thaipk-mtipk, the gene inserts encoding Idi and trGPPS2 ("tr" means "truncated" as first 84 aa of GPPS2 was truncated to improve the activity) were PCR amplified with idi-f1/idi-r1 and trgpps2-f1/trgpps2-r1 respectively and

inserted together into pETDuet-1 cleaved by NcoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1idi-trGPPS2. Then, the gene insert encoding GES was PCR amplified with ges-f1/ges-r1 primers and inserted into vector pET-P1-idi-trGPPS2 cleaved by NdeI and KpnI through 5 In-Fusion HD Eco-Dry Cloning system to generate pET-P1idi-trGPPS2-P2-ges. When constructing pET-P1-iditrGPPS2-P2-ges-ychB-mtipk, the gene inserts encoding YchB and MtIPK were PCR amplified with ychB-f1/ychBr1 and mtipk-f1/mtipk-r1 respectively and inserted together 10 into pET-P1-idi-trGPPS2-P2-ges cleaved by XhoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1idi-trGPPS2-P2-ges-ychB-mtipk. When constructing pET-P1-idi-trGPPS2-P2-ges-thaipk-mtipk, the gene insert encoding ThaIPK (with V73I, Y141V and K204G mutations) was 15 PCR amplified with thaipk-f1/thaipk-r1 and inserted into pET-P1-idi-trGPPS2-P2-ges cleaved by XhoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1idi-trGPPS2-P2-ges-thaipk, and then the gene encoding MtIPK was PCR amplified with mtipk-f2/mtipk-r1 and 20 inserted into pET-P1-idi-trGPPS2-P2-ges-thaipk cleaved by XhoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-idi-trGPPS2-P2-ges-thaipk-mtipk. The sequences of required primers can be seen in Table N. The sequences of constructed plasmids were further confirmed 25 by DNA sequencing. Then, the sequence confirmed plasmids were introduced to competent cells of the host strain.

Among above enzymes, in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol 30 dehydrogenases ChnD, YjgB and YahK on oxidization of prenol have been proven through enzymatic spectrophotometric assay. *E. coli* alcohol dehydrogenases FucO (NP\_417279.2), YqhD (NP\_417484.1), YiaY (YP\_026233.1) were also assayed on prenol, but as men-35 tioned below, they did not show the activity on prenol oxidization.

For the tested enzymes, *E. coli* enzymes were expressed in pCA24N-gene (-gfp) plasmids from the ASKA collection (Kitagawa et al., 2005). Gene encoding Maqu\_2507 and ChnD were codon optimized and synthesized by either GeneArt or GenScript. The gene encoding CbjALD was amplified from the genomic DNA of *C. beijerinckii*. The primers required for cloning of these genes are listed in Table O. The cbjALD gene insert was PCR amplified from the genomic DNA of *C. beijerinckii*. with cbjALD-f1 and cbjALD-r1 primers and inserted into vector pCDFDuet-1 cleaved by EcoRI through In-Fusion HD Eco-Dry Cloning system to construct pCDF-ntH6-cbjALD. The sequence of the cbjALD gene insert was further confirmed by DNA sequencing. The protein was expressed with an n-terminal 6 His-tag.

The codon-optimized maqu\_2507 gene insert was PCR amplified with maqu\_2507-f1 and maqu\_2507-r1 primers and inserted into vector pCDFDuet-1 (Novagen, Darmstadt, 55 Germany) cleaved by EcoRI through In-Fusion HD Eco-Dry Cloning system to construct pCDF-ntH6-maqu\_2507. The sequence of the maqu\_2507 gene insert was further confirmed by DNA sequencing. The protein was expressed with an n-terminal 6 His-tag. 60

The codon-optimized chnD gene insert was PCR amplified with chnD-f1 and chnD-r1 primers and inserted into vector pCDFDuet-1 (Novagen, Darmstadt, Germany) cleaved by EcoRI through In-Fusion HD Eco-Dry Cloning system to construct pCDF-ntH6-chnD. The sequence of the 65 chnD gene insert was further confirmed by DNA sequencing. The protein was expressed with an n-terminal 6 His-tag.

For expression of enzymes, cultures were grown in 25 mL of LB media in 125 mL flasks (Wheaton Industries, Inc., Millville, N.J.) at  $37^{\circ}$  C. A single colony of the desired strain was cultivated overnight (14-16 hrs) in 10 mL of LB medium in baffled flasks (Wheaton Industries, Inc., Millville, N.J.) with appropriate antibiotics and used as the inoculum (3%). The cells were induced with 0.1 mM IPTG at an OD550–0.6.

After post-induction growth for 4 h for ASKA strains, or 16 for other strains, the cells were collected and washed twice by 9 g/L sodium chloride solution. Cells were then re-suspended in lysis buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 10 mM imidazole, pH 8.0) to an OD ~40. After re-suspension, the cells were disrupted using glass beads and then centrifuged at 4° C., 13000 g, 10 min in an Optima L-80XP Ultracentrifuge (Beckman-Coulter, Schaumburg, Ill.). The resultant supernatant is the crude enzyme extract. The His-tagged enzymes were then purified from crude extract by using Ni-NTA spin kit (Qiagen, Valencia, Calif.). The crude extracts are centrifuged (270 g, 5 min) in spin columns that were equilibrated with lysis buffer and then washed twice by wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 20 mM imidazole, pH 8.0). After washing, the enzyme was eluted twice in elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 500 mM imidazole, pH 8.0). Both washing and elution steps are centrifuged at 890 g for 2 min. The purified enzyme extracts were then further concentrated and dialyzed through Amicon® Ultra 10K Device (Millipore, Billerica, Mass.). The enzymes were first filtered by centrifugation at 4° C., 14000 g, 10 min, and then washed with 100 mM potassium phosphate, pH 7 buffer under the same centrifugation conditions. Finally, the concentrated and dialyzed enzymes were recovered through 4° C., 1000 g, 2 min centrifugation. The protein concentration was established using the Bradford Reagent (Thermo Scientific, Waltham, Mass.) using BSA as the protein standard. SDS-PAGE monitor of purified proteins was performed through Calif.) with gels (12% acrylamide resolving gel and 4% acrylamide stacking gel) prepared through SureLock™ Mini-cell system (Invitrogen, Carlsbad, Calif.). The composition of the running buffer for SDS-PAGE was 3 g/L tris base, 14.4 g/L glycine and 1 g/L SDS in water.

Enzymatic reactions were monitored on either a Synergy HT plate reader (BioTek Instruments, Inc., Winooski, Vt.) or a Biomate 5 Spectrophotometer (Thermo Scientific, Waltham, Mass.) according to established protocols. Measurement of 3-methylcrotonyl-CoA reduction by acyl-CoA reductases was measured by following the decrease (oxidation of NAD(P)H) in absorbance at 340 nm from a reaction mixture containing 100 mM Tris-HCl (pH 7.5), 5 mM DTT, 0.3 mM NAD(P)H, and 1 or 5 mM 3-methylcrotonyl-CoA. Measurement of alcohol dehydrogenase activity on prenol was measured by following the increase (reduction of NAD (P)<sup>+</sup>) in absorbance at 340 nm from a reaction mixture containing 100 mM Tris-HCl (pH 8.0), 1 mM NAD(P)<sup>+</sup>, and 1 mM prenol.

For assays of acyl-CoA reductases, the crude extract of CbjALD did not show the detectable reduction activity on 1 mM 3-methylcrotonyl-CoA, but the activity was detected (0.008 µmol/mg/min) when the enzyme was purified and the concentration of 3-methylcrotonyl-CoA was 5 mM. The crude extract of Maqu\_2507 showed 0.08±0.01 µmol/mg/min towards 1 mM 3-methylcrotonyl-CoA. These results indicate that CbjALD and Maqu\_2507 are suitable for

reduction of 3-methylcrotonyl-CoA to prenol. CbjALD uses NADH as cofactor, while Maqu\_2507 uses NADPH as cofactor.

Among the assayed alcohol dehydrogenases, YahK, YjgB and ChnD showed the activity on oxidization of prenol to 5 3-methyl-1-butenal. They should be suitable for catalyzing the required reverse reduction reaction of 3-methyl-1-butenal, which is converted from 3-methylcrotonyl-CoA by CbjALD, to prenol. The results are shown in Table P.

3-methylcrotonyl-CoA, which is then converted to GPP 10 via prenol through the pathway described above, can also be supplied through two different versions of reverse betaoxidation pathways incorporated with methyl-group transferring mutase. The first pathway starts from non-decarboxylative Claisen condensation between propionyl-CoA, 15 which serves as the primer, and glycolyl-CoA, which serves as the extender unit, catalyzed by thiolase. In this pathway, propionyl-CoA is activated from propionic acid, which is either supplemented or synthesized through overexpressed native pathway of conversion of succinate to propionic acid. 20 while glycolyl-CoA is activated from glycolic acid, which is either supplemented or synthesized through overexpressed native pathway of conversion of glyoxylate, the intermediate of glyoxylate shunt, to glycolic acid. The activations of both propionic acid and glycolic acid are catalyzed by Pct. After 25 three beta-reduction steps catalyzed by hydroxyacyl-CoA dehydrogenase, enoyl-CoA hydratase and enoyl-CoA reductases, 2-hydroxypentanoyl-CoA is generated. Then, mutase moves the methyl group from  $\gamma$ -site to beta-site on 2-hydroxypentanoyl-CoA, generating 2-hydroxy-3-meth- 30 ylbutanoyl-CoA, and 2-hydroxyacyl-CoA dehydratase converts 2-hydroxy-3-methylbutanoyl-CoA to 3-methylcrotonyl-CoA. The second pathway starts from nondecarboxylative Claisen condensation between propionyl-CoA, which serves as the primer, and acetyl-CoA, which 35 serves as the extender unit, catalyzed by thiolase. In the pathway, propionyl-CoA is activated from propionic acid, which is either supplemented or synthesized through overexpressed native pathway of conversion of succinate to propionic acid, catalyzed by Pct. After two beta-reduction 40 steps catalyzed by hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase, 3-hydroxypentanoyl-CoA is generated. Then, mutase moves the methyl group from -site to beta-site on 3-hydroxypentanoyl-CoA, generating 3-hydroxy-3-methylbutanoyl-CoA, and enoyl-CoA hydratase 45 converts 3-hydroxy-3-methylbutanoyl-CoA to 3-methylcrotonyl-CoA.

The non-decarboxylative Claisen condensation between primer acetyl-CoA, similar to propionyl-CoA required in the above described pathway, and extender unit glycolyl-CoA, 50 and the subsequent beta-reduction by hydroxyacyl-CoA dehydrogenase have been in vivo demonstrated in E. coli. MG1655(DE3) AglcD (glcD gene encoding a subunit of glycolate oxidase was deleted to block degradation of glycolic acid) strain overexpressing thiolase BktB 55 (AAC38322.1) from Ralstonia eutropha, hydroxyacyl-CoA dehydrogenase PhaB1 (P14697.1) from R. eutropha, enoyl-CoA hydratase PhaJ (032472.1) from Aeromonas caviae and enoyl-CoA reductase TdTer (4GGO\_A) from Treponema denticola along with activation enzyme Pct, which was 60 supposed to produce 4-hydroxybutyric acid through reverse beta-oxidation pathway starting from non-decarboxylative Claisen condensation between primer glycolyl-CoA and extender unit acetyl-CoA, was also found to produce 2,3dihydroxybutyric acid detected by GC-MS, after 96 h 65 growth under 30° C. in LB supplemented with glucose and glycolic acid. The GC-MS chromatogram showing the peak

of 2,3-dihydroxybutyric acid is shown in FIG. **19**. This result indicates that thiolase BktB can accept glycolyl-CoA as extender unit and acetyl-CoA as primer in the condensation, generating 2-hydroxy-3-oxobutanoyl-CoA, and PhaB1 can reduce 2-hydroxy-3-oxobutanoyl-CoA to 2,3-dihydroxybutanoyl-CoA, which is hydrolyzed to 2,3-dihydroxybutyric acid by native *E. coli* enzymes.

In the strain producing 2,3-dihydroxybutyric acid, genes encoding BktB, PhaB1 and PhaJ were overexpressed from pET-P1-bktB-phaB1-P2-phaJ and genes encoding Pct and TdTer were overexpressed from pCDF-P1-pct-P2-tdter, as shown in Table Q, along with primer sequences required for construction of these plasmids. The genes used for 2,3dihydroxybutyric acid production were were codon optimized and synthesized by either GeneArt or GenScript, except bktB and phaB1, which were amplified from the genomic DNA of R. eutropha, and pct, which was amplified from the genomic DNA of M. elsdenii. To construct pET-P1-bktB-phaB1-P2-phaJ, the gene insert encoding phaJ was amplified with phaJ-f1/phaJ-r1 and inserted into pETDuet-1 cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to generate pET-P2-phaJ. Then, the gene insert encoding BktB was PCR amplified with bktB-f1/bktB-r1 and inserted into pET-P2-phaJ cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-bktB-P2-phaJ. Then, the gene insert encoding PhaB1 was PCR amplified with phaB1-f1/phaB1-r1 primers and inserted into vector pET-P1-bktB-P2-phaJ cleaved by EcoRI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-bktB-phaB1-P2-phaJ. To construct pCDF-P1-pct-P2-tdter, the gene encoding TdTer was was amplified with tdter-f1/tdter-r1 and inserted into pCDFDuet-1 cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P2-tdter. Then, the gene insert encoding pct was PCR amplified with pct-f1/pct-r1 primers and inserted into vector pCDF-P2-tdter cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P1-pct-P2-tdter. The sequences of required primers can be seen in Table Q. The sequences of constructed plasmids were further confirmed by DNA sequencing. Then, the sequence confirmed plasmids were introduced to competent cells of the host strain.

Fermentations for 2,3-dihydroxybutric acid production were conducted in 250 mL Erlenmeyer Flasks filled with 50 mL LB media supplemented with 10 g/L glucose and appropriate antibiotics. A single colony of the desired strain was cultivated overnight (14-16 h) in LB medium with appropriate antibiotics and used as the inoculum (2%). After inoculation, cells were cultivated at 30° C. and 250 rpm in a NBS 124 Benchtop Incubator Shaker (New Brunswick Scientific Co., Inc., Edison, N.J.) until an optical density of ~0.8 was reached, at which point IPTG (0.1 mM) and neutralized glycolic acid (40 mM) were added. Flasks were then incubated under the same conditions for 96 hours.

Besides above pathways, there is also a novel pathway of GPP synthesis employing beta-oxidation reversal without usage of methyl-group transferring mutase and via 3-methyl-3-butenol (isoprenol) instead of prenol. This pathway starts from non-decarboxylative Claisen condensation between glycolyl-CoA, which serves as the primer, and propionyl-CoA, which serves as the extender unit, catalyzed by thiolase. In this pathway, propionyl-CoA is activated from propionic acid, which is either supplemented or synthesized through overexpressed native pathway of conversion of succinate to propionic acid, while glycolyl-CoA is activated from glycolic acid, which is either supplemented or synthesized through overexpressed native pathway of

conversion of glyoxylate, the intermediate of glyoxylate shunt, to glycolic acid. The activations of both propionic acid and glycolic acid are catalyzed by Pct. After three beta-reduction steps catalyzed by hydroxyacyl-CoA dehydrogenase, enoyl-CoA hydratase and enoyl-CoA reductases, 4-hydroxy-2-methylbutanoyl-CoA is generated. 4-hydroxy-2-methylbutanoyl-CoA is converted to 2-methyl-1,4-butanediol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected 10 from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Then, an alcohol dehydratase converts 2-methyl-1,4-butanediol to 3-methyl-3-butenol (isoprenol). Isoprenol is then converted to IPP by one or two steps of 15 phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) and the second step is catalyzed by M. phosphate thermautotrophicus kinase MtIPK (AAB84554.1) or Thermoplasma acidophilum phosphate 20 forming acyl-CoA reductase or aldehyde forming acyl-CoA kinase ThaIPK (WP 010900530.1) or Methanocaldococcus jannaschii phosphate kinase MjIPK (3K4Y\_A). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. DMAPP and IPP 25 are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, the proxy 30 product for the synthesis pathway. For this pathway, JST06 (DE3) serves as the E. coli host strain for demonstration. Vector creation, strain creation, growth and analysis of supernatant are conducted as described above.

#### (Prophetic) GPP Biosynthesis Via 2-hydroxyisovaleric Acid and Prenol Starting from Decarboxylative Acyloin Condensation Between Two Pyruvates

The purpose of this example is to demonstrate the biosynthesis of GPP through a novel pathway that starts from decarboxylative acyloin condensation between two pyruvates 2-hydroxyisovaleric acid and prenol, using E. coli as the host organism. This pathway starts from decarboxylative 45 acyloin condensation of two pyruvates to (S)-2-acetolactone by B. subtilis acetolactate synthase AlsS (NP 391482.2). E. coliacetohydroxy acid isomeroreductase 11vC (NP\_418222.1) converts (S)-2-acetolactone to (2R)-2,3-dihydroxy-3-methylbutyric acid. E. coli dihydroxy acid dehy- 50 dratase IlvD (YP\_026248.1) dehydrates (2R)-2,3-dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutyric acid (2-oxoisovaleric acid). Then, L. lactis 2-hydroxyacid dehydrogenase PanE (AIS03659.1) reduces 2-oxoisovaleric acid to (2R)-3-methyl-2-hydroxybutyric acid (2-hydroxyisovael- 55 eric acid). 2-hydroxyisovaleric acid is then activated to (2R)-3-methyl-2-hydroxybutanoyl-CoA (2-hydroxyisovaleryl-CoA) by acyl-CoA transferase selected from the group consisting M. elsdenii Pct (BAU59368.1) and C. propionicum Pct540 (CAB77207.1, with V193A mutation to 60 enhance the expression in E. coli, Choi et al. 2016). 2-hydroxyisovaleryl-CoA can be directly dehydrated to 3-methyl-2-butenoyl-CoA (3-methylcrotonyl-CoA) by C. difficlle 2-hydroxyacyl-CoA dehydratase HadBCI (ÄJP10092.1, AJP10093.1, AJP10091.1 or C. propionicum 65 2-hydroxyacyl-CoA dehydratase LcdABC (G3KIM4.1, G3KIM3.1, G3KIM5.1. HadBCI is originally a 2-hydroxyi-

socaproyl-CoA dehydratase. Kim et al. 2005). LcdABC is originally a lactonyl-CoA dehydratase. (Hofmeister et al. 1992).

2-hydroxyisovaleryl-CoA can also be converted to 3-methylcrotonyl-CoA by a multi-step pathway. In that pathway, 2-hydroxyisovaleryl-CoA is first reduced to (2R)-3-methyl-1,2-butanediol catalyzed by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. (2R)-3-methyl-1,2-butanediol is dehydrated to 3-methylbutanal by diol dehydratase which is then converted to isovaleryl-CoA by aldehyde-forming acyl-CoA reductase. Isovaleryl-CoA is converted to 3-methylcrotonyl-CoA by P. aeruginosa acyl-CoA dehydrogenase acyl-CoA dehydrogenase LiuA (APJ52511.1).

3-methylcrotonyl-CoA is converted to prenol by alcoholreductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from group consisting C. acetobutylicum AdhE2 the (YP\_009076789.1) and *M. aquaeolei* VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YigB (NP\_418690.4) and Acinetobacter sp. ChnD (BAC80217.1).

In another route, 2-hydroxyisovaleric acid is dehydrated 35 to 3-methylcrotonic acid by 2-hydroxyacid dehydratase. 3-methylcrotonic acid is either activated to 3-methylcrotonyl-CoA, which is then converted to prenol by alcoholforming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase, or directly converted 40 to prenol by two step reductions by carboxylate reductase and alcohol dehydrogenase. Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP 414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, the proxy product for the synthesis pathway. Because 2-hydroxyacyl-CoA dehydratase is oxygen-sensitive, the strain harboring this pathway is grown under microaerobic or anoxic or anaerobic conditions.

As above, JST06(DE3) serves as the E. coli host strain for demonstration of novel pathway. The genes for overexpression are either cloned into appropriate vectors or inserted into chromosome with strong synthetic constitutive promoter M1-93, as described in the previous example. Transformed cells are grown, and supernatant analyzed, also as described in the previous example.

Among above enzymes, as mentioned in the previous example, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases ChnD, YjgB and YahK on oxidization of prenol have been 5 proven through enzymatic spectrophotometric assay. E. coli alcohol dehydrogenases FucO (NP\_417279.2), YqhD (NP\_417484.1), YiaY (YP\_026233.1) were also assayed on prenol, but as mentioned above, they did not show the activity on prenol oxidization. The results of assays on 10 alcohol dehydrogenases can be seen in Table P, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

Pct540 on activation of 2-hydroxyisovaleric acid to 2-hydroxyisovaleryl-CoA have also been proven through enzymatic spectrophotometric assay.

Genes encoding Pct540 was codon optimized and synthesized by GeneArt. The gene encoding Pct was PCR 20 amplified from the genomic DNA of M. elsdenii. The primers required for cloning of these genes are listed in Table R. The pct gene insert was PCR amplified from the genomic DNA of Megasphaera elsdenii with pct-f2 and pct-r2 primers and inserted into vector pUCBB-ctH6-eGFP 25 (Vick et al. 2011) cleaved by BgIII and XhoI through In-Fusion HD Eco-Dry Cloning system to construct pUCBB-ctH6-pct. The sequence of the pct gene insert was further confirmed by DNA sequencing. The protein was expressed with a c-terminal 6 His-tag. 30

The codon-optimized pct540 gene insert was PCR amplified with pct540-f1 and pct540-r1 primers and inserted into vector pTrcHis2A (Invitrogen, Carlsbad, Calif.) cleaved by NcoI and SalI through In-Fusion HD Eco-Dry Cloning system to construct pTH-ctH6-pct540. The sequence of the 35 pct540 gene insert was further confirmed by DNA sequencing. The protein was expressed with a c-terminal 6 His-tag. The sequence-confirmed plasmids were introduced into BL21(DE3) (Studier et al. 1986).

For expression of enzymes, cultures were grown in 25 mL 40 of LB media in 125 mL flasks (Wheaton Industries, Inc., Millville, N.J.) at 37° C. A single colony of the desired strain was cultivated overnight (14-16 hrs) in 10 mL of LB medium in baffled flasks (Wheaton Industries, Inc., Millville, N.J.) with appropriate antibiotics and used as the 45 inoculum (3%). Except for the expression of pct, the cells were induced with 0.1 mM IPTG at an OD550~0.6, while pct was expressed constitutively.

After post-induction growth for 16 hours, the cells were collected and washed twice by 9 g/L sodium chloride 50 solution. Cells were then re-suspended in lysis buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 10 mM imidazole, pH 8.0) to an OD ~40. After re-suspension, the cells were disrupted using glass beads and then centrifuged at 4° C., 13000 g, 10 min in an Optima L-80XP Ultracentrifuge (Beckman- 55 Coulter, Schaumburg, Ill.). The resultant supernatant is the crude enzyme extract. The His-tagged enzymes were then purified from crude extract by using Ni-NTA spin kit (Qiagen, Valencia, Calif.). The crude extracts are centrifuged (270 g, 5 min) in spin columns that were equilibrated with 60 lysis buffer and then washed twice by wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 20 mM imidazole, pH 8.0). After washing, the enzyme was eluted twice in elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 500 mM imidazole, pH 8.0). Both washing and elution steps are centrifuged at 890 g for 65 2 min. The purified enzyme extracts were then further concentrated and dialyzed through Amicon® Ultra 10K

Device (Millipore, Billerica, Mass.). The enzymes were first filtered by centrifugation at 4° C., 14000 g, 10 min, and then washed with 100 mM potassium phosphate, pH 7 buffer under the same centrifugation conditions. Finally, the concentrated and dialyzed enzymes were recovered through 4° C., 1000 g, 2 min centrifugation. The protein concentration was established using the Bradford Reagent (Thermo Scientific, Waltham, Mass.) using BSA as the protein standard. SD S-PAGE monitor of purified proteins was performed through XCell SureLock™ Mini-cell system (Invitrogen, Carlsbad, Calif.) with gels (12% acrylamide resolving gel and 4% acrylamide stacking gel) prepared through Sure-Lock<sup>TM</sup> Mini-cell system (Invitrogen, Carlsbad, Calif.). The composition of the running buffer for SDS-PAGE was 3 g/L The in vitro activities of acyl-CoA transferases Pct and 15 tris base, 14.4 g/L glycine and 1 g/L SDS in water.

> Enzymatic reactions were monitored on either a Synergy HT plate reader (BioTek Instruments, Inc., Winooski, Vt.) or Biomate 5 Spectrophotometer (Thermo Scientific, Waltham, Mass.) according to established protocols.

> Measurement of acvl-CoA transferase activity was conducted in a two-step reaction in which the residual amount of acetyl-CoA after incubation of the enzyme with the substrate of interest was measured. Each assay was carried out in 100 mM Tris-HCL (pH 7.4). First, 0.1 mM acetyl-CoA and 1 or 10 mM of the substrate was incubated with purified enzyme for 15 min at 30° C. After denaturation of the enzyme (90 s at 95° C.), 0.1 mM oxaloacetate, 5 µg citrate synthase and 0.5 mM DTNB were added, and the reaction was further incubated for 15 min at 30° C. The amount of generated CoASH was determined by measuring the absorbance at 412 nm.

> Pct and Pct540 were assayed on CoA transfer from acetyl-CoA to three different substrates: original substrate propionic acid, 2-hydroxyisovaleric acid and 3-methylcrotonic acid, which are required for this novel GPP synthesis pathway. The results of activation of different substrates by Pct and Pct540 are shown in FIG. 20. Pct and Pct540 were shown to have slight activity towards 3-methylcrotonic acid. These enzymes have higher activity towards 2-hydroxyisovaleric acid, and the activity of Pct is higher than that of Pct540, though their activities on 2-hydroxyisovaleric acid are lower than those on original substrate propionic acid. Thus, Pct and Pct540 are suitable acyl-CoA transferases for activation of 2-hydroxyisovaleric acid.

> Also, JST06(DE3) strain overexpressing B. subtilis acetolactate synthase AlsS, E. coli acetohydroxy acid isomeroreductase IlvC, E. coli dihydroxy acid dehydratase IlvD and Lactococcus lactis 2-hydroxyacid dehydrogenase PanEthe enzymes of first four steps of the pathway-have been grown in shake flasks with 20 mL LB-like MOPS supplemented with 20 g/L glycerol or 32 g/L glucose (55 g/L CaCO<sub>3</sub> was also added when glucose was used) for 48 hours under 37° C. with 5 µM IPTG induction. The genes encoding AlsS, IlvC, IlvD and PanE were expressed from the plasmid pET-P1-ilvC-ilvD-P2-alsS-panE. The genes encoding AlsS and PanE were codon optimized and synthesized by either GeneArt or GenScript, while the genes encoding IlvC and IlvD were amplified from genomic DNA of wild type E. coli MG1655 strain. The plasmids used for the construction of plasmid are listed in Table R. The codon-optimized alsS and panE gene inserts were PCR amplified with alsS-f1/alsS-r1 and panE-f1/panE-r1 primers respectively, and inserted together into vector pETDuet-1 cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system, resulting in pET-P2-alsS-panE plasmid. The ilvC and ilvD gene inserts were PCR amplified from the genomic DNA of E. coli with ilvC-f1/ilvC-r1 and ilvD-f1/ilvD-r1 primers respectively,

and inserted together into vector pET-P2-alsS-panE cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system, generating pET-P1-ilvC-ilvD-P2-alsS-panE. The sequences of constructed plasmids are further confirmed by DNA sequencing. The quantification of 2-hydroxyisovaleric 5 acid was performed via ion-exclusion HPLC using a Shimadzu Prominence SIL 20 system (Shimadzu Scientific Instruments, Inc., Columbia, Md.) equipped with an HPX-87H organic acid column (Bio-Rad, Hercules, Calif.) with operating conditions to optimize peak separation (0.3 10 mL/min flow rate, 30 mM  $H_2SO_4$  mobile phase, column temperature 42° C.). Concentration of 2-hydroxyisovaleric acid in fermentation samples was determined through calibration to known 2-hydroxyisovaleric acid standards (5, 1, 0.5, 0.2 and 0.1 g/L).

As shown in FIG. **21**, this strain shows high production of 2-hydroxyisovaleric acid, especially when glucose was used as carbon source, in which the titer was 8.27 g/L. This indicates that AlsS, IlvC, IlvD and PanE can supply 2-hydroxyisovaleric acid with high flux, providing sufficient 20 intermediates supply for the subsequent conversion into prenol and GPP.

Plasmids containing the codon optimized gene encoding  $6 \times$ HIS-tagged Lmo1179 and PddABC were constructed. The resulting construct was transformed into *E. coli* BL21 25 (DE3) for expression. The resulting strain was cultured in 50 mL of TB media containing appropriate antibiotics in a 250 mL flask. When the culture reached an OD550 of approximately 0.6, expression was induced by the addition of 0.1 mM IPTG, and the cells were harvested by centrifugation 30 after overnight incubation at room temperature.

The HIS-tagged Lmo1179 protein was purified from the cell extract using Talon Metal Affinity Resin (Clontech lab., CA). In short, a 250  $\mu$ L resin bed was equilibrated twice using 2.5 mL of a buffer containing 50 mM sodium phos- 35 phate, 300 mM NaCl, and 10 mM imidazole at pH 7.5 (NPI-10). The cell extract was added to the resin and the mixture shaken gently for 20 minutes on ice. The resin was then washed twice with 2.5 mL buffer NPI-20 (same as NPI-10 but with 20 mM imidazole), shaking gently on ice 40 for 15 minutes each wash. The resin was then transferred to a gravity column and washed once with 1.25 mL NPI-20. Finally, the desired protein was eluted using 1.25 mL of buffer NPI-250 (same as buffer NPI-10 but with 250 mM imidazole), and the eluate collected in 500  $\mu$ L fractions. 45

Clarified cell lysates of BL21(DE3) strain overexpressing His-tagged PddABC was prepared by resuspending a saved pellet in 50 mM potassium phosphate buffer pH 7.5 containing 0.2 M ethylene glycol. The resuspended cells were broken by glass beads and supernatant was reserved after 50 centrifugation. Assays were performed by coupling the dehydration of ethylene glycol to acetaldehyde to acyl-CoA reductase Lmo1179 to give acetyl-CoA with the reduction of NAD<sup>+</sup> to NADH, which was monitored at 340 nm. The final assay mixture was 250  $\mu$ L and contained 50 mM potassium 55 phosphate buffer pH 7.5, 5 mM CoASH, 0.5 mM NAD<sup>+</sup>, 0.2 M ethylene glycol, 7  $\mu$ L purified Lmo1179, 50  $\mu$ L cell lysate, and 15  $\mu$ M coenzyme B12 (the cofactor of PddABC). The relevant controls included were no cell lysates (replaced with 50  $\mu$ L of buffer) and no coenzyme B12. 60

The in vitro activity of dehydration of ethylene glycol to acetaldehyde by diol dehydratae PddABC (AFJ04717.1, AFJ04718.1, AFJ04719.1) from *Klebsiella oxytoca* has been proven, as shown in FIG. **22**. This assay was coupled with oxidization of resultant acetaldehyde to acetyl-CoA by *List-* 65 *eria monocytogenes* acyl-CoA reductase (ACR) Lmo1179 (CAC99257.1) and the activity was measured through

observation of increased NADH absorbance. Based on these results, PddABC should be a good candidate of diol dehydratase for dehydration of (2R)-3-methyl-1,2-butanediol required for GPP synthesis pathway.

(Prophetic) GPP Biosynthesis Via 2-hydroxyisovaleric Acid and Prenol Starting from Aldol Condensation Between Acetaldehyde and Pyruvate

The purpose of this experiment is to demonstrate the biosynthesis of GPP through a novel pathway that starts from aldol condensation between pyruvate and acetaldehyde via 2-hydroxyisovaleric acid and prenol, using E. coli as the host organism. This pathway starts from aldol condensation between pyruvate and acetaldehyde to (S)-4-hydroxy-2oxopentaonoic acid by E. coli aldolase MhpE (NP\_414886.1). Acetaldehyde is supplied either through decarboxylation of pyruvate by Saccharomyces cerevisiae alpha-keto acid decarboxylase PDC1 (CAA97573.1) or through reduction of acetyl-CoA by E. coli aldehyde forming acyl-CoA reductase MhpF (NP\_414885.1). Then, a mutase moves the ---(C==O)COOH group of (S)-4-hydroxy-2-oxopentanoic acid from C-3 site to C-4 site, forming 3-hydroxy-2-oxo-3-methylbutyric acid. 2-hydroxyacid dehydrogenase converts 3-hydroxy-2-oxo-3-methylbutyric acid to (2R)-2,3-dihydroxy-3-methylbutyric acid. E. coli dihydroxy acid dehydratase IlvD (YP\_026248.1) dehydrates (2R)-2,3-dihydroxy-3-methylbutanoate to 3-methyl-2oxobutyric acid (2-oxoisovaleric acid). Then, L. lactis 2-hydroxyacid dehydrogenase PanE (AIS03659.1) reduces 2-oxoisovaleric acid to (2R)-3-methyl-2-hydroxybutyric acid (2-hydroxyisovaeleric acid). 2-hydroxyisovaleric acid is then activated to (2R)-3-methyl-2-hydroxybutanoyl-CoA (2-hydroxyisovaleryl-CoA) by acyl-CoA transferase selected from the group consisting M. elsdenii Pct (BAU59368.1) and C. propionicum Pct540 (CAB77207.1, with V193A mutation to enhance the expression in E. coli, Choi et al. 2016). 2-hydroxyisovaleryl-CoA can be directly dehydrated to 3-methyl-2-butenoyl-CoA (3-methylcrotonyl-CoA) by C. difficile 2-hydroxyacyl-CoA dehydratase HadBCI (AJP10092.1, AJP10093.1, AJP10091.1. HadBCI is originally a 2-hydroxyisocaproyl-CoA dehydratase. Kim et al. 2005) or C. propionicum 2-hydroxyacyl-CoA dehydratase LcdABC (G3KIM4.1, G3KIM3.1, G3KIM5.1. Lcd-ABC is originally a lactonyl-CoA dehydratase, Hofmeister et al. 1992). 2-hydroxyisovaleryl-CoA can also be converted to 3-methylcrotonyl-CoA by a multi-step pathway.

In that pathway, 2-hydroxyisovaleryl-CoA is first reduced to (2R)-3-methyl-1,2-butanediol catalyzed by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. (2R)-3-methyl-1,2-butanediol is dehydrated to 3-methylbutanal by diol dehydratase which is then converted to isovaleryl-CoA by aldehyde-forming acyl-CoA reductase. Isovaleryl-CoA is converted to 3-methylcrotonyl-CoA by P. 60 aeruginosa acyl-CoA dehydrogenase acyl-CoA dehydrogenase LiuA (APJ52511.1). 3-methylcrotonyl-CoA is converted to prenol by an alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acylCoA reductase is selected from the group consisting C. acetobutylicum AdhE2 (YP\_009076789.1) and M. aquaeolei VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. ChnD (BAC80217.1).

In another route, 2-hydroxyisovaleric acid is dehydrated to 3-methylcrotonic acid by 2-hydroxyacid dehydratase. 3-methylcrotonic acid is either activated to 3-methylcrotonyl-CoA, which is then converted to prenol by alcoholforming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase, or directly converted to prenol by two step reductions by carboxylate reductase and alcohol dehydrogenase. Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, 20 V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate 25 isomerase Idi (NP\_417365.1) converts DMAPP to IPP. DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP 414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, the proxy product for the synthesis pathway. Because 2-hydroxyacyl-CoA dehydratase is oxygen-sensitive, the strain harboring this pathway is grown under microaerobic or anoxic or anaerobic conditions.

JST06(DE3) serves as the E. coli host strain for demon-35 stration of this novel pathway. Vector creation, strain creation, growth and analysis of supernatant are as described above in previous examples.

Among above enzymes, as mentioned in the previous example, The in vitro activities of acyl-CoA transferases Pct 40 3-methyl-2-butenoyl-CoA (3-methylcrotonyl-CoA) by C. and Pct540 on activation of 2-hydroxyisovaleric acid to 2-hydroxyisovaleryl-CoA, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases ChnD, YjgB and YahK on oxidization of 45 prenol have been proven through enzymatic spectrophotometric assay. E. coli alcohol dehydrogenases FucO (NP 417484.1), (NP 417279.2), YqhD YiaY (YP\_026233.1) were also assayed on prenol, but as mentioned above, they did not show the activity on prenol oxidization. The results of assays on alcohol dehydrogenases and acyl-CoA transferases can be seen in Table R and FIG. 20 respectively, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

The in vitro activity of dehydration of ethylene glycol to 55 acetaldehyde by diol dehydratae PddABC (AFJ04717.1, AFJ04718.1, AFJ04719.1) from Klebsiella oxytoca has been proven, as shown in FIG. 22. The assay method is described in the previous examples.

(Prophetic) GPP Biosynthesis Via 2-hydroxyisovaleryl-CoA and Prenol Starting from Non-Decarboxylative Acyloin Condensation Vetween Isobutanal and Formyl-CoA

The purpose of this experiment is to demonstrate the biosynthesis of GPP through a novel pathway that starts

38

from non-decarboxylative acyloin condensation between formyl-CoA and isobutanal via 2-hydroxyisovaleryl-CoA and prenol, using E. coli as the host organism. This pathway starts from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA to (2R)-3-methyl-2-(2-hydroxyisovaleryl-CoA) hydroxybutanoyl-CoA bv Homo sapiens 2-hydroxyacyl-CoA lyase HACL1 (NP\_036392.2). Formyl-CoA is activated from formate, which is a byproduct of conversion of pyruvate to acetyl-CoA by E. coli pyruvate-formate lyase PflB (NP\_415423.1), catalyzed by activation enzymes selected from the group consisting acyl-CoA synthase, acyl-CoA transferase, carboxylate kinase plus phosphotransacylase. Isobutanal is reduced from isobutyryl-CoA by aldehyde forming acyl-CoA reductase. Isobutyryl-CoA is converted from butyryl-CoA by mutase. Butyryl-CoA can be supplied from butyric acid, either supplemented or intracellularly synthesized through beta-oxidation reversal starting from two acetyl-CoAs composed of ketoacyl-CoA thiolase **BktB** (AAC38322.1) from R. eutropha or thiolase AtoB (NP 416728.1) from E. coli, hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase multifunctional enzyme FadB from E. coli (NP\_418288.1) and enoyl-CoA reductase EgTer from E. gracilis (Q5EU90.1) or fatty acid biosynthesis pathway starting from acetyl-CoA and malonyl-CoA composed of beta-ketoacyl-ACP synthase FabH (NP\_415609.1), beta-ketoacyl-ACP reductase FabG (NP\_415611.1), 3-hydroxyacyl-ACP dehydratase FabZ (NP 414722.1) and enoyl-ACP reductase FabI (NP\_415804.1), all from E. coli, with termination by E. coli thioesterase TesA (NP\_415027.1, with truncation of 26 aa leader sequence) and activation by E. coli acyl-CoA synthetase FadD (NP\_416319.1), or directly synthesized through overexpressed beta-oxidation reversal pathway without termination. If malonyl-CoA is used to enhance its supply, E. coli acetyl-CoA carboxylase AccABCD (NP 414727.1, NP\_417721.1, NP 417722.1, NP\_416819.1) is overexpressed.

2-hydroxyisovaleryl-CoA can be directly dehydrated to difficile 2-hydroxyacyl-CoA dehydratase HadBCI (AJP10092.1, AJP10093.1, AJP10091.1. HadBCI is originally a 2-hydroxyisocaproyl-CoA dehydratase. Kim et al. 2005) or C. propionicum 2-hydroxyacyl-CoA dehydratase LcdABC (G3KIM4.1, G3KIM3.1, G3KIM5.1. LcdABC is originally a lactonyl-CoA dehydratase. Hofmeister et al. 1992). 2-hydroxyisovaleryl-CoA can also be converted to 3-methylcrotonyl-CoA by a multi-step pathway. In that pathway, 2-hydroxyisovaleryl-CoA is first reduced to (2R)-3-methyl-1,2-butanediol catalyzed by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. (2R)-3-methyl-1,2-butanediol is dehydrated to 3-methylbutanal by diol dehydratase which is then converted to isovaleryl-CoA by aldehyde-forming acyl-CoA reductase. Isovaleryl-CoA is converted to 3-methylcrotonyl-CoA by P. aeruginosa acyl-60 CoA dehydrogenase acyl-CoA dehydrogenase LiuA (APJ52511.1). 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxy-

late reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from the group consisting *C. acetobutylicum* AdhE2 (YP\_009076789.1) and *M. aquaeolei* VT8 Maqu\_2507 (YP\_959769.1). CbjALD from *C. beijerinckii* aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol 5 dehydrogenase is selected from the group consisting *E. coli* YahK (NP\_414859.1), *E. coli* YjgB (NP\_418690.4) and *Acinetobacter* sp. ChnD (BAC80217.1).

Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first 10 step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phos- 15 phate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, 20 S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, the proxy product for the synthesis pathway. Because diol dehydratase is oxygen-sensitive, the 25 strain harboring this pathway is grown under microaerobic or anoxic or anaerobic conditions.

JST06(DE3) serves as the *E. coli* host strain for demonstration of this novel pathway. Vector creation, strain creation, growth and analysis of supernatant are as described 30 above in previous examples.

The in vivo butyryl-CoA and butyric acid synthesis through beta-oxidation reversal composed of AtoB, FadB and EgTer has been demonstrated in E. coli. JC01 (MG1655 ΔldhA ΔpoxB Δpta ΔadhE ΔfrdA, an E. coli strain with 35 removal of mixed-acid fermentation for improved supply of acetyl-CoA), overexpressing AtoB, FadB and EgTer produced 3.3 g/L of butyric acid when grown in LB-like MOPS media with glycerol as carbon source for 48 hours, indicating that beta-oxidation reversal composed of AtoB, FadB 40 and EgTer is functional of supplying butyric acid with acetyl-CoA as primer and extender unit, and native endogenous thioesterases are able to hydrolyze butyryl-CoA to butyric acid. Overexpression of different E. coli thoesterases FadM (NP\_414977.1), TesA (NP\_415027.1), TesB 45 (NP\_414986.1), YciA (NP\_415769.1), YdiI (NP\_416201.1) and YbgC (NP 415264.1) was added, but as seen in FIG. 23, it did not greatly improve butyric acid production. The detailed methods of fermentation conditions and HPLC analysis for butyric acid are described in previous examples. 50

The vectors and primers used in overexpression of AtoB, FadB, EgTer and thioesterases are listed in Table S. The E. coli genes were PCR amplified from genomic DNA of wild type E. coli strain, while the gene encoding EgTer was codon-optimized and synthesized by GenScript. For the 55 construction of pTH-atoB-fadB-egter, the atoB gene insert was first PCR amplified with atoB-f1/atoB-r1 primers and inserted into vector pTrcHis2A (Invitrogen, Carlsbad, Calif.) cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system to construct pTH-atoB. Then, the fadB gene 60 insert was PCR amplified with fadB-f1/fadB-r1 primers and inserted into vector pTH-atoB cleaved by HindIII through In-Fusion HD Eco-Dry Cloning system to generate pTHatoB-fadB. Finally, the egter gene insert was PCR amplified with egter-f1/egter-r1 primers and inserted into vector pTH- 65 atoB-fadB cleaved by HindIII through In-Fusion HD Eco-Dry Cloning system to generate pTH-atoB-fadB-egter. The

thioesterases were overexpressed from pZS vector backbone (Invitrogen, Carlsbad, Calif.). The genes encoding thioesterases were PCR amplified with relevant primers (fadM-f1/fadM-r1, tesA-f1/tesB-r1, tesA-f1/tesA-r1, ydi1-f1/ydi1r1, ybgC-f1/ybgC-r1, yciA-f1/yciA-r1) and inserted into pZS cleaved by KpnI and MluI through In-Fusion HD Eco-Dry Cloning system.

The condensations between formyl-CoA and different kinds of aldehyde (pentadecanal, acetaldehyde, formaldehyde) by 2-hydroxyacyl-CoA lyase HACL1 have been proven in vitro, as shown in FIG. **24**. HACL1 is a good candidate to also accept required isobutanal as the substrate for acyloin condensation.

2-hydroxyhexadecanoyl-CoA was prepared by the n-hydroxysuccinimide method (Blecher, 1981). In summary, the n-hydroxysuccinimide ester of 2-hydroxyhexadecanoic acid is prepared by reacting n-hydroxysuccinimide with the acid in the presence of dicyclohexylcarbodiimide. The product is filtered and purified by recrystallization from methanol to give pure n-hydroxysuccinimide ester of 2-hydroxyhexadecanoic acid. The ester is reacted with CoA-SH in presence of thioglycolic acid to give 2-hydroxyhexadecanoyl-CoA. The 2-hydroxyhexadecanoyl-CoA is purified precipitation using perchloric acid, filtration, and washing the filtrate with perchloric acid, diethyl ether, and acetone.

Formyl-CoA was prepared by first forming formic ethylcarbonic anhydride as previously described (Parasaran & Tarbell, 1964). Briefly, formic acid (0.4 mmol) and ethyl chloroformate (0.4 mmol) were combined in 4 mL anhydrous diethyl ether and cooled to  $-20^{\circ}$  C. 0.4 mmol triethylamine was added to the mixture and the reaction was allowed to proceed at -20° C. for 30 minutes. The reaction mixture was filtered over glass wool to give a solution containing formic ethylcarbonic anhydride in diethyl ether. To obtain formyl-CoA, 7 µmol CoASH was dissolved in 5 mL 3:2 water:tetrahydrofuran, to which 10 mg of sodium bicarbonate were added. The solution of formic ethylcarbonic anhydride was added dropwise to the CoASH solution with vigorous agitation, after which the organic phase was evaporated under a stream of nitrogen. The mixture was kept at 4° C. for two hours, after which any remaining diethyl ether was evaporated under nitrogen. Solid phase extraction using a C18 column was used to purify formyl-CoA from the reaction mixture. Formyl-CoA was eluted from the C18 column in methanol and stored in 2:1 methanol:ammonium acetate pH 5.5.

The resulting cell pellet was resuspended in Bacterial Protein Extraction Reagent (B-PER) (THERMO SCIE., MA) to an OD550 of approximately 40, to which approximately 5000 U of lysozyme and approximately 250 U of Benzonase nuclease (Sigma-Aldrich CO., MO) were added. The cell mixture was left at room temperature until completely clarified to give the cell extract. 1 M stock solution of imidazole was added to provide a final concentration of 10 mM imidazole in the cell extract.

A plasmid containing the codon optimized gene encoding human HIS-tagged HACL1 was constructed as described. The resulting construct, was transformed into *S. cerevisiae* InvSC1 (Life Technologies, Carlsbad, Calif.). The resulting strain was cultured in 50 mL of SC-URA media containing 2% glucose at 30° C. for 24 hours. The cells were pelleted and the required amount of cells were used to inoculate a 250 mL culture volume of SC-URA media containing 0.2% galactose, 1 mM MgCl<sub>2</sub>, and 0.1 mM thiamine to 0.4 OD600. After 20 hours of incubation with shaking at 30° C., the cells were pelleted and saved.
When needed, the cell pellets were resuspended to an OD600 of approximately 100 in a buffer containing 50 mM potassium phosphate pH 7.4, 0.1 mM thiamine pyrophosphate, 1 mM MgCl<sub>2</sub>, 0.5 mM AEBSF, 10 mM imidazole, and 250 units of Benzonase nuclease. To the cell suspension, 5 approximately equal volumes of 425-600  $\mu$ m glass beads were added. Cells were broken in four cycles of 30 seconds of vortexing at 3000 rpm followed by 30 seconds on ice. The glass beads and cell debris were pelleted by centrifugation and supernatant containing the cell extract was collected. 10 The HIS-tagged HACL1 was purified from the cell extract using Talon Metal Affinity Resin as described above, with the only modification being the resin bed volume and all subsequent washes were halved. The eluate was collected in two 500  $\mu$ L fractions. 15

Human HACL1 was cloned, expressed, and purified in *S. cerevisiae* as described above. Purified HACL1 was tested for its native catabolic activity by assessing its ability to cleave 2-hydroxyhexadecanoyl-CoA to pentadecanal and formyl-CoA. Enzyme assays were performed in 50 mM 20 tris-HCl pH 7.5, 0.8 mM MgCl<sub>2</sub>, 0.02 mM TPP, 6.6  $\mu$ M BSA, and 0.3 mM 2-hydroxyhexadecanoyl-CoA. The assay mixtures were incubated for one hour at 37° C., after which the presence of pentadecanal was assessed by extraction with hexane and analysis by GC-FID. As shown in FIG. **24**, 25 pentadecanal was produced in the sample containing HACL1, but not in the control sample, which did not contain HACL1, indicating that the protein was expressed and purified in an active form.

The ability of purified HACL1 to run in the anabolic 30 direction (reverse from the physiological direction) was also determined. An aldehyde and formyl-CoA were tested for ligation in a buffer comprised of 60 mM potassium phosphate pH 5.4, 2.5 mM MgCl2, 0.1 mM TPP, 6.6 µM BSA, 5 mM aldehyde, 20% DMSO, approximately 1 mM freshly 35 prepared formyl-CoA, and approximately 0.5 mg/mL purified HACL1. The reaction was allowed to take place at room temperature for 16 hours, after which acyl-CoAs were hydrolyzed to their corresponding acids by adjusting to pH >12.0. For situations in which a short carbon chain product 40 was expected, for example lactate production from acetaldehyde, samples were analyzed by HPLC. In the case of longer products, for example the production of 2-hydroxyhexadecanoic acid from pentadecanal, samples were acidified with HCl and extracted with diethyl ether. The extracted 45 diethyl ether was evaporated to dryness under a stream of nitrogen and derivatized by the addition of 1:1 BSTFA: pyridine. After incubation at 70° C. for 30 min, these samples were analyzed by GC-FID.

When the purified enzyme was supplied with pentadeca- 50 nal and formyl-CoA, as in FIG. **24**, HACL1 was shown to catalyze the ligation of these molecules to 2-hydroxyhexa-decanoyl-CoA as hypothesized. After hydrolysis of acyl-CoAs, the chromatogram of the sample containing enzyme shows similar peaks to the 2-hydroxyhexadecanoyl-CoA 55 spiked standard, which are absent from the sample containing no enzyme.

The purified HACL1 was further tested for activity on shorter aldehydes, such as the ligation of acetaldehyde or formaldehyde with formyl-CoA to produce lactoyl-CoA or 60 glycolyl-CoA, respectively. After hydrolysis of acyl-CoAs to their acid forms, these samples were analyzed by HPLC. The presence of lactate from elongation of acetaldehyde and formyl-CoA was identified in the sample containing HACL1, but not in the no enzyme control as shown in FIG. 65 **24**. Similar results were observed for glycolate from formaldehyde and formyl-CoA as shown in FIG. **24**. The pres42

ence of lactate in the relevant samples was confirmed by NMR. This demonstrates that HACL1 is capable of catalyzing the ligation of aldehydes with chain lengths ranging at least from C1-C15 with formyl-CoA, making it suitable for acyloin condensation between C5 aldehyde isobutanal with formyl-CoA, required for the GPP synthesis pathway.

Also, the required activity of activation of formate to formyl-CoA by *E. coli* acyl-CoA synthase ACS (NP\_418493.1) was also proven in vitro as shown in FIG. **25**. This assay was coupled with reduction of resultant formyl-CoA to formaldehyde by *Listeria monocytogenes* acyl-CoA reductase (ACR) Lmo1179 (CAC99257.1) and the activity was measured through observation of NADH oxidization.

A plasmid containing the codon optimized gene encoding  $6 \times$ HIS-tagged Lmo1179 from *Lysteria monocytogenes* was constructed. The resulting construct was transformed into *E. coli* BL21(DE3) for expression. The resulting strain was cultured in 50 mL of TB media containing appropriate antibiotics in a 250 mL flask. When the culture reached an OD550 of approximately 0.6, expression was induced by the addition of 0.1 mM IPTG, and the cells were harvested by centrifugation after overnight incubation at room temperature.

The HIS-tagged Lmo1179 protein was purified from the cell extract using Talon Metal Affinity Resin (Clontech lab., CA). In short, a 250  $\mu$ L resin bed was equilibrated twice using 2.5 mL of a buffer containing 50 mM sodium phosphate, 300 mM NaCl, and 10 mM imidazole at pH 7.5 (NPI-10). The cell extract was added to the resin and the mixture shaken gently for 20 minutes on ice. The resin was then washed twice with 2.5 mL buffer NPI-20 (same as NPI-10 but with 20 mM imidazole), shaking gently on ice for 15 minutes each wash. The resin was then transferred to a gravity column and washed once with 1.25 mL NPI-20. Finally, the desired protein was eluted using 1.25 mL of buffer NPI-250 (same as buffer NPI-10 but with 250 mM imidazole), and the eluate collected in 500  $\mu$ L fractions.

*E. coli* ACS was cloned, expressed, and purified in *E. coli* as described above. The purified enzyme was evaluated for its ability to convert formate into the extender unit formate. Enzyme assays were performed in 23 mM potassium phosphate buffer pH 7.0, 1 mM CoASH, 0.5 mM NADH, 5 mM ATP, 2.5 mM MgCl<sub>2</sub>, 50 mM formate. *E. coli* ACS was added along with *Lysteria monocytogenes* Lmo1179, and the reduction of resulting formyl-CoA was monitored by measuring absorbance of NADH at 340 nm. The sample containing ACS resulted in an increased rate of NADH oxidation, indicating that formyl-CoA was produced by ACS.

Among above enzymes, as mentioned in the previous example, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases ChnD, YjgB and YahK on oxidization of prenol have been proven through enzymatic spectrophotometric assay. *E. coli* alcohol dehydrogenases FucO (NP\_417279.2), YqhD (NP\_417484.1), YiaY (YP\_026233.1) were also assayed on prenol, but as mentioned above, they did not show the activity on prenol oxidization. The results of assays on alcohol dehydrogenases can be seen in Table P, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

The in vitro activity of dehydration of ethylene glycol to acetaldehyde by diol dehydratae PddABC (AFJ04717.1,

5

AFJ04718.1, AFJ04719.1) from *Klebsiella oxytoca* has been proven, as shown in FIG. **22**. The assay method is described in the previous examples.

(Prophetic) GPP Biosynthesis Via 4-methyl-2-oxo-4-pentenoic Acid and Isoprenol Starting Aldol Condensation Between Acetaldehyde and 2-oxobutyric Acid

The purpose of this experiment is to demonstrate the 10 biosynthesis of GPP through a novel pathway that starts from aldol condensation between 2-oxobutyric acid and acetaldehyde via 4-methyl-2-oxo-4-pentenoic acid and isoprenol, using E. coli as the host organism. This pathway starts from aldol condensation between pyruvate and acet- 15 aldehyde to 4-hydroxy-2-oxo-3-methylpentaonoic acid by E. coli aldolase MhpE (NP\_414886.1). Acetaldehyde is supplied either through decarboxylation of pyruvate by Saccharomyces cerevisiae alpha-keto acid decarboxylase PDC1(CAA97573.1) or through reduction of acetyl-CoA by 20 E. coli aldehyde forming acyl-CoA reductase MhpF (NP\_414885.1). 2-oxobutyric acid is elongated from pyruvate through alpha-keto acid pathway composed of: citramalate synthase CimA from Methanocaldococcus jannaschii (WP 010870909.1) or Leptospira interrogans serovar 25 Lai str. 56601 (NP\_712531.1); citramalate isomerase LeuCD from E. coli (NP\_414614.1, NP\_414613.1) or Methanocaldococcus jannaschii (AAB98487.1, AAB99283.1) or Leptospira interrogans serovar Lai str. 56601 (NP\_712276.1, NP\_712277.1); Methanocaldococcus 30 jannaschii 3-methylmalate dehydrogenase MJ0720 (WP\_010870225.1) or Leptospira interrogans serovar Lai 56601 3-methylmalate dehydrogenase str. LeuB (NP 712333.1).

After the aldol condensation, a mutase transfers the 35 methyl group of 4-hydroxy-2-oxo-3-methylpentanoic acid from C-3 to C-4 site, generating 4-hydroxy-2-oxo-4-methylpentanoic acid. Then, E. coli 2-oxopent-4-enoate dehydratase MhpD (NP\_414884.2) dehydrates 4-hydroxy-2-oxo-4-methylpentanoic acid into 4-methyl-2-oxo-4-pentenoic 40 acid. 4-methyl-2-oxo-4-pentenoic acid can be converted to 3-methyl-3-butenoyl-CoA by alpha-keto acid dehydrogenase and 3-methyl-3-butenoyl-CoA is converted to isoprenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxy- 45 late reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. 4-methyl-2-oxo-4-pentenoic acid can also be converted to isoprenol by two steps of reactions catalyzed by alpha- 50 keto acid decarboxylase and alcohol dehydrogenase. Alcohol-forming acyl-CoA reductase is selected from the group consisting C. acetobutylicum AdhE2 (YP 009076789.1) and *M. aquaeolei* VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA 55 reductase (AAT66436.1) is selected for conversion of 3-methyl-3-butenoyl-CoA to isoprenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. SE19 ChnD (BAC80217.1).

Isoprenol is then converted to IPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by *E. coli* alcohol kinase YchB (NP\_415726.1) and the second is catalyzed by *M. thermau-totrophicus* phosphate kinase MtIPK (AAB84554.1) or 65 *Thermoplasma acidophilum* phosphate kinase ThaIPK (WP\_010900530.1) or *Methanocaldococcus jannaschii* 

phosphate kinase MjIPK (3K4Y\_A)). The one step phosphorylation is catalyzed by alcohol diphosphokinase. *E. coli* isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. DMAPP and IPP are condensed to

GPP catalyzed by *E. coli* GPP synthase IspA (NP\_414955.1, S80F) or *A. grandis* GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). *Ocimum basilicum* geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, the proxy product for the synthesis pathway.

JST06(DE3) serves as the *E. coli* host strain for demonstration of this novel pathway. Vector creation, strain creation, growth and analysis of supernatant are as described above in previous examples.

(Prophetic) GPP Biosynthesis Via 2-oxoisovaleric Acid, 2-oxoisocaproic Acid and Prenol Starting from Decarboxylative Acyloin Condensation Between Two Pyruvates

The purpose of this example is to demonstrate the biosynthesis of GPP through a novel pathway via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol. E. coli serves as the host organism. This pathway starts from decarboxylative acyloin condensation of two pyruvates to (S)-2-acetolactone by B. subtilis acetolactate synthase AlsS (NP\_391482.2). E. acid isomeroreductase coli acetohydroxy IlvC (NP\_418222.1) converts (S)-2-acetolactone to (2R)-2,3-dihydroxy-3-methylbutyric acid. E. coli dihydroxy acid dehydratase IlvD (YP\_026248.1) dehydrates (2R)-2,3-dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutyric acid (2-oxoisovaleric acid). Then, 2-oxoisovaleric acid is elongated into 2-oxoisocaproic acid through alpha-keto acid pathway composed of: E. coli isopropylmalate synthase LeuA (NP\_414616.1, with a G462D mutation to maximize 2-oxoisocaprate production and minimize 2-oxoisovalerate, Connor et al. 2008) which condenses 2-oxoisovaleric acid and acetyl-CoA to (2S)-2-isopropylmalate; E. coli isopropyl isomerase LeuCD (NP\_414614.1, NP\_414613.1) which converts (2S)-2-isopropylmalate to (2R, 3S)-3-isopropylmalate; E. coli isopropylmalate dehydrogenase LeuB (NP\_414615.4) which oxidizes and decarboxylates (2R, 3S)-3-isopropylmalate, generating 4-methyl-2-oxopen-tanoic acid (2-oxoisocaproic acid). Then, *S. avermitilis* alpha-keto acid dehydrogenase complex BkdFGH-LpdA1 (BAC72088.1, BAC72089.1, BAC72090.1, KUN54417.1) converts 2-oxoisocaproic acid into isovaleryl-CoA. Overexpression of heterologous branched alpha-keto acid dehydrogenase complex requires improved lipoylation, which can be realized though supplementation of lipoic acid accompanied with overexpression of E. coli lipoate-protein ligase LplA (NP\_418803.1), or overexpression of E. coli endogenous lipoylation pathway consisting lipolate synthase LipA (NP\_415161.1) and lipoyl(octanoyl) transferase LipB (NP\_415163.2). P. aeruginosa acyl-CoA dehydrogenase LiuA (APJ52511.1) converts isovaleryl-CoA to 3-methylcrotonyl-CoA. 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxy-60 late reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from group consisting C. acetobutylicum AdhE2 the (YP\_009076789.1) and M. aquaeolei VT8 Maqu\_2507 (YP 959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for

conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. SE19 ChnD (BAC80217.1). Prenol is then converted to DMAPP by one or two steps of phosphory- 5 lation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the 10 second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. Then, DMAPP and IPP are condensed to 15 GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, with N-terminal 65 aa truncation) converts GPP to geraniol, which serves as a proxy to 20 demonstrate a functioning pathway.

JST06(DE3) serves as the *E. coli* host strain for demonstration of this novel pathway. Vector creation, strain creation, growth and analysis of supernatant is conducted as described in previous examples.

The required plasmids and primers for this example are listed in Table T. The genes encoding E. coli enzymes are PCR amplified from the genomic DNA of wild type strain, while genes encoding other enzymes are codon optimized and synthesized by either GeneArt or GenScript. For con- 30 struction of pET-P1-ilvC-ilvD-P2-alsS-liuA, the codon-optimized alsS and liuA gene inserts were first PCR amplified with alsS-f1/alsS-r2 and liuA-f1/liuA-r1 primers respectively, and inserted together into vector pETDuet-1 cleaved by NdeI and KpnI through In-Fusion HD Eco-Dry Cloning 35 system, resulting in pET-P2-alsS-panE plasmid. The ilvC and ilvD gene inserts were then PCR amplified from the genomic DNA of E. coli with ilvC-f1/ilvC-r1 and ilvD-f1/ ilvD-r1 primers respectively, and inserted together into vector pET-P2-alsS-liuA cleaved by NcoI and EcoRI 40 through In-Fusion HD Eco-Dry Cloning system, generating pET-P1-ilvC-ilvD-P2-alsS-liuA. For construction of pCDF-P1-bkdF-bkdG-bkdH-P2-lplA-lpdA1, the lplA and lpdA1 gene inserts were first PCR amplified with lplA-f1/lplA-r1 and lpdA1-f1/lpdA1-r1 primers respectively, and inserted 45 together into vector pCDFDuet-1 cleaved by NdeI and KpnI through In-Fusion HD Eco-Dry Cloning system, resulting in pCDF-P2-lp1A-lpdA1. The codon-optimized bkdF, bkdG and bkdH gene inserts were then PCR amplified with bkdF-f1/bkdF-r1, bkdG-f1/bkdG-r1, bkdH-f1/bkdH-r1 50 respectively and inserted together into pCDF-P2-lplAlpdA1 cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system, generating pCDF-P1-bkdF-bkdGbkdH-P2-lplA-lpdA1. For construction of pRSF-P1-leuA (G462D)-leuB-P2-leuC-leuD, the leuA and leuB genes were 55 PCR amplified together into two pieces from the genomic DNA of E. coli with leuA(G462D)B-f11/leuA(G462D)Br11 and leuA(G462D)B-f12/leuA(G462D)B-r12 respectively, and attached together through overlap PCR with leuA(G462D)B-f2/leuA(G462D)B-r2 to generate G462D 60 mutation. The overlap PCR product was inserted into pRSF-Duet-1 cleaved by NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system, generating pRSF-P1-leuA (G462D)-leuB. Then leuC and leuD genes were amplified together from from the genomic DNA of E. coli with 65 leuCD-f1/leuCD-r1 and the resulting gene insert was inserted into pRSF-P1-leuA(G462D)-leuB cleaved by KpnI,

generating pRSF-P1-leuA(G462D)-leuB-P2-leuC-leuD. Before the introduction to host strain, the sequences of constructed plasmids were confirmed by DNA sequencing.

Among above enzymes, as mentioned in the previous example, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases ChnD, YjgB and YahK on oxidization of prenol have been proven through enzymatic spectrophotometric assay. *E. coli* alcohol dehydrogenases FucO (NP\_417279.2), YqhD (NP\_417484.1), YiaY (YP\_026233.1) were also assayed on prenol, but as mentioned above, they did not show the activity on prenol oxidization. The results of assays on alcohol dehydrogenases can be seen in Table P, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

#### (Prophetic) GPP Biosynthesis Via 2-oxoisovaleric Acid, 2-O Xoisocaproic Acid and Prenol Starting from Aldol Condensation Between Pyruvate and Acetaldehyde

The purpose of this experiment is to demonstrate the 25 biosynthesis of GPP through a novel pathway that starts from aldol condensation between pyruvate and acetaldehyde via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol, using E. coli as the host organism. This pathway starts from aldol condensation between pyruvate and acetaldehyde to (S)-4-hydroxy-2-oxopentanoic acid by E. coli aldolase MhpE (NP\_414886.1). Acetaldehyde is supplied either through decarboxylation of pyruvate by Saccharomyces cerevisiae alpha-keto decarboxylase acid PDC1 (CAA97573.1) or through reduction of acetyl-CoA by E. coli aldehyde forming acyl-CoA reductase MhpF (NP\_414885.1). Then, a mutase moves the ---(C==O)COOH group of (S)-4-hydroxy-2-oxopentanoic acid from C-3 site to C-4 site, forming 3-hydroxy-2-oxo-3-methylbutyric acid. 2-hydroxyacid dehydrogenase converts 3-hydroxy-2-oxo-3methylbutyric acid to (2R)-2,3-dihydroxy-3-methylbutyric acid. E. coli dihydroxy acid dehydratase IlvD (YP\_026248.1) dehydrates (2R)-2,3-dihydroxy-3-methylbutanoate to 3-methyl-2-oxobutyric acid (2-oxoisovaleric acid). Then, 2-oxoisovaleric acid is elongated into 2-oxoisocaproic acid through alpha-keto acid pathway composed of: E. coli isopropylmalate synthase LeuA (NP\_414616.1, with a G462D mutation to maximize 2-oxoisocaprate production and minimize 2-oxoisovalerate, Connor et al. 2008) which condenses 2-oxoisovaleric acid and acetyl-CoA to (2S)-2-isopropylmalate; E. coli isopropyl isomerase LeuCD (NP\_414614.1, NP\_414613.1) which converts (2S)-2-isopropylmalate to (2R, 3S)-3-isopropylmalate; E. coli isopropylmalate dehydrogenase LeuB (NP 414615.4) which oxidizes and decarboxylates (2R, 3S)-3-isopropylmalate, generating 4-methyl-2-oxopentanoic acid (2-oxoisocaproic acid). Then, S. avermitilis alpha-keto acid dehydrogenase complex BkdFGH-LpdA1 (BAC72088.1, BAC72089.1, BAC72090.1, KUN54417.1) converts 2-oxoisocaproic acid into isovaleryl-CoA.

Overexpression of heterologous branched alpha-keto acid dehydrogenase complex requires improved lipoylation, which can be realized though supplementation of lipoic acid accompanied with overexpression of *E. coli* lipoate-protein ligase LplA (NP\_418803.1), or overexpression of *E. coli* endogenous lipoylation pathway consisting lipolate synthase LipA (NP\_415161.1) and lipoyl(octanoyl) transferase LipB (NP\_415163.2). *P. aeruginosa* acyl-CoA dehydrogenase LiuA (APJ52511.1) converts isovaleryl-CoA to 3-methylcrotonyl-CoA. 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acvl-CoA reductase or aldehvde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the 5 group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from the group consisting C. acetobutylicum AdhE2 (YP\_009076789.1) and *M. aquaeolei* VT8 Maqu\_2507 10 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and 15 Acinetobacter sp. SE19 ChnD (BAC80217.1). Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK 20 (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl 25 pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. Then, DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol 30 synthase GES (AR11765.1, with N-terminal 65 aa truncation) converts GPP to geraniol, which serves as a proxy to demonstrate a functioning pathway.

JST06(DE3) serves as the E. coli host strain for demonstration of this novel pathway. Vector creation, strain cre- 35 ation, growth and analysis of supernatant are largely as described in previous examples.

The plasmids listed in Table T can be used for required gene expression. The primers required for construction of these plasmids are also listed in Table T and their construc- 40 tion process is described in previous examples.

Among above enzymes, as mentioned in the previous example, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases 45 ChnD, YjgB and YahK on oxidization of prenol have been proven through enzymatic spectrophotometric assay. E. coli alcohol dehydrogenases FucO (NP 417279.2), YqhD (NP 417484.1), YiaY (YP 026233.1) were also assayed on prenol, but as mentioned above, they did not show the 50 activity on prenol oxidization. The results of assays on alcohol dehydrogenases can be seen in Table P, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

GPP Biosynthesis Via 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) and Prenol Starting from Non-Decarboxylative Claisen Condensation Between Two Acetyl-CoAs or Decarboxylative Claisen Condensation Between Acetyl-CoA and Malonyl-CoA

60

The purpose of this example is to demonstrate the biosynthesis of GPP through a novel pathway via HMG-CoA and prenol. E. coli serves as the host organism. This pathway 65 starts from non-decarboxylative Claisen condensation between two acetyl-CoAs to acetoacetyl-CoA catalyzed by

E. coli thiolase AtoB (NP 416728.1) or decarboxylative Claisen condensation between acetyl-CoA and malonyl-CoA by ketoacyl-CoA synthase. Malonyl-CoA is supplied from acetyl-CoA by E. coli acetyl-CoA carboxylase AccABCD (NP\_414727.1, NP\_417721.1, NP\_417722.1, NP\_416819.1). Then, S. aureus 3-hydroxy-3-methylglutaryl-CoA synthase HMGS (BAU36102.1) condenses acetoacetyl-CoA with another acetyl-CoA to generate 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is dehydrated to 3-methylglutaconyl-CoA by M. xanthus enoyl-CoA hydratase LiuC (WP 011553770.1). M. xanthus glutaconyl-CoA decarboxylase AibAB (WP\_011554267.1, WP\_011554268.1) decarboxylates 3-methylglutaconyl-CoA to 3-methylcrotonyl-CoA. 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehydrogenase or carboxylate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacvlase. Alcohol-forming acvl-CoA reductase is selected from the group consisting C. acetobutylicum AdhE2 (YP\_009076789.1) and M. aquaeolei VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. SE19 ChnD (BAC80217.1). Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP. Then, DMAPP and IPP are condensed to GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa is truncated). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, which serves as the proxy for pathway function.

JST06(DE3) atoB<sup> $\tilde{C}T5$ </sup>  $\Delta$ fadB serves as the *E. coli* host strain for demonstration of novel pathway. The genotype atoB<sup>CT5</sup> refers to chromosomal atoB gene, encoding the thiolase that condenses acetyl-CoA to acetoacetyl-CoA, under the  $p^{CT5}$  promoter for controlled induction by cumate. To enable the cumate-inducible chromosomal expression of atoB gene in JST06(DE3), E. coli atoB gene was first PCR amplified from genomic DNA extracted through Genomic DNA Purification kit (Promega, Fitchburg, Wis., USA), 55 digested with BgIII and NotI, and ligated by T4 ligase (Invitrogen, Carlsbad, Calif.) into pUCBB-ntH6-eGFP (Vick et al. 2011) that was previously digested with BgIII and NotI to produce pUCBB-P<sup>CT5</sup>-atoB. The resulting ligation products were used to transform E. coli DH5alpha (Invitrogen, Carlsbad, Calif.), and positive clones identified by PCR were confirmed by DNA sequencing. To integrate the cumate-controlled atoB construct into the chromosome of JST06(DE3), first the cumate repressor (cymR), promoter/operator regions  $(p^{CT5})$  and respective ORFs were PCR amplified, as was the kanamycin drug construct via pKD4 (Datsenko and Wanner, 2000). These respective products were linked together via overlap extension PCR to

create a final chromosomal targeting construct. Integration of the cumate-controlled constructs was achieved via standard recombineering protocols by using strain HME45 and selection on LB drug plates (Thomason et al. 2001). The primers used in the construction of JST06(DE3) atoB<sup>CT5</sup> are 5 listed in Table U.

The gene fadB, encoding hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase is deleted to minimize the flux of acetoacetyl-CoA entering the competing beta-oxidation reversal pathway. The gene deletion is performed using 10 P1 phage transduction (Yazdani et al. 2008) with single gene knockout mutants from the National BioResource Project (NIG, Japan, Baba et al. 2006) as the specific deletion donor.

The other genes for overexpression are made, put into cells and tested as described above. The quantification of 15 intermediate prenol is also performed via ion-exclusion HPLC using a Shimadzu Prominence SIL 20 system equipped with an HPX-87H organic acid column (Bio-Rad, Hercules, Calif.) with operating conditions to optimize peak separation (0.3 mL/min flow rate, 30 mM H<sub>2</sub>SO<sub>4</sub> mobile 20 phase, column temperature 42° C.). Concentration of 2-oxoisovaleric acid in fermentation samples is determined through calibration to known prenol standards (5, 1, 0.5, 0.2 and 0.1 g/L).

The first part of pathway to prenol has demonstrated been 25 in vivo. The plasmids used for demonstration of in vivo prenol production are listed in Table V and the primers required for constructions of these plasmids are listed in Table W. First, the pathway to prenol was expressed in two vectors: the genes encoding acyl-CoA reductases were 30 inserted into pETDuet-1 vector, while other genes were expressed from plasmid pCDF-P1-HMGS-aibA-aibB-P2liuC. When using CbjALD, endogenous alcohol dehyrogenases without overexpression was used. Except for genes encoding E. coli enzymes YjgB and YahK, which were PCR 35 amplified from the genomic DNA of wild type E. coli MG1655 strain, and the gene encoding CbjALD, which was PCR amplified from the genomic DNA of C. beijerinckii, the genes were codon optimized and synthesized by either GeneArt or GenScript. The adhE2, cbjALD and maqu\_2507 40 gene inserts were PCR amplified with adhE2-f1/adhE2-r1, cbjALD-f2/cbjALD-r2 and maqu\_2507-f2/maqu\_2507-r2 primers respectively and inserted into vector pETDuet-1 cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to construct pET-P2-adhE2, pET-P2-cbjALD, pET- 45 P2-maqu\_2507 respectively. For construction of pCDF-P1-HMGS-aibA-aibB-P2-liuC, the codon-optimized liuC gene insert was first PCR amplified with liuC-f1/liuC-r1 primers and inserted into vector pCDFDuet-1, cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to generate 50 pCDF-P2-liuC. Then, the codon-optimized hmgs gene insert was PCR amplified with hmgs-f1/hmgs-r1 primers and inserted into vector pCDF-P2-liuC cleaved with NcoI and EcoRI through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P1-HMGS-P2-liuC. Finally, the codon opti- 55 mized aibA and aibB gene inserts were PCR amplified with aibA-f1/aibA-r1 and aibB-f1/aibB-r1 primers respectively and inserted into vector pCDF-P2-liuC cleaved with EcoRI and Sall through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P1-HMGS-aibAB-P2-liuC. The sequences 60 of constructed plasmids were further confirmed by DNA sequencing. Then, the sequence confirmed plasmids were introduced to competent cells of host strain JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB.

As shown in FIG. **26**, under the two-vector system, the  $_{65}$  strain expressing AdhE2 showed 190 mg/L of prenol production when grown under  $_{37^\circ}$  C. for 48 hours in shake

flasks with 20 mL LB-like MOPS media supplemented with 20 g/L glycerol, induced under 10 µM IPTG and 100 µM cumate, while prenol production was not detected when expressing CbjALD and Maqu\_2507. To test whether the burden caused by multiple vector system led to undetected prenol production when using CbjALD and Maqu\_2507, the cbjALD and maqu\_2507 gene inserts were PCR amplified with cbjALD-f2/cbjALD-r3 and maqu\_2507-f2/ maqu\_2507-r3 primers respectively and inserted into vector pCDF-P2-HMGS-aibAB-P2-liuC cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P2-HMGS-aibAB-P2-cbjALD-liuC and pCDF-P2-HMGSaibAB-P2-maqu\_2507-liuC respectively, so that whole prenol supplying pathway is expressed through single vector. As a result, while the strain JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB pCDF-P2-HMGS-aibAB-P2-maqu\_2507-liuC still did not produce detectable prenol, JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB pCDF-P2-HMGS-aibAB-P2-cbjALD-liuC produced 475 mg/L of prenol production, higher than the strain with two-vector system using AdhE2, when grown under same conditions as above, possibly due to the added metabolic burden of maintaining two plasmids in the cell.

To test whether co-expression of alcohol dehydrogenases YahK, YjgB and ChnD, which had been proven to be active on oxidizing prenol to 3-methyl-1-butenal through in vitro assay according to the second experiment, can improve prenol production with usage of CbjALD, the chnD, yigB, yahK gene inserts were PCR amplified with chnD-f2/chnDr2, yjgB-f1/yjgB-r1 and yahK-f1/yahK-r1 primers respectively and inserted into vector pCDF-P2-HMGS-aibAB-P2cbjALD-liuC cleaved by BglII and XhoI through In-Fusion HD Eco-Dry Cloning system to generate pCDF-P2-HMGSaibAB-P2-cbjALD-liuC-chnD, pCDF-P2-HMGS-aibAB-P2-cbjALD-liuC-yjgB and pCDF-P2-HMGS-aibAB-P2cbjALD-liuC-yahK respectively, and the resultant plasmids were introduced into JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB. As a result, the strain overexpressing ChnD and YigB did not show the detectable prenol production, while the strain overexpressing YahK produced 535 mg/L of prenol, higher than that of JST06(DE3) atoB<sup>CT5</sup> ΔfadB pCDF-P2-HMGSaibAB-P2-cbjALD-liuC, which uses endogenous alcohol dehydrogenase without overexpression, when grown under same conditions as above. To summarize, the pathway to prenol is effective in vivo when using acyl-CoA reductases CbjALD and AdhE2, and co-expression of YahK can further improve prenol production when using CbjALD.

After demonstrating the in vivo prenol production, the rest of the pathway, which converts prenol to geraniol, was added. A three-vector system was first used as shown in Table V. The pathway to 3-methylcrotonyl-CoA was expressed through pCDF-P1-HMGS-aibA-aibB-P2-liuC; acyl-CoA reductases AdhE2 or CbjALD were expressed through pRSF-P2-adhE2 or pRSF-P2-cbjALD; the rest of the pathway converting prenol to geraniol was expressed through pET-P1-idi-trGPPS2-P2-ges-ychB-mtipk. For construction of other plasmids, the E. coli genes encoding Idi and YchB were PCR amplified from the genomic DNA of wild type E. coli MG1655 strain, while the other genes were codon optimized and synthesized by either GeneArt or GenScript. The adhE2 and cbjALD gene inserts were PCR amplified with were PCR amplified with adhE2-f1/adhE2-r1 and cbjALD-f2/cbjALD-r2 primers respectively and inserted into vector pRSFDuet-1 cleaved by NdeI through In-Fusion HD Eco-Dry Cloning system to construct pRSF-P2-adhE2 and pRSF-P2-cbjALD respectively. To construct pET-P1-idi-trGPPS2-P2-ges-ychB-mtipk, the gene inserts encoding Idi and trGPPS2 ("tr" means "truncated" as first 84 aa of GPPS2 was truncated to improve the activity) were PCR amplified with idi-f1/idi-r1 and trgpps2-f1/trgpps2-r1 respectively and inserted together into pETDuet-1 cleaved by NcoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-idi-trGPPS2. Then, the gene insert encoding GES was PCR amplified with ges-f1/ges-r1 primers and inserted into vector pET-P1-idi-trGPPS2 cleaved by NdeI and KpnI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-idi-trGPPS2-P2-ges. Finally, the gene inserts encoding YchB and MtIPK were PCR amplified with 10 ychB-f1/ychB-r1 and mtipk-f1/mtipk-r1 respectively and inserted together into pET-P1-idi-trGPPS2-P2-ges cleaved by XhoI through In-Fusion HD Eco-Dry Cloning system to generate pET-P1-idi-trGPPS2-P2-ges-ychB-mtipk. The sequences of required primers can be seen in Table W. The 15 sequences of constructed plasmids were further confirmed by DNA sequencing. Then, the sequence confirmed plasmids were introduced to competent cells of host strain JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB.

As shown in FIG. **27**, the resultant strain using AdhE2 did <sup>20</sup> not show detectable geraniol production, while the strain using CbjALD and endogenous alcohol dehydrogenases without overexpression had 0.54 mg/L of geraniol production when grown under 30° C. for 48 hours in shake flasks with 20 mL LB-like MOPS media supplemented with 20 g/L <sup>25</sup> glycerol, induced under 10  $\mu$ M IPTG and 100  $\mu$ M cumate. Though the titer was small and further improvement measures, like decreasing the vector number and optimizing fermentation conditions, were required, this result indicates that the claimed novel GPP synthesis pathway via HMG-<sup>30</sup> CoA and prenol is effective in vivo when using acyl-CoA reductase CbjALD.

A two-vector system was also tested for geraniol production with usage of acyl-CoA reductase CbjALD with or without alcohol dehydrogenase YahK. One plasmid was 35 pCDF-P2-HMGS-aibAB-P2-cbjALD-liuC or pCDF-P2-HMGS-aibAB-P2-cbjALD-liuC-yahK that expresses the pathway from acetoacetyl-CoA to prenol (or most of "upper alcohol pathway", as shown in FIG. 1), and the other plasmid was pET-P1-idi-trGPPS2-P2-ges-ychB-mtipk that 40 expresses the pathway converting from prenol to geraniol (or "lower alcohol pathway", as shown in FIG. 1). As shown in FIG. 27, the resultant strain using two-vector system and CbjALD and endogenous alcohol dehydrogenases without overexpression had 3.7 mg/L of geraniol production when 45 grown under 30° C. for 48 hours in shake flasks with 20 mL LB-like MOPS media supplemented with 20 g/L glycerol, induced under 50 µM IPTG and 100 µM cumate, indicating that reduction of expression vector can improve the geraniol production. The addition of YahK overexpression further 50 improved the titer to 7.0 mg/L. When YahK was overexpressed, the strain was grown under 30° C. for 48 hours in shake flasks with 15 mL LB-like MOPS media supplemented with 20 g/L glycerol, induced under 10 µM IPTG and 100 µM cumate.

(Prophetic) GPP Biosynthesis Via 3-methyl-3-hydroxybutyryl-CoA and Prenol Starting from Non-Decarboxylative Claisen Condensation Between Two Acetyl-CoAs or Decarboxylative Claisen Condensation Between Acetyl-CoA and Malonyl-CoA

The purpose of this example is to demonstrate the biosynthesis of GPP through a novel pathway via 3-methyl-3-65 hydroxybutyryl-CoA and prenol. *E. coli* serves as the host organism. This pathway starts from non-decarboxylative 52

Claisen condensation between two acetyl-CoAs to acetoacetyl-CoA catalyzed by E. coli thiolase AtoB (NP\_416728.1) or decarboxylative Claisen condensation between acetyl-CoA and malonyl-CoA by ketoacyl-CoA synthase. Malonyl-CoA is supplied from acetyl-CoA by E. coli acetyl-CoA carboxylase AccABCD (NP\_414727.1, NP\_417721.1, NP\_417722.1, NP\_416819.1). Then. acetoacetyl-CoA is hydrolyzed to acetoacetic acid by enzymes selected from the group consisting thioesterase, acyl-CoA transferase and phosphotransacylase plus carboxylate kinase. Acetoacetate decarboxylase removes the carboxyl group of acetoacetic acid, generating acetone. 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase then performs a condensation between acetone and another acetyl-CoA, generating 3-methyl-3-hydroxybutyryl-CoA. Enoyl-CoA hydratase dehydrates 3-methyl-3-hydroxybutyryl-CoA to 3-methylcrotonyl-CoA. 3-methylcrotonyl-CoA is converted to prenol by alcohol-forming acyl-CoA reductase or aldehyde forming acyl-CoA reductase and alcohol dehvdrogenase or carboxvlate reductase and the hydrolysis enzyme selected from the group consisting thioesterase, acyl-CoA synthase, acyl-CoA transferase and carboxylate kinase plus phosphotransacylase. Alcohol-forming acyl-CoA reductase is selected from the group consisting C. acetobutvlicum AdhE2 (YP 009076789.1) and M. aquaeolei VT8 Maqu\_2507 (YP\_959769.1). CbjALD from C. beijerinckii aldehyde forming acyl-CoA reductase (AAT66436.1) is selected for conversion of 3-methylcrotonyl-CoA to prenol. Alcohol dehydrogenase is selected from the group consisting E. coli YahK (NP\_414859.1), E. coli YjgB (NP\_418690.4) and Acinetobacter sp. SE19 ChnD (BAC80217.1).

Prenol is then converted to DMAPP by one or two steps of phosphorylation. If phosphorylated by two steps, the first step is catalyzed by E. coli alcohol kinase YchB (NP\_415726.1) or Thermoplasma acidophilum phosphate kinase ThaIPK (WP\_010900530.1, V73I, Y141V and K204G mutations to increase specificity on prenol. Liu et al. 2016) and the second is by M. thermautotrophicus phosphate kinase MtIPK (AAB84554.1). The one step phosphorylation is catalyzed by alcohol diphosphokinase. E. coli isopentenyl pyrophosphate isomerase Idi (NP\_417365.1) converts DMAPP to IPP, which is condensed with DMAPP to form GPP catalyzed by E. coli GPP synthase IspA (NP\_414955.1, S80F) or A. grandis GPP synthase GPPS2 (AAN01134.1, N-terminal 84 aa truncation). Ocimum basilicum geraniol synthase GES (AR11765.1, N-terminal 65 aa truncation) converts GPP to geraniol, which serves as the proxy product.

JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB serves as the *E. coli* host strain for demonstration of novel pathway. The genes for overexpression are made and put into cells, which are gown and the supernatants analyzed as described above.

The quantifications of intermediates prenol and acetone 55 are also performed via ion-exclusion HPLC using a Shimadzu Prominence SIL 20 system equipped with an HPX-87H organic acid column with operating conditions to optimize peak separation (0.3 mL/min flow rate, 30 mM H<sub>2</sub>SO<sub>4</sub> mobile phase, column temperature 42° C.). Concen-60 tration of 2-oxoisovaleric acid in fermentation samples is determined through calibration to known acetone and prenol standards (5, 1, 0.5, 0.2 and 0.1 g/L).

The in vivo production of acetone has been demonstrated in *E. coli*. The JC01 (MG1655  $\Delta$ IdhA  $\Delta$ poxB  $\Delta$ pta  $\Delta$ adhE  $\Delta$ frdA, an *E. coli* strain with removal of mixed-acid fermentation for improved supply of acetyl-CoA) strain overexpressing thiolase AtoB and thioesterase YbgC showed 53 mg/L of acetone production when grown in LB-like MOPS media with glycerol under  $37^{\circ}$  C. for 48 hours. This result indicates that YbgC can hydrolyze acetoaceetyl-CoA, the product of non-decarboxylative Claisen condensation between two acetyl-CoAs by AtoB, to acetoaceetic acid, and 5 aetoacetic acid can be decarboxylated to acetone spontaneously or by endogenous *E. coli* enzymes. These enzymes can be used in this GPP synthesis pathway. The media, fermentation conditions and method of HPLC analysis on acetone are described in previous example. In this fermentation, the 10 atoB gene was expressed from pTH-atoB, while the ybgC gene was expressed from pZS-ybgC. The primers required for construction of these plasmids can be seen in Table S, and the process of construction of these plasmids is described in the previous example. 15

Among above enzymes, as mentioned in the previous example, the in vitro activities of acyl-CoA reductases CbjALD and Maqu\_2507 on reduction of 3-methylcrotonyl-CoA and the in vitro activities of alcohol dehydrogenases ChnD, YjgB and YahK on oxidization of prenol have been <sup>20</sup> proven through enzymatic spectrophotometric assay. *E. coli* alcohol dehydrogenases FucO (NP\_417279.2), YqhD (NP\_417484.1), YiaY (YP\_026233.1) were also assayed on prenol, but as mentioned above, they did not show the activity on prenol oxidization. The results of assays on <sup>25</sup> alcohol dehydrogenases can be seen in Table P, and the results of assays on acyl-CoA reductases and relevant enzyme preparation and assay methods are described in the previous example.

#### (Prophetic) Synthesis of Isoprenoids

The purpose of this example is to demonstrate the biosynthesis of isoprenoids other than geraniol from isoprenoid precursor GPP or others, which are supplied from claimed 35 novel pathways. E. coli serves as the host strain. The possible isoprenoid products are monoterpenes like limonene and pinene, which are derived from GPP, and sesquiterpenes like beta-caryophyllene, valencene, vetispiradiene, amorphadiene and farnesene, which are derived from farne- 40 syl diphosphate (FPP), as shown in FIG. 15. FPP is a isoprenoid precursor with five more carbons than GPP and supplied through condensation between GPP and IPP, which are supplied from above novel claimed pathways, by E. coli FPP synthase IspA (NP\_414955.1). These mentioned iso- 45 prenoids are with great industrial importance and can be used as biofuels and solvents and be used in the fields of cosmetics, pharmaceutics and perfumery. The conversion of GPP to limonene is catalyzed by Mentha spicata limonene synthase LS (AGN90914.1). The conversion of GPP to 50 pinene is catalyzed by Pinus taeda pinene synthase Pt30 (AAO61228.1). The conversion of FPP to beta-caryophyllene is catalyzed by Artemisia annua beta-caryophyllene synthase QHS1 (AAL79181.1). The conversion of FPP to valencene is catalyzed by Callitropsis nootkatensis vale- 55 necene synthase VALC (AFN21429.1). The conversion of FPP to vetispiradiene is catalyzed by *Hvoscvamus muticus* vetispiradiene synthase VS1 (Q39978.2). The conversion of FPP to amorphadiene is catalyzed by Artemisia annua amorphadiene synthase ADS (AAF61439.1). The conver- 60 sion of FPP to farnesene is catalyzed by Malta domestica farnesene synthase FS (NP 001280822.1). The genes encoding enzymes for productions of above isoprenoids are separately cloned into pACYCDuet-1 vector (Novagen, Darmstadt, Germany), and the resultant plasmids can be 65 directly used and introduced to GPP-synthesizing strains as described in previous examples to realized productions of

isoprenoids. The resultant vectors are listed in Table X. Except ispA, which is PCR amplified from the genomic DNA of wild type *E. coli*, the genes encoding synthases of isoprenoids are codon-optimized and synthesized by Gen-Script (Piscataway, N.J.) or GeneArt® (Life Technologies, Carlsbad, Calif.).

#### In Vivo Synthesis of Olivetolic Acid in E. coli

The purpose of this example is to demonstrate in vivo synthesis of olivetolic acid with E. coli as host organism. Olivetolic acid is a suitable aromatic acceptor of geranyl group donated from GPP, which is synthesized by claimed novel pathways, MVA, MEP/DXP, or other pathways, the prenylation reaction generating the valuable cannabinoid, cannabigerolic acid (CBGA). Olivetolic acid is synthesized through multiple possible pathways. The first pathway starts from three series of decarboxylative Claisen condensation with hexanoyl-CoA as the initial primer and malonyl-CoA as the extender unit by e.g., C. sativa olivetol synthase OLS (BAG14339.1), generating 3,5,7-trioxododecanoyl-CoA. Then, C. sativa olivetolic acid cyclase OAC (AFN42527.1, several non-conservative substitutions of residues are performed to improve the activity) cyclizes 3,5,7-trioxododecanoyl-CoA to olivetolic acid.

The second pathway also starts from three series of decarboxylative Claisen condensation with hexanoyl-CoA as the initial primer and malonyl-CoA as the extender unit, but catalyzed by other polyketide synthases selected from e.g., H. macrophylla stilbenecarboxylate synthase STCS (AAN76183.1, with a subset of mutations of T135S, T198M and I200C to accept hexanoyl-CoA as the active substrate), a type III polyketide synthase, and type I polyketide synthases AviM from Streptomyces viridochromogenes Tue57 (AAK83194.1), ArmB from Armillaria mellea (AFL91703.1) and CalO5 from Micromonospora echinospora ssp. Calichensis (AAM70355.1). These polyketide synthases directly perform the cyclization of 3,5,7-trioxododecanoyl-CoA to olivetolic acid.

The third pathway starts from three series of condensations with hexanoyl-CoA as the initial primer and acetyl-CoA as the extender unit by polyketoacyl-CoA thiolase selected e.g., from the group consisting FadAx (AAK18171.1) and PcaF (AAA85138.1) from *P. putida*, DcaF (CAG68532.1) from *Acinetobacter* sp. ADP1, and ScFadA (AAL10298.1) from *S. collinus*, generating 3,5,7trioxododecanoyl-CoA, which is then cyclized to olivetolic acid by OAC.

Hexanoyl-CoA can be supplied from hexanoic acid, either supplemented or intracellularly synthesized through betaoxidation reversal composed of e.g., ketoacyl-CoA thiolase BktB (AAC38322.1) from R. eutropha, 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase multifunctional enzyme FadB from E. coli (NP\_418288.1) and enoyl-CoA reductase EgTer from E. gracilis (Q5EU90.1) or fatty acid biosynthesis pathway composed of beta-ketoacyl-ACP synthases FabH (NP 415609.1) and FabB (NP 416826.1), acetoacetyl-ACP reductase FabG (NP\_415611.1), 3-hydroxyacyl-ACP dehydratase FabZ (NP\_414722.1) and enoyl-ACP reductase FabI (NP\_415804.1), all from E. coli, with termination by E. coli thioesterase TesA (NP\_415027.1, with truncation of 26 aa leader sequence) and activation by E. coli acyl-CoA synthetase FadD (NP\_416319.1), or directly synthesized through overexpressed beta-oxidation reversal pathway without termination.

If malonyl-CoA is used as the extender unit, to enhance its supply, e.g., *E. coli* acetyl-CoA carboxylase AccABCD

(NP\_414727.1, NP\_417721.1, NP\_417722.1, NP\_416819.1) is overexpressed. Also, to improve acetyl-CoA supply, e.g., *E. coli* pyruvate dehydrogenase complex AceEF-Lpd is overexpressed (e.g., NP\_414658.1, NP\_414656.1, NP\_414657.1, A358V mutation in Lpd sub- <sup>5</sup> unit to increase the activity of pyruvate dehydrogenase by reducing inhibition by NADH, Chen et al. 2014).

JST06(DE3)  $\Delta$ fadE bktB<sup>CT5</sup>  $\Delta$ atoB fadB<sup>CT5</sup>  $\Delta$ fadA egter<sup>CT5</sup>, which is able to intracellularly supply hexanoyl-CoA and hexanoic acid through beta-oxidation reversal, can serve as the host strain for the in vivo production of olivetolic acid. JST06(DE3) is described in previous examples and is selected to maximize the flux of betaoxidation reversal for hexanoyl-CoA supply required for the 15 synthesis of olivetolic acid via polyketoacyl-CoA thiolases. ∆atoB fadB<sup>CT5</sup> are as described above. BktB, FadB and EgTer are chromosomally expressed under  $p^{CT5}$  promoter with control by cumate. To integrate the cumate-controlled bktB construct into the chromosome of the target strain, first 20 the cumate repressor (cymR), promoter/operator regions (PCT5), and respective ORFs are PCR amplified using appropriate primers, as is chloramphenicol drug construct via pKD4 (Datsenko and Wanner, 2000). These respective products are linked together via overlap extension PCR to create 25 a final chromosomal targeting construct. The fadA gene was separately deleted via recombineering in the HME45 derivative harboring the cumate-controlled fadBA construct by replacement of the fadA ORF with a zeocin resistance marker amplified from pKDzeo (Magner et al. 2007).

For the creation of the cumate-controlled egTER, the cat gene, cymR repressor gene, hybrid cumate-controlled phage T5 promoter, and egTER gene are PCR amplified from genomic DNA of a strain with egTER seamlessly replacing fadBA at the cumate controlled fadBA locus (See below for 35 details). This product is recombineered into strain HME45 at the end of the fabI locus, selecting on chloramphenicol (12.5  $\mu$ g/ml) LB plates. Integration is done in a manner to duplicate the last 22 bp of fabI (including stop codon) so as retain an overlapping promoter for the next native downstream 40 gene.

Construction of the strain serving as the PCR template for egTER described above was accomplished by first creating a kan-sacB fusion cassette via overlap extension PCR using pKD4 and genomic DNA, respectively. This kan-sacB cas-45 sette was integrated between fadB and fadA of the fadBA<sup>C75</sup> strain formerly constructed (Vick et al., 2015) through subsequent recombineering. Seamless replacement of the kan-sacB cassette to create the cat-cymR-P<sup>C75</sup>-egTER at the fadBA locus was done via recombineering and subsequent 50 sucrose selection with codon optimized egter (Genscript) PCR product. The primers for construction of this strain are listed in Table Y.

The gene fadE, encoding acyl-CoA dehydrogenase is deleted to block the degradation of hexanoyl-CoA through 55 beta-oxidation. The gene deletion is performed using P1 phage transduction (Yazdani et al. 2008) with single gene knockout mutants from the National BioResource Project (NIG, Japan, Baba et al. 2006) as the specific deletion donor.

The constructed vectors for expression of different routes 60 of olivetolic acid synthesis pathways are listed in Table Z. To construct pET-P1-OLS-P2-OAC, the OLS gene insert was first PCR amplified with OLS-BamHI-F/OLS-EcoRI-R primers and inserted into vector pETDuet-1 cleaved by BamHI and EcoRI through Gibson Assembly cloning sys-65 tem, generating pET-P1-OLS. Then, the OAC gene insert was PCR amplified with OAC-NdeI-Up/OAC-XhoI-Dn

primers and inserted into pET-P1-OLS cleaved by NdeI and XhoI through Gibson Assembly cloning system, generating pET-P1-OLS-P2-OAC.

The in vivo synthesis of olivetolic acid in E. coli has been demonstrated by using C. sativa olivetol synthase OLS and olivetolic acid cyclase OAC. JST06(DE3) ΔfadE bktB<sup>CT5</sup>  $\Delta$ atoB fadB<sup>CT5</sup>  $\Delta$ fadA egter<sup>CT5</sup> @fabI served as the host strain containing plasmid pET-P1-OLS-P2-OAC. The genes encoding OLS and OAC were codon optimized and synthesized by either GeneArt or GenScript. The resultant strain for olivetolic acid production was grown in shake flasks with 15 mL LB-like MOPS media supplemented with 20 g/L glycerol and 55 g/L CaCO<sub>3</sub> at 30° C. for 48 hours. Extracellular olivetolic acid was extracted and derivatized following the protocols described in previous examples and the resulting sample analyzed via GC-MS. FIG. 28 shows GC-MS identification of in vivo olivetolic acid synthesis through comparison with an olivetolic acid standard. This result demonstrates that OLS and OAC are effective for in vivo biosynthesis of olivetolic acid which can be used as the acceptor group donated from GPP synthesized through claimed pathways for production of valued compound cannabigerolic acid (CBGA).

#### (Prophetic) In Vivo Synthesis of Divarinolic Acid in *E. coli*

The purpose of this example is to demonstrate in vivo synthesis of divarinolic acid with E. coli as host organism. 30 Divarinolic acid is a suitable aromatic acceptor of geranyl group donated from GPP, which is synthesized by claimed novel pathways or the known MVA, MEP/DXP pathways, or otherwise, in the prenylation reaction generating cannabinoid cannabigerovarinic acid (CBGVA). Divarinolic acid is synthesized through multiple possible pathways. The first pathway starts from three series of condensation with butyryl-CoA as the initial primer and malonyl-CoA as the extender unit by e.g., C. sativa olivetol synthase OLS (BAG14339.1), generating 3,5,7-trioxodecanoyl-CoA. Then, C. sativa olivetolic acid cyclase OAC (e.g., AFN42527.1, several non-conservative substitutions of residues are performed to improve the activity) cyclizes 3,5,7trioxodecanoyl-CoA to divarinolic acid.

The second pathway also starts from three series of condensations with butyryl-CoA as the initial primer and malonyl-CoA as the extender unit, but catalyzed by catalyzed by other polyketide synthases selected from e.g., H. stilbenecarboxylate macrophylla synthase STCS (AAN76183.1, with a subset of mutations of T135S, T198M and I200C), a type III polyketide synthase, and type I polyketide synthases AviM from Streptomyces viridochromogenes Tue57 (AAK83194.1), ArmB from Armillaria mellea (AFL91703.1) and CalO5 from Micromonospora echinospora ssp. Calichensis (AAM70355.1). These polyketide synthases then directly perform the cyclization of 3,5,7trioxodecanoyl-CoA to divarinolic acid.

The third pathway starts from three series of condensations with butyryl-CoA as the initial primer and acetyl-CoA as the extender unit by polyketoacyl-CoA thiolase from e.g., FadAx (AAK18171.1) and PcaF (AAA85138.1) from *P. putida*, DcaF (CAG68532.1) from *Acinetobacter* sp. ADP1, and ScFadA (AAL10298.1) from *S. collinus*, generating 3,5,7-trioxodecanoyl-CoA, which is then cyclized to divarinolic acid by OAC.

Butyryl-CoA can be supplied from butyric acid, either supplemented or intracellularly synthesized through betaoxidation reversal composed of e.g., ketoacyl-CoA thiolase 25

35

BktB (AAC38322.1) from R. eutropha or thiolase AtoB (NP\_416728.1) from E. coli, 3-hydroxyacyl-CoA dehydrogenase and enovl-CoA hydratase multifunctional enzyme FadB from E. coli (NP 418288.1) and enoyl-CoA reductase EgTer from E. gracilis (Q5EU90.1) or fatty acid biosynthe- 5 sis pathway composed of beta-ketoacyl-ACP synthase FabH (NP\_415609.1), beta-ketoacyl-ACP reductase FabG (NP\_415611.1), 3-hydroxyacyl-ACP dehydratase FabZ (NP\_414722.1) and enoyl-ACP reductase FabI (NP\_415804.1), all from E. coli, with termination by e.g., E. 10 coli thioesterase TesA (NP\_415027.1, with truncation of 26 aa leader sequence) and activation by E. coli acyl-CoA synthetase FadD (NP 416319.1), or directly synthesized through overexpressed beta-oxidation reversal pathway without termination. If malonyl-CoA is used as the extender 15 unit, to enhance its supply, e.g., E. coli acetyl-CoA carboxylase AccABCD is overexpressed. Also, to improve acetyl-CoA supply, e.g., E. coli pyruvate dehydrogenase complex AceEF-Lpd is overexpressed.

JST06(DE3)  $\Delta fadE$  bktB<sup>CT5</sup>  $\Delta atoB$  fadB<sup>CT5</sup>  $\Delta fadA$  20 egter<sup>CT5</sup> @fabI, which is able to intracellularly supply butyryl-CoA through beta-oxidation reversal, can serve as the host strain for the in vivo production of olivetolic acid. Its construction, growth and analysis of products are as described above in previous examples.

The in vivo butyryl-CoA and butyric acid synthesis through beta-oxidation reversal composed of AtoB, FadB and EgTer has been demonstrated in E. coli. The results are shown in FIG. 23. Strain and vector constructions, fermentation conditions and analysis method are as described above  $^{-30}$ in previous examples.

#### (Prophetic) In Vivo Synthesis of Orsellinic Acid in E. coli

The purpose of this example is to demonstrate in vivo synthesis of orsellinic acid with E. coli as host organism. Orsellinic acid is a suitable aromatic acceptor of geranyl group donated from GPP, which is synthesized by claimed novel pathways or other pathways, in the prenylation reac- 40 tion. Orsellinic acid is synthesized through multiple possible pathways. The first pathway starts from three series of decarboxylative Claisen condensations with acetyl-CoA as the initial primer and malonyl-CoA as the extender unit by e.g., C. sativa olivetol synthase OLS (BAG14339.1), gen- 45 erating 3,5,7-trioxooctanoyl-CoA. Then, C. sativa olivetolic acid cyclase OAC (AFN42527.1) cyclizes 3,5,7-trioxooctanoyl-CoA to orsellinic acid.

The second pathway also starts from three series of decarboxylative Claisen condensations with acetyl-CoA as 50 the initial primer and malonyl-CoA as the extender unit, but catalyzed by other polyketide synthases selected from e.g., H. macrophylla stilbenecarboxylate synthase STCS (AAN76183.1, with a subset of mutations of T135S, T198M and I200C), a type III polyketide synthase, and type I 55 polyketide synthases AviM from Streptomyces viridochromogenes Tue57 (AAK83194.1), ArmB from Armillaria mellea (AFL91703.1) and CalO5 from Micromonospora echinospora ssp. Calichensis (AAM70355.1). These polyketide synthases then directly performs the cyclization of 3,5,7- 60 trioxooctanoyl-CoA to orsellinic acid.

The third pathway starts from condensation between two acetyl-CoAs to acetoacetyl-CoA catalyzed by E. coli thiolase AtoB (NP\_416728.1). Then, two series of condensation reactions with acetoacetyl-CoA as the primer and acetyl- 65 CoA as the extender unit by polyketoacyl-CoA thiolase selected from e.g., FadAx (AAK18171.1) and PcaF

(AAA85138.1) from P. putida, DcaF (CAG68532.1) from Acinetobacter sp. ADP1, and ScFadA (AAL10298.1) from S. collinus, generates 3,5,7-trioxooctanoyl-CoA, which is then cyclized to orsellinic acid by OAC. If malonyl-CoA is used as the extender unit E. coli acetyl-CoA carboxylase AccABCD is preferably overexpressed. Also, to improve acetyl-CoA supply, E. coli pyruvate dehydrogenase complex AceEF-Lpd is overexpressed.

JST06(DE3) atoB<sup>CT5</sup>  $\Delta$ fadB serves as the *E. coli* host strain for demonstration of the novel pathway. Vector and strain creation, growth and analysis are as described in previous examples.

#### In Vivo Synthesis of CBGA in E. coli

The purpose of this example is to demonstrate in vivo synthesis of cannabigerolic acid (CBGA) with E. coli as host organism. In this example, Streptomyces sp. strain CL190 prenyltransferase NphB (BAE00106.1), which is soluble and desirable for functional expression and operation in E. coli, was used to convert GPP, which was synthesized through mevalonate pathway and GPP synthase in this example, and extracellularly supplemented olivetolic acid, into CBGA. Besides NphB, Lithospermum ervthrorhizon PGT-1(Q8W405), Lithospermum erythrorhizon PGT-2 (Q8W404), E. coli UbiA (P0AGK1), Arabidopsis thaliana PPT1 (Q93YP7), Schizosaccharomyces pombe Coq2 (Q10252), Cannabis sativa CsPT1, Streptomyces coelicolor SCO7190 (BAE00107.1), Streptomyces sp. CNQ-509 CnqP3 (AKH84817.1) and Phleum pretense Phlp4 (ABB78007.1) can be another options of prenyltransferases for transfer of geranyl group from GPP to olivetolic acid forming CBGA.

The mevalonate pathway used herein is composed of 3-hydroxy-3-methylglutaryl-CoA synthase HMGS 3-hydroxy-3-methylglutaryl-CoA (BAU36102.1) and reductase HMGR (OLN67110.1) from S. aureus, mevalonate kinase MK (NP\_013935.1), phosphomevalonate kinase PMK (NP\_013947.1) and phosphomevalonate decarboxylase PMD (NP\_014441.1) from S. cerevisiae and E. pyrophosphate coliisopentenvl isomerase Idi (NP\_417365.1). A. grandis GPP synthase TrGPPS2 (AAN01134.1, N-terminal 84 aa truncation) was selected for condensation of IPP and DMAPP to GPP.

Except for the gene encoding Idi, which was amplified from the genomic DNA of E. coli wild type MG1655 strain, the required genes were codon optimized and synthesized by either GeneArt or GenScript. The genes encoding HMGS, HMGR, MK, PMK and PMD were expressed through pCDF-P1-MK-PMK-PMD-P2-HMGS-HMGR, while the genes encoding Idi, TrGPPS2 and NphB were expressed through pET-P1-idi-trGPPS2-CymR-CT5-NphB. The primers used for constructions of these plasmids are listed in Table AA.

Primers NphB-IF-fwd and NphB-IF-rev were used to PCR amplify NphB gene from the synthesized DNA fragment with usage of Phusion polymerase, and the amplified DNA fragment was assembled with NdeI/KpnI digested pETDuet-1 vector by In-Fusion HD Eco-Dry Cloning system, resulting in plasmid pET-P2-NphB. Primers idi-GBfwd, idi-GB-rev, trGPPS2-IF-fwd, and GPPS2-GB-rev were utilized to PCR amplify DNA fragments containing idi and trGPPS2 with usage of Phusion polymerase, respectively. These two amplified DNA fragments were assembled with NcoI digested pET-P2-NphB by Gibson assembly cloning system, resulting in plasmid pET-P1-idi-trGPPS2-P2-NphB.

Later, primers CymR-GB-fwd and CymR-GB-rev were used to amplify CymR with CT5 promoters, and NphBcumate-GB-fwd and NphB-cumate-GB-rev were used to PCR amplify NphB fragment with usage of Phusion polymerase. Two amplified DNA fragments were assembled with 5 NotI/XhoI digested pET-P1-idi-trGPPS2-P2-NphB by Gibson assembly, providing plasmid pET-P1-idi-trGPPS2-CymR-CT5-NphB.

For cloning plasmid pCDF-P1-MK-PMK-PMD-P1-HMGS-HMGR, the synthesized DNA fragments containing HMGS genes and HMGR genes were assembled with NdeI digested pCDFDuet-1 vector by In-Fusion HD Eco-Dry Cloning system, resulting plasmid pCDF-P2-HMGS-HMGR. Primers MK-IF-fwd and MK-IF-rev were used to 15 PCR amplify DNA containing MK gene with usage of Phusion polymerase, and the amplified DNA fragment was assembled with NcoI/EcoRI digested pCDF-P2-HMGS-HMGR by in-fusion cloning, producing plasmid pCDF-P1-MK-P2-HMGS-HMGR.

Similarly, primer PMK-IF-fwd and PMK-IF-rev were used to PCR amplify PMK with usage of Phusion polymerase and the DNA fragment was assembled with EcoRI digested pCDF-P1-MK-P2-HMGS-HMGR by In-fusion cloning, resulting in plasmid pCDF-P1-MK-PMK-P2- 25 HMGS-HMGR.

Finally, primers PMD-IF-fwd and PMD-IF-rev were utilized to PCR amplify PMD gene with usage of Phusion polymerase, and the amplified DNA fragments were assembled with EcorI digested pCDF-P1-MK-PMK-P2- 30 HMGS-HMGR by In-fusion cloning, resulting in the plasmid pCDF-P1-MK-PMK-PMD-P2-HMGS-HMGR.

Host strain JST06(DE3) atoB<sup>CT5</sup> containing plasmid pCDF-P1-MK-PMK-PMD-P2-HMGS-HMGR and pET-P1idi-trGPPS2-CymR-CT5-NphB was inoculated into 5 ml LB 35 medium in 25 ml flask with antibiotic and shaking under 37° C. with 200 rpm in NBS 124 Benchtop Incubator Shaker for overnight. The overnight culture was used as the seed culture to start the subculture with appropriate volume of LB-like MOPS medium as described above supplied with 20 40 Baba, T. et al. Construction of Escherichia coli K-12 ing/L glucose in 25 ml flask. After 3 hours shaking under 37° C. at 200 rpm, the culture OD550 reached about 0.5. 20  $\mu$ M IPTG and 100 µM cumate, and 500 mg/L olivetolic acid were added into the culture to induce enzyme expression and supply the substrate. Then, the flasks were transferred into 45 another same type of shaker to grow under 30° C. After growing for 48 hours, 2 mL of fermentation broths with or without cells were collected for GC-MS identification and GC-FID quantification of CBGA. If without cell, the 5000 g, 5 min centrifuge in an Optima L-80XP Ultracentrifuge 50 (Beckman-Coulter, Schaumburg, Ill.) was performed to remove the cells.

The fermentation broths of 2 mL were transferred to 5 mL glass vials (Fisher Scientific Co., Pittsburgh, Pa.). Then, organic solvent (typically hexane) was added at a 1:1 ratio 55 to a fermentation broth sample (e.g. 2 mL for a 2 mL aqueous solution) for extraction. Before extraction, the samples were acidified with sulfuric acid (80 uL per 2 mL sample) and 30% (w/v) NaCl was added (340 uL per 2 mL). Following an appropriate extraction (vortex samples for 15 60 seconds, spin on a rotator at 60 rpm for 2 hours, and vortex again for 15 seconds), 1 mL of the organic phase was removed and evaporated to dryness under a gentle N<sub>2</sub> stream. 100 µL pyridine and 100 µL BSTFA were then added for derivatization, with the reaction allowed to proceed at 65 Gao, Y. et al., Terpenoid synthase structures: a so far 70° C. for 60 minutes. After cooling to room temperature, this mixture was used for GC analysis.

60

GC analysis was conducted on an Agilent 7890B Series Custom Gas Chromatography system equipped with a 5977B Inert Plus Mass Selective Detector Turbo EI Bundle (for identification) or a Flame Ionization Detector (for quantification) and an Agilent HP-5 capillary column (0.25 mm internal diameter, 0.25 µm film thickness, 30 m length). The following temperature profile was used with helium as the carrier gas at a flowrate of 1.2 mL/min: Initial 200° C. (hold 1 min); ramp at 30° C./min to 300° C. (hold 5 min). The injector and detector temperature were 290° C. and 350° C., respectively. 1 µL of sample was injected with a 4:1 split ratio.

Cells grown with 10 mL medium in 25 ml flasks produced 0.2 mg/L CBGA after 48 hours of fermentation, and cells grown with 5 ml medium in 25 ml flasks produced 0.38 mg/L CBGA. FIG. 29 shows GC-MS identification of in vivo CBGA synthesis. This result indicates that prenyltransferase NphB is well expressed and functional on transferring 20 geranyl group from GPP to olivetolic acid to synthesize CBGA in E. coli.

Although GPP in this example was supplied through traditional mevalonate pathway, the GPP could also be generated through claimed novel pathways or MEP/DXP pathway or commercially supplied. Alternative to the extracellular supplementation in this example, olivetolic acid can also be intracellularly synthesized through the series of condensations priming from hexanoyl-CoA as described in a previous example. Alternative to NphB used in this example, prenyl transfer can be catalyzed by other suitable enzymes such as those examples listed in Table L. The vectors for expression of some of prenyltransferases have been constructed, which are shown in Table AB.

The following are incorporated by reference herein in its entirety for all purposes:

- Atsumi, S. et al. Metabolic engineering of Escherichia coli for 1-butanol production. Metab. Eng. 10, 305-311 (2008).
- frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2 (2006).
- Blecher, M. (1981). Synthesis of long-chain fatty acyl-CoA thioesters using N-hydroxysuccinimide esters. Methods in Enzymology, 72: 404-408.
- Chen, J. et al. Activating C4-dicarboxylate transporters DcuB and DcuC for improving succinate production. Appl. Microbiol. Biotechnol. 98, 2197-2205 (2014).
- Cheong, S., et al. Energy- and carbon-efficient synthesis of functionalized small molecules in bacteria using nondecarboxylative Claisen condensation reactions. Nat Biotech 34, 556-561 (2016).
- Choi, S. Y. et al. One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli. Nat Biotech 34, 435-440 (2016).
- Clomburg, J. M., et al., A Synthetic Biology Approach to Engineer a Functional Reversal of the beta-Oxidation Cycle. ACS Synthetic Biology 1, 541-554 (2012).
- Cracan, V., & Banerjee, R. Novel B12-dependent acyl-CoA mutases and their biotechnological potential. Biochemistry 51(31), 6039-6046 (2012).
- Dellomonaco, C., et al., Engineered reversal of the betaoxidation cycle for the synthesis of fuels and chemicals. Nature 476, 355-359 (2011).
- incomplete view of complex catalysis. Natural product reports 29, 1153-1175 (2012).

- Haapalainen, A. M., et al., The thiolase superfamily: condensing enzymes with diverse reaction specificities. Trends in Biochemical Sciences 31, 64-71 (2006).
- Heath, R. J. & Rock, C. O. The Claisen condensation in biology. Nat. Prod. Rep. 19, 581-596 (2002).
- Iijima, Y., et al., Characterization of Geraniol Synthase from the Peltate Glands of Sweet Basil. *Plant Physiol.* 134, 370-379 (2004).
- Jiang, C., et al., Divergent evolution of the thiolase superfamily and chalcone synthase family. Molecular Phylogenetics and Evolution 49, 691-701 (2008).
- Jiang, Y. et al. Multigene Editing in the Escherichia coli Genome via the CRISPR-Cas9 System. Appl. Environ. Microbiol. 81, 2506-2514 (2015).
- Kim, J., et al., W. 2-Hydroxyisocaproyl-CoA dehydratase and its activator from *Clostridium difficile*. *Febs J.* 272, 550-561 (2005).
- Kitagawa, M. et al. Complete set of ORF clones of *Escherichia coli* ASKA library (A complete Set of *E. coli* K-12 ORF archive): Unique resources for biological research. DNA Res. 12, 291-299 (2005).
- Kuzuyama, T., et al., Structural basis for the promiscuous biosynthetic prenylation of aromatic natural products. Nature 435, 983-987 (2005).
- Liu, Y., Yan, Z., Lu, X., Xiao, D. & Jiang, H. Improving the catalytic activity of isopentenyl phosphate kinase through <sup>25</sup> protein coevolution analysis. Scientific Reports 6, 24117 (2016).
- Mabanglo, M. F., et al., Mutagenesis of Isopentenyl Phosphate Kinase To Enhance Geranyl Phosphate Kinase Activity. *ACS Chem. Biol.* 7, 1241-1246 (2012). 30
- Magner, D. B. et al. RecQ Promotes Toxic Recombination in Cells Lacking Recombination Intermediate-Removal Proteins. *Mol. Cell* 26, 273-286 (2007).
- Miller, J. H. Experiments in molecular genetics. (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; <sup>35</sup> 1972).
- Neidhardt, F. C., Bloch, P. L. & Smith, D. F. Culture medium for enterobacteria J. Bacteriol. 119, 736-747 (1974).
- Parasaran, T., & Tarbell, D. S. (1964). Formic Ethylcarbonic Anhydride. The Journal of Organic Chemistry, 29(11): 3422-3423.

- Reiling, K. K. et al. Mono and diterpene production in *Escherichia coli*. *Biotechnol Bioeng* 87 (2004).
- Sambrook, J. & Russell, D. W. Molecular cloning: a laboratory manual Edn. 3rd. (Cold Spring Harbor Laboratory Press., Cold Spring Harbor, N.Y.; 2001).
- Schrader, J. & Bohlmann, J., eds. Biotechnology of Isoprenoids. Vol. 149. Springer, (2015).
- Studier, F. W. & Moffatt, B. A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189, 113-130 (1986).
- Thomason, L. C., Sawitzke, J. A., Li, X., Costantino, N. & Court, D. L. in Current Protocols in Molecular Biology (John Wiley & Sons, Inc., 2001).
- Vick, J. E. et al. *Escherichia coli* enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of the beta-oxidation cycle. Appl. Environ. Microbiol. 81, 1406-1416 (2015).
- Vick, J. E. et al. Optimized compatible set of BioBrick<sup>™</sup> vectors for metabolic pathway engineering. *Appl. Microbiol. Biotechnol.* 92, 1275-1286 (2011).
- Yazdani, S. S. & Gonzalez, R. Engineering *Escherichia coli* for the efficient conversion of glycerol to ethanol and co-products. *Metab. Eng.* 10, 340-351 (2008).
- US20130316413 WO2012109176 61/440,192, Reverse Beta Oxidation Pathway
- US20140273110 WO2013036812 61/531,911 61/440,192, Functionalized Carboxylic Acids And Alcohols By Reverse Fatty Acid Oxidation
- WO2015191972 62/011,474, 62/012,113, 62/011,465, 61/531,911, WO2013036812, US20140273110, Omega-Carboxylated Carboxylic Acids And Derivatives
- WO2015191422 62/011,465, 62/012,113, 62/011,474, 61/531,911, WO2013036812, Ser. No. 14/199,528, Omega-Hydroxylated Carboxylic Acids
- WO2016007258 62/011,474, 62/012,113, 62/011,465, 61/531,911, WO2013036812, US20140273110, Omega-Aminated Carboxylic Acids
- WO2017020043, BIOSYNTHESIS OF POLYKETIDES, filed Aug. 1, 2016, and 62/198,764, filed Jul. 30, 2015
- U.S. Ser. No. 62/308,937, filed Mar. 16, 2016 U.S. Ser. No. 62/198,764, filed Jul. 30, 2015
- 5.5. Sel. No. 02/198,704, med Jul. 50, 201.

TADLE A
---------

Example reactions and enzymes of the Claisen condensation platform for the synthesis of isoprenoid
precursors

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
Acyl-CoA 1 + acyl-CoA 2 → beta-ketoacyl- CoA	$\begin{array}{c} 0\\ R_1 \\ An acyl-CoA 1 \\ 0\\ R_2 \\ S-CoA \\ An acyl-CoA 2 \end{array}$	2.3.1	Thiolase	E. coli atoB E. coli yqeF E. coli fadA E. coli fadI Ralstonia eutropha bktB Pseudomonas sp. Strain B13 catF E coli paaJ Pseudomonas putida pcaF Rhodococcus opacus pcaF Streptomyces sp. pcaF Ralstonia eutropha phaA Clostridium acetobutylicum thIA	NP_416728.1 NP_417321.2 YP_026272.1 NP_416844.1 AAC38322.1 AAL02407.1 NP_415915.1 AAA85138.1 YP_002778248.1 AAD22035.1 AEI80291.1 AAC26023.1

#### 64

TER

#### TABLE A-continued

63

Example reactions and enzymes of the Claisen condensation platform for the synthesis of isoprenoid precursors Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers Numbers names name Clostridium AAC26026.1 acetobutylicum thIB AAK18168.1 Pseudomonas putida fadA *P. putida* fadAx AAK18171.1 Acinetobacter sp. CAG68532.1 ADP1 dcaF E. coli paaJ NP\_415915.1 Acyl-CoA + 2.3.1.-Ketoacyl-AAW59909.1 Gluconobacter oxydans GOX0115 beta-CoA synthase carboxylic Pseudomonas NP\_252023.1 acyl-CoA → aeruginosa FabH2 beta-ketoacylacyl-CoA Streptomyces sp. MMG1121 WP\_053666104.1 HS-CoA CO<sub>2</sub>  $CoA + CO_2$ beta-ketoacyl-CoA PRK09352 Streptomyces AFS18568.1 CoA tendae Acs2 BAJ10048.1 Streptomyces sp. strain CL190 beta-carboxylic acyl-CoA NphT7 Physaria fendleri AAK62348.1 KCS3 Saccharomyces NP\_009963.1 cerevisiae ELO2 Arabidopsis NP\_171620.2 thaliana col KCS1 Arabidopsis NP\_195178.1 thaliana col FAE1 Arabidopsis NP\_177020.1 thaliana col CER6 NP\_418288.1 beta-1.1.1.35; Hydroxyacyl- $E.\ coli\ {\rm fadB}$ .CoA<sup>1.1.1.36</sup> ketoacvl-CoA NAD(P)H CoA E. coli fadJ NP\_416843.1 R<sub>1</sub> `S E. coli paaH NP\_415913.1  $CoA \rightarrow beta$ dehydrogenase hydroxyacyl-P. putida fadB AAK18167.2 P. putida fadB2x CoA AAK18170.1 Acinetobacter sp. CAG68533.1 A β-keto acyl-CoA A β-hydroxy acyl-CoA ADP1 dcaH P14697.1 Ralstonia eutrophus phaB Clostridium AAA95971.1 acetobutylicum hbd E. coli fabG NP 415611.1 3-oxoacvl-[acyl-carrierprotein] reductase NP\_418288.1 4.2.1.17; enovl-CoA E. coli fadB beta-4.2.1.119 E. coli fadJ NP\_416843.1 hydroxyacylhydratase CoA .CoA Rí E. coli paaF NP\_415911.1  $CoA \rightarrow enoyl-$ AAK18167.2 P. putida fadB CoA AAK18173.1 P. putida fadB1x An enoyl-CoA Acinetobacter sp. CAG68535.1 A 8-hydroxyacyl-CoA ADP1 dcaE AAA95967.1 Clostridium acetobutylicum crt Aeromonas caviae O32472.1 phaJ E. coli fabA NP\_415474.1 3-E. coli fabZ NP\_414722.1 hydroxyacyl-[acyl-carrierprotein] dehydratase Enoyl-CoA  $\rightarrow$ 1.3.1.44 enoyl-CoA Euglena gracilis Q5EU90.1 Acyl-CoA TER reductase CoA R<sub>1</sub> CoA. 4GGO\_A Treponema denticola TER Clostridium 4EUH\_A acetobutylicum An enoyl-CoA An acyl-CoA

1	1
0	0

#### TABLE A-continued

Example reactions and enzymes of the Claisen condensation platform for the synthesis of isoprenoid precursors Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names name Numbers E. coli fabI NP\_415804.1 enoyl-[acylcarrier Enterococcus NP\_816503.1 *faecalis* fabK protein] reductase Bacillus subtilis KFK80655.1 fabL Vibrio cholerae ABX38717.1 fabVacyl-CoA E. coli fadE NP\_414756.2 dehydrogenase E. coli ydiO NP\_416210.4 acyl-CoA AAC08713.1. Carbon 5.4.99.-Streptomyces  $\xrightarrow{O}_{S-CoA} \longrightarrow \xrightarrow{O}_{S-CoA}$ rearrangement mutase cinnamonensis CAB59633.1 (select icmAB Metallosphaera A4YEG1, examples) sedula A4YIE3 Msed\_0638, Msed\_2055 Cupriavidus Q1LRY0 metallidurans icmF o ↓ S-CoA - O S-CoA D5WTR7, Kyrpidia tusciae rcmAB Rhodobacter D5WTR8 ABA80144.1 sphaeroides meaA óн ЬH

TABLE B

		Example termination	pathways and	enzymes		
Reaction	Illustration		EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
Acyl-CoA → Carboxylic acid	R An acyl-CoA	A carboxylic acid	3.1.2	Thioesterase	E. coli tesA E. coli tesB E. coli yciA E. coli fadM E. coli ybgC E. coli ybgC E. coli ybgC E. coli paal Mus musculus acot8 Lycopersicon hirsutum f glabratum mks2 Alcanivorax borkumensis tesB2 Fibrobacter succinogenes Fs2108 Prevotella ruminicola Pr1687	NP_415027.1 NP_414986.1 NP_414986.1 NP_415769.1 NP_414977.1 NP_416201.1 NP_415264.1 NP_415264.1 NP_415214.1 P58137.1 ADK38536.1 YP_692749.1 YP_005822012.1 YP_003574018.1 YP_003574982.1
			2.8.3.8	Acyl- CoA:acetyl- CoA transferase	E. coli atoD Clostridium kluyveri cat2 Clostridium acetobutylicum ctfAB E. coli vdiF	NP_416725.1 AAA92344.1 NP_149326.1, NP_149327.1 NP_416209.1
			2.3.1; 2.7.2.1; 2.7.2.15	Phosphotrans- acylase + Carboxylate kinase	Clostridium acetobutylicum ptb Enterococcus faecalis ptb Salmonella enterica pduL Clostridium	NP_349676.1 AAD55374.1 AAD39011.1 AAK81015.1
					pduL Clostridium acetobutylicum buk	AAK81015.1

# 

				Source organism	Protein
Reaction	Illustration	EC Numbers	Enzyme names	and gene/enzyme name	Accession Numbers
				Enterococcus	AAD55375.1
				<i>faecalis</i> buk <i>Salmonella enterica</i> pduW	AAD39021.1
Acyl-CoA → Alcohol	$\int_{-\infty}^{0} c_{OA} \longrightarrow R c_{OH}$	1.2.1.84	Alcohol- forming CoA reductase	<i>Clostridium acetobutylicum</i> adhE2	YP_009076789.1
	R S An alcohol An acyl-CoA			Arabidopsis thaliana At3g11980	AEE75132.1
				Arabidopsis thaliana At3g44560	AEE77915.1
				Arabidopsis	AEE79553.1
				Arabidopsis	AED93034.1
				thaliana At5g22500 Arabidopsis	AEE86278.1
				thaliana CER4 Marinobacter	YP_959486.1
				aquaeolei VT8 magu 2220	
				Marinobacter aquaeolei VT8 maqu_2507	YP_959769.1
cyl-CoA →	0. O.	1.2.1.10	Aldehyde	Acinetobacter	AAC45217.1
ldehyde			forming CoA reductase	<i>calcoaceticus</i> acr1 <i>Acinetobacter</i> sp	BAB85476.1
	R S R H			Strain M-1 acrM Clostridium	AAT66436.1
	An acyl-CoA An andenyde			<i>beijerinckii</i> ald <i>E. coli</i> eutE	NP_416950.1
				<i>Salmonella enterica</i> eutE	AAA80209.1
				E. coli mhpF	NP_414885.1
arboxylic		1.2.1	Carboxylic	E. coli PaoABC	NP_414820.1,
ldehyde			(Carboxylate)		NP_414819.1, NP_414818.1
	K OH K H		reductase	<i>Mycobacterium</i> <i>marinum</i> Car	WP_012393886.J
	carboxyne acid ardenyde			<i>Nocardia iowensis</i> Car	AAR91681.1
				<i>Segniliparus</i> <i>rotundus</i> Car	WP_013138593.1
Aldehyde →		1.1.1	Alcohol dehydrogen-	E. coli betA	NP_414845.1 NP_417485.4
1001101	R OH		ase	E. coli eutG	NP_416948.4
	R <sup>•</sup> H An alcohol			E. coli fucO	NP_417279.2
	An aldehyde			E. coli yahK	NP_414859.1
				E. coli ybbO	NP_415026.1
				E. coli ybdH	NP_415132.1
				E. coli vigB	NP 418690.4
				Acinetobacter sp.	AAG10028.1
				SE19 ChnD Marinobacter	YP_959769.1
				aquaeolei VT8 magu 2507	
				Saccharomyces	Q04894.1
				cerevisiae ADH6 Clostridium kluyveri 4hbD	EDK35022.1
ldehyde → lkane		4.1.99.5	Aldehyde decarbonylase	Synechococcus elongatus	Q54764.1
	R $H$ $H$ $An alkaneAn aldehyde$			PCC/942 ort1593 Nostoc punctiforme PCC73102	B2J1M1.1

70

### TABLE B-continued

ction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
				Prochlorococcus marinus MIT9313 pmt1231	Q7V6D4.1
ohol → enyl		4.2.1	Dehydratase	Elizabethkingia meningoseptica ohyA	GQ144652.1
ohol → spho		2.7.1	Alcohol Kinase/	Saccharomyces cerevisiae ERG12	P07277
	$R' \to R' \to - P - 0^-$		Phosphotrans-	Saccharomyces	P24521
	alcohol O-		Ierase	cerevisiae ERG8 Arabidopsis	Q67ZM7
	mono-phosphate			thaliana At5g58560 Mantha y piparita	D56848
	1 1			ipk	130848
				<i>Methanocaldococcus</i> jannaschii mvk	Q58487
				Arabidopsis	AT5G27450.1
				<i>thaliana</i> mvk	
				E. coli ychB	NP_415726.1
				<i>E. cou</i> gip <b>k</b> <i>Methanothermobacter</i>	AAB84554.1
				thermautotrophicus	
				ipk	
				Thermoplasma acidophilum ipk	WP_010900530.
				Methanocaldococcus	3K4Y_A
				<i>jannaschii</i> ipk	
oho → ospho	$ \begin{array}{c} 0 \\ R \frown 0 - \stackrel{0}{{}{}{}{}{}{}{\overset$	-O-	Phosphate Kinase/ Phosphotrans-	Methanothermobacter thermautotrophicus ipk	AAB84554.1
	0- 0- 0	r-	ferase	Thermoplasma	WP_010900530.
	mono-phosphate di-phosphate			acidophilum ipk Enterococcus	Q9FD67
				<i>faecalis</i> mvaK2	
				Streptococcus	A0A0I7UH23
				mvaK2	
				Staphylococcus	A0A0E8GDF5
				aureus mvaK2	
				<i>Methanocaldococcus jannaschii</i> ipk	3K4Y_A
ıol →	0 0	2.7.6-	Alcohol	Escherichia coli Prs	NP 415725.1
ospho	$R \longrightarrow R \longrightarrow 0 - P - 0 - P - 0^{-1}$		diphosphoki-	Mycoplasma	NP_109761.1
	o- o-		11000	PrsA	
				Arabidopsis	BAH19964.1
				Arabidopsis	BAH57065.1
				thaliana col TPK2	
<b>→</b> PP		5.3.3.2	isopentenyl diphosphate	<i>E. coli</i> idi	Q46822
	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		isomerase		

#### 71 TABLE B-continued Example termination pathways and enzymes Source organism and gene/enzyme Protein Accession Enzyme EC Numbers Numbers Reaction Illustration names name olivetolic acid cyclase 3,5,7-trioxododecanoyl-*Cannabis sativa* OAC Ö Ö 4.4.1.26 I6WU39 0 II Ö $CoA \rightarrow$ olivetolate S-CoA 3,5,7-trioxododecanoyl-CoA OH 0 ΟН HO olivetolic acid

TABLE C

				Source organism	Protein
Reaction	Illustration	EC Numbers	Enzyme names	and gene/enzyme name	Accession Numbers
2 acetyl- CoA → acetoacetyl- CoA	Acetyl-CoA Acetyl-CoA S-CoA Acetyl-CoA Acetyl-CoA	2.3.1	Thiolase	E. coli atoB E. coli yqeF E. coli fadA E. coli fadI Ralstonia eutropha bktB Pseudomonas sp. Strain B13 catF E coli paaJ Pseudomonas putida pcaF Rhodococcus opacus pcaF Streptomyces sp. pcaF Ralstonia eutropha phaA Clostridium acetobutylicum thIA Clostridium acetobutylicum thIB Pseudomonas putida fadAx Acinetobacter sp.	NP_416728.1 NP_417321.2 YP_026272.1 NP_416844.1 AAC38322.1 AAL02407.1 NP_415915.1 AAA85138.1 YP_002778248.1 AAD22035.1 AEI80291.1 AAC26023.1 AAC26026.1 AAK18168.1 AAK18168.1 AAK18171.1 CAG68532.1
				ADP1 dcaF E. coli paaJ	NP_415915.1
Acetyl- CoA + malonyl-	S-CoA	2.3.1	Ketoacyl- CoA synthase	Gluconobacter oxydans GOX0115	AAW59909.1
CoA → acetoacetyl- CoA + CO <sub>2</sub>	$ \begin{array}{c} \text{acetyl-CoA} \\ 0 & 0 \\ 1 & 1 \end{array}  $			Pseudomonas aeruginosa FabH2 Streptomyces sp. MMG1121 PPK00352	NP_252023.1 WP_053666104.1
	HO S-COA CO <sub>2</sub> acetoacetyl-CoA			Streptomyces tendae Acs2	AFS18568.1
	maonyi oozi			<i>Streptomyces</i> sp. strain CL190 NphT7	BAJ10048.1
				Physaria fendleri KCS3	AAK62348.1
				Saccharomyces cerevisiae ELO2	NP_009963.1
				Arabidopsis thaliana col KCS1	NP_171620.2

## 74

*ruminicola* Pr1687

#### TABLE C-continued

				Source organism	Protein
Reaction	Illustration	EC Numbers	Enzyme names	and gene/enzyme name	Accession Numbers
				Arabidopsis thaliana col FAE1	NP_195178.1
				Arabidopsis thaliana col CER6	NP_177020.1
Acetoacetyl- CoA +	0 0 	2.3.3.10	Hydrox- ymethyl	Staphylococcus aureus HMGS	BAU36102.1
etyl- oA → 3-	S-CoA OH O		glutaryl- CoA	Saccharomyces cerevisiae HMGS	NP_013580.1
ydroxy-3- ieth-	Acetoacetyl-CoA HO S-CoA		synthase	<i>Enterococcus</i> <i>faecalis</i> mvaS	AAG02438.1
CoA S-CoA Acetyl-CoA CoA (S)-3-hydroxy- 3-methylglutaryl-CoA (HMG-CoA)	(S)-3-hydroxy- 3-methylglutaryl-CoA			Ustilago maydis hcs1	KIS66367.1
	S-COA COA (HMG-COA) Acetyl-CoA			Arabidopsis thaliana BAP1	AAD00297.1
				Homo sapiens HMGCS1	NP_001317592.1
				<i>Homo sapiens</i> HMGCS2	NP_001159579.
-hydroxy-3- neth-		4.2.1.17; 4.2.1.119	Enoyl- CoA	<i>Myxococcus</i> <i>xanthus</i> liuC	WP_011553770.
lglutaryl- oA → 3-	HO S-COA		hydratase	E. coli fadB Aeromonas	NP_418288.1 O32472.1
lglutaconyl-	3-methylglutaryl-CoA (IMCC CoA) 3-methylglutaconyl-CoA			<i>E. coli</i> fadJ	NP_416843.1
οA	(IIMG-COA)			<i>E. coli</i> paaF <i>P. putida</i> fadB	NP_415911.1 AAK18167.2
				P. putida fadB1x Acinetobacter sp.	AAK18173.1 CAG68535.1
				ADP1 dcaE Clostridium acetobutylicum	AAA95967.1
				crt Aeromonas	032472 1
				caviae phaJ	ND 415474.1
				E. coli fabA E. coli fabZ	NP_415474.1 NP_414722.1
meth- glutaconyl-	$\begin{array}{ccc} & & & & \\ O & & & & \\ \end{array}$	4.1.1.70	Gluta- convl-	Myxococcus xanthus aibAB	WP_011554267. WP_011554268
$oA \rightarrow$	HO S-CoA		CoA decarbox-		,,, <u>,</u> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
utenoyl-	3-methylglutaconyl-CoA 3-methyl-		ylase		
$OA + CO_2$	2-butanoyl-CoA (3-methylcrotonyl-				
	CoA)				
methyl-2- itenoyl-		3.1.2	Thioes- terase	E. coli tesA E. coli tesB	NP_415027.1 NP_414986.1
$_{oA} \rightarrow 3$ -				E. coli yciA E. coli fadM	NP_415769.1
itenoate				E. coli radivi E. coli ydiI	NP_416201.1
	3-methyl- 3-methyl-2-butenoate 2-butenoyl-CoA			E. coli ybgC	NP_415264.1
				Mus musculus	P58137.1
				Lycopersicon hirsutum f	ADK38536.1
				glabratum mks2 Alcanivorax borkumensis tesB2	YP_692749.1
				Fibrobacter succinogenes Fs2108	YP_005822012.
				Prevotella	YP_003574018.
				ruminicola Pr655 Prevotella	YP_003574982.

# 76

*enterica* eutE

E. coli mhpF

NP\_414885.1

### TABLE C-continued

		EC	Enzyme	Source organism and gene/enzyme	Protein Accession
eaction	Illustration	2.8.3.8	Acyl- CoA:a-	name E. coli atoD Clostridium	NUMBERS NP_416725.1 AAA92344.1
			cetyl- CoA trans- ferase	kluyveri cat2 Clostridium acetobutylicum ctfAB	NP_149326.1, NP_149327.1
		2.3.1; 2.7.2.1; 2.7.2.15	Phos- photrans- acylase +	E. coli ydiF Clostridium acetobutylicum	NP_416209.1 NP_349676.1
		2.7.2.13	Carbox- ylate	Enterococcus faecalis ptb	AAD55374.1
			kinase	<i>Salmonella</i> <i>enterica</i> pduL	AAD39011.1
				Clostridium acetobutylicum buk	AAK81015.1
				Enterococcus faecalis buk	AAD55375.1
				Salmonella enterica pduW	AAD39021.1
methyl-2- itenoate $\rightarrow$		1.2.1	Carbox- ylic	E. coli PaoABC	NP_414820.1, NP_414819.1,
nethyl-2- tenal	OH NAD(P)H		Acid (Carbox- ylate)	Mycobacterium marinum Car	NP_414818.1 WP_012393886
	3-methyl-2-butenoate 3-methyl-2-butenal		reductase	Nocardia iowensis Car	AAR91681.1
				Segniliparus rotundus Car	WP_013138593
nethyl-2- tenoyl-		1.2.1	Alcohol- forming	Clostridium acetobutylicum adhF2	YP_009076789.
methyl- butenol	S-CoA 2 NAD(P)H OH		CoA reductase	Arabidopsis thaliana	AEE75132.1
	2-butenoyl-CoA (prenol)			Arabidopsis thaliana	AEE77915.1
				Arabidopsis thaliana	AEE79553.1
				At3g56700 Arabidopsis thaliana	AED93034.1
				At5g22500 Arabidopsis thaliana CER4	AEE86278.1
				Marinobacter aquaeolei VT8	YP_959486.1
				maqu_2220 Marinobacter aquaeolei VT8 maqu_2507	YP_959769.1
methyl-2- tenoyl-		1.2.1	Aldehyde forming	Acinetobacter calcoaceticus	AAC45217.1
methyl- butenal	S-CoA NAD(P)H		reductase	Acinetobacter sp Strain M-1 acrM	BAB85476.1
	2-butenoyl-CoA			<i>Clostridium</i> <i>beijerinckii</i> ald <i>E_coli</i> eutE	AAT66436.1
				Salmonella	AAA80209.1

77

### 78

#### TABLE C-continued



80

79

	TAE	BLE C-continued						
	Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) and prenol based on Claisen condensation reactions							
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers			
				<i>Arabidopsis thaliana</i> col TPK2	BAH57065.1			
DMAPP ↔ IPP	$\downarrow \qquad \bigcirc $	5.3.3.2	iso- pentenyl diphos- phate isomerase	<i>E. coli</i> idi	Q46822			
	isopenten	$\begin{array}{c} O & O \\ -P - O - P - O - P - O^{-1} \\ O - O^{-1} \\ O - O^{-1} \end{array}$						
	I	2.5.1	Commit	E li i A	<b>D22020</b>			
JMAPP + $\text{PP} \rightarrow \text{GPP}$	$ \begin{array}{c} 0 \\ -P \\ 0 \\ 0 \\ -P \\ 0 \\ 0 \\ -P \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ $	2.3.1-	pyrophos- phate synthase	<i>E. coli</i> IspA <i>Abies grandis</i> GPPS2	Q8LKJ2			
	dimethyallyl pyrophosphate O O P O D O O O O O O O O							
	isopentenyl pyrophosphate							
		$\begin{array}{ccc} 0 & 0 \\ -P & -P & -P & -O \\ 1 & 1 \\ O^{-} & O^{-} \end{array}$						
	geranyl pyropl	hosphate						

### TABLE D

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 3-hydroxy-3methylbutyryl-CoA and prenol based on Claisen condensation reactions

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
2 acetyl- CoA → acetoacetyl- CoA	S-CoA Acetyl-CoA S-CoA Acetyl-CoA Acetyl-CoA	2.3.1	Thiolase	E. coli atoB E. coli yqeF E. coli fadA E. coli fadI Ralstonia eutropha bktB Pseudomonas sp. Strain B13 catF E coli paaJ Pseudomonas putida pcaF Rhodococcus opacus pcaF Streptomyces sp. pcaF Ralstonia eutropha phaA Clostridium acetobutylicum thIA	NP_416728.1 NP_417321.2 YP_026272.1 NP_416844.1 AAC38322.1 AAL02407.1 NP_415915.1 AAA85138.1 YP_002778248.1 AAD22035.1 AEI80291.1 AAC26023.1

## 82

NP\_746081.1 NP\_746082.1

*Pseudomonas putida* pcalJ

#### TABLE D-continued

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
				Clostridium acetobutylicum	AAC26026.1
				Pseudomonas putida fadA	AAK18168.1
				<i>P. puttaa</i> fadAx <i>Acinetobacter</i> sp. ADP1 dcaF	CAG68532.1
				E. coli paaJ	NP_415915.1
cetyl-CoA + alonyl- oA →		2.3.1	Ketoacyl- CoA synthase	Gluconobacter oxydans GOX0115	AAW59909.1
cetoacetyl- oA + $CO_2$	acetyl-CoA		Synthase	Pseudomonas aeruginosa	NP_252023.1
	HO HO Malonyl-CoA HO CO <sub>2</sub> Acetoacetyl-CoA			FabH2 Streptomyces sp. MMG1121 PRK09352	WP_053666104.
				Streptomyces	AFS18568.1
				Streptomyces sp. strain CL190	BAJ10048.1
				Physaria fendleri	AAK62348.1
				Saccharomyces cerevisiae	NP_009963.1
				Arabidopsis thaliana col	NP_171620.2
				Arabidopsis thaliana col FAE1	NP_195178.1
				Arabidopsis thaliana col CER6	NP_177020.1
cetoacetyl-	0 0 CoA 0 0	3.1.2	Thioes-	E. coli tesA E. coli tesB	NP_415027.1
etoacetic			terase	E. coli yciA	NP_415769.1
id + CoA	S-CoA OH			E. coli fadM	NP_414977.1 NP_416201_1
	Acetoacetyl-CoA Acetoacetic acid			E. coli ybgC	NP_415264.1
nethyl-2-				E. coli paal Mus musculus	NP_415914.1 P58137.1
$A \rightarrow 3$ - ethyl-2-	S-CoA - OH			Lycopersicon hirsutum f	ADK38536.1
itenoate	3-methyl- 2-butenoyl-CoA 3-methyl-2-butenoate			glabratum mk52 Alcanivorax	YP_692749.1
				Fibrobacter succinogenes	YP_005822012.
				Prevotella ruminicola Pr655	YP_003574018.
				Prevotella ruminicola Pr1687	YP_003574982.
		2.8.3-	CoA	E. coli atoD	NP_416725.1
			trans- ferace	E. coli atoA	NP_416726.1
			101250	<i>Clostridium kluyveri</i> cat1	AAA92346.1
				<i>Clostridium kluyveri</i> cat2	AAA92344.1
				Clostridium acetobutylicum ctfAB	NP_149326.1, NP_149327.1

Q	Λ
• • •	-

#### TABLE D-continued

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
		2.3.1; 2.7.2.1; 2.7.2.15	Phos- photrans- acylase + Carbox- ylate kinase	Megasphaera elsdenii pct Acidaminococcus fermentans gctAB Acetobacter aceti aarC E. coli ydiF Clostridium acetobutylicum ptb Enterococcus faecalis ptb Salmonella enterica pduL Clostridium acetobutylicum buk Enterococcus faecalis buk Salmonella enterioa	WP_014015705.1 CAA57199.1 CAA57200.1 AGG68319.1 NP_416209.1 NP_349676.1 AAD55374.1 AAD39011.1 AAK81015.1 AAD55375.1
acetoacetic cid $\rightarrow$ cetone + $CO_2$	O O CO <sub>2</sub> O O Acetone	4.1.1.56;	Decar- boxylase	pduW Lycopersicon hirsutum f glabratum mks1 Clostridium acetobutylicum adc	ADK38535.1 AAA63761.1
vcetone + cetyl- loA → 3- .ydroxy-3- nethylbutyryl- loA	Acetone  O S-CoA  Acetyl-CoA  Acetyl-CoA $Acetyl-CoA  Acetyl-CoA  Acetyl-$	2.3.3	Hydrox- ymethyl butyryl- CoA synthase	Staphylococcus aureus HMGS Saccharomyces cerevisiae HMGS Enterococcus aecalis mvaS Ustilago maydis hcs1 Arabidopsis thaliana BAP1 Homo sapiens HMGCS1 Homo sapiens HMGCS2	BAU36102.1 NP_013580.1 AAG02438.1 KIS66367.1 AAD00297.1 NP_001317592.1 NP_001159579
hydroxy-3- ethylbutyryl- oA → 3- .ethyl-2- .tenoyl- oA	HO + G 3-methyl- 3-hydroxybutyryl-CoA H2O S-CoA 3-methyl- 2-butenoyl-CoA (3-methyl- CoA)	4.2.1.17; 4.2.1.119	Enoyl- CoA hydratase	Myxococcus xanthus liuC E. coli fadB Aeromonas punctata phaJ E. coli fadJ E. coli paaF P. putida fadB1x Acinetobacter sp. ADP1 dcaE Clostridium acetobutylicum crt Aeromonas caviae phaJ E. coli fabA E. coli fabA E. coli fabZ	WP_011553770.1 NP_418288.1 O32472.1 NP_416843.1 NP_415911.1 AAK18167.2 AAK18173.1 CAG68535.1 AAA95967.1 O32472.1 NP_415474.1 NP_415474.1 NP_414722.1
-methyl-2- utenoate → -methyl-2- utenal	OH 3-methyl-2-butenoate	1.2.1	Carbox- ylic Acid (Carbox- ylate) reductase	E. coli PaoABC Mycobacterium marinum Car Nocardia iowensis Car Segniliparus mamdus Car	NP_414820.1, NP_414819.1, NP_414818.1 WP_012393886.1 AAR91681.1 WP_013138593.1

# 86

### TABLE D-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 3-hydroxy-3- methylbutyryl-CoA and prenol based on Claisen condensation reactions					
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
3-methyl-2- butenoyl- CoA → 3-methyl- 2-butenol	John S-CoA 3-methyl- 2-butenoyl-CoA John S-CoA 2 NAD(P)H 3-methyl-2-butenol (prenol)	1.2.1	Alcohol- forming Acyl- CoA reductase	Clostridium acetobutylicum adhE2 Arabidopsis thaliana At3g11980 Arabidopsis thaliana At3g44560 Arabidopsis thaliana At3g56700 Arabidopsis thaliana At3g25070 Arabidopsis thaliana CER4 Marinobacter aquaeolei VT8 maqu_2220 Marinobacter aquaeolei VT8 maqu_2507	YP_009076789.1 AEE75132.1 AEE77915.1 AEE79553.1 AED93034.1 AEE86278.1 YP_959486.1 YP_959769.1
3-methyl-2- butenoyl- CoA → 3-methyl- 2-butenal	3-methyl- 2-butenoyl-CoA	1.2.1	Aldehyde forming CoA reductase	Acinetobacter calcoaceticus acrl Acinetobacter sp Strain M-1 acrM Clostridium beijerinckii ald E. coli eutE Salmonella enterica eutE E. coli mhpF	AAC45217.1 BAB85476.1 AAT66436.1 NP_416950.1 AAA80209.1 NP_414885.1
3-methyl-2- butenal → 3-methyl-2- butenol	3-methyl-2-butenal	1.1.1	Alcohol dehydro- genase	E. coli betA E. coli dkgA E. coli eutG E. coli fucO E. coli ucpA E. coli ybbO E. coli ybbO E. coli ybbH E. coli ybdH E. coli ybgB Acinetobacter sp. SE19 ChnD Marinobacter aquaeolei VT8 maqu_2507 Saccharomyces cerevisiae ADH6 Clostridium kluyveri 4hbD	NP_414845.1 NP_417485.4 NP_416948.4 NP_416948.4 NP_416921.4 NP_414859.1 NP_414859.1 NP_415026.1 NP_415132.1 YP_026233.1 NP_418690.4 AAG10028.1 YP_959769.1 Q04894.1 EDK35022.1
3-methyl-2- butenol → dimethylallyl phosphate	JO- 3-methyl-2-butenol ATP J-O- (prenol) dimethylallyl phosphate	2.7.1	Alcohol Kinase/ Phos- photrans- ferase	Saccharomyces cerevisiae ERG12 Saccharomyces cerevisiae ERG8 Arabidopsis thaliana At5g58560 Mentha x piperita ipk Methanocaldo- coccus jannaschii mvk Arabidopsis thaliana mvk E. coli ychB E. coli ychB E. coli glpK Methanothermo- bacter thermautotrophicus ipk Thermoplasma acidophilum ipk	P07277 P24521 Q67ZM7 P56848 Q58487 AT5G27450.1 NP_415726.1 P0A6F3 AAB84554.1 WP_010900530.1

88

#### TABLE D-continued

87

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 3-hydroxy-3methylbutyryl-CoA and prenol based on Claisen condensation reactions Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names name Numbers Methanocaldo-3K4Y\_A coccus *jannaschii* ipk dimethylallyl 2.7.4-Phos-Methanothermo-AAB84554.1 phosphate → phate bacter -0-**`**Odimethylallyl . Kinase/ thermautotrophicus pyrophos-Phosipk phate photrans-Thermoplasma WP\_010900530.1 dimethylallyl phosphate acidophilum ipk dimethylallyl pyrophosphate ferase Q9F067 Enterococcus faecalis mvaK2 A0A0I7UH23 Streptococcus pneumoniae mvaK2 Staphylococcus A0A0E8GDF5 aureus mvaK2 Methanocaldo-3K4Y\_A coccus *jannaschii* ipk 3-methyl-2-2.7.6-Alcohol Escherichia coli Prs NP\_415725.1 NP\_109761.1 butenol → diphos-Mycoplasma 'OH -0 phokinpneumoniae M129 dimethylallyl 2 ATP pyrophos-3-methylase PrsA BAH19964.1 phate Arabidopsis 2-butenol dimethylallyl pyrophosphate thaliana col TPK1 (prenol) Arabidopsis BAH57065.1 thaliana col TPK2 E. coli idi DMAPP ↔ 5.3.3.2 Q46822 isopen-IPP tenyl **`**o−₽ diphosphate isomerase dimethylallyl pyrophosphate -P-O-P-Oisopentenyl pyrophosphate DMAPP + 2.5.1-P22939 E. coli ispA Geranyl  $IPP \rightarrow GPP$ Q8LKJ2 pyrophos-Abies grandis -O-P-O-O-GPPS2 phate synthase dimethyallyl pyrophosphate -0 ·Ω ò ò isopentenyl pyrophosphate ₽–0<sup>-</sup> geranyl pyrophosphate

#### 89

### 90

TABLE E



91

### 92

TABLE E-continued



## 93

## 94

TABLE E-continued

		dehydratase				
Reaction	Illustration		EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
					Peptoclostridium difficile hadIBC Clostridium propionicum IcdCAB	AAV40818.1, AAV40819.1, AAV40820.1 G3KIM3, G3KIM4, G3KIM5
3-methyl-2- butenoyl- CoA → 3- methyl-2- butenoate 3-methyl-2- hydrox- ybutanoyl- CoA → 3-methyl-2- hydroxy- butanoate	$\begin{array}{c} & & & \\ & &$	OH thyl-2-butenoate OH OH 3-methyl- droxybutanoate	3.1.2	Thioes- terase	E. coli tesA E. coli tesB E. coli tesB E. coli fadM E. coli ydiI E. coli ybgC E. coli paaI Mus musculus acot8 Lycopersicon hirsutum f glabratum mks2 Alcanivorax borkumensis tesB2 Fibrobacter succinogenes Fs2108 Prevotella	NP_415027.1 NP_414986.1 NP_415769.1 NP_414977.1 NP_415264.1 NP_415204.1 NP_415914.1 P58137.1 ADK38536.1 YP_692749.1 YP_005822012.1
			2.8.3.8	Acyl- CoA:acyl- CoA transferase	ruminicola ruminicola Pr655 Prevotella ruminicola Pr1687 E. coli atoD Clostridium kluyveri cat2 Clostridium acetobutylicum ctfAB	YP_003574982.1 NP_416725.1 AAA92344.1 NP_149326.1, NP_149327.1
			2.3.1; 2.7.2.1:	Phos-	E. coli ydıF Clostridium acetobutylicum ptb Enterococcus faecalis ptb Salmonella enterica pduL Clostridium acetobutylicum	NP_416209.1 NP_349676.1 AAD55374.1 AAD39011.1 AAK81015.1
			2.7.2.15	acylase + Carbox- ylate kinase	buk Enterococcus faecalis buk Salmonella enterica pduW	AAD55375.1 AAD39021.1
3-methyl-2- butenoate → 3-methyl-2- butenal 3-methyl-2- hydrox- ybu- tanoate → 3-methyl-2- hydrox- ybutanal	3-methyl-2-butenoate 3-methyl-2-butenoate 0 0 0 0 0 0 0 0 0 0	o nethyl-2-butenal OH 3-methyl-	1.2.1	Carbox- ylic Acid (Carbox- ylate) reductase	E. coli PaoABC Mycobacterium marinum Car Nocardia iowensis Car Segniliparus rotundus Car	NP_414820.1, NP_414819.1, NP_414818.1 WP_012393886.1 AAR91681.1 WP_013138593.1

95

#### 96

#### TABLE E-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin

condensation via 2-hydroxyisovaleric acid and prenol through utilization of 2-hydroxyacid/2-hydroxyacyl-CoA

dehydratase



#### 97

### 98

TABLE E-continued



99

### 100

#### TABLE E-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin

condensation via 2-hydroxyisovaleric acid and prenol through utilization of 2-hydroxyacid/2-hydroxyacyl-CoA

dehydratase



#### TABLE F

Reaction	Example reactions and enzymes o condensation via 2-oxoisovaleric acid, bran Illustration	f the pathway for isoprenoid prec 2-oxoisocaproic acid and prenol ched alpha-keto acid dehydrogen EC Numbers	ursor synthesi through alpha ase Enzyme names	s based on acyloin -keto acid pathway and Source organism and gene/enzyme name	d Protein Accession Numbers
2 pyruvate → acetolactate	ОН	2.2.1.6	Acetolac- tate synthase	E. coli ilvBN E. coli ilvIH B. subtilis alsS	P08142, P0ADF8 P00893, P00894 Q04789
	OH CO <sub>2</sub> (S)-2-ace	OH OH tolactate			

pyruvate

### 101

### 102

TABLE F-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin condensation via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol through alpha-keto acid pathway and branched alpha-keto acid dehydrogenase



## 103

## 104

#### TABLE F-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin condensation via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol through alpha-keto acid pathway and branched alpha-keto acid dehydrogenase

orancied apria-keto acid denydrogenase						
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers	
				bfmBAA-bfmBAB- bfmBB-pdhD <i>E. coli</i> IpdA-aceEF	WP_004398638.1 WP_003230323.1 WP_003232309.1 NP_414657.1 NP_414658.1 NP_414656.1	
Isovaleryl- CoA $\rightarrow$ 3- methyl-2- butenoyl- CoA	S-CoA isovaleryl-CoA 	1.3.8.4	Acyl-CoA dehy- drogenase	Pseudomonas aeruginosa liuA E. coli aidB E. coli fadE Streptomyces avermitilis acdH	APJ52511.1 NP_418608.6 NP_414756.2 AAD44196.1	
3-methyl-2- butenoyl- CoA → 3-methyl-2- butanoate	$\begin{array}{c} \overbrace{} \\ \overbrace{} \\ 3 \text{-methyl-} \\ 2 \text{-butenoyl-CoA} \end{array} \xrightarrow{} \\ 3 \text{-methyl-} \\ 3 \text{-methyl-} 2 \text{-butenoate} \end{array}$	3.1.2	Thioes- terase	E. coli tesA E. coli tesB E. coli yciA E. coli yciA E. coli ydiI E. coli ybgC E. coli paaI Mus musculus acot8 Lycopersicon hirsutum f glabratum mks2 Alcanivorax borkumensis tesB2 Fibrobacter succinogenes Fs2108 Prevotella ruminicola Pr655 Prevotella	NP_415027.1 NP_414986.1 NP_415769.1 NP_414977.1 NP_416201.1 NP_415264.1 NP_415914.1 P58137.1 ADK38536.1 YP_692749.1 YP_005822012.1 YP_003574018.1 YP_003574982.1	
		2.8.3.8	Acyl- CoA:a- cetyl-CoA transferase	ruminicola FF1087 E. coli atoD Clostridium kluyveri cat2 Clostridium acetobutylicum ctfAB E. coli vdiF	NP_416725.1 AAA92344.1 NP_149326.1, NP_149327.1 NP_416209.1	
		2.3.1; 2.7.2.1; 2.7.2.15	Phos- photrans- acylase + Carbox- ylate kinase	Clostridium acetobutylicum ptb Enterococcus faecalis ptb Salmonella enterica pduL Clostridium acetobutylicum buk	NP_349676.1 AAD55374.1 AA039011.1 AAK81015.1	
				faecalis buk Salmonella enterica pduW	AA039021.1	
3-methyl-2- butenoate → 3-methyl-2- butenal	OH 3-methyl-2-butenoate	1.2.1	Carbox- ylic Acid (Carbox- ylate) reductase	E. coli PaoABC Mycobacterium marinum Car Nocardia iowensis Car Segniliparus rotundus Car	NP_414820.1, NP_414819.1, NP_414818.1 WP_012393886.1 AAR91681.1 WP_013138593.1	

## 105

## 106

#### TABLE F-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin condensation via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol through alpha-keto acid pathway and branched alpha-keto acid dehydrogenase

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
3-methyl-2- butenoyl-		1.2.1	Alcohol- forming	Clostridium acetobutylicum adhE2	YP_009076789.1
3-methyl- 2-butenol	3-methyl- 2 NAD(P)H 3-methyl-2-butenol		reductase	Arabidopsis thaliana At3g11980	AEE75132.1
	2-butenoyl-CoA (prenol)			Arabidopsis	AEE77915.1
				Arabidopsis thaliana At3g 56700	AEE79553.1
				Arabidopsis thaliana At5g22500	AED93034.1
				Arabidopsis thaliana CER4	AEE86278.1
				Marinobacter aquaeolei VT8	YP_959486.1
				maqu_2220 Marinobacter aquaeolei VT8 maqu_2507	YP_959769.1
3-methyl-2-		1.2.1	Aldehyde	Acinetobacter	AAC45217.1
butenoyl- CoA → 3-methyl-	NAD(P)H		forming CoA	calcoaceticus acrl Acinetobacter sp Strain M-1 acrM	BAB85476.1
2-butenal	3-methyl- 3-methyl-2-butenal		Teddetase	Clostridium heijerinckij ald	AAT66436.1
	2-butenoyl-CoA			E. coli eut E Salmonella enterica	NP_416950.1 AAA80209.1
				eutE <i>E. coli</i> mhpF	NP_414885.1
3-methyl-2- butenal → 3- methyl-2- butenol	OH 3-methyl-2-butenal	1.1.1	Alcohol dehy- drogenase	E. coli betA E. coli dkgA E. coli eutG E. coli fucO E. coli ucpA E. coli yahK E. coli ybbO E. coli ybdH E. coli ybdH E. coli yigY E. coli yjgB Acinetobacter sp. SE19 ChnD Marinobacter aquaeolei VT8 maqu_2507 Saccharomyces cerevisiae ADH6 Clostridium kluyveri 4hbD	NP_414845.1 NP_417485.4 NP_416948.4 NP_417279.2 NP_416921.4 NP_414859.1 NP_415026.1 NP_415132.1 YP_026233.1 NP_418690.4 AAG10028.1 YP_959769.1 Q04894.1 EDK35022.1
3-methyl-2- butenol → dimethylallyl		2.7.1	Alcohol Kinase/ Phos-	Saccharomyces cerevisiae ERG12 Saccharomyces	P07277 P24521
phosphate	3-methyl-2-butenol AIP 1 (prenol) O <sup>-</sup>		pnotrans- ferase	cerevisiae ERG8 Arabidopsis	Q67ZM7
	dimethylallyl phosphate			thaliana At5g58560 Mentha x piperita	P56848
				ирк Methanocaldo- coccus	Q58487
				<i>jannaschii</i> mvk Arabidopsis thaliana mvk	AT5G27450.1
				<i>E. coli</i> ispE <i>E. coli</i> glpK	P62615 P0A6F3
				E. coli ychB	NP_415726.1
				Thermoplasma acidophilum IPK	WP_010900530.1

107

### 108

#### TABLE F-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis based on acyloin condensation via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol through alpha-keto acid pathway and

branched alpha-keto acid dehydrogenase



# 109

### TABLE G

110

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA

Reaction	Illustration	EC Nun	nbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
pyruvate → formate + acetyl-CoA	O H formate O O O H	2.3.1	1.54	Pruvate formate lyase	E. coli pflB E. coli tdcE Chlamydomonas reinhardtii pfl1 Streptococcus mutans pfl	NP_415423.1 YP_026205.1 CAF04129.1 WP_002262619.1
	, , , , , , , , , , , , , , , , , , ,	O S-CoA acetyl-CoA				
formate + CoA → formyl-CoA	O acyl-CoA/ATP	6.2.1	1	Acyl-CoA synthetase	E. coli paaK E. coli sucCD	NP_415916.1 NP_415256.1 NP_415257.1
	H OH				<i>E. coli</i> fadK <i>E. coli</i> fadD	NP_416216.4 NP_416319.1
	H formyl-	о 			<i>E. coli</i> prpE <i>E. coli</i> menE	NP_414869.1 NP_416763.1
		S-CoA ormyl-CoA			Penicillium chrysogenum phl E. coli acs Salmonella typhimurium LT2	CAJ5517.1 NP_418493.1 AAL19325.1
					prpE Bacillus subtilis bioW	AAC00261.1
					Cupriavidus	ADE20402.1
					Rhodopseudomon	CAJ18317.1
					R. palustris balA Pseudomonas aeruginosa PAO1 pasA	CAE26113.1 NP_249687.1
					Arabidopsis	Q42524.1
		2.8.3	3-	CoA	<i>E. coli</i> atoD	NP_416725.1
				transferase	E. coli atoA E. coli scpC	NP_416726.1 NP_417395.1
					Clostridium kluyveri	AAA92346.1
					cat1 Clostridium kluyveri	AAA92344.1
					Clostridium	NP_149326.1,
					acetobutylicum ctfAB	NP_149327.1
					Pseudomonas	NP_746081.1
					putida pcalJ Megasphaera elsdenii pct	NP_746082.1 WP_014015705.1
					Acidaminococcus	CAA57199.1
					fermentans gctAB Acetobacter aceti aarC	CAA57200.1 AGG68319.1
					E. coli ydiF	NP_416209.1
					Clostridium	CAB77207.1
					Pct540	

# 111

## 112

TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA

	isobutanai and iomiyi-CoA							
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers			
		2.3.1;	Carboxylate	Clostridium	NP_349676.1			
		2.7.2	kinase + Phosphotran- asacylase	acetobutylicum ptb Enterococcus faecalis ptb	AAD55374.1			
			40409 1400	Salmonella	AAD39011.1			
				enterica poul Clostridium acetobutylicum buk	AAK81015.1			
				Enterococcus faecalis buk	AAD55375.1			
				Salmonella enterica pduW	AAD39021.1			
acetyl-CoA + CO <sub>2</sub> → malonyl-CoA	$\begin{array}{c} O \\ O \\ CO_2 + ATP \\ \hline \\ acetyl-CoA \\ acetyl-CoA \\ carboxylase \\ HO \\ HO \\ HO \\ Malonyl-CoA \end{array}$	6.4.1.2 DA	Acetyl-CoA carboxylase	E. coli accABCD Saccharomyces cerevisiae HFA1 Homo sapiens ACC2 Acidianus brierleyi accBC + pccB Mycobacterium tuberculosis H37Rv	NP_414727.1 NP_417721.1 NP_417722.1 NP_416819.1 P32874.2 NP_001084.3 BAC55868.1 BAC558667.1 BAC55869.1 WP_003900487.1			
				accD6 <i>Streptomyces</i> <i>venezuelae</i> ATCC 10712 jadJ	AAD37851.1			
2 acetyl- CoA → acetoacetyl- CoA	$ \begin{array}{c}                                     $	2.3.1 DA	Thiolase	E. coli atoB E. coli yqeF E. coli fadA Ralstonia eutropha bktB Pseudomonas sp. Strain B13 catF E coli paaJ Pseudomonas putida pcaF Rhodococcus opacus pcaF Streptomyces sp. pcaF Ralstonia eutropha phaA Clostridium acetobutylicum thIA Clostridium acetobutylicum thIA Clostridium acetobutylicum thIB Pseudomonas putida fadA P. putida fadAx Acinetobacter sp. ADP1 dcaF E. coli paaJ	NP_416728.1 NP_417321.2 YP_026272.1 NP_416844.1 AAC38322.1 AAL02407.1 NP_415915.1 AAA85138.1 YP_002778248.1 AAD22035.1 AEI80291.1 AAC26026.1 AAC26026.1 AAK18168.1 AAK18171.1 CAG68532.1 NP_415915.1			
acetyl-CoA + malonyl- CoA → aceoacetyl- CoA + CO <sub>2</sub>	HO A A A A A A A A	2.3.1	ketoacyl- CoA synthase	Gluconobacter oxydans GOX0115 Pseudomonas aeruginosa FabH2 Streptomyces sp. MMG1121 PRK09352 Streptomyces tendae Acs2 Streptomyces sp. CL 190 nphT7	AAW59909.1 NP_252023.1 WP_053666104.1 AFS18568.1 BAJ10048.1			
113

## 114

TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA

Reaction	Illustration		EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
		0 0			Physaria fendleri	AAK62348.1
					KCS3 Saccharomyces	NP_009963.1
		/ \S-Cc	A		cerevisiae ELO2	NP 171620.2
		acetoacetyl-CoA			thaliana col KCS1	141_171020.2
					Arabidopsis thaliana ool EAE1	NP_195178.1
					Arabidopsis	NP 177020.1
					thaliana col CER6	_
Acetoacetyl-	0 0		1.1.1.35;	Hydroxy-	<i>E. coli</i> fadB	NP_418288.1
$CoA \rightarrow$		NAD(P)H	1.1.1.36	acyl-CoA	E. coli fadJ	NP_416843.1
butyryl-CoA	S-CoA			genase	P. putida fadB	AAK18167.2
	acetoacetyl-CoA			0	<i>P. putida</i> fadB2x	AAK18170.1
		OH O			Acinetobacter sp. ADP1_dcaH	CAG68533.1
					Ralstonia	P14697.1
		3-hydroxybutyryl-CoA	A A		<i>eutrophus</i> phaB Clostridium acetobutylicum hbd	AAA95971.1
				3-oxoacyl-	E. coli fabG	NP_415611.1
				[acyl-carrier-		
				reductase		
3-hydroxy-	OH O	ша	4.2.1.17;	enoyl-CoA	E. coli fadB	NP_418288.1
butyryı- CoA →		H <sub>2</sub> O	4.2.1.119	nydratase	E. coli fadj E. coli paaF	NP_416843.1 NP_415911.1
crotonyl-CoA	S-CoA	$\rightarrow$			P. putida fadB	AAK18167.2
	3-hydroxybutyryl-CoA				<i>P. putida</i> fadB1x	AAK18173.1
		o II			<i>Acinetobacter</i> sp. ADP1 dcaE	CAG68535.1
					Clostridium	AAA95967.1
		crotonyl-CoA	ЪA		acetobutylicum crt Aeromonas caviae	O32472.1
					phaJ	
				3-	E. coli fabA	NP_415474.1
				hydroxyacyl-	E. coli fabZ	NP_414/22.1
				protein]		
				dehydratase		
Crotonyl- CoA →	o II	NAD(P)H	1.3.1.44	enoyl-CoA reductase	<i>Euglena gracilis</i> TER	Q5EU90.1
butyryl-CoA		$\overline{}$			Treponema danticola TEP	4GGO_A
	crotonyl-CoA				Clostridium	4EUH_A
	clotenyr corr	O II			acetobutylicum	
		$\sim \downarrow$		enoyl-	E. coli fabl	NP_415804.1
		- S-Co	ЪА	[acyl-carrier- protein]	<i>Enterococcus</i> <i>faecalis</i> fabK	NP_816503.1
		dutanoyi-CoA		reductase	Bacillus subtilis	KFK80655.1
					fabL	
					Vibrio cholerae	ABX38717.1
				acyl-CoA	<i>E. coli</i> fadE	NP_414756.2
				dehydrogenase	E. coli ydiO	NP_416210.4

115

#### 116

#### TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA



117

#### 118

TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA

Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names Numbers name P58137.1 3-methyl-2-Mus musculus hydroxyacot8 butanoyl-Lycopersicon ADK38536.1  $CoA \rightarrow 3$ hirsutum f S-CoA methyl-2glabratum mks2 hydroxy-ÓН Alcanivorax YP\_692749.1 butanoate borkumensis tesB2 3-methyl-Fibrobacter YP\_005822012.1 2-hydroxybutanoyl-CoA succinogenes Fs2108 Prevotella YP\_003574018.1 ΟH ruminicola Pr655 Prevotella YP\_003574982.1 Ġн ruminicola Pr1687 3-methyl-2-hydroxybutanoate 2.8.3-CoA E. coli atoD NP\_416725.1 transferase E. coli atoA NP\_416726.1 E. coli scpC NP\_417395.1 Clostridium kluyveri AAA92346.1 cat1 Clostridium kluyveri AAA92344.1 cat2 NP\_149326.1, Clostridium acetobutylicum NP\_149327.1 ctfAB NP\_746081.1 Pseudomonas putida pcalJ NP\_746082.1 Megasphaera WP\_014015705.1 elsdenii pct Acidaminococcus CAA57199.1 CAA57200.1 fermentans gctAB Acetobacter aceti AGG68319.1 aarC E. coli ydiF NP\_416209.1 NP\_349676.1 2.3.1.-; Phospho-Clostridium 2.7.2.1; transacylase + acetobutylicum ptb 2.7.2.15 Carboxylate Enterococcus AAD55374.1 kinase *faecalis* ptb Salmonella AAD39011.1 enterica pduL Clostridium AAK81015.1 acetobutylicum buk Enterococcus AAD55375.1 faecalis buk Salmonella AAD39021.1 enterica pduW 1.2.1.-3-methyl-2-E. coli PaoABC NP\_414820.1, Carboxylic butenoate → Acid NP\_414819.1, 3-methyl-2-(Carboxylate) NP\_414818.1 butenal reductase Mycobacterium WP\_012393886.1 OH NAD(P)H marinum Car 3-methyl-2-butenoate Nocardia iowensis AAR91681.1 (3-methylcrotonate) Car Segniliparus WP\_013138593.1 rotundus Car

3-methyl-2-butenal

TABLE G-continued

#### 119

### 120

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2-

hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between



3-methyl-1,2-butanediol

121

#### 122

#### TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2-

hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between

isobutanal and formyl-CoA



123

#### 124

#### TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between isobutanal and formyl-CoA



126

#### TABLE G-continued

Example reactions and enzymes of the novel isoprenoid precursor synthesis pathway via 2-

hydroxyisovaleric acid and prenol starting from non-decarboxylative acyloin condensation between

### isobutanal and formyl-CoA

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers			
DMAPP + IPP → GPP	$\begin{array}{c} & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$	2.5.1-	Geranyl pyrophosphate synthase	E. coli ispA Abies grandis GPPS2	NP_414955.1 AAN01134.1			
	$ \begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ $							

## TABLE H

	Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2- hydroxyisovaleric acid and prenol starting from aldol condensation between acetaldehyde and pyruvate						
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers		
pyruvate → acetaldehyde	OH OH OU pyruvate	4.1.1.1	alpha-ketoacid decarboxylase	Saccharomyces cerevisiae PDC1 Saccharomyces cerevisiae PDC5 Saccharomyces cerevisiae PDC6 Pisum sativum PDC1	NP_013145.1 NP_013235.1 NP_011601.3 CAA91444.1		
		acetaldehyde		Saccharomyces cerevisiae ARO10 Saccharomyces cerevisiae TH13 Lactococcus lactis kivd Pantoea agglomerans idpC	NP_010668.3 NP_010203.1 CAG34226.1 WP_003848906.1		
				<i>Enterobacter</i> <i>cloacae</i> idpC	WP_073396207.1		

## 125

#### 127

#### 128

#### TABLE H-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2hydroxyisovaleric acid and prenol starting from aldol condensation between acetaldehyde and pyruvate Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers Numbers names name E. coli mhpE pyruvate + 4.1.3.39 aldolase NP\_414886.1 C Pseudomonas WP\_011005904.1 acetaldeputida xylK hyde  $\rightarrow$  4-.OH Pseudomonas sp. CF600 dmpG WP\_017849278.1 hydroxy-2oxopentan-oate pyruvate 0 acetaldehyde QH OН (S)-4-hydroxy-2-oxopentanoate 4-hydroxy-OH 5.4.99.mutase Streptomyces AAC08713.1. 2cinnamonensis CAB59633.1 OH. icmAB oxopentan-Metallosphaera oate  $\rightarrow$  3-A4YEG1, hydroxy-2sedula Msed\_0638, A4YIE3 Msed\_2055 oxo-3methyl-Cupriavidus Q1LRY0 (S)-4-hydroxymetallidurans icmF butanoate 2-oxopentanoate D5WTR7, Kyrpidia tusciae D5WTR8 rcmAB HO ABA80144.1 Rhodobacter OH sphaeroides meaA 3-hydroxy-2-oxo-3-methylbutanoate P05791 2,3- $H_2O$ 4.2.1.9 Dihydroxyacid E. coli ilvD dihydroxy-HO dehydratase 3-methylbutanoate OH 3-methyl-2-Ōн oxobutanoate (2R)-2,3-dihydroxy-3-methylbutanoate ΌН

3-methyl-2-oxobutanoate

#### 129

#### 130

#### TABLE H-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2hydroxyisovaleric acid and prenol starting from aldol condensation between acetaldehyde and pyruvate



#### 131

## 132

#### TABLE H-continued



#### 133

#### 134

#### TABLE H-continued





## 

#### 137

### 138





(prenol)

#### 139

#### 140

#### TABLE H-continued



#### 141

#### 142

TABLE H-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2hydroxyisovaleric acid and prenol starting from aldol condensation between acetaldehyde and pyruvate



### 143

### 144

TABLE I

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from aldol condensation between pyruvate and acetaldehyde Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names name Numbers pyruvate → 4.1.1.1 alpha-ketoacid Saccharomyces NP\_013145.1 acetaldehyde decarboxylase cerevisiae PDC1 Saccharomyces NP\_013235.1 OH cerevisiae PDC5  $\dot{CO}_2$ Saccharomyces NP\_011601.3 ö cerevisiae PDC6 Pisum sativum CAA91444.1 pyruvate PDC1 Saccharomyces NP\_010668.3 0 cerevisiae ARO10 NP\_010203.1 Saccharomyces cerevisiae TH13 CAG34226.1 acetaldehyde Lactococcus lactis 4-methyl-2kivd Pantoea WP\_003848906.1 oxoagglomerans idpC pentanoate → Enterobacter WP\_073396207.1 OH 3methylcloacae idpC butanal + ö  $\hat{b}_{co}$  $CO_2$ 4-methyl-2-oxopentanoate (2-oxoisocaproate) 3-methylbutanal pyruvate + 4.1.3.39 aldolase E. coli mhpE NP\_414886.1 acetalde-Pseudomonas WP\_011005904.1 hyde  $\rightarrow$  4-OH putida xylK hydroxy-2-Pseudomonas sp. WP\_017849278.1 CF600 dmpG oxopentan-oate pyruvate acetaldehyde ΟH OH ö (S)-4-hydroxy-2-oxopentanoate 4-hydroxy-5.4.99.-AAC08713.1. mutase Streptomyces QН CAB59633.1 2cinnamonensis oxopentan-OH. icmAB A4YEG1, oate  $\rightarrow$  3-Metallosphaera hydroxy-2sedula Msed\_0638, A4YIE3 ö oxo-3-Msed\_2055 methyl-Cupriavidus Q1LRY0 (S)-4-hydroxybutanoate metallidurans icmF 2-oxopentanoate Kyrpidia tusciae D5WTR7, rcmAB D5WTR8 HC Rhodobacter ABA80144.1 sphaeroides meaA OH

> 3-hydroxy-2-oxo-3-methylbutanoate

#### 145

#### 146

#### TABLE I-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from aldol condensation between pyruvate and acetaldehyde



#### 147

#### 148

#### TABLE I-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from aldol condensation between pyruvate and acetaldehyde



(3-methylcrotonyl-CoA)

#### 149

#### 150

#### TABLE I-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from aldol condensation between pyruvate and acetaldehyde Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names name Numbers 3-methyl-2-3.1.2.-E. coli tesA NP\_415027.1 Thioesterase butenoyl-E. coli tesB NP\_414986.1 NP\_415769.1  $CoA \rightarrow 3-$ E. coli yciA methyl-2-E. coli fadM NP\_414977.1 S-CoA butenoate E. coli ydil NP\_416201.1 3-methyl-NP\_415264.1 E. coli ybgC 2-butenoyl-CoA E. coli paal NP\_415914.1 Mus musculus P58137.1 acot8 ОH Lycopersicon ADK38536.1 *hirsutum* f 3-methyl-2-butenoate glabratum mks2 Alcanivorax YP\_692749.1 borkumensis tesB2 Fibrobacter YP\_005822012.1 succinogenes Fs2108 Prevotella YP\_003574018.1 ruminicola Pr655 Prevotella YP\_003574982.1 ruminicola Pr1687 NP\_416725.1 2.8.3.8 Acyl-CoA: E. coli atoD acetyl-CoA Clostridium kluyveri AAA92344.1 transferase cat2 Clostridium NP\_149326.1, NP\_149327.1 acetobutylicum ctfAB E. coli ydiF NP\_416209.1 2.3.1.-; Phospho-Clostridium NP\_349676.1 2.7.2.1; transacylase + acetobutylicum ptb 2.7.2.15 Carboxylate Enterococcus AAD55374.1 *faecalis* ptb kinase Salmonella enterica AAD39011.1 pduL Clostridium AAK81015.1 acetobutylicum buk Enterococcus AAD55375.1 *faecalis* buk Salmonella enterica AAD39021.1 pduW 3-methyl-2-1.2.1-Carboxylic Acid E. coli PaoABC NP\_414820.1, butenoate -> (Carboxylate) NP\_414819.1, 3-methyl-2reductase NP\_414818.1 butenal ЭH Mycobacterium WP\_012393886.1 NAD(P)H marinum Car 3-methyl-2-butenoate Nocardia iowensis AAR91681.1 Car Segniliparus WP\_013138593.1 rotundus Car 3-methyl-2-butenal 3-methyl-2-1.2.1-Alcohol-Clostridium YP\_009076789.1 butenoylforming Acylacetobutylicum CoA → CoA reductase adhE2 3-methyl-2-Arabidopsis AEE75132.1 ·CoA 2 NAD(P)H butenol thaliana At3g11980 3-methyl-Arabidopsis AEE77915.1 2-butenoyl-CoA thaliana At3g44560 Arabidopsis AEE79553.1 thaliana At3g56700 Arabidopsis AED93034.1 ΟН thaliana At5g22500 Arabidopsis AEE86278.1 3-methyl-2-butenol thaliana CER4 (prenol)

152

## TABLE I-continued

151

Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
				Marinobacter aquaeolei VT8 maqu_2220 Marinobacter aquaeolei VT8 maqu_2507	YP_959486.1 YP_959769.1
3-methyl-2- butenoyl- CoA →		1.2.1-	Aldehyde forming CoA	Acinetobacter calcoaceticus acr1 Acinetobacter sp	AAC45217.1 BAB85476.1
-methyl-2- outenal	S-CoA NAD(P)H 3-methyl- 2-butenovl-CoA		reductase	Strain M-1 acrM <i>Clostridium</i> <i>beijerinckii</i> ald	AAT66436.1
	3-meth 2-bute	yl-		<i>E. coli</i> eutE	NP_416950.1
cetyl-Coa →	0			Salmonella enterica	AAA80209.1
cetaidenyde	S-CoA acetyl-CoA NAD(P)H acetaldehyde			eure E. coli mhpF	NP_414885.1
-methyl-2- utenal $\rightarrow$ 3- nethyl-2- utenol	O 3-methyl- 2-butenal	1.1.1	Alcohol dehydrogenase	E. coli betA E. coli dkgA E. coli eutG E. coli fucO E. coli ucpA E. coli ucpA	NP_414845.1 NP_417485.4 NP_416948.4 NP_417279.2 NP_416921.4 NP_414859.1
	3-methyl-2-but (prenol)	OH enol		E. coli ybbO E. coli ybdH E. coli yiaY E. coli yigB Acinetobacter sp. SE19 ChnD	NP_415026.1 NP_415132.1 YP_026233.1 NP_418690.4 AAG10028.1
				Marinobacter aquaeolei VT8 maqu_2507 Saccharomyces	YP_959769.1
				cerevisiae ADH6 Clostridium kluyveri 4hbD	EDK35022.1
methyl-2- itenol →		2.7.1	Alcohol Kinase/	Saccharomyces cerevisiae ERG12	P07277
methylallyl 10sphate	OH 3-methyl-2-butenol		Phospho- transferase	Saccharomyces cerevisiae ERG8 Arabidopsis	P24521 Q67ZM7
	(prenol)			thaliana At5g58560 Mentha x piperita	P56848
		—0 <sup>-</sup>		ipk Methanocaldococ- cus iamasahii mult	Q58487
				Arabidopsis thaliana mvk	AT5G27450.1
	dimethylallyl phosph	ate		E. coli ispE	P62615
				E. coli ychB Thermoplasma acidophilum IPK	NP_415726.1 WP_01090053

#### 153

#### 154

#### TABLE I-continued

Example reactions and enzymes of the pathway for isoprenoid precursor synthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from aldol condensation between pyruvate and acetaldehyde



TABLE J

#### 155

156

Reactions of the isoprenoid precursor synthesis pathway via 4-methyl-2-oxopent-4-enoic acid and isoprenol starting from aldol condensation between acetaldehyde and 2-oxobutyric acid Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers Numbers names name acetyl-Coa  $\rightarrow$ 1.2.1.-Aldehyde Acinetobacter AAC45217.1 0 acetaldehyde forming CoA calcoaceticus acr1 Acinetobacter sp reductase BAB85476.1 Strain M-1 acrM S-CoA NAD(P)H Clostridium AAT66436.1 acetyl-CoA *beijerinckii* ald acetaldehyde E. coli eutE 3-methyl-2-NP\_416950.1 butenoyl-Salmonella enterica NAD(P)H CoA AAA80209.1 CoA → eutE 3-methyl-E. coli mhpF NP\_414885.1 CoA 2-butenal 3-methyl-3butenoyl-CoA 3-methyl-3-butenal pyruvate → NP\_013145.1 4.1.1.1 alpha-Saccharomyces cerevisiae PDC1 acetaldehyde ketoacid Saccharomyces OH decarboxylase NP\_013235.1  $CO_2$ cerevisiae PDC5 Saccharomyces NP\_011601.3 cerevisiae PDC6 C Pisum sativum CAA91444.1 pyruvate PDC1 acetaldehyde 4-methyl-2-Saccharomyces NP\_010668.3  $CO_2$ oxopent-4cerevisiae ARO10 enoate  $\rightarrow 3$ . Saccharomyces NP\_010203.1 OH methylcerevisiae TH13 3-butenal Lactococcus lactis CAG34226.1 ö kivd Pantoea WP\_003848906.1 4-methyl-2agglomerans idpC oxopent-4-enoate Enterobacter WP\_073396207.1 cloacae idpC  $\cap$ 3-methyl-3-butenal Pyruvate + 2.3.1.182 Citramalate Methanocaldococ-WP\_10870909.1 acetylsynthase cus jannaschii cimA CoA→ Leptospira NP\_71253.1 citramalate S-CoA interrogans serovar Lai str. acetyl-CoA 56601 cimA .OH CoA 0 pyruvate .OH HC Ö OH

(R)-citramalate

#### 157

#### 158

#### TABLE J-continued

Reactions of the isoprenoid precursor synthesis pathway via 4-methyl-2-oxopent-4-enoic acid and isoprenol starting from aldol condensation between acetaldehyde and 2-oxobutyric acid Source organism Protein EC and gene/enzyme Accession Enzyme Reaction Illustration Numbers names name Numbers Citramalate -4.2.1.35 Citramalate E. coli leuCD NP\_414614.1 3-methylisomerase NP\_414613.1 malate OH Methanocaldococ-AAB98487.1 HC cus jannaschii AAB99283.1 leuĆD ΟН ö NP\_712276.1 Leptospira interrogans NP\_712277.1 (R)-citramalate serovar Lai str. 56601 leuCD HC ΟН ōн (2R,3S)-3-methylmalate 3-methylmalate 3-methyl-1.2.1-Methanocaldococcus WP\_010870225.1 jannaschii malate  $\rightarrow$  2dehydrogenase oxobutyric HC MJ0270 NP\_712333.1 Leptospira acid +  $CO_2$ ОH Бн interrogans ö serovar Lai str.  $NAD(P)H + CO_2$ 56601 leuB (2R,3S)-3-methylmalate OH 2-oxobutanoate 2-oxobutyric 4.1.3.aldolase E. coli mhpE NP\_414886.1 acid + Pseudomonas WP\_011005904.1 putida xylK acetaldehyde  $\rightarrow$  4-Pseudomonas sp. WP\_017849278.1 hydroxy-2-CF600 dmpG acetaldehyde oxo-3-methylpentanoate ΌΗ Ĉ 2-oxobutanoate OH OН 4-hydroxy-2-oxo-3methylpentanoate 4-hydroxy-2-OH 5.4.99.-AAC08713.1. mutase Streptomyces oxo-3-methylcinnamonensis CAB59633.1 pentanoate -OH. icmAB 4-hydroxy-Metallosphaera A4YEG1, A4YIE3 2-oxosedula 4-methyl-Msed\_0638, ö Msed\_2055 pentanoate 4-hydroxy-2-oxo-3-Cupriavidus Q1LRY0 methylpentanoate metallidurans icmF

#### TABLE J-continued Reactions of the isoprenoid precursor synthesis pathway via 4-methyl-2-oxopent-4-enoic acid and isoprenol starting from aldol condensation between acetaldehyde and 2-oxobutyric acid Source organism Protein EC Enzyme and gene/enzyme Accession Reaction Illustration Numbers names name Numbers *Kyrpidia tusciae* rcmAB OH D5WTR7. 0 D5WTR8 Rhodobacter ABA80144.1 OH sphaeroides meaA 4-hydroxy-2-oxo-4methylpentanoate 4-hydroxy-2-4.2.1.-E. coli mhpD NP\_414884.2 OH 2-oxopentoxo-4-methyl-H<sub>2</sub>O 4-enoate Comamonas WP\_012478201.1 pentanoate hydratase testosteroni CNB-OH 4-methyl-2-1 cnbE Pseudomonas WP\_011005906.1 oxopent-4enoate *putida* xylJ 4-hydroxy-2-oxo-4methylpentanoate ΟН 4-methyl-2oxopent-4-enoate 4-methyl-2-BAC72088.1 1.2.1.,alpha-keto acid Streptomyces BAC72089.1 oxopent-4dehydrogenase avermitilis enoate → .OH bkdFGH-lpdA1 BAC72090.1 CoA $CO_2 + NAD(P)H$ KUN54417.1 3-methyl-3butenoyl-CoA Homo sapiens NP\_000700.1 ö BKDHAB-NP\_000047.1 DBT-NP\_001909.3 4-methyl-2-DLD NP\_000099.2 oxopent-4-enoate Bacillus subtilis WP\_004398565.1 bfmBAA-bfmBAB-WP\_004398638.1 bfmBB-pdhD WP\_003230323.1 WP\_003232309.1 S-CoA E. coli lpdA-aceEF NP\_414657.1 NP\_414658.1 3-methyl-3-NP\_414656.1 butenoyl-CoA 3-methyl-3-3.1.2.-Thioesterase E. coli tesA NP\_415027.1 butenoyl-E.~coli~tesBNP\_414986.1 $CoA \rightarrow 3-$ E. coli yciA NP\_415769.1 methyl-3-E. coli fadM NP\_414977.1 CoA butenoate E. coli ydil NP\_416201.1 3-methyl-3-CoA/acyl-CoA/ATP E. coli ybgC NP\_415264.1 butenoyl-CoA E. coli paal NP 415914.1 Mus musculus P58137.1 acot8 OН Lycopersicon ADK38536.1 hirsutum f 3-methyl-2-butenoate glabratum mks2 (3-methylcrotonate) Alcanivorax YP\_692749.1 borkumensis tesB2 Fibrobacter YP\_005822012.1 succinogenes Fs2108 Prevotella YP\_003574018.1 ruminicola Pr655

159

### 160

YP\_003574982.1

Prevotella ruminicola Pr1687

# 

# 

TABLE	J-continued

	Reactions of the isoprenoid precursor synthe isoprenol starting from aldol condensat	esis pathway via tion between ace	4-methyl-2-oxoper taldehyde and 2-ox	nt-4-enoic acid and cobutyric acid	
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers
		2.8.3-	CoA transferase	E. coli atoD E. coli atoA E. coli sepC Clostridium kluyveri cat1 Clostridium kluyveri cat2 Clostridium acetobutylicum etfAB Pseudomonas putida pcalJ Megasphaera elsdenii pct Acidaminococcus fermentans gctAB Acetobacter aceti aarC E. coli vdiE	NP_416725.1 NP_416726.1 NP_417395.1 AAA92346.1 AAA92344.1 NP_149326.1, NP_149327.1 NP_746081.1 NP_746082.1 WP_014015705.1 CAA57199.1 CAA57200.1 AGG68319.1 NP_416209.1
		2.3.1; 2.7.2.1; 2.7.2.15	Phosphotranas- cylase + Carboxylate kinase	Clost yan Clostndium acetobutylicum ptb Enterococcus faecalis ptb Salmonella enterica pduL	NP_349676.1 AAD55374.1 AAD39011.1
				Clostridium acetobutylicum buk Enterococcus faecalis buk Salmonella enterica pduW	AAK81015.1 AAD55375.1 AAD39021.1
3-methyl-3- butenoate → 3-methyl- butenal	3-methyl-2-butenoate-	1.2.99.6	Carboxylic Acid (Carboxylate) reductase	E. coli PaoABC Mycobacterium marinum Car	NP_414820.1, NP_414819.1, NP_414818.1 WP_012393886.1
	(3-methylcrotonate)	Ĵ		Car Segniliparus rotund us Car	WP_013138593.1
	3-methyl-3-b	utenal			
3-methyl-3- butenal → 3-methyl- butenol	3-methyl-3-butenal NAD(P)H	0H	Alcohol dehydrogenase	E. coli betA E. coli dkgA E. coli eutG E. coli fucO E. coli ucpA E. coli yahK E. coli yahK E. coli ybbO E. coli ybdH E. coli ybdH E. coli yigY Acinetobacter sp. SE19 ChnD	NP_414845.1 NP_417485.4 NP_416948.4 NP_416921.4 NP_416921.4 NP_414859.1 NP_415026.1 NP_415132.1 YP_026233.1 NP_418690.4 AAG10028.1
				warnobacter aquaeolei VT8 maqu_2507 Saccharomyces cerevisiae ADH6 Clostridium kluyveri 4hbD	Q04894.1 EDK35022.1

#### 163

#### 164

#### TABLE J-continued

Reactions of the isoprenoid precursor synthesis pathway via 4-methyl-2-oxopent-4-enoic acid and isoprenol starting from aldol condensation between acetaldehyde and 2-oxobutyric acid



1	65	
.1	0.3	

### 166

#### TABLE J-continued

Reactions of the isoprenoid precursor synthesis pathway via 4-methyl-2-oxopent-4-enoic acid and isoprenol starting from aldol condensation between acetaldehyde and 2-oxobutyric acid



167

#### 168

### TABLE K



rv3398c

170

#### TABLE K-continued

169



172

#### TABLE K-continued



#### TABLE L

	Example reactions for the production of prenylated aromatic compounds and example enzymes							
Reaction	Illustration	EC Numbers	Enzyme names	Source organism and gene/enzyme name	Protein Accession Numbers			
Olivetolic acid + GPP → canna- bigerolic acid	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & &$	2.5.1	geranl pyrophosphate: olivetolate geranyl- transferase	Lithospermum erythrorhizon PGT-1 Lithospermum erythrorhizon PGT-2 E. coli ubiA Arabidopsis thaliana PPT1 Schizosaccharomy ces pombe coq2 Cannabis sativa CsPT1 Streptomyces sp. strain CL190 nphE Streptomyces Sco2190 Sc27190 Sc27190 Sc27190 Streptomyces sp. CNQ-509 cnqp3 Phi p4	Q8W405 Q8W404 P0AGK1 Q93YP7 Q10252 BAE00106.1 BAE00107.1 AKH84817.1 ABB78007.1			
	HO cannabigerolic acid							

171

## 173

#### TABLE M

Plasmid	s and <u>p</u>	primers used for in vivo tiglic acid production	
		Plasmids pCDF-P1-pct-fadAx pET-P1-fadB2x-fadB1x pET-P1-fadB2x-fadB1x-P2-ydil Primers	5
	SEQ ID		10
Name	NO:	Sequence	
pct-f1	1	5 ' - AGGAGATATACCATGAGAAAAGTAGAA ATCATTAC - 3 '	
pct-r1	2	5 ' - CGCCGAGCTCGAATTCTTATTTTTCA GTCCCATGGGAC - 3 '	
fadAx-f1	3	5'-GAAAAAATAAGAATTTAAGGAGGAATA AACC ATGACCCTGGCAAATGATCC-3'	20
fadAx-r1	4	5 ' - CGCCGAGCTCGAATTCTTAATACAGAC ATTCAACTGCC-3 '	
fadB2x-f1	5	5 ' - AGGAGATATACCATGCATATCGCCAAC AAACAC - 3 '	25
fadB2x-r1	6	5 ' - CGCCGAGCTCGAATTCTTATTTTGCTG CCATGCGCAG-3 '	
fadB1x-f1	7	5'-AGCAAAATAAGAATTTAAGGAGGAATA AACC ATGGCCTTTGAAACCATTCTG-3'	30
fadB1x-r1	8	5 ' - CGCCGAGCTCGAATTCTTAGCGATCTT TAAACTGTGC - 3 '	
ydil-f1	9	5 ' - AAGGAGATATACATATGATATGGAAAC GGAAAATCAC - 3 '	35
ydil-r1	10	5 ' - TTGAGATCTGCCATATGTCACAAAATG GCGGTCGTC-3 '	

## 174

TABLE N-continued

plasmid	s and pre	d primers used for conversion of nol to GPP and geraniol
	PE PET	Plasmids T-P1-idi-trGPPS2-P2-ges-ychB-mtipk -P1-idi-trGPPS2-P2-ges-thaipk-mtipk Primers
Name	SEQ ID NO:	Sequence
ychB-r1	18	TTTCAGGATGATCATTTGTTATTCCTCCTTAAGG TCTTAAAGCATGGCTCTGTGCAA
mtipk-f1	19	ATGATCATCCTGAAACTGGGT
mtipk-r1	20	CTTTACCAGACTCGAGTTAGTGTTTACCTGTAAT ACGTG
mtipk-f2	21	GATCCGCTAACTCGATAAGGAGGAATAACAA AT GATCATCCTGAAACTGGGT
taipk-f1	22	ACCCAGTAACCTCGAAAGGAGGAATAAGGCATGA TGATCCTGAAAATTGGTG
taipk-r1	23	CTTTACCAGACTCGAGTTAGCGGATCACGGTGCC A

#### TABLE O

#### List of primers SEQ ID NO: Sequence Name Description maqu\_2507-24 GCCAGGATCCGAATTCGAACTA maqu\_2507 40 f1 CTTTCTGACCGGTGG forward maqu\_2507-25 CGCCGAGCTCGAATTCTTACCA maqu\_2507 r1GTAAATGCCACGCA reverse cbjALD-f1 26 GCCAGGATCCGAATTCGAATAA cbjALD AGACACACTAATACCTAC forward cbjALD-r1 27 CGCCGAGCTCGAATTCTTAGCC cbjALD GGCAAGTACACATC reverse chnD-f1 28 GCCAGGATCCGAATTCGCACTG chnD CTATTGTGTTACCCAC forward chnD-r1 29 CGCCGAGCTCGAATTCTCAATT chnD TTCGTGCATCAGAAC reverse

#### TABLE P

	Measured activities of different alcohol dehydrogenases on oxidization of prenol.								
60	Enzyme (cofactor)	Specific activity (µmol/mg/min)							
	FucO (NAD <sup>+</sup> )	N.D.							
	YqhD (NADP <sup>+</sup> )	N.D.							
	YigB (NADP <sup>+</sup> )	$0.30 \pm 0.03$							
	YahK (NADP <sup>+</sup> )	$0.167 \pm 0.005$							
	YiaY (NAD <sup>+</sup> )	N.D.							
65	ChnD (NAD+)	$0.123 \pm 0.007$							

#### TABLE N

plasmids and primers used for conversion of prenol to GPP and geraniol						
	pE' pET	Plasmids F-P1-idi-trGPPS2-P2-ges-ychB-mtipk -P1-idi-trGPPS2-P2-ges-thaipk-mtipk Primers	45			
Name	SEQ ID NO:	Sequence	50			
idi-f1	11	AGGAGATATACCATGCAAACGGAACACGTCATTT				
idi-r1	12	TGCGCTATATGCCATGGTTTATTCCTCCTTAAAT TATTTAAGCTGGGTAAATGCAGATA	55			
trgpps2-f1	13	ATGGCATATAGCGCAATGGC				
trgpps2-r1	14	GTGATGGCTGCTGCCTTAGTTCTGACGAAATGCA ACAT				
ges-fl	15	AAGGAGATATACATAATGGAAGAAAGCAGCAGCA AA	60			
ges-r1	16	TTACCAGACTCGAGGTTACTGGGTAAAAAACAGG GC				
ychB-f1	17	ACCCAGTAACCTCGAAAGGAGGAATAAGGC ATG CGGACACAGTGGCCCT	65			

## 175

## 176

TABLE Q				TABLE Q-continued				
plasmids and primers used for in vivo 2,3- dihydroxybutyric acid production				plasmids and primers used for in vivo 2,3- dihydroxybutyric acid production				
-	Plasmids pET-P1-bktB-phaB1-P2-phaJ pCDF-P1-pct-P2-tdter Primers			5 Plasmids pET-P1-bktB-phaB1-P2-phaJ pCDF-P1-pct-P2-tdter Primers				
Name	SEQ ID NO:	Sequence	10	Name	SEQ ID NO:	Sequence		
tdTer-f1	30	5 ' - AAGGAGATATACATATGATTGTTAAG CCGATGGTCC - 3 '	-	bktB-r1	35	5 ' - CGCCGAGCTCGAATTCTCAGATACGC TCGAAGATGG-3 '		
tdTer-r1	31	5 ' - TTGAGATCTGCCATATGTTAGATGCG GTCAAAACGTTCA - 3 '	15	phaB1-f1	36	5 ' - GCGTATCTGAGAATTAGGAGGCTCTC TATGACTCAGCGCATTGCGTA		
pct-f1	32	5 ' - AGGAGATATACCATGAGAAAAGTAGA AATCATTAC - 3 '		phaB1-r1	37	5 ' - CGCCGAGCTCGAATTCTCAGCCCATG TGCAGGCC - 3 '		
pct-r1	33	5 ' - CGCCGAGCTCGAATTCTTATTTTTC AGTCCCATGGGAC - 3 '	20	phaJ-f1	38	5 ' - AAGGAGATATACATATGTCGGCACAA AGCCTG - 3 '		
bktB-f1	34	5 ' - AGGAGATATACCATGATGACGCGTGA AGTGGTAGT - 3 '		phaJ-r1	39	5 ' - TTGAGATCTGCCATATGTTACGGCAG TTTCACCACC - 3 '		

TABLE R

List of primers used in example of GPP BIOSYNTHESIS VIA 2-HYDROXYISOVALERIC ACID AND PRENOL STARTING FROM DECARBOXYLATIVE ACYLOIN CONDENSATION BETWEEN TWO PYRUVATES

Name	SEQ ID NO:	Sequence	Description
pct540- f1	40	GAGGAATAAACCATGCGTAAAGTGCCGATTATTA	pct540 forward
pct540- r1	41	GATGATGATGGTCGACGCTTTTCATTTCTTTCAGGCC	pct540 reverse
pct-f2	42	TAGAAGGAGGAGATCTATGAGAAAAGTAGAAATCATTACAG	pct forward
pct-r2	43	GGGGGACCAGCTCGAGTTTTTTCAGTCCCATGGGACC	pct reverse
alsS-f1	44	AAGGAGATATACATATGACCAAAGCAACCAAAGAA	alsS forward
alsS-r1	45	AATGGTAATACGCATGTTAATTTCCTCCTAGAATTACAGGG CTTTGGTTTTCAT	alsS reverse
panE-f1	46	ATGCGTATTACCATTGCCGG	panE forward
panE-r1	47	TTGAGATCTGCCATATTATTTGGCTTTCAGCAGTTCTT	panE reverse
ilvC-f1	48	AGGAGATATACCATGGCTAACTACTTCAATAC	ilvC forward
ilvC-r1	49	ACGGTACTTAGGCATGGTTTATTCCTCCTTAAACTCTTAAC CCGCAACAGCAATAC	ilvC reverse
ilvD-f1	50	ATGCCTAAGTACCGTTCCG	ilvD forward
ilvD-r1	51	CGCCGAGCTCGAATTCTTAACCCCCCAGTTTCGATTT	ilvD reverse

-5

## 177

plasmids and primers used for in vivo butyric acid production through betaoxidation reversal

-

\_

plasmids and primers required for GPP biosynthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from decarboxylative acyloin condensation between two pyruvates

		Plaqmida	two pyruvates				
	pTH-atoB-fadB-egter pZS-fadM pZS-tesA pZS-tesB pZS-yciA pZS-ybgC pZS-ydil pCDE-P1-pct-P2-tdter		10		Plasmids pET-P1-ilvC-ilvD-P2-alsS-liuA pCDF-P1-bkdF-bkdG-bkdH-P2- IpIA-IpdA1 pRSF-P1-leuA(G462D)-leuB-P2- leuC-leuD Primers		
-	SEQ	Primers	15	Name	SEQ ID NO:	Sequence	
Name	ID NO:	Sequence	_	alsS-f1	44	AAGGAGATATACATATGACCA AAGCAACCAAAGAA	
fadM-f1	129	5 ' - TTAAAGAGGAGAAAAGGTACCATGC AAACACAAAATCAAAGT - 3 '	20	alsS-r2	69	GCTCGGATAGGTCATGTGATA TTCCTCCTAGCTATGTTACAG	
fadM-r1	52	5 ' - TGCCTCTAGCACGCGTCGTTTACT TAACCATCTGCTCCA- 3 '		ilvC-f1	48	GGCTTTGGTTTTCATC AGGAGATATACCATGGCTAAC	
tesA-f1	53	5 ' - TTAAAGAGGAGAAAGGTACCATGA TGAACTTCAACAATGTTTTC - 3 '	25	ilvC-r1	49	TACTTCAATAC ACGGTACTTAGGCATGGTTTA	
tesA-r1	54	5 ' - TGCCTCTAGCACGCGTTCCGTTGC TTTATGAGTCATG- 3				TTCCTCCTTAAACTCTTAACC CGCAACAGCAATAC	
tesB-f1	55	5 ' - TTAAAGAGGAGAAAGGTACCATGA		ilvD-f1	50	ATGCCTAAGTACCGTTCCG	
		GTCAGGCGCTAAAAAA-3 '	30	ilvD-r1	51	CGCCGAGCTCGAATTCTTAAC CCCCCAGTTTCGATTT	
tesB-rl	56	5'-TGCCTCTAGCACGCGTAACAGCCG GACGGTTTTC-3		liuA-f1	70	ATGACCTATCCGAGCCTGAA	
ybgC-f1	57	5 ' - TTAAAGAGGAGAAAGGTACCGTGA ATACAACGCTGTTTCGAT - 3 '	35	liuA-r1	71	TTACCAGACTCGAGGGTACCT TAGCGGGTTTCATTAAACAGT	
ybgC-r1	58	5 ' - TGCCTCTAGCACGCGTTCACTGCT TAAACTCCGCGA-3 '		bkdF-f1	72	AGGAGATATACCATGACCGTT GAAAGCACCGC	
yciA-f1	59	5 ' - TTAAAGAGGAGAAAGGTACCATGT CTACAACACATAACGTCCC- 3 '	40	bkdF-r1	73	CATTTTTTCTGCCATGAGTTA TTCCTCCTACAACTCTTAATT ACCACCTTGACCGG	
yciA-r1	60	5 ' - TGCCTCTAGCACGCGTTTCAGTAA GCAGAAAGTCAAAAGC - 3 '		bkdG-f1	74	ATGGCAGAAAAAATGGCAATC G	
ydil-f1	61	5 ' - TTAAAGAGGAGAAAGGTACCATGA TATGGAAACGGAAAATCA - 3 '	45	bkdG-r1	75	GCTTGCTTCGGTCATGCTTTA TTCCTCCTTTAATTGTTAATA TGCCAGGCTACGATC	
ydil-r1	62	5 ' - TGCCTCTAGCACGCGTGGTGACAA CGTCACAAAATGG-3 '		bkdH-f1	76	ATGACCGAAGCAAGCGTTCG	
atoB-f1	63	5 ' - GAGGAATAAACCATGAAAAATTGT GTCATCGTCA-3 '	50	bkdH-r1	77	TTACCAGACTCGAGGGTACCT TAGCGGGTTTCATTAAACAGT	
atoB-r1	64	5 ' - CCCAAGCTTCGAATTCTTAATTCA ACCGTTCAATCAC- 3 '		IpIA-f1	78	AAGGAGATATACATATGTCCA CATTACGCCTGCT	
fadB-f1	65	5 ' - TAAGAATTCGAAGCTGCGGATTCA GGAGACTGACA - 3 '	55	IpIA-r1	79	TGCATCATTTGCCATCCATTA TTCCTCCTTGGGTAACTACCT TACAGCCC	
fadB-r1	66	5 ' - GTTCGGGGCCCAAGCTTTAAGCCGT TTTCAGGTCGC-3 '		IpdA1-f1	80	ATGGCAAATGATGCAAGCAC	
egter-f1	67	5 ' - AAACGGCTTAAAGCTAATAAGGAG GAATAAACCATGGCAATGTTTACCACG	60	IpdA1-r1	81	TTACCAGACTCGAGGGTACCT TAATCATGGCTATGCAGCGG	
egter-r1	68	AC-3' 5'- GTTCGGGCCCAAGCTTGCGGCCG		leuA(G462D)B- f11	82	AGGAGATATACCatgAGCCAG CAAGTCAT	
		CTTATTGCTGTGCTGCGGAC -3'	65	leuA(G462D)B- r11	83	CACCTGgtCaAGCGCATCTTT ACCGTGGC	

5

## 179

TABLE T-continued

plasmids and primers required for GPP biosynthesis via 2-oxoisovaleric acid,

2-oxoisocaproic acid and prenol starting from

decarboxylative acyloin condensation between two pyruvates

SEQ ID

NO:

Sequence

Name

Plasmids pET-P1-ilvC-ilvD-P2-alsS-liuA pCDF-P1-bkdF-bkdG-bkdH-P2-IpIA-IpdA1 pRSF-P1-leuA(G462D)-leuB-P2leuC-leuD Primers **180** 

TABLE T-continued

plasmids and primers required for GPP biosynthesis via 2-oxoisovaleric acid, 2-oxoisocaproic acid and prenol starting from decarboxylative acyloin condensation between two pyruvates

10		Plasmids pET-P1-ilvC-ilvD-P2-alsS-liuA pCDF-P1-bkdF-bkdG-bkdH-P2- IpIA-IpdA1 pRSF-P1-leuA(G462D)-leuB-P2- leuC-leuD Primers				
15	Name	SEQ ID NO:	Sequence			
-	leuCD-r1	89	TTACCAGACTCGAGGGTACCt t aATTCATAAACGCAGGTTGT T			
20						

#### TABLE U

leuA(G462D)B-	84	AAGATGCGCTtGacCAGGT	25	List of prime str	ers used ain JST00	in the construction of 5(DE3) atoB <sup>CT5</sup>
leuA(G462D)B-	85	CGCCGAGCTCGAATTCTTACA		Name	SEQ ID NO:	Sequence
r12	86	CCCCTTCTGCTACATA	30	kan-homatoE-L	90	TTGGTTTAACGCTGTTCTGACG GCACCCCTACAAACAGAAGGAA TATAAACATATGAATATCCTCC
f2	00			kan-ovcymatoB- R	91	TTA TCTGAAATTCTGCCTCGTGAGT GTAGGCTGGAGCTGCTTCG
leuA(G462D)B- r2	87	CGCCGAGCTCGAATTCTTAC	35	cym-pCTC- atoB-ovkan-L	92	CGAAGCAGCTCCAGCCTACACT CACGAGGCAGAATTTCAGA
leuCD-f1	88	CGATCGCTGACGTCGatgGCT AAGACGTTATACGAAAA		atoBintrecomb- R	93	GCCAGCCCGCTTTTTAAC

#### TABLE V

Strains and plasmids							
Host strain	Plasmid 1	Plasmid 2	Plasmid 3	Product			
JST06(DE3) atoBCT5	pCDF-P1-HMGS-	pET-P2-maqu_2507		Prenol			
$\Delta fadB$	aibAB-P2-liuC						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-	pET-P2-adhE2		Prenol			
∆fadB	aibAB-P2-liuC						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-	pET-P2-cbjALD		Prenol			
∆fadB	aibAB-P2-liuC						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-			Prenol			
∆fadB	aibAB-P2-cbjALD-liuC						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-			Prenol			
∆fadB	aibAB-P2-						
	maqu_2507-liuC						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-			Prenol			
∆fadB	aibAB-P2-cbjALD-						
-	liuC-chnD						
JST06(DE3) atoB <sup>CT5</sup>	pCDF-P1-HMGS-			Prenol			
∆fadB	aibAB-P2-cbjALD-						
	liuC-yjgB						
JST06(DE3) atoBCT5	pCDF-P1-HMGS-			Prenol			
∆fadB	aibAB-P2-cbjALD-						
	liuC-yahK						
JST06(DE3) atoBCT5	pCDF-P1-HMGS-	pRSF-P2-adhE2	pET-P1-idi-trGPPS2-	Geraniol			
ΔfadB	aibAB-P2-liuC	•	P2-ges-ychB-mtipk				
JST06(DE3) atoBCT5	pCDF-P1-HMGS-	pRSF-P2-cbiALD	pET-P1-idi-trGPPS2-	Geraniol			
ΔfadB	aibAB-P2-liuC	1	P2-ges-vchB-mtipk				
			0 /r				

## TABLE V-continued

181

Strains and plasmids						
Host strain	Plasmid 1	Plasmid 2	Plasmid 3	Product		
JST06(DE3) atoB <sup>CT5</sup> AfadB	pCDF-P1-HMGS- aibAB-P2-cbiALD-liuC	pET-P1-idi-trGPPS2- P2-ges-ychB-mtipk		Geraniol		
JST06(DE3) atoB <sup>CT5</sup> ΔfadB	pCDF-P1-HMGS- aibAB-P2-cbjALD- liuC-yahK	pET-P1-idi-trGPPS2- P2-ges-ychB-mtipk		Geraniol		

TABLE W
---------

		Primers used	
	SEQ ID		
Name	NO:	Sequence	Description
maqu_250 7-f2	94	AAGGAGATATACATATGAACTACTTTCTGACCGGT	maqu_2507 forward
maqu_250 7-r2	95	TTGAGATCTGCCATATGTTACCAGTAAATGCCACGCAT	maqu_2507 reverse
maqu_250 7-r3	96	TTAAATTCCGGCATAATTACTCCTTCACTGCCATATTAC CAGTAAATGCCACGCAT	maqu_2507 reverse
cbjALD-f2	97	AAGGAGATATACATATGAATAAAGACACACTAATACCTA	cbjALD forward
cbjALD-r2	98	TTGAGATCTGCCATATGTTAGCCGGCAAGTACACATC	cbjALD reverse
cbjALD-r3	99	TTAAATTCCGGCATAATTACTCCTTCACTGCCATATTAG CCGGCAAGTACACATC	cbjALD reverse
adhE2-f1	100	AAGGAGATATACATATGAAAGTTACAAATCAAAAAGAAC	adhE2 forward
adhE2-r1	101	TTGAGATCTGCCATATGTTAAAATGATTTTATATAGATA TCCTTAAG	adhE2 reverse
hmgs-f1	102	AGGAGATATACCATGACCATCGGCATCGATAAG	hmgs forward
hmgs-r1	103	CGCCGAGCTCGAATTCTTATTCCGGACGATGATATTCG	hmgs reverse
aibA-f1	104	TCCGGAATAAGAATTGTAGGAGGAATACTACATGAAAAC CGCACGTTGGTG	aibA forward
aibA-r1	105	CAGGGTTGCGCTCATGGTTTATTCCTCCTTAAAATCTTA TGCTGCACGACGGGTCA	aibA reverse
aibB-f1	106	ATGAGCGCAACCCTGGATAT	aibB forward
aibB-r1	107	CCTGCAGGCGCGCGCGAGCTCTTATGCACCAACCAGTGCA T	aibB reverse
liuC-f1	108	AAGGAGATATACATATGCCGGAATTTAAAGTTGATG	liuC forward
liuC-r1	109	TTGAGATCTGCCATATTAACGACCTTTATAAACCGGT	liuC reverse
chnD-f2	110	TTAATATGGCAGATCAGGAGGAATAGCTGATGCACTGCT ATTGTGTTACC	chnD forward
chnD-r2	111	CTTTACCAGACTCGAGTCAATTTTCGTGCATCAGAAC	chnD reverse
yjgB-f1	112	TTAATATGGCAGATCAGGAGGAATAGCTGATGTCGATGA TAAAAAGCTATG	yjgB forward
yjgB-r1	113	CTTTACCAGACTCGAGTCAAAAATCGGCTTTCAACAC	yjgB reverse

kan-cymR-P<sup>CT5</sup>-bktB

bktB for

replacement

of atoB-cat-

cat-cymR-P<sup>CT5</sup>-egTER

cat-cymR-

egTER with

homology

cat-cymR-P<sup>CT5</sup>-egTER

egTER for

of fadB-

fadA cassette

(kansacB) -

replacement

@ fadBA

∆fadBA

@ fabl

PCT5-

fabl

∆atoB

sacB cassette 117,

119,

120

121,

122

118

F-

CAACAAACAGACAATCTGGTCTGTT

TABLE W-CONTIN	TABLE	W-conti	inued
----------------	-------	---------	-------

		Primers used	
Name	SEQ ID NO:	Sequence	Description
yahK-f1	114	TTAATATGGCAGATCAGGAGGAATAGCTGATGAAGATCA AAGCTGTTGGTG	yahK forward
yahK-r1	115	CTTTACCAGACTCGAGTCAGTCTGTTAGTGTGCGATT	yahK reverse

TABLE X				TABLE Y-continued			
Plasmids for the synthesis of isoprenoids Name			_ 15 _	List of primers used in the construction of strain JSTO6(DE3) AfadE bktB <sup>CTS</sup> AatoB fadB <sup>CTS</sup> AfadA eqter <sup>CTS</sup>			
pACYC-P1-ls pACYC-P1-pt30				Construct/P CR Product	SEQ ID NO:	Sequences	
pACYC-P1-qhs1-P2-ispA pACYC-P1-valc-P2-ispA pACYC-P1-vs1-P2-ispA pACYC-P1-fs-P2-ispA			25	cat-cymR- P <sup>C75</sup> fadB- (kan-sacB)- fadA @ fadBA	123, 124, 125, 126	F1- ATCCTCCGGTTGAGCCAGCCCGTCC GGTTGGCGACCTGAAAACGGCTTAA ATGATTGAACAAGATGGATTGC R1-	
TABLE Y List of primers used in the construction of strain JSTO6(DE3) AfadE bktB <sup>C75</sup> AatoB fadB <sup>C75</sup> AfadA egter <sup>C75</sup>			30	Overlap extension of kan and sacB with fadBA junction homology		TAAGGGGTGACGCCAAAGTATCAGA AGAACTCGTCAAGAAGG F2 - CCTTCTTGACGAGTTCTTCTGATAC TTTGGCGTCACCCCTTA R2 - ATCGGGGTGCGAATTGCATCGACAA	
SE Construct/P ID CR Product NC	EQ D D :	Sequences	35	fadA	127,	TGACAACCTGTTCCATTGTGACTCC ATCAAAGGGAAAACTGTCCATAT F-	
kan-cymR- 13 P <sup>C75</sup> -atoB- 11 (cat-sacB) cat-sacB cassette with atoB homology	30, 16	F- GATGTTCAAGAAAACACCCGATAAC TTTCGCTATCGGGTGTTTTTATTGA ATCAAAGGGAAAACTGTCCATAT R- GCATTGGCGGCGGTCAGGGAATTGC GATGGTGATTGAACGGTTGAATTAA AAAATGAGACGTTGATCGGC	40	deletion	128	TTGAGCCAGCCCGTCCGGTTGGCGA CCTGAAAACGGCTTAAGGAGTCACA ATGGCCAAGTTGACCAGTG R- TTAAACCCGCTCAAACACCGTCGCA ATACCCTGACCCAGACCGATACACA TCAGTCCTGCTCCTCTGC	

#### TABLE Z

TGTATTATGAACGAAGGAGAGATCT	45	IADLE L	
ATGACGCGTGAAGTGGTAGT		Plasmids for expression of olivetolic acid synthesis pathways	
R- GATGTTCAAGAAAACACCCGATAAC TTTCGCTATCGGGTGTTTTTTATTGA		Name	Synthesis pathway
TCAGATACGCTCGAAGATGG	50	pRSF-P1-OLS-P2-OAC	Olivetol synthase with olivetolic acid cyclase
F- TTGACGGCGGTTTCAGCATTGCTGC		pCDF-P1-OLS-P2-OAC	Olivetol synthase with olivetolic acid cyclase
AATGAACGAACTCGAACTGAAATAA GTGTAGGCTGGAGCTGCTTCG		pET-P1-OLS-P2-OAC	Olivetol synthase with olivetolic acid cyclase
R- AACAGAGATAACGGGCGGCAGAACG	55	pET-P1-OLS-P2-OAC(Y27F)	Olivetol synthase with olivetolic acid cyclase
CCGCCCATCTTTACCAACAGAACGA TTATTTCAGTTCGAGTTCGTTTTAT TGCTGTGCTG	55	pRSF-P1-STC pET-P1-STCS pET-P1-STCS (T135S) pET-P1-STCS (T198M)	Polyketide synthase without cyclase Polyketide synthase without cyclase Polyketide synthase without cyclase Polyketide synthase without cyclase
F- CAACAAACAGACAATCTGGTCTGTT TGTATTATGAACGAAGGAGAGATCT ATGGCAATGTTTACCACGAC R- TTAAACCCGGCTCAAACACCGTCGCA	60	pET-P1-STCS (1200C) pET-P1-STCS (T135S T198M) pET-P1-STCS (T135S 1200C) pET-P1-STCS (T135S 1200C) pET-P1-STCS (T198M 1200C) pET-P1-STCS (T135S T198M 1200C)	Polyketide synthase without cyclase Polyketide synthase without cyclase Polyketide synthase without cyclase Polyketide synthase without cyclase Polyketide synthase without cyclase
ATACCCTGACCCAGACCGATACACA TTATTGCTGTGCTG	65	pET-P1-dcaF-P2-OAC pET-P1-fadAx-P2-OAC	Polyketoacyl-CoA thiolase with olivetol cyclase Polyketoacyl-CoA thiolase with olivetol cyclase
### 185

#### TABLE Z-continued

Plasmids for expression of olivetolic acid synthesis pathwa	
Name	Synthesis pathway
pET-P1-ScfadA-P2-OAC	Polyketoacyl-CoA thiolase with olivetol cyclase
pET-P1-dcaF-P2-OAC	Polyketoacyl-CoA thiolase with olivetol cyclase
pET-P1-bktB-P2-OAC	Polyketoacyl-CoA thiolase with olivetol cyclase

#### TABLE AA

Primers for constructions of plasmids	
used for demonstration of in vivo	
production of CBGA in E. coli.	

Name	SEQ ID NO:	Sequence
MK-IF-fwd	131	AGGAGATATACCATGAGCCTGCCGT TTCTG
MK-IF-rev	132	CGCCGAGCTCGAATTCTTAGCTGGT CCACGGCAG
PMK-IF-fwd	133	GACCAGCTAAGAATTTAGGAGGAAT AACTCATGAGCG
PMK-IF-rev	134	CGCCGAGCTCGAATTCATTCCTCCT TTAATTGTTATTTGTC
PMD-IF-fwd	135	AAGGAGGAATGAATTATGACCGTTT ATACCGCAAG
PMD-IF-rev	136	CGCCGAGCTCGAATTCTTATTCTTT CGGCAGACC
idi-GB-fwd	137	GTTTAACTTTAAGAAGGAGATATAC atgCAAACGGAACACGTC
idi-GB-rev	138	ATGGTTTATTCCTCCTTAAAttaTT TAAGCTGGGTAAATGCAG
trGPPS2-IF- fwd	139	TTTAAGGAGGAATAAACCATGGTGG AATTTGACTTTAACAAATATAT

	_	TABLE	AA-continued
5	Primers used pro	s for cc for dem duction	onstructions of plasmids constration of in vivo of CBGA in <i>E. coli</i> .
5		SEQ ID	
	Name	NO:	Sequence
10	GPPS2-GB- rev	140	GTGATGGCTGCTGCCTTAGTTCTGA CGAAATGCAAC
	CymR-GB- fwd	141	CTGCAGGTCGACAAGCTTGCAGGCG TATCACGAGGCAG
15	CymR-GB- rev	142	CATCTGCTGCTTCGCTCATATGAGA TCTCTCCTTCGTTCATAATACAAAC
	NphB- cumate-GB- fwd	143	TCTCATATGAGCGAAGCAGCAGATG
20	NphB- cumate-GB- rev	144	AGCAGCGGTTTCTTTACCAGACTCG AGGTCAATCTTCCAGGCTATCAA
25	NphB-IF-fwd	145	AAGGAGATATACATAATGAGCGAAG CAGCAGAT
	NphB-IF-rev	146	TTACCAGACTCGAGGTCAATCTTCC AGGCTATCAA
30		-	TABLE AB
	Plasmids for expression of prenyltransferase		

25	Plasmids for expression of prenyltransferase and CBGA in vivo synthesis in <i>E. coli</i> Name	
35	pET-P1-idi-trGPPS2-P2-NphB	
	pET-P1-idi-trGPPS2-CT5-NphB	
	pET-P1-idi-trGPPS2-CT5-CnqP3	
	pET-P1-idi-trGPPS2-CT5-CphB	
	pET-P1-idi-trGPPS2-CT5-SCO7190	
40	pET-P1-idi-trGPPS2-CT5-SCO7190(R65S)	
	pET-P1-idi-trGPPS2-CT5-SCO7190(E278G)	

#### SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 146 <210> SEQ ID NO 1 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: pct-f1 <400> SEQUENCE: 1

#### aggagatata ccatgagaaa agtagaaatc attac

<210> SEQ ID NO 2 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: pct-r1

#### <400> SEQUENCE: 2

### 186

187

### -continued

<210> SEQ ID NO 3	
<211> LENGTH: 51 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: radAx-II	
<400> SEQUENCE: 3	
gaaaaaataa gaatttaagg aggaataaac catgaccctg gcaaatgatc c	51
<210> SEQ ID NO 4 <211> LENGTH: 38	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<pre>&lt;223&gt; OTHER INFORMATION: Synthetic: fadAx-r1</pre>	
<400> SEQUENCE: 4	
	3.8
egelgagete gaattettaa tacagacatt taactgee	50
<210> SEQ ID NO 5	
<211> LENGTH: 33	
<212> TYPE: DNA <213> OPCINISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: fadB2x-f1	
<400> SEQUENCE: 5	
aggagatata ccatgcatat cgccaacaaa cac	33
<210> SEO ID NO 6	
<211> LENGTH: 37	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<pre>&lt;223&gt; OTHER INFORMATION: Synthetic: fadB2x-r1</pre>	
<400> SEQUENCE: 6	
cgccgagctc gaattettat tttgetgeea tgegeag	37
<210> SEQ 1D NO / <211> LENGTH: 52	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: SYNCHECIC: TABLE-TI	
<400> SEQUENCE: 7	
agcaaaataa gaatttaagg aggaataaac catggccttt gaaaccattc tg	52
<210> SEQ ID NO 8	
<211> LENGTH: 37	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEALORE: <223> OTHER INFORMATION: Synthetic: fadB1x-r1	
- 	
TION DEQUERCE. C	
cgccgagctc gaattettag egatetttaa aetgtge	37
<210> SEQ ID NO 9	
<211> LENGTH: 37	
SALAZ TITE: DIA	

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic: ydiI-f1

188

0.0 11,070,770 D2	US	11	,046.	,978	<b>B</b> 2
-------------------	----	----	-------	------	------------

-continued	
<400> SEQUENCE: 9	
aaggagatat acatatgata tggaaacgga aaatcac	37
<210> SEQ ID NO 10 <211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: ydiI-r1	
<400> SEQUENCE: 10	
ttgagatctg ccatatgtca caaaatggcg gtcgtc	36
<210> SEQ ID NO 11 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: idi-f1	
<400> SEQUENCE: 11	
aggagatata ccatgcaaac ggaacacgtc attt	34
<210> SEQ ID NO 12 <211> LENGTH: 59 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: idi-r1 <400> SEQUENCE: 12	
tgcgctatat gccatggttt attcctcctt aaattattta agctgggtaa atgcagata	59
<210> SEQ ID NO 13 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: trgpps2-f1	
<400> SEQUENCE: 13	
atggcatata gcgcaatggc	20
<210> SEQ ID NO 14 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: trgpps2-r1	
<400> SEQUENCE: 14	
gtgatggctg ctgccttagt tctgacgaaa tgcaacat	38
<210> SEQ ID NO 15 <211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: ges-f1 <400> SEQUENCE: 15	
aaggagatat acataatgga agaaagcagc agcaaa	36

191

### 192

-continued

<210> SEQ ID NO 16	
<211> LENGTH: 36	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: ges-r1	
<400> SEQUENCE: 16	
ttaccagact cgaggttact gggtaaaaaa cagggc	36
<210> SEO ID NO 17	
<211> LENGTH: 49	
<212> TYPE: DNA	
<213> ORGANISM: Artificial sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: ychB-f1	
<400> SEQUENCE: 17	
acccagtaac ctogaaagga ggaataaggo atgoggacac agtggocot	49
<210> SEQ ID NO 18	
<211> LENGTH: 57	
<212> IYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: ychB-r1	
<400> SEQUENCE: 18	
tttcaggatg atcatttgtt attcctcctt aaggtcttaa agcatggctc tgtgcaa	57
<210> SEQ ID NO 19	
<211> LENGTH: 21	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: mtipk-f1	
<400> SEQUENCE: 19	
atgatcatcc tgaaactggg t	21
<210> SEQ ID NO 20	
<211> LENGTH: 39	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: mtipk-r1	
<400> SEQUENCE: 20	
ctttaccaga ctcgagttag tgtttacctg taatacgtg	39
<210> SEQ ID NO 21	
<211> LENGTH: 52	
<212> TYPE: DNA	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: mtipk-f2	
<400> SEQUENCE: 21	
gatccgctaa ctcgataagg aggaataaca aatgatcatc ctgaaactgg gt	52
<210> SEQ ID NO 22	
<211> LENGTH: 52	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	

<223> OTHER INFORMATION: Synthetic: taipk-fl

- 4	0.0
	u z
	7.1

<pre>4400 &gt; SEQUENCE: 22 accomptence clogasaggs ggestangge atgstgstor tgaaastigg tg 52 +210 &gt; SEQ ID NO 23 +311 : LHKNTH: 35 +312 : DEAR TIFICIAL Sequence +2200 &gt; SEQUENCE: 23 outtaccags obcgagting oggstcaoggs tgota 35 +210 &gt; SEQUENCE: 23 outtaccags obcgagting oggstcaoggs tgota 35 +210 &gt; SEQUENCE: 24 gecaggstor gastings: synthetic: magu 2507 - f1 +400 &gt; SEQUENCE: 24 gecaggstor gastings at stificial Sequence +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - f1 +400 &gt; SEQUENCE: 24 gecaggstor gastings at stificial Sequence +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - f1 +400 &gt; SEQUENCE: 24 gecaggstor gastings at stificial Sequence +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - f1 +400 &gt; SEQUENCE: 24 gecaggstor gastings at stificial Sequence +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - r1 +400 &gt; SEQUENCE: 24 gecaggstor gastings at stificial Sequence +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - r1 +400 &gt; SEQUENCE: 25 gecaggstor gastings at assignment +220 &gt; OUHER INFORMATION: Synthetic: magu 2507 - r1 +400 &gt; SEQUENCE: 25 gecaggstor gastings at assignment +220 &gt; SEQUENCE: 25 gecaggstor gastings assignment +220 &gt; SEQUENCE: 25 gecaggstor gasting assignment +220 &gt; SEQUENCE: 25 gecaggstor gasting assignment +220 &gt; SEQUENCE: 25 gecaggstor gasting caggsagts cacatc</pre>	-continued	
accagtac degmangin gegentanger ingangated teamining to 52 	<400> SEQUENCE: 22	
<pre>edibs SRQ ID NO 23 edibs URMURH 35 edibs ORGANISM Artificial Sequence edibs SRQ DD NO 24 edibs SRQ DD NO 24 edibs SRQ DD NO 24 edibs SRQ DD NO 24 edibs URMURH 17 edibs URMUR</pre>	acccagtaac ctcgaaagga ggaataaggc atgatgatcc tgaaaattgg tg	52
<pre>4005 SRQUENCE: 23 2100 SRQUENCE: 23 2100 SRQUENCE: 24 2100 SRQUENCE: 25 2111 LENOTH: 10 2120 SRQUENCE: 25 2120 SPANURG: 2120 SRQUENCE: 25 2220 SPANURG: 2220 SRQUENCE: 25 2220 SRQUENCE: 26 2220 SRQUENCE: 27 220 SRQUENCE: 27 20 SRQUENCE: 27 20 SRQUENCE: 27 20 SRQUENCE:</pre>	<210> SEQ ID NO 23 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: taipk-r1	
<pre>cttaccaga ctogagttag oggatcagg tgoca 35 clib SEQ ID NO 24 clib LENGTH: 37 clib SEQ ID NO 24 clib LENGTH: 37 clib SEQ ID NO 24 clib SEQ UNFORM reficial Sequence clob SEQ UNFORM reform requi2507- f1 clob SEQ UNFORM reficial Sequence clob SEQ</pre>	<400> SEQUENCE: 23	
<pre>clib SEQ ID NO 24 clib LENGTH: 37 clib SEQUENCE: DNA clib SEQUENCE: 24 gccaggatoc gaatocgaat actottotga coggtgg 37 clib SEQUENCE: 24 gccaggatoc gaatocgaat actottotga coggtgg 37 clib SEQUENCE: 24 gccaggatoc gaatocgaat actottotga coggtgg 37 clib SEQUENCE: 25 clib LENGTH: 36 clib SEQUENCE: 25 gccgaggoto gaatocgaatagca cacgoa 36 clib SEQUENCE: 25 gccgaggoto gaatoctgaat acago cacgoa 36 clib SEQUENCE: 25 cgccgaggoto gaatocgaatagca cacgoa 36 clib SEQUENCE: 25 gccgaggoto gaatocgaatagca cacgoa 40 clib SEQUENCE: 26 gccgaggoto gaatogaat acagoaca catatacotac 40 clib SEQUENCE: 26 gccgaggoto gaatogaat acagoaca acatagca 40 clib SEQUENCE: 26 gccgaggoto gaatogaat acagoaca 36 clib SEQUENCE: 26 gccgaggoto gaatogaat acagoaca catatacotac 40 clib SEQUENCE: 26 gccgaggoto gaatogaat acagoacaca catatacotac 40 clib SEQUENCE: 27 cgccgaggoto gaatottag coggcaagta cacata 36 clib SEQUENCE: 27 cgccgaggoto gaatottag coggcaagta cacatac 36 clib SEQUENCE: 27 cgccgaggoto gaattottag coggcaagta cacatac 36 clib SEQUENCE: 27 cgccgaggoto gaattottag coggcaagta cacatac 36 clib SEQUENCE: 27 cgccgaggoto gaattottag coggcaagta cacatac 36 clib SEQUENCE: 27 cgccgagoto gaattottag coggcaagta cacatac 36 clib</pre>	ctttaccaga ctcgagttag cggatcacgg tgcca	35
gccaggatcc gaatcgaac tatttcga ccgtgg 37 <li>210, SEQ ID NO 25 <li>213, DCKNISM: Artificial Sequence <li>223, OTHER INFORMATION: Synthetic: maqu_2507- r1 <doc 25<br="" sequence:="">cgccgagetc gaattcttac cagtaaatgc cacgca 36 <li>210, SEQ ID NO 26 <li>211, LENOTH: 40 <li>222, TYPE: DNA <li>223, OTHER INFORMATION: Synthetic: cbjALD-f1 <doc 26<br="" sequence:="">gccaggatcc gaattcgaat aaagacaac taatacctac 40 <li>210, SEQ UENCE: 26 gccaggatcc gaattctag ccgcaagta cacatc 40 <li>211, LENOTH: 36 <li>212, TYPE: DNA <li>213, OKCANISM: Artificial Sequence <li>220, FEATURE: <li>223, OTHER INFORMATION: Synthetic: cbjALD-f1 <doc 26<br="" sequence:="">gccaggatcc gaattctag ccgcaagta cacatc 40 <li>210, SEQUENCE: 27 cgccgagetc gaattctag ccgcaagta cacatc 36 <li>210, SEQUENCE: 28 spccaggetc gaattctag ccgcaagta cacatc 36 <li>210, SEQUENCE: 29 spccaggetc gaattctag ccgcaagta cacatc 36 <li>210, SEQUENCE: 20 spccaggetc gaattctag ccgcaagta cacatc 36 <li>211, LENOTH: 38 <li>212, TYPE: DNA</li> <li>213, OKCANISM: Artificial Sequence <li>220, FEATURE: <li>221, LENOTH: 38 <li>221, TYPE: DNA</li> <li>221, SPC ID NO 28 <li>221, TYPE: DNA</li> <li>221, SPC ID NO 28 <li>221, TYPE: DNA</li> <li>221, SPC ID NO 28 <li>221, TYPE: DNA</li> <li>221, TYPE: TNA</li> <li>2222, TYPE: TNA</li> <li>223, OTHER INFORMATION: Synthetic: chD-f1</li> </li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></li></doc></li></li></li></li></li></li></doc></li></li></li></li></doc></li></li></li>	<210> SEQ ID NO 24 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: maqu_2507- f1 <400> SEQUENCE: 24	
<pre>&lt;210 &gt; SEQ ID NO 25 &lt;211 &gt; LENGTH: 36 2212 &gt; TTPE: DNA &lt;223 &gt; OTHER INFORMATION: Synthetic: maqu_2507 - r1 &lt;400 &gt; SEQUENCE: 25 cgccaggctc gaattottac cagtaaatgc cacgca 36 &lt;210 &gt; SEQ ID NO 26 &lt;211 &gt; LENGTH: 40 &lt;212 &gt; TTPE: DNA &lt;213 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;223 &gt; OTHER INFORMATION: Synthetic: cbjALD-f1 &lt;400 &gt; SEQUENCE: 26 gccaggatc gaattotgaat aaagacacac taatacotac 40 &lt;210 &gt; SEQ ID NO 27 &lt;211 &gt; LENGTH: 36 &lt;212 &gt; TTPE: DNA &lt;213 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;223 &gt; OTHER INFORMATION: Synthetic: cbjALD-r1 &lt;400 &gt; SEQUENCE: 26 gccaggatc gaattotgaat aagacacac taatacotac 40 &lt;210 &gt; SEQ ID NO 27 &lt;211 &gt; LENGTH: 36 &lt;212 &gt; TTPE: DNA &lt;213 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;223 &gt; OTHER INFORMATION: Synthetic: cbjALD-r1 &lt;400 &gt; SEQUENCE: 27 cgccgagct gaattottag ccggcaagta cacatc 36 &lt;210 &gt; SEQUENCE: 27 cgccgagct gaattottag ccggcaagta cacatc 36 &lt;211 &gt; LENGTH: 38 &lt;212 &gt; TTPE: DNA &lt;213 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;213 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;214 &gt; LENGTH: 38 &lt;215 &gt; TOPE: DNA &lt;215 &gt; ORGANISM: Artificial Sequence &lt;220 &gt; FEATURE: &lt;216 &gt; SEQUENCE: 27 cgccgagct gaattottag ccggcaagta cacatc 36 </pre>	gccaggatcc gaattcgaac tactttctga ccggtgg	37
cgccgagete gaattettae eagtaaatge eaegea 36 <210 > SEQ ID NO 26 <211 > LENGTH: 40 <212 > TYPE: DNA <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <220 > FEATURE: <220 > SEQ ID NO 27 <211 > LENGTH: 36 <212 > TYPE: DNA <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <220 > FEATURE: <220 > FEATURE: <220 > FEATURE: <220 > FEATURE: <220 > FEATURE: <221 > OTHER INFORMATION: Synthetic: cbjALD-r1 <400 > SEQUENCE: 27 Ggccgagete gaattettag ccggcaagta cacata <210 > SEQ ID NO 28 <211 > LENGTH: 38 <212 > TYPE: DNA <212 > TYPE: DNA <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <210 > SEQ ID NO 28 <211 > LENGTH: 38 <212 > TYPE: DNA <212 > TYPE: DNA <213 > OTHER INFORMATION: Synthetic: chnD-f1 213 OTHER INFORMATION: Synthetic: chnD-f1	<210> SEQ ID NO 25 <211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: maqu_2507- r1 <400> SEQUENCE: 25	
<pre>&lt;210&gt; SEQ ID N0 26 &lt;211&gt; LENGTH: 40 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;400&gt; SEQUENCE: 26 gccaggatcc gaattcgaat aaagacacac taatacctac 40 </pre>	cgccgagete gaattettae cagtaaatge caegea	36
<pre>&lt;400&gt; SEQUENCE: 26 gccaggatcc gaattcgaat aaagacacac taatacctac 40 &lt;210&gt; SEQ ID NO 27 &lt;211&gt; LENGTH: 36 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;2223&gt; OTHER INFORMATION: Synthetic: cbjALD-r1 &lt;400&gt; SEQUENCE: 27 cgccgagctc gaattcttag ccggcaagta cacatc 36 &lt;210&gt; SEQ ID NO 28 &lt;211&gt; LENGTH: 38 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: chnD-f1 </pre>	<210> SEQ ID NO 26 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: cbjALD-f1	
<pre>gccaggatec gaattegaat aaagacacac taatacetae 40 </pre>	<400> SEQUENCE: 26	
<pre>cgccgagctc gaattettag ccggcaagta cacate 36 &lt;210&gt; SEQ ID NO 28 &lt;211&gt; LENGTH: 38 &lt;211&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: chnD-f1</pre>	<pre><cupselect <210="" gaattegaattaagatataa="" taagatatat="" taatatetat=""> SEQ ID NO 27 &lt;211&gt; LENGTH: 36 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;220&gt; FEATURE: &lt;220&gt; OTHER INFORMATION: Synthetic: cbjALD-r1 &lt;400&gt; SEQUENCE: 27</cupselect></pre>	
<210> SEQ ID NO 28 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: chnD-fl	cgccgagete gaattettag eeggeaagta eacate	36
<400> SEQUENCE: 28	<pre>&lt;210&gt; SEQ ID NO 28 &lt;211&gt; LENGTH: 38 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: chnD-f1 &lt;400&gt; SEQUENCE: 28 gccaggatcc gaattcgcac tgctattgtg ttacccac</pre>	38

195

#### -continued

	concinaca
<210> SEQ ID NO 29	
<211> LENGTH: 37	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Synthetic: chnD-r1	
<400> SEQUENCE: 29	
cgccgagete gaatteteaa ttttegtgea teagaae	37
<210> SEQ ID NO 30	
<211> LENGTH: 36	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Synthetic: tdTer-f1	
-	
<400> SEQUENCE: 30	
	26
aaggagatat acatatgatt gitaageega tggtee	50
<210> SEQ ID NO 31	
<211> LENGTH: 39	
<212> TYPE: DNA <213> OPCINISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: tdTer-r1	
<400> SEQUENCE: 31	
ttqaqatctq ccatatqtta qatqcqqtca aaacqttca	39
<210> SEQ ID NO 32 <211> LENGTH, 25	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: pct-f1	
<400> SEOUENCE: 32	
·····	
aggagatata ccatgagaaa agtagaaatc attac	35
<210> SEO TO NO 33	
<211> LENGTH: 39	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: pct-r1	
<400 SECUENCE: 33	
(100) Shgolmen. 55	
cgccgagctc gaattettat tttttcagte ceatgggae	39
<210> SEQ ID NO 34	
<211> LENGIH: 35 <2125 TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: bktB-f1	
<400> SEQUENCE: 34	
addadatata ccatdatdac dcdtdaadtd dtadt	35
ayyayacaca ceaeyaeyae yeyeyaayey yeaye	
<210> SEQ ID NO 35	
<211> LENGTH: 36	
<212> TYPE: DNA	

- <213> ORGANISM: Artificial Sequence
  <220> FEATURE:
  <223> OTHER INFORMATION: Synthetic: bktB-r1

197	198
-continued	
<400> SEQUENCE: 35	
cgccgagete gaatteteag ataegetega agatgg	36
<210> SEQ ID NO 36 <211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: phaB1-f1	
<400> SEQUENCE: 36	
gcgtatctga gaattaggag gctctctatg actcagcgca ttgcgta	47
<210> SEQ ID NO 37 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: phaB1-r1	
<400> SEQUENCE: 37	
cgccgagete gaatteteag eccatgtgea ggee	34
<210> SEQ ID NO 38 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: phaJ-f1	
<400> SEQUENCE: 38	
aaggagatat acatatgtcg gcacaaagcc tg	32
<210> SEQ ID NO 39 <211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: phaJ-r1	
<400> SEQUENCE: 39	
ttgagatctg ccatatgtta cggcagtttc accacc	36
<210> SEQ ID NO 40 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: pct540- f1	
<400> SEQUENCE: 40	
gaggaataaa ccatgcgtaa agtgccgatt atta	34
<210> SEQ ID NO 41 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: pct540- r1	
<400> SEQUENCE: 41	

### gatgatgatg gtcgacgctt ttcatttctt tcaggcc

199

-continued	

Concinued	
<210> SEQ ID NO 42 <211> LENGTH: 41	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Synthetic: pct-f2	
<400> SEQUENCE: 42	
tagaaggagg agatctatga gaaaagtaga aatcattaca g	41
<210> SEQ ID NO 43 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: pct-r2	
<400> SEQUENCE: 43	
gggggaccag ctogagtttt ttoagtocca tgggaco	37
<210> SEQ ID NO 44 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: alsS-f1	
<400> SEQUENCE: 44	
aaggagatat acatatgacc aaagcaacca aagaa	35
<210> SEQ ID NO 45 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: alsS-r1	
<400> SEQUENCE: 45	
aatggtaata cgcatgttaa tttcctccta gaattacagg gctttggttt tcat	54
<210> SEQ ID NO 46 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: panE-f1	
<400> SEQUENCE: 46	
atgcgtatta ccattgccgg	20
<210> SEQ ID NO 47 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: panE-r1	
<400> SEQUENCE: 47	
ttgagatetg ceatattatt tggettteag eagttett	38
<210> SEQ ID NO 48 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: ilvC-f1	

201	202	
	-continued	
<400> SEQUENCE: 48		
aggagatata ccatggctaa ctacttcaat ac	32	
<210> SEQ ID NO 49 <211> LENGTH: 56		
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence		
<220> FEALORE: <223> OTHER INFORMATION: Synthetic: ilvC-r1		
<400> SEQUENCE: 49		
acggtactta ggcatggttt attcctcctt aaactcttaa co	ccgcaacag caatac 56	
<210> SEQ ID NO 50 <211> LENGTH: 19		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: ilvD-f1		
<400> SEQUENCE: 50		
atgeetaagt acegtteeg	19	
<210> SEQ ID NO 51		
<211> LENGTH: 37 <212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: ilvD-r1		
<400> SEQUENCE: 51		
cgccgagete gaattettaa eeecceagtt tegattt	37	
<210> SEQ ID NO 52		
<211> LENGTH: 39 <212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: fadM-r1		
<400> SEQUENCE: 52		
tgeetetage acgegtegtt taettaacea tetgeteea	39	
<210> SEQ ID NO 53		
<211> LENGTH: 44 <212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: tesa.f1</pre>		
<pre>&lt;400&gt; SEQUENCE: 53</pre>		
ttaaagagga gaaaggtacc atgatgaact tcaacaatgt tt	tc 44	
<210> SEQ ID NO 54		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: tesA-r1		
<400> SEQUENCE: 54		

tgcctctagc	acgcgttccg	ttgctttatg	agtcatg

204

203

### -continued

<210> SEO ID NO 55		
<211> LENGTH: 40		
<212> TYPE: DNA		
<213> ORGANISM: Artifi	cial Sequence	
<220> FEATURE:		
<223> OTHER INFORMATIC	)N: Synthetic: tesB-f1	
<400> SEQUENCE: 55		
		10
ttaaagagga gaaaggtatt	argagreagy eyeraaaaaa	40
<210> SEO ID NO 56		
<211> LENGTH: 34		
<212> TYPE: DNA		
<213> ORGANISM: Artifi	cial Sequence	
<220> FEATURE:		
<223> OTHER INFORMATIC	N: Synthetic: tesB-rl	
<400 SECUENCE: 56		
CHOUS SEQUENCE: SU		
tgcctctagc acgcgtaaca	gccggacggt tttc	34
5 5 5 5	3 33 33	
<210> SEQ ID NO 57		
<211> LENGTH: 42		
<212> TYPE: DNA		
<213> ORGANISM: Artifi	.cial Sequence	
<220> FEATURE:	$\mathbb{N}_{\cdot}$ Synthetic, where fi	
<223> OTHER INFORMATIC	M: Synchecic: ybgc-ii	
<400> SEOUENCE: 57		
~~~~~		
ttaaagagga gaaaggtacc	gtgaatacaa cgctgtttcg at	42
<210> SEQ ID NO 58		
<211> LENGTH: 36		
<212> TYPE: DNA		
<213> ORGANISM: AILIII	cial sequence	
<2205 FEATORE: <2235 OTHER INFORMATIC	)N· Synthetic· vbgC-r1	
	A. Synemeere. Joge II	
<400> SEQUENCE: 58		
tgcctctagc acgcgttcac	tgcttaaact ccgcga	36
<210> SEQ ID NO 59		
<211> LENGTH: 43		
<212> IIPE: DNA	inial Company	
<213> ORGANISM: AICIII	cial sequence	
<220 FEATORE: <223 OTHER INFORMATIC	N. Synthetic, vciA-fl	
(22) OTHER INFORMATIO	M. Synthetite. yelk II	
<400> SEOUENCE: 59		
· · · · · · · · · · · · · · · · · · ·		
ttaaaqaqqa qaaaqqtacc	atqtctacaa cacataacqt ccc	43
5 55 5 55	5 5	
<210> SEQ ID NO 60		
<211> LENGTH: 40		
<212> TYPE: DNA		
<213> ORGANISM: Artifi	cial Sequence	
<220> FEATURE:		
<223> OTHER INFORMATIC	N: Synthetic: yciA-rl)	
<400> SEQUENCE: 60		
		4.0
tgeetetage acgegtttea	gtaagcagaa agtcaaaagc	40
<210 SEO ID NO 61		
<211 \ LENGTU · 42		
<212> TYPE · DNA		
<213> ORGANISM: Artifi	icial Sequence	

- <220> FEATURE:
- <223> OTHER INFORMATION: Synthetic: ydiI-f1

US 11	1,046,978	B2
-------	-----------	----

205	206	
-continued		
<400> SEQUENCE: 61		
ttaaaqaqqa qaaaqqtacc atqatatqqa aacqqaaaat ca	42	
<210> SEO ID NO 62		
<211> LENGTH: 37		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: vdiI-r1		
(220) onnek infoktition. Synchoolo: yall li		
<400> SEQUENCE: 62		
	37	
	<i></i>	
<210> SEQ ID NO 63		
<211> LENGIN: 34 <212> TYPE: DNA		
<pre>&lt;213&gt; ORGANISM: Artificial Sequence</pre>		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: atoB-f1		
ADDS SECUENCE: 63		
gaggaataaa ccatgaaaaa ttgtgtcatc gtca	34	
<210> SEQ ID NO 64		
<211> LENGTH: 37		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<2220> FEALORE: <223> OTHER INFORMATION: Synthetic: atoB-r1		
<400> SEQUENCE: 64		
cccaagcttc gaattettaa tteaacegtt caateae	37	
5 5 5		
210, SEO ID NO SE		
<211> LENGTH: 35		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: SYNCHECIC: TAGE-II		
<400> SEQUENCE: 65		
	25	
taayaattey aayetyeyya tteayyayat tyaca	35	
<210> SEQ ID NO 66		
<211> LENGTH: 35		
<212> THE DWA <213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: fadB-r1		
<400> SEOUENCE: 66		
~		
gttcgggccc aagctttaag ccgttttcag gtcgc	35	
<210> SEQ ID NO 67		
<211> LENGTH: 53		
<212> TYPE: DNA		
<213> ORGANISM: ATTILICIAL SEQUENCE <220> FRATURE:		
<pre>&lt;223&gt; OTHER INFORMATION: Synthetic: egter-f1</pre>		
<400> SEQUENCE: 67		
aaacggctta aagctaataa ggaggaataa accatqqcaa tqtttaccac qac	53	

aaacggctta aagctaataa ggaggaataa accatggcaa tgtttaccac gac

-continued

207

<223> OTHER INFORMATION: Synthetic: bkdG-f1

208

<210> SEQ ID NO 68 <211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: egter-r1 <400> SEQUENCE: 68 gttcgggccc aagcttgcgg ccgcttattg ctgtgctgcg gac 43 <210> SEQ ID NO 69 <211> LENGTH: 58 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: alsS-r2 <400> SEQUENCE: 69 gctcggatag gtcatgtgat attcctccta gctatgttac agggctttgg ttttcatc 58 <210> SEQ ID NO 70 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: liuA-f1 <400> SEQUENCE: 70 atgacctatc cgagcctgaa 20 <210> SEQ ID NO 71 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: liuA-r1 <400> SEQUENCE: 71 ttaccagact cgagggtacc ttagcgggtt tcattaaaca gt 42 <210> SEQ ID NO 72 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: bkdF-f1 <400> SEOUENCE: 72 aggagatata ccatgaccgt tgaaagcacc gc 32 <210> SEQ ID NO 73 <211> LENGTH: 56 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: bkdF-r1 <400> SEQUENCE: 73 cattttttct gccatgagtt attcctccta caactcttaa ttaccacctt gaccgg 56 <210> SEQ ID NO 74 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:

209	210
-cont.	inued
<400> SEQUENCE: 74	
atggcagaaa aaatggcaat cg	22
<210> SEQ ID NO 75 <211> LENGTH: 57	
<pre>&lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic: bkdG-r1	
<400> SEQUENCE: 75	
gcttgcttcg gtcatgcttt attcctcctt taattgttaa tatgccagg	c tacgatc 57
<210> SEQ ID NO 76 <211> LENGTH: 20	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: bkdH-f1	
<400> SEQUENCE: 76	
atgaccgaag caagcgttcg	20
<210> SEQ ID NO 77 <211> LENGTH: 42	
<212> TYPE: DNA	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: bkdH-r1	
<400> SEQUENCE: 77	
ttaccagact cgagggtacc ttagcgggtt tcattaaaca gt	42
<210> SEQ ID NO 78	
<211> LENGTH: 34	
<212> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<pre></pre>	
	24
aayyayatat acatatytee acattatyte tytt	57
<210> SEQ ID NO 79	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Synthetic: lplA-r1	
<400> SEQUENCE: 79	
tgcatcattt gccatccatt attcctcctt gggtaactac cttacagco	c 50
<210> SEQ ID NO 80	
<211> LENGTH: 20 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: lpdA1-f1	
<400. SECTIENCE. 80	
KARRY PROFILE: ON	

atggcaaatg atgcaagcac

211

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-r2

### -continued

212

<210> SEQ ID NO 81 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: lpdA1-r1 <400> SEQUENCE: 81 ttaccagact cgagggtacc ttaatcatgg ctatgcagcg g 41 <210> SEQ ID NO 82 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-f11 <400> SEQUENCE: 82 aggagatata ccatgagcca gcaagtcat 29 <210> SEQ ID NO 83 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-r11 <400> SEQUENCE: 83 cacctggtca agcgcatctt taccgtggc 29 <210> SEQ ID NO 84 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-f12 <400> SEQUENCE: 84 aagatgcgct tgaccaggtg gatatcgtcg ctaa 34 <210> SEQ ID NO 85 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-r12 <400> SEOUENCE: 85 cgccgagete gaattettae acceettetg etacata 37 <210> SEQ ID NO 86 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuA(G462 D)B-f2 <400> SEQUENCE: 86 21 aggagatata ccatgagcca g <210> SEQ ID NO 87 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence

- ^	1	2
- 2	T	

213	214
-continued	
<400> SEQUENCE: 87	
cgccgagctc gaattettac	20
<210> SEQ ID NO 88 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuCD-f1	
<400> SEQUENCE: 88	
cgatcgctga cgtcgatggc taagacgtta tacgaaaa	38
<210> SEQ ID NO 89 <211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: leuCD-r1	
<400> SEQUENCE: 89	
ttaccagact cgagggtacc ttaattcata aacgcaggtt gtt	43
<210> SEQ ID NO 90 <211> LENGTH: 69 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: kan-homatoE-L <400> SEQUENCE: 90	
ttqqtttaac qctqttctqa cqqcacccct acaaacaqaa qqaatataaa catatqaata	60
tcctcctta	69
<210> SEQ ID NO 91 <211> LENGTH: 41 <212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: kan-ovcymatoB- R	
<400> SEQUENCE: 91	
tctgaaattc tgcctcgtga gtgtaggctg gagctgcttc g	41
<210> SEQ ID NO 92 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: cym-pCTC- atoB-ovkan-L	
<400> SEQUENCE: 92	
cgaagcagct ccagcctaca ctcacgaggc agaatttcag a	41
<210> SEQ ID NO 93 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: atoBintrecomb- R <400> SEQUENCE: 93	
~	

gccagcccgc tttttaac

215

# -continued

216

<210> SEQ ID NO 94 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: maqu\_250 7-f2 <400> SEQUENCE: 94 aaggagatat acatatgaac tactttctga ccggt 35 <210> SEQ ID NO 95 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: maqu\_250 7-r2 <400> SEQUENCE: 95 ttgagatetg ceatatgtta ceagtaaatg ceaegeat 38 <210> SEQ ID NO 96 <211> LENGTH: 56 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: maqu\_250 7-r3 <400> SEOUENCE: 96 ttaaattccg gcataattac tccttcactg ccatattacc agtaaatgcc acgcat 56 <210> SEQ ID NO 97 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: cbjALD-f2 <400> SEQUENCE: 97 aaggagatat acatatgaat aaagacacac taataccta 39 <210> SEQ ID NO 98 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: cbjALD-r2 <400> SEOUENCE: 98 ttgagatetg ceatatgtta geeggeaagt acaeate 37 <210> SEQ ID NO 99 <211> LENGTH: 55 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: cbjALD-r3 <400> SEQUENCE: 99 ttaaattccg gcataattac tccttcactg ccatattagc cggcaagtac acatc 55 <210> SEQ ID NO 100 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic: adhE2-f1

-cont	inued
<400> SEQUENCE: 100	
aaggagatat acatatgaaa gttacaaatc aaaaagaac	39
<pre>&lt;210&gt; SEQ ID NO 101 &lt;211&gt; LENGTH: 47 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: adhE2-r1</pre>	
<400> SEQUENCE: 101	
ttgagatctg ccatatgtta aaatgatttt atatagatat ccttaag	47
<pre>&lt;210&gt; SEQ ID NO 102 &lt;211&gt; LENGTH: 33 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: hmgs-f1</pre>	
<400> SEQUENCE: 102	
aggagatata ccatgaccat cggcatcgat aag	33
<210> SEQ ID NO 103 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: hmgs-r1	
<400> SEQUENCE: 103	
cgccgagete gaattettat teeggaegat gatatteg	38
<210> SEQ ID NO 104 <211> LENGTH: 51 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: aibA-f1	
<400> SEQUENCE: 104	
tccggaataa gaattgtagg aggaatacta catgaaaacc gcacgttg	gt g 51
<210> SEQ ID NO 105 <211> LENGTH: 56 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: aibA-r1	
<400> SEQUENCE: 105	
cagggttgcg ctcatggttt attcctcctt aaaatcttat gctgcacg	ac gggtca 56
<210> SEQ ID NO 106 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: aibB-f1	

#### <400> SEQUENCE: 106

atgagegeaa eeetggatat

### 217

219

### 220

-continued

<pre>&lt;210&gt; SEQ ID NO 107 &lt;211&gt; LENGTH: 40 </pre>	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: aibB-rl	
<400> SEQUENCE: 107	
cctgcaggcg cgccgagctc ttatgcacca accagtgcat	40
<210> SEQ ID NO 108	
<211> LENGTH: 36	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: Iluc-Il	
<400> SEQUENCE: 108	
aaggagatat acatatgccg gaatttaaag ttgatg	36
<210> SEQ ID NO 109	
<211> LENGTH: 37	
<212> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: liuC-r1	
<400> SEQUENCE: 109	
ttgagatctg ccatattaac gacctttata aaccggt	37
<210> SEQ ID NO 110	
<211> LENGTH: 50 <212> TYDE: DNA	
<212> THE DATA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: ChnD-12	
<400> SEQUENCE: 110	
ttaatatggc agatcaggag gaatagetga tgeaetgeta ttgtgttaee	50
<210> SEQ ID NO 111	
<211> LENGTH: 37	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: chnD-r2	
<400> SEQUENCE: 111	
ctttaccaga ctogagtoaa ttttogtgoa toagaac	37
<210> SEQ ID NO 112	
<211> LENGTH: 51	
<212> TYPE: DNA	
<213> ORGANISM: Artificial sequence <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: yjgB-f1	
<400> SEQUENCE: 112	
ttaatatggc agatcaggag gaatagctga tgtcgatgat aaaaagctat g	51
<210> SEO ID NO 113	
<211> LENGTH: 37	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Synthetic: yjgB-r1	

	~	-
- 44	~	л.

-continued

<400> SEQUENCE: 113	
ctttaccaga ctcgagtcaa aaatcggctt tcaacac	37
<210> SEQ ID NO 114 <211> LENGTH: 51 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: yahK-f1	
<400> SEQUENCE: 114	
ttaatatggc agatcaggag gaatagctga tgaagatcaa agctgttggt g	51
<210> SEQ ID NO 115 <211> LENGTH: 37 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic: yahK-r1	
<400> SEQUENCE: 115	
ctttaccaga ctcgagtcag tctgttagtg tgcgatt	37
<210> SEQ ID NO 116	
<211> LENGTH: 70 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synchecic: Reverse primer	
<400> SEQUENCE: 116	
gcattggcgg cggtcaggga attgcgatgg tgattgaacg gttgaattaa aaaatgagac	60
gttgatcggc	70
<210> SEQ ID NO 117	
<211> LENGTH: 70	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: Forward primer	
<400> SEQUENCE: 117	
caacaaacag acaatctggt ctgtttgtat tatgaacgaa ggagagatct atgacgcgtg	60
aagtggtagt	70
<210> SEQ ID NO 118	
<211> LENGTH: 70 <212> TYPE: DNA	
<212> THE. DAR <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic: Reverse primer	
<400> SEQUENCE: 118	
gatgttcaag aaaacacccg ataactttcg ctatcgggtg tttttattga tcagatacgc	60
tcgaagatgg	/0
<210> SEQ ID NO 119	
<211> LENGTH: /1 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<225> OTHER INFORMATION: Synchecte: Folward primer	

- ^	1	2
- 2	4	Э

-continued

224

<400> SEQUENCE: 119	
ttgacggcgg tttcagcatt gctgcaatga acgaactcga actgaaataa gtgtaggctg	60
gagetgette g	71
<pre>&lt;210&gt; SEQ ID NO 120 &lt;211&gt; LENGTH: 90 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Synthetic: Reverse primer</pre>	
<400> SEQUENCE: 120	
aacagagata acgggcggca gaacgccgcc catctttacc aacagaacga ttatttcagt	60
tcgagttcgt tttattgctg tgctgcggac	90
<210> SEQ ID NO 121 <211> LENGTH: 70 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: Forward primer <400> SEQUENCE: 121	
caacaaacag acaatctggt ctgtttgtat tatgaacgaa ggagagatct atggcaatgt	60
ttaccacgac	70
<210> SEQ ID NO 122 <211> LENGTH: 69 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: Reverse primer	
<400> SEQUENCE: 122	
ttaaacccgc tcaaacaccg tcgcaatacc ctgacccaga ccgatacaca ttattgctgt	60
gctgcggac	69
<210> SEQ ID NO 123 <211> LENGTH: 72 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: F1 primer	
<400> SEQUENCE: 123	
ateeteeggt tgageeagee egteeggttg gegaeetgaa aaeggettaa atgattgaae	60
aagatggatt gc	72
<210> SEQ ID NO 124 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: R1 primer	
<400> SEQUENCE: 124	
taaggggtga cgccaaagta tcagaagaac tcgtcaagaa gg	42
<210> SEQ ID NO 125 <211> LENGTH: 42	

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence

$\mathbf{a}$	$\mathbf{a}$	5
∠	∠	э.

-continued

226

<220> FEATURE: <223> OTHER INFORMATION: Synthetic: F2 primer	
<400> SEQUENCE: 125	
cettettgae gagttettet gataetttgg egteaceeet ta	42
<210> SEQ ID NO 126 <211> LENGTH: 73 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: R2 primer	
<400> SEQUENCE: 126	
atcggggtgc gaattgcatc gacaatgaca acctgttcca ttgtgactcc atcaaaggga	60
aaactgtcca tat	73
<210> SEQ ID NO 127 <211> LENGTH: 69 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: Forward primer	
<400> SEQUENCE: 127	
ttgagccagc ccgtccggtt ggcgacctga aaacggctta aggagtcaca atggccaagt	60
tgaccagtg	69
<210> SEQ ID NO 128 <211> LENGTH: 68 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: Reverse primer	
~	60
teetetge	68
<210> SEQ ID NO 129 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: fadM-f1	
<400> SEQUENCE: 129	
ttaaagagga gaaaggtacc atgcaaacac aaatcaaagt	40
<210> SEQ ID NO 130 <211> LENGTH: 73 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: Forward primer	
<400> SEQUENCE: 130	
gatgttcaag aaaacacccg ataactttcg ctatcgggtg tttttattga atcaaaggga	60
aaactgtcca tat	73

227

<223> OTHER INFORMATION: Synthetic: idi-GB-fwd

-continued

228

<210> SEQ ID NO 131 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: MK-IF-fwd <400> SEQUENCE: 131 aggagatata ccatgagcct gccgtttctg 30 <210> SEQ ID NO 132 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: MK-IF-rev <400> SEQUENCE: 132 cgccgagete gaattettag etggteeacg geag 34 <210> SEQ ID NO 133 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: PMK-IF-fwd <400> SEQUENCE: 133 gaccagctaa gaatttagga ggaataactc atgagcg 37 <210> SEQ ID NO 134 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: PMK-IF-rev <400> SEQUENCE: 134 cgccgagete gaatteatte eteettaat tgttatttgt e 41 <210> SEQ ID NO 135 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: PMD-IF-fwd <400> SEOUENCE: 135 aaggaggaat gaattatgac cgtttatacc gcaag 35 <210> SEQ ID NO 136 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic: PMD-IF-rev <400> SEQUENCE: 136 34 cgccgagete gaattettat tettteggea gace <210> SEQ ID NO 137 <211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:

229	230	
-continued	d	
<400> SEQUENCE: 137		
gtttaacttt aagaaggaga tatacatgca aacggaacac gtc	43	
<210> SEQ ID NO 138		
<211> LENGTH: 43		
<212> TYPE: DNA		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: idi-GB-rev		
<400> SEQUENCE: 138		
atggtttatt cctccttaaa ttatttaagc tgggtaaatg cag	43	
<210> SEQ ID NO 139		
<211> LENGTH: 47		
<212> HIFE: DNA <213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: trGPPS2-IF-fwd		
<400> SEQUENCE: 139		
tttaaggagg aataaaccat ggtggaattt gactttaaca aatatat	47	
<210> SEQ ID NO 140		
<211> LENGTH: 36		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<223> OTHER INFORMATION: Synthetic: GPPS2-GB-rev		
<400> SEQUENCE: 140		
gtgatggctg ctgccttagt tctgacgaaa tgcaac	36	
<210> SEQ ID NO 141		
<211> LENGTH: 38		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATORE: <223> OTHER INFORMATION: Synthetic: CymR-GB-fwd		
<400> SEQUENCE: 141		
ctgcaggtcg acaagcttgc aggcgtatca cgaggcag	38	
<210> SEQ ID NO 142		
<211> LENGTH: 50		
<212> IFFE: DNA <213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: CymR-GB-rev		
<400> SEQUENCE: 142		
catetgetge ttegeteata tgagatetet eettegttea taatacaaac	50	
<210> SEQ ID NO 143		
<211> LENGTH: 25		
<212> TYPE: DNA		
<213> ORGANISM: ATTILICIAL Sequence <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: NphB- cumate-GB- fwd		

<400> SEQUENCE: 143

tctcatatga gcgaagcagc agatg

-continued

<210> SEQ ID NO 144		
<211> LENGTH: 48		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: NphB- cumate-GB- re	ev	
<400> SEQUENCE: 144		
agcagcggtt tetttaccag actegaggte aatetteeag getateaa	48	
<210> SEO ID NO 145		
<211> LENGTH: 33		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: NphB-IF-fwd		
<400> SEQUENCE: 145		
aaggagatat acataatgag cgaagcagca gat	33	
-2105 SEO ID NO 146		
<211> LENGTH: 35		
<212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic: NphB-IF-rev		
<400> SEQUENCE: 146		
ttaccagact cgaggtcaat cttccaggct atcaa	35	

35

60

The invention claimed is:

**1**. A process for the production of an isoprenoid(s) or an isoprenoid derivative(s), said process comprising:

- a) providing one or more alcohol(s) selected from prenol, isoprenol, or both;
- b) catalyzing conversion of said alcohol(s) to dimethylally pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) using a) an alcohol kinase (EC 2.7.1.-)
  b) catalyzing conversion of said alcohol(s) to dimethylally ally pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) using a) an alcohol kinase (EC 2.7.1.-)
  c) a cell free system.
  c) a cell free system.
  d) a cell free system.
  <lid>d) a cell free system.
  d
- c) catalyzing conversion of said DMAPP and IPP to geranyl diphosphate (GPP) using a GPP synthase; and 45
- d) catalyzing conversion of said GPP to an isoprenoid(s) or an isoprenoid derivative(s) using one or more enzyme(s) selected from a group comprising farnesyl diphosphate synthase, geranylgeranyl-diphosphate synthase, prenyl transferase, terpene synthase, terpene 50 cyclase, tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, cannabichromenic acid synthase, tetrahydrocannabivarinic acid synthase, cannabidivarinic acid synthase, and cannabichrovarinic acid synthase. 55

2. The process of claim 1, wherein said process comprises catalyzing a prenyl transfer from said GPP or said isoprenoid to an aromatic polyketide(s) forming a prenylated aromatic compound(s) using an aromatic prenyltransferase or a 4-hy-droxybenzoate geranyltransferase.

**3**. The process of claim **2**, wherein said prenylated aromatic compound(s) is a cannabinoid(s).

**4**. The process of claim **1**, wherein said process occurs in a recombinant organism grown in a culture medium and said isoprenoid(s) or isoprenoid derivative(s) is isolated from 65 said culture medium or said recombinant microorganism or both.

5. The process of claim 3, wherein said process occurs in a recombinant organism grown in a culture medium.

- **6**. The process of claim **1**, wherein said process occurs in a cell free system.
- 7. The process of claim 2, wherein said process occurs in a cell free system.
- 8. The process of claim 3, wherein said process occurs in a cell free system.

**9**. A process for the production of a cannabinoid, said process comprising:

- a) providing an alcohol selected from prenol, isoprenol, or both;
- b) catalyzing conversion of said alcohol to DMAPP and IPP using a) an alcohol kinase (EC 2.7.1.-) plus a phosphate kinase (EC 2.7.4.-), or b) an alcohol diphosphokinase (EC 2.7.6.-), plus optionally c) an IPP isomerase (5.3.3.2);
- c) catalyzing conversion of said DMAPP and IPP to GPP using GPP synthase;
- d) catalyzing a prenyl transfer from said GPP to an aromatic polyketide to form a cannabinoid using an aromatic prenyltransferase or a 4-hydroxybenzoate geranyltransferase;
- e) optionally catalyzing conversion of said cannabinoid to another cannabinoid using one or more enzymes selected from the group comprising tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, cannabichromenic acid synthase, tetrahydrocannabivarinic acid synthase, cannabidivarinic acid synthase, and cannabichrovarinic acid synthase; and
- e) isolating said cannabinoid.

**10**. The process of claim **9**, wherein said aromatic polyketide is selected from olivetolic acid, olivetol, divarinolic acid or divarinol.

**11**. A process for the production of a cannabinoid, said process comprising:

- a) providing one or more alcohol(s) selected from prenol and isoprenol;
- b) catalyzing conversion of said alcohol(s) to DMAPP or 5 IPP using one or more enzyme(s) selected from i) an alcohol kinase (EC 2.7.1.-) plus a phosphate kinase (EC 2.7.4.-), or ii) an alcohol diphosphokinase (EC 2.7.6.-);
- c) catalyzing a prenyl transfer from said DMAPP or IPP to an aromatic polyketide to form a cannabinoid using 10 an aromatic prenyltransferase or a 4-hydroxybenzoate geranyltransferase;
- d) optionally catalyzing conversion of said cannabinoid to another cannabinoid using one or more enzymes selected from the group comprising tetrahydrocannabinolic acid synthase, cannabidiolic acid synthase, cannabichromenic acid synthase, tetrahydrocannabivarinic acid synthase, cannabidivarinic acid synthase, and cannabichrovarinic acid synthase; and
- e) isolating said cannabinoid.

20

12. The process of claim 11, wherein said aromatic polyketide is selected from olivetolic acid, olivetol, divarinolic acid or divarinol.

\* \* \* \* \*